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ABSTRACT 
 
Purine receptors are involved in the pathophysiology of most disorders of the central 
nervous system (CNS) taking part in the early synaptic dysfunction and being in the genesis 
and propagation of the inflammatory response in the brain. However, the different ways that 
ATP and adenosine receptors contribute to the evolution or to the arrest of deleterious 
conditions are still being unraveled. 
The broad spectrum of neuroprotection afforded with the blockade of adenosine A2A 
receptors under different adverse conditions in the brain can be underlain by a general 
mechanism through which these receptors may operate. One possibility is the control of 
neuroinflammation, a common event in most CNS disorders. However, while in the peripheral 
nervous system A2A receptors have a well established role as a “stop signal” of the 
inflammatory cascade, it is not clear whether these receptors trigger or arrest the reactivity of 
microglia, the brain immune-competent cells. To tackle this question, it was tested if the 
blockade of A2A receptors could prevent biochemical and morphological consequences of 
neuroinflammation triggered by the systemic administration of lipopolysaccharide (LPS). In 
this work it is shown that the intracerebroventricular injection of a selective A2A receptor 
antagonist (SCH58261) was able to prevent the LPS-induced recruitment of activated 
microglial cells and the release of the pro-inflammatory cytokine interleukin-1β in the 
hippocampus. Moreover, SCH58261 also prevented the LPS-induced activation of mitogen-
activated protein kinases (MAPKs) such as c-Jun N-terminal kinases (JNK) and p38 and the 
activation of caspase-3, a key mediator of apoptosis. These results indicate a tight control 
mainly of the genesis of neuroinflammation by the blockade of A2A receptors. Therefore, it 
was next investigated if A2A receptors were also able to control the direct effects on neurons 
of the pro-inflammatory cytokines IL-1β and tumor necrosis factor-α (TNF-α), known to be 
important effectors of neuroinflammation-induced deleterious consequences in the 
hippocampus. To answer this question, cultured hippocampal neurons were exposed for 
different periods to different concentrations of these cytokines and their activation of MAPKs 
was evaluated by Western blot and immunocytochemistry. Both TNF-α and IL-1β increased 
the phosphorylation (i.e. the activation) of p38 in neurons and IL-1β also increased the 
phosphorylation of JNK. In addition, the exposure of hippocampal neurons to IL-1β just 
before adding glutamate increased the susceptibility of cells to glutamate-mediated 
excitotoxicity. The blockade of A2A receptors with SCH58261 abrogated the activation of 
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 xviii 
MAPKs induced by IL-1β and prevented the IL-1β-induced exacerbation of excitotoxicity. 
Taking advantage of single cell calcium imaging it was found that IL-1β increased both the 
calcium entry and the calcium deregulation caused by glutamate exposure in hippocampal 
neurons. Pre-incubation of cells with SCH58261 also prevented this effect of IL-1β. Thus, it is 
concluded that the antagonism of A2A receptors can control not only the genesis of 
neuroinflammation in vivo but also the direct effects of pro-inflammatory cytokines on 
neurons, which gives a further insight into the mechanisms operated by these receptors under 
pathological conditions. 
In addition to adenosine receptors, the ATP (P2) receptors are involved in the 
pathophysiology of brain cells in several brain disorders, when the extracellular levels of ATP 
are significantly raised. In particular, the pharmacological blockade or the genetic deletion of 
P2Y1 receptors conferred a robust neuroprotection against the toxicity induced by the Aβ1-42 
peptide (an Alzheimer’s disease related peptide) in hippocampal neuronal cultures and against 
Aβ1-42-induced early loss of synaptic markers and mnemonic deficits in rodents. Moreover, 
the antagonism of P2Y1 receptors ameliorates the consequences of ischaemic/hypoxic insults 
to hippocampal slices. Given the involvement of neuroinflammation in the deleterious effects 
of the above conditions, it was hypothesized that the blockade of these receptors could not 
only control synaptotoxicity but also neuroinflammation. To begin answering this question it 
was investigated whether blocking the P2Y1 receptors could prevent the direct effects of pro-
inflammatory cytokines on hippocampal neuronal cultures. The results showed that the 
selective antagonism of P2Y1 receptors either prevented or attenuated the IL-1β-mediated 
effects in hippocampal neurons but, importantly, it prevented the effects of glutamate per se. 
Thus it was investigated if the same occurred upon different excitotoxic stimuli to 
hippocampal neurons. The results obtained show that neurons are protected against the 
toxicity induced by N-methyl-D-aspartic acid (NMDA) or by quinolinic acid when exposed in 
the presence of a general P2 receptor antagonist or in the presence of a selective P2Y1 
receptor antagonist. This suggests a coupling between P2Y1 receptors and the 
neurodegeneration mediated by glutamate NMDA receptors. An impaired function of 
glutamate receptors is implicated in the pathophysiology of chronic neurodegenerative 
diseases such as epilepsy and in the excitotoxic environment of ischaemia. The previous 
results obtained with the antagonism of P2Y1 receptors prompted the testing of the blockade 
of these receptors in animal models of temporal lobe epilepsy and stroke.  
Epileptic seizures were induced in rats by the intraperitoneal administration of kainate, 
which results in a clear neurodegeneration of hippocampal neurons. In this work it is shown 
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 xix 
that kainate-induced seizures cause a long-term modification of the density of most P2 
receptors, in both synaptic and glial membranes, predicting a central role of these receptors in 
the aberrant neurotransmission observed in the brain of epileptic animals. In this model, the 
blockade of P2Y1 receptors through the intracerebralventricular administration of a selective 
antagonist (MRS2500) clearly prevented the early kainate-induced activation of microglia and 
the loss of synaptic markers in the hippocampus. Moreover, it also attenuated the seizure-
induced neurodegeneration in hippocampal circuits. Likewise, in a mice model of focal 
ischaemia generated by the permanent occlusion of the middle cerebral artery, the general 
blockade of P2 receptors or the selective antagonism of P2Y1 receptors prevented both the 
ischaemia-induced lesion in the brain and the resultant mnemonic deficits.  
Overall, the work presented in this thesis provides evidence supporting the control of 
neuroinflammation by the blockade of A2A and of P2Y1 receptors and also the control of 
excitotoxicity by the antagonism of P2Y1 receptors in the hippocampus, contributing to the 
unraveling of the mechanisms through which these receptors may operate to aggravate 
deleterious conditions in the brain. 
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RESUMO 
Os receptores purinérgicos estão envolvidos na patofisiologia da maioria das 
doenças do sistema nervoso central (SNC), contribuindo para a disfunção sináptica e 
estando na génese e propagação da resposta inflamatória no cérebro. Contudo, as 
diferentes formas através das quais estes receptores contribuem para a evolução ou 
suspensão de condições deletérias estão ainda em estudo. 
Tendo em conta o largo espectro de neuroprotecção conferido pelo 
bloqueamento dos receptors de adenosina do tipo A2A no cérebro, é possível que esteja 
subjacente um mecanismo geral através do qual estes receptores operam. Esse 
mecanismo poderá resultar no controlo da neuroinflamação, visto ser um fenómeno 
comum à maioria das patologias do SNC. Contudo, embora a activação dos receptores 
A2A seja reconhecidamente um sinal de “stop” da inflamação no sistema periférico, é 
ainda discutível se o mesmo desencadeia ou diminui a reactividade da microglia, as 
células imunocompetentes do cérebro. Para responder a esta questão, avaliou-se a 
influência do bloqueio destes receptores nas alterações bioquímicas e morfológicas 
resultantes da neuroinflamação induzida pela administração sistémica de 
lipopolissacarídeo (LPS). Neste trabalho é demonstrado que a injecção 
intracerebroventricular de um antagonista selectivo dos receptores A2A (SCH58261) é 
capaz de prevenir o recrutamento de células da microglia induzido por LPS e a 
libertação da citocina pró-inflamatória interleucina-1β (IL-1β), no hipocampo. 
Adicionalmente, o SCH58261 preveniu a activação induzida por LPS das proteínas 
cinases activadas por mitógenos (MAPKs) c-Jun N-terminal (JNK) e p38 e ainda a 
activação da caspase-3, um mediador-chave da apoptose. Estes resultados estão de 
acordo com um controlo da génese da neuroinflamação pelo bloqueio dos receptores 
A2A. Assim, em seguida foi investigado se o mesmo seria capaz de controlar os efeitos 
directos das citocinas pró-inflamatórias IL-1β e factor de necrose tumoral-α (TNF-α), 
dois dos principais efectores dos danos causados pela neuroinflamação, nos neurónios. 
Para responder a esta questão, neurónios de hipocampo em cultura foram expostos por 
diferentes períodos de tempo a várias concentrações destas citocinas e a consequente 
activação de MAPKs foi avaliada por Western blot e imunocitoquímica. Tanto o TNF-
α como a IL-1β aumentaram a fosforilação (ou seja, a activação) da p38 nos neurónios 
e a IL-1β ainda aumentou a fosforilação da JNK. Adicionalmente, a exposição dos 
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neurónios de hipocampo à IL-1β imediatamente antes da exposição a glutamato  
aumentou a susceptibilidade dos mesmos à excitotoxicidade induzida pelo glutamato. 
O bloqueio dos receptores A2A com o SCH58261 preveniu a activação das MAPKs 
despoletada pela IL-1β assim como a exacerbação da excitotoxicidade induzida pela 
mesma. A análise da variação do cálcio intracelular através da técnica de imagiologia 
de cálcio em células individuais permitiu demonstrar que a IL-1β aumenta tanto a 
entrada de cálcio como a sua desregulação causadas pela exposição de culturas 
neuronais de hipocampo a glutamato. A pré-incubação de células com SCH58261 
também preveniu este efeito da IL-1β. Assim, conclui-se que o antagonismo dos 
receptores A2A pode controlar não só a génese de neuroinflamação mas também os 
efeitos directos das citocinas pró-inflamatórias em neurónios, permitindo uma maior 
comprensão dos mecanismos operados por estes receptores em condições patológicas. 
Para além dos receptores de adenosina, também os receptores P2 de ATP estão 
envolvidos na patofisiologia das células cerebrais em condições adversas, 
precisamente quando os níveis extracelulares de ATP são mais elevados. Em 
particular, o bloqueio farmacológico ou a delecção genética dos receptores P2Y1 
confere uma robusta neuroprotecção contra a toxicidade induzida pelo péptido β-
amilóide (Aβ1-42), um péptido relacionado com a doença de Alzheimer, em neurónios 
de hipocampo em cultura e contra a perda inicial de marcadores sinápticos e défices 
mnemónicos em roedores induzidos pelo mesmo. Adicionalmente, o antagonismo dos 
receptores P2Y1 é também efectivo na prevenção ou atenuação das alterações 
morfológicas, bioquímicas e fisiológicas resultantes de um episódio de 
isquémia/hipóxia em fatias de hipocampo. Dado o envolvimento da neuroinflamação 
nos efeitos deletérios das condições acima descritas, foi colocada a hipótese do 
bloqueio destes receptores não só controlarem a sinaptotoxicidade mas também a 
neuroinflamação. Inicialmente foi investigado se o bloqueio dos receptors P2Y1 era 
capaz de prevenir os efeitos directos de citocinas pró-inflamatórias em neurónios de 
hipocampo. Os resultados obtidos demonstram que o antagonismo selectivo destes 
receptores confere uma prevenção ou atenuação dos efeitos mediados pela IL-1β 
contudo, previne principalmente a neurotoxicidade induzida por glutamato. Assim, em 
seguida foi investigado se a mesma protecção ocorria com diferentes estímulos 
excitotóxicos aos neurónios do hippocampo. Observou-se que os neurónios em cultura 
estavam protegidos contra a toxicidade induzida por N-metil-D-aspartato (NMDA) ou 
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por ácido quinolínico na precença de um antagonista geral de receptores P2 ou de um 
antagonista selectivo dos receptores P2Y1. Os resultados sugerem uma ligação entre os 
receptores P2Y1 e a neurodegeneração induzida por glutamato mediada pelos 
receptores NMDA. A disfunção dos receptores de glutamato está implicada na 
patofisiologia de doenças neurodegenerativas crónicas como a epilepsia e no ambiente 
excitotóxico decorrente de episódios isquémicos. Desta forma, o antagonismo dos 
receptores P2Y1 foi testado num modelo animal de epilepsia do lóbulo temporal e num 
modelo de isquémia. No primeiro caso, foram induzidas convulsões epilépticas em 
ratos, através da administração intraperitoneal de cainato, que resultaram numa clara 
neurodegeneração dos neurónios hipocampais. Neste trabalho foi observado que as 
convulsões induzidas por cainato alteram a longo termo a densidade da maioria dos 
receptores P2 em  membranas sinápticas e gliais do hipocampo. Estas alterações 
sugerem um papel central dos receptores P2 na neurotransmissão e inervação 
aberrantes observadas no hipocampo de animais epilépticos. O bloqueio dos 
receptores P2Y1, através da administração intracerebroventricular de um antagonista 
selectivo destes receptores (MRS2500), preveniu a activação inicial da microglia e a 
perda de proteínas sinápticas no hipocampo induzidas pelas consulsões. Além disso,  
atenuou também a neurodegeneração nos circuitos hipocampais. Igualmente, num 
modelo animal de isquémia focal, gerada pela oclusão permanente da artéria cerebral 
média em ratinhos, o bloqueio geral dos receptores P2 ou o antagonismo selectivo dos 
receptores P2Y1 preveniram tanto a lesão induzida por isquémia como os défices 
mnemónicos resultantes da mesma.  
No geral, os resultados aqui apresentados suportam o controlo da 
neuroinflamação pelo bloqueio dos receptores A2A e dos receptores P2Y1 e ainda a 
prevenção da excitotoxicidade pelo antagonismo dos receptores P2Y1 no hipocampo, 
contribuindo para a elucidação dos mecanismos através dos quais estes receptores 
podem operar no agravamento de condições deletérias no cérebro. 
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1.1 ATP AS A NEUROTRANSMITTOR  
 
Adenosine 5'-triphosphate (ATP), first discovered by Karl Lohmann in 1929, is a purine 
nucleotide composed of an adenine attached to a ribose sugar molecule (adenosine) that links to a chain 
of three phosphate groups and is the major source of chemical energy used in the metabolism of all 
living cells (Lipmann, 1941; Yu et al., 2008). Given the importance of ATP within cells, the release 
and presence of this molecule in the extracellular environment was regarded as a contradiction and an 
unlikely event. Notwithstanding, the effects of extracellular purines on heart and blood vessels (Drury 
and Szent-Gyorgyi, 1929), on autonomic ganglia (Feldberg and Hebb, 1948) and their release during 
antidromic stimulation of sensory nerves (Holton, 1959) were already known when the idea of ATP as 
a neurotransmitter was first introduced in 1970 by professor Geoffrey Burnstock and collegues, when 
they found that ATP was the signalling molecule released during non-adrenergic, non-cholinergic 
neurotransmission in the smooth muscle (Burnstock et al., 1970). The establishment of ATP as a 
neurotransmitter in the peripheral nervous system (PNS) impelled the search of a similar role in the 
central nervous system (CNS). Indeed, in the brain, ATP was found to transiently facilitate cortical 
excitability, an effect not mimicked by other purines (Phillis et al., 1975). However, it was only 10 
years later that the depolaring effects of ATP in the CNS were well described in a subpopulation of 
dorsal horn neurons (Jahr and Jessell, 1983) and in the caudal trigeminal nucleus (Salt and Hill, 1983). 
The functional data was supported by evidences of a strong expression of ATP receptors in the brain 
and contributed to the establishment of ATP as a fast neurotransmitter in the CNS (Edwards and Gibb, 
1993). Nowadays it is well documented that ATP is released from all cell types in the brain, acting not 
only as a fast transmitter but also as a modulator of neuronal, glial and neuron-glia communication 
(Burnstock, 2007a). Moreover, ATP is co-released and sometimes co-stored with classical 
neurotransmitters both in the PNS and in the CNS (Burnstock, 2004; Burnstock, 2009a) contradicting 
what became known as the Dale‟s principle that neurons can only synthesize, store and release a single 
substance (Strata and Harvey, 1999). Nevertheless, in the brain terminals, ATP is primarily stored and 
released from a distinct pool of vesicles (Pankratov et al., 2006). 
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1.2 ATP STORAGE, RELEASE AND BREAKDOWN  
 
Under physiological conditions, ATP is found in a concentration range of 2-5 mM in the 
cytoplasm of cells and at even higher concentrations (up to 100 mM) inside synaptic vesicles 
(Burnstock, 2007a) whereas it is usually found in the nanomolar range in the extracellular space 
(Agteresch et al., 1999). Consequently, in normal resting conditions, there is a constant efflux of ATP, 
which is balanced by its extracellular enzymatic breakdown (Schwiebert, 1999; Lazarowski et al., 
2003). Accumulation of ATP into secretory vesicles was found to be mediated by a specific recently 
identified ADP/ATP translocase (Sawada et al., 2008) or by passive diffusion through non-specific ion 
channels (Lange and Brandt, 1993). In neurons, the vesicular release of ATP depends on membrane 
depolarization, sodium channels activation and the presence of calcium (Pankratov et al., 2006). This 
was first shown in synaptosome preparations from the whole brain (White, 1977; Potter and White, 
1982) and later in synaptosomes from specific brain regions like the cortex (White, 1977; Salgado et 
al., 1997), the mossy fibers (Terrian et al., 1989) and the spinal cord (Sawynok et al., 1993). ATP was 
also shown to be released in a frequency and Ca
2+
 dependent manner from hippocampal slices 
(Wieraszko et al., 1989; Cunha et al., 1996c)  and in a stimulation-dependent manner from the medial 
habenula (Sperlagh et al., 1998a) and the hypothalamus (Sperlagh et al., 1998b). In addition to the 
vesicular release, in non-neuronal cells, the efflux of ATP can be mediated by ATP-binding cassette 
(ABC) transporters (Schwiebert, 1999; Ballerini et al., 2002), connexin or pannexin hemichannels 
(Dahl and Locovei, 2006; De Vuyst et al., 2007; Iglesias et al., 2009), plasmalemmal voltage-
dependent anion channels (Sabirov and Okada, 2005) and P2X7 channels (Suadicani et al., 2006). 
Pharmacological relevant amounts of ATP can be released from these cells through mechanical 
stimulation, membrane swelling and upon activation of membrane receptors by several 
neurotransmitters, including purines themselves (Lazarowski et al., 2003).  
Once in the extracellular space, ATP is rapidly hydrolysed into its metabolites by a group of 
enzymes denominated ecto-nucleotidases as illustrated in Figure 1, which are ubiquitously expressed in 
the brain (Zimmermann, 2006). There are four main types of ecto-nucleotidases: the ecto-nucleoside 
triphosphate diphosphohydrolases (E-NTPDases) that convert ATP into ADP and ADP into AMP, 
comprising eight subtypes (E-NTPDases1 to 8) of which the E-NTPDases 1,2,3 and 8 are typically 
located on the plasmatic membrane (Robson et al., 2006); the ecto-nucleotide 
pyrophosphatases/phosphodiesterases (E-NPPs), that hydrolyse 5‟-phosphodiester bonds in nucleotides 
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and their derivatives originating 5´-nucleotide monophosphates, composed of 5 members of which E-
NPP 1-3 are the best characterized (Goding et al., 2003); the GPI-anchored alkaline phosphatases 
(APs) that convert ADP directly into adenosine and finally, the ecto-5‟-nucleotidase (Ecto-5´-NT/ 
CD73) which converts AMP into adenosine (Zimmermann et al., 1998; Zimmermann, 2000; 
Zimmermann, 2006). On the other hand, ATP can be synthesised by the enzymatic activity of the ecto-
nucleoside diphosphate kinanes (E-NDPKs) or by the ecto-adenylate kinases (E-AKs) that mediate the 
trans-phosphorylation of extracellular ADP to ATP, using UTP, GTP and other nucleotide 
triphosphates as phosphate donors (Yegutkin, 2008). However, the catalytic action of E-NDPKs can be 
reverse and convert two extracellular ADPs into ATP and AMP. Overall, the mencioned enzymes 
contribute to a tight regulation of the extracellular levels of purines (Joseph et al., 2004). 
 
 1.3 P2 RECEPTORS  
 
The role of ATP as a neurotransmitter implied the existence of ATP receptors present at cell 
surface membranes. Since these receptors were found in the early nineties, several have already been 
cloned and characterized (Volonte et al., 2006). The large number of ATP receptors and their 
ubiquitous distribution in the CNS accounts for the importance of this purine as a major mediator and 
neuromodulator of communication between cells (Khakh and Burnstock, 2009). The extracellular ATP 
and its breakdown products act on two types of receptors: the P2 receptors (P2R) selective to ATP and 
ADP, and the P1 receptors (P1R) selective to adenosine and antagonized by methylxanthines (Fields 
and Burnstock, 2006). 
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Figure 1. Extracellular catabolism of ATP by the ecto-nucleotidases. Once in the extracellular space, ATP is rapidly 
degraded into its metabolites by a group of enzymes denominated ecto-nucleotidases. Four major types of ecto-
nucleotidases are involved in the catabolism of ATP: the E-NTPDases (ecto-nucleoside triphosphate diphosphohydrolases) 
and the E-NPP (ecto-nucleotide pyrophosphatases/phosphodiesterases) families, which convert ATP into ADP and ADP 
into AMP; the ecto-5‟-nucleotidase (Ecto-5´-NT/CD73) family that hydrolyse AMP to adenosine and finally the AP 
(alkaline phosphatase) family which catalyse ATP to adenosine (Fields and Burnstock, 2006).  
 
A pharmacological basis for distinguishing between different P2R was first proposed in 1985 
(Burnstock and Kennedy, 1985) and when these receptors started being cloned it was confirmed the 
existence of two different subtypes, based on protein structure, physiology and signalling mechanisms: 
the P2X ion channel receptors (P2XR) and the P2Y G-protein coupled receptors (P2YR) (Lustig et al., 
1993; Webb et al., 1993; Brake et al., 1994; Valera et al., 1994).  One main criteria to distinguish 
between P2XR and P2YR is the affinity for ATP and analogue molecules such as the α,β-
methyleneATP (αβmeATP) and  the 2-methyltioATP (2-MeSATP). It was shown that P2XR are 
sensitive to low concentrations of αβmeATP and that 2-MeSATP is the most potent agonist at P2YR 
(Abbracchio and Burnstock, 1994). Later on, selective antagonists allowed a better distinction between 
the two classes of P2R.  
1. INTRODUCTION 
7 
 
 
1.3.1 P2X RECEPTORS 
 
 The P2XR are ATP-gated, non-selective cation channels (ionotropic receptors) with an equal 
permeability to sodium (Na
+
) and potassium (K
+
) ions and significant higher permeability to calcium 
ions (Ca
2+
). The P2XR channels respond to ATP binding in the micromolar range and mediate ATP 
fast transmission (Fountain and Burnstock, 2009). These receptors are part of the Ligand-gated ion 
channels superfamily which comprise two other major groups: the glutamate-gated channels (kainate 
receptors, AMPA receptors and NMDA receptors) and the Cys-loop receptors that include nicotinic 
acetylcholine receptors, serotonin receptors, GABAA receptors and glycine receptors (Green et al., 
1998; Khakh, 2001). So far, seven mammalian P2XR subunits have been cloned (P2X1-7) which 
contain from 384 (P2X4) to 595 (P2X7) aminoacid residues. Each subunit has two hydrophobic regions 
of sufficient length to cross the plasma membrane: the first transmembrane (TM)- spanning region is 
involved in the channel gating and the second lines the ion pore, placing both the -NH2 and -COOH 
termini in the cytoplasm (Li et al., 2008a). The -COOH terminal regions diverge considerably in 
sequence between subunits and bind the motifs for protein kinases responsible for the receptor kinetics, 
permeation and desensitization properties. The -NH2 terminal is glycosylated and seems to be essential 
for the trafficking of receptors to the plasmatic membrane. On the other hand, the extracellular domain 
presents considerable aminoacid homology, with ten conserved cysteine residues forming a series of 
disulphide bridges where the ATP, the antagonists and other modulators have their binding sites 
(Khakh, 2001; Surprenant and North, 2009). Their simple ion channel architecture, illustrated in Figure 
2, is shared only with the acid-sensing ion channels and the trimeric intracellular cation channels 
families (Li et al., 2010). 
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Figure 2. P2X receptor subunit topology. In the panel (a) is the representation of the receptor channel across the plasma 
membrane and in the panel (b) is a representation of the pore domain. The receptors are composed of a transmembrane 
(TM) domain containing three subunits, each with two TM helices and an extracellular domain with three ATP-binding sites 
(Li et al., 2010). 
 
Functional P2XR result from the assembly of three subunits in both homo- and heteromeric 
combinations. Both functional and structural data gathered from the heterologous expression of P2XR 
subunits point to the existence of trimeric or hexameric forms (Nicke et al., 1998).  
The P2X homomeric receptors can be divided into three different groups according to their 
kinetics and pharmacological properties: one composed of P2X1 and P2X3 receptors presenting a 
relative high sensitivity to αβmeATP (an ATP analogue resistant to enzymatic breakdown) and to ATP 
(both at an EC50 ~ 1 μM) and a rapid desensitization upon agonist application (Khakh et al., 2001); a 
second group comprising P2X2, P2X4 and P2X5 receptors, which present a lower sensitivity  to ATP  
(EC50 ~ 10 μM) and a very low sensitivity to αβmeATP (EC50 >100 μM) together with a slow 
desensitization (1-2 s). The P2X2 receptor can be further distinguished due to being more sensitive to 
ATP in an acidified medium, as well as in the presence of μM concentrations of zinc (Zn2+) and copper 
(Cu
2+
) ions. In addition, the P2X4 receptors can be distinguished in this group for being little 
antagonized by the P2R antagonists suramin and PPADS (Khakh et al., 2001). Finally, the third group 
is composed of P2X7 receptors which present a lower sensitivity to ATP (EC50 >300 μM) and little to 
no desensitization (even displaying an increased permeability to organic cations and small peptides 
with prolonged activation). Moreover, unlike the other P2XR, the P2X7 is more potently activated by 
the ATP analogue 2‟-3‟-O-(4-benzoyl)ATP (BzATP) than by ATP itself and its currents decrease in 
amplitude in the presence of μM concentrations of magnesium (Mg2+) (Surprenant, 1996). In addition, 
there are at least 11 different and functional heteromeric P2XR with distinct characteristics from their 
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homomeric counterparts (Khakh et al., 2001). In fact, P2X6 subunits are only found in heteromeric 
combinations (Barrera et al., 2005) whereas P2X7 subunits only form homomeric channels (Torres et 
al., 1999). One of the best known heteromers are the P2X2/3 combinations, studied at sensory neurons 
(Brederson and Jarvis, 2008). However, P2X4/6 (Wong et al., 2000), P2X2/6 (Egan and Khakh, 2004) 
and P2X1/5 (Surprenant et al., 2000) combinations are also possible. In Table 1 is summarized the 
potential for assembly of the P2XR subunits. 
 
Table 1. Potential assembly of P2XR subunits. The P2XR subunits carrying either one of two epitope tag units were 
expressed in pairs of HEK293 cells. The (+) signal means that the subunits immunoprecipitated with antibody to one 
epitope could be detected with an antibody to the second epitope (Torres et al., 1999; North, 2002). 
 P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7 
P2X1 + + + - + + - 
P2X2  + + - + + - 
P2X3   + - + - - 
P2X4    + + + - 
P2X5     + + - 
P2X6      - - 
P2X7       + 
 
 
One of the limitations to study the P2R is the lack of selective pharmacological tools to 
discriminate between them. PPADS and suramin are the most used general P2R antagonists as they 
block both P2XR and P2YR. However, suramin can block other ionotropic receptors together with 
P2XR (Nakazawa et al., 1995; Peoples and Li, 1998) and therefore, PPADS is still the preferred 
general P2R antagonist. Nevertheless, more selective antagonists such as the TNP-ATP (Evans et al., 
1995) and the NF023 have been developed for P2X1 and P2X3 containing receptors, respectively (Soto 
et al., 1999). In Table 2, are resumed the most used agonists and antagonists (and respective potencies) 
for the different P2XR. 
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Table 2. Principal agonists and antagonists (with the respective EC50 and IC50 values) of P2XR and their potency at 
functional homomeric and heteromeric receptors. The values of EC50 and IC50 are at μM unless otherwise stated (Khakh, 
2001; Burnstock, 2007b).      
  
P2X1 P2X1/5 P2X2 P2X2/3 P2X3 P2X4 P2X4/6 P2X5 P2X6 P2X7 
Agonists 
ATP                                                                                                                                             
αβmeATP                                                                                                                                       
BzATP                     
2-MeSATP 
1                                        
1-3                                       
3                        
x 
1
5
x             
x 
10                         
>100
30              
x 
1
1           
x                            
x 
1
1
x                
x 
10
>>100                         
x                      
x 
10  
30
x                 
x 
10                         
>100                            
>500             
x 
12                
>100                
x                   
x 
>100                  
>>300                 
3                
x 
Antagonists 
Suramin                                                                                                                                 
PPADS                                                                                                                                            
NF023                                                                                                                                        
TNP-ATP                                                                                                                                                                    
Brilliant blue 
G                                                                                                                           
NF449 
Calmidazolium      
IP5I 
1                    
1                                                                                                                                                                            
200 
nM
6 nM                     
>10
0,3                     
x                      
3 nM 
x
x                                            
x                                                                              
200
nM                
>10                            
0.7 nM                     
x          
x 
10                                    
1                                                                                                                                                                                                                                                                                   
100                                                                                  
1                     
>10                             
47                      
x                    
ineffective 
x                                    
5                                                                                                                                                                                       
1                                                                           
7 nM                     
>10                             
0.3                 
x               
x 
3                
1                
1                
1 nM                
>10                
1.8                
x                   
2.8 
>300                                    
>300                                                                                                      
>100                                                    
15                
>10                             
>300                    
x             
potentiates 
x                                    
x                                    
x                                    
x                      
x                          
x                      
x               
x 
4                
3                
x                   
x               
x                    
x             
x                  
x 
>100                   
>100                         
x                                          
x                
x                
x               
x                
x 
500                                    
50                          
x                  
>30                    
10 nM                    
x                     
x       
x 
 
1.3.2 P2Y RECEPTORS 
 
  The P2YR are G-protein coupled receptors (GPCR) endogenously triggered by ATP, ADP and 
pyrimidine nucleotides (UTP, UDP and UDP-glucose) uncomplexed to Mg
2+
 or Ca
2+
 and, to date, eight 
different mammalian subtypes have been cloned (P2Y1,2,4,6,11,12,13,14). The P2YR general structure 
comprises seven transmembrane regions with an extracellular –NH2 terminal and an intracellular –
COOH terminal as illustrated in Figure 3 (Abbracchio et al., 2006; Burnstock, 2007b).  
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Figure 3. P2Y receptor subunit topology. S–S, disulphide bond; e1–e4, extracellular domain loops 1–4; i1–i4, 
intracellular domain loops 1–4. Figure taken from (Fields and Burnstock, 2006).   
 
The missing numbers represent non-mammalian orthologs or receptors with some sequencing 
homology to P2YR but with no functional response to nucleotides. The hydrophobic transmembrane 
regions (especially TM3, TM6 and TM7), crucial for receptor activation by nucleotides, present a high 
homology between subtypes but the intracellular loop and -COOH terminus are quite diverse and 
influence the coupling to the G-protein types (Gq/11, GS and Gi) that link the P2YR (Abbracchio et al., 
2006). The P2YR can be pharmacologically divided into four subgroups: those that mainly respond to 
ADP and ATP, comprised of the human and rodent P2Y1, P2Y12 and P2Y13 receptors; those that 
respond mainly to UTP or UDP like the human P2Y4 and P2Y6 receptors; a group of mixed selectivity 
like the human and rodent P2Y2 and the rodent P2Y4 receptors and finally, those that respond only to 
sugar nucleotides (UDP-glucose and UDP-galactose) like the P2Y14 receptor (Abbracchio et al., 2006). 
On the other hand, P2YR can be divided into 2 main subgroups from the phylogenetic and structural 
point of view: one group comprising the P2Y1,2,4,6,11 receptors and another comprising the P2Y12,13,14 
receptors (Abbracchio et al., 2006). These two groups present a high level of sequence divergence and 
differences in specific amino acid motifs in the TM6 and TM7 regions and also differ in their primary 
coupling to G proteins: the P2Y1,2,4,6,11 receptors use mainly Gq/G11 to activate the phospholipase Cβ 
(PLCβ)/ inositol-(1,4,5)-triphosphate (IP3) pathway and trigger the release of intracellular Ca
2+
 whereas 
the  P2Y12,13,14 receptors couple almost exclusively to the Gi/o family of G proteins (Abbracchio et al., 
2006). However, the P2YR subtypes and even the same subtype can link different G proteins and 
consequently trigger different signalling pathways. For instance, the P2Y11R when activated by ATP 
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leads to a rise in cAMP, IP3 and in the cytosolic Ca
2+
 whereas activation by UTP can result in Ca
2+
 
mobilization without cAMP or IP3 increase (White et al., 2003). Moreover, the P2Y13R can 
simultaneously couple to G16 and Gi proteins and, at high ADP concentrations, to GS proteins in a way 
that suggests ligand-specific conformations of the receptor (Marteau et al., 2003).  
The activation of several P2YR can trigger mitogen-activated protein kinases (MAPK) and  
particularly of the extracellular signal-regulated protein kinase 1/2 (ERK1/2 or p42/p44 MAPK) 
(Abbracchio et al., 2006). Native P2YR have also been reported to activate the phospholipases A2 
(Ralevic and Burnstock, 1998; von Kugelgen and Wetter, 2000) and D (Martin and Michaelis, 1989; 
Benitez-Rajal et al., 2006), receptor tyrosine kinases and the serine-threonine kinase Akt (Lazarowski 
et al., 2003). In addition, P2YR were found to couple and modulate voltage-gated ion channels, 
including various classes of K
+
 channels and voltage-gated Ca
2+
 channels (Lee and O'Grady, 2003). In 
particular, they modulate the N-type Ca
2+
 channels and the M-type K
+
 currents, both critical in the 
neuronal response to stimulation (Abbracchio et al., 2006; Filippov et al., 2006; Hussl and Boehm, 
2006). These channel interactions occur in a short timescale (about 100 ms) by a direct or almost direct 
pathway in the cell membrane (Abbracchio et al., 2006). The N-type and P/Q-type of voltage-sensitive 
Ca
2+
 currents are typically involved in the pre-synaptic vesicular release of neurotransmitters upon 
neuronal excitation while the other type of channels are usually found at post-synaptic sites, in 
somatodendritic regions (Hussl and Boehm, 2006). Usually, the N-type and the P/Q-type are inhibited 
by P2YR via G-protein interaction (since it is abolished by the pertussis toxin) and independent of 
second messengers and protein kinases but dependent on voltage (as it is attenuated by large 
depolarizations), implying a direct interaction between the βγ subunits of the receptor-coupled G 
protein and the Ca
2+
 channel (Hussl and Boehm, 2006). In particular, both the Gi/o coupled P2Y12,13R 
and the Gq/11 linked P2Y1,2R were found to inhibit the N-type Ca
2+
 currents (Hussl and Boehm, 2006). 
On the other hand, the L-type currents are either enhanced or inhibited by P2YR independently of 
voltage and involving diffusible second messengers, protein kinases, the α subunits of the Gq/11 protein 
and a PLCβ-dependent depletion of phosphatidylinositol-4,5-bisphosphate (PIP2) from the cell 
membrane (Hussl and Boehm, 2006). The M-type K
+
 currents can be inhibited by Gq/11-linked P2YR 
and thus by the activation of most P2YR subtypes (P2Y1,2,4,6,11,14) (Hussl and Boehm, 2006). Several 
neurotransmitters depolarize neurons by reducing the M-type K
+
 currents (KM), which open in the 
subthreshold voltage range for action potentials and are completely activated when neurons are further 
depolarized (Robbins, 2001). Consequently, the inhibition of these channels by P2YR increases 
neuronal excitability (Brown and Passmore, 2009). In addition, P2YR are known to control outwardly 
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rectifying K
+
 currents in striatal (Ikeuchi and Nishizaki, 1995), cerebellar (Ikeuchi and Nishizaki, 1996) 
and  hippocampal neurons (Ikeuchi et al., 1996) and inward rectifier K
+
 channels (Kir) through 
pertussis toxin (PTX)-sensitive G proteins (Hussl and Boehm, 2006). The Gi/o-linked P2YR can open 
Kir channels whereas the Gq/11-linked P2YR close them, as was shown for P2Y1,2,4,6 subtypes 
(Filippov et al., 1998; Filippov et al., 1999; Brown et al., 2000; Filippov et al., 2003). Since the 
activation of Kir channels hyperpolarize neurons, their closure by P2YR may also contribute to 
increased neuronal excitability (Luscher and Slesinger, 2010).  
Another type of ion channels modulated by P2YR are transmitter-gated ion channels such as the 
NMDA receptor of glutamate. Adenine and uridine nucleotides enhance NMDA currents in the rat 
prefrontal cortex, in the pyramidal neurons of the V layer, through activation of P2Y2R (Wirkner et al., 
2002) and inhibit these currents through P2Y1R (Luthardt et al., 2003). However, ATP can also inhibit 
these currents by its direct binding to the glutamate binding site at the NR2B subunit of NMDA 
receptors (Ortinau et al., 2003). The capsaicin vanilloid receptor 1 (VR1 OR TRPV1) is also a 
transmitter-gated ionotropic receptor modulated by nucleotides and its currents are enhanced by the 
activation of P2Y1R at nociceptive sensory nerves, through a protein kinase C (PKC)- dependent 
pathway (Tominaga et al., 2001; Kennedy et al., 2003). Finally, P2YR can modulate P2XR channels 
by either inhibiting (Gerevich et al., 2005) or enhancing their currents (Vial et al., 2004). 
 G-protein coupled receptors are found in functional monomers but many can form dimmers 
(homodimers or heterodimers) and oligomers. In fact, interaction between GPCRs can occur through 
the formation of oligomers or downstream, through the action of second messengers (Abbracchio et al., 
2006; Burnstock, 2007b). The most extensively characterized dimerisation involving P2YR and non-
P2YR is the one between the P2Y1R and the A1 receptor (A1R) of adenosine (Yoshioka et al., 2001; 
Yoshioka and Nakata, 2004; Tonazzini et al., 2007; Tonazzini et al., 2008). This heterodimeric 
complex can be co-immunoprecipitated from whole cell membrane lysates and displays mixed 
characteristics: the A1R couples to Gi proteins resulting in decreased cAMP levels and the P2Y1R 
interacts with Gq/11 having no effect on cAMP levels; however, activation by ADPβS (a P2Y1R agonist) 
of the P2Y1/A1 complex inhibits the production of cAMP, an effect that is prevented by the A1R 
antagonist DPCPX but not by the P2Y1R antagonist MRS2179 and is PTX-sensitive, characteristic of 
the Gi/o-coupled A1R (Yoshioka et al., 2001). This A1/P2Y1 complex was described in native tissue, 
including the rat cortex, hippocampus and the cerebellum (Yoshioka et al., 2002) and even though its 
biological significance is still poorly understood, some studies suggest that this interaction may be 
relevant at elevated concentrations of agonists of both receptors, as occurs in pathological situations 
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(Tonazzini et al., 2007; Tonazzini et al., 2008). Cross-talk between GPCRs has also been extensively 
described. For example, co-expression of native P2Y1R and P2Y2R in HEK293 cells with the 
recombinant human chemokine receptor CXCR2 (a Gi-coupled receptor with no effect on intracellular 
Ca
2+
) results in significant increase of [Ca
2+
]i upon the binding of interleukin-8 to the CXCR2, after 
prestimulation of cells with ATP or UTP (Werry et al., 2002). On the other hand, P2YR can inhibit 
other non-P2Y GPCRs and an exemple of this is the P2YR-mediated inhibition of the signalling 
triggered by an agonist of the sphingosine-1-phosphate receptor to induce mitogenesis in renal 
mesangial cells (Xin et al., 2004).  
An important modulatory feature of P2YR is that as G-protein coupled receptors their signalling 
regulates nuclear gene transcription and protein synthesis. This has been mostly described for GS 
protein coupled P2YR that induce an increase of cAMP levels and consequently the activation of 
cAMP response element-binding transcription factor (CREB), which in turn activates gene 
transcription. An example of this is the P2Y11R-induced production of cytokines in dendritic cells 
(Wilkin et al., 2001; Marteau et al., 2004; Marteau et al., 2005). Nevertheless, some studies showed a 
similar modulatory role for Gq-coupled P2YR: in 1321N1 astrocytoma cells, the agonism of P2Y2R 
resulted in the activation of genes like the anti-apoptotic bcl-2 and bcl-xl preceded by the 
phosphorylation of CREB and cell proliferation (Chorna et al., 2004) and the activation of P2Y1R 
activated the transcription factor Elk-1 through the ERK1/2 MAPK pathway, resulting in apoptosis and 
inhibition of cell proliferation (Sellers et al., 2001). Moreover, in rat astrocytes, the activation of native 
PTX-sensitive P2YR increased the binding to DNA of transcription factors such as the activator 
protein-1 and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) which may 
explain the increase in the production of cyclooxygenase-2 (COX-2) and the resultant astrogliosis 
(Brambilla and Abbracchio, 2001). Finally, P2YR can also control the synthesis and the insertion in the 
membrane of subunits of other receptors, as was shown for P2Y1 and P2Y2 receptors in relation to 
nicotinic receptors of acetylcholine in the neuromuscular junction (Choi et al., 2001; Tung et al., 2004).      
The development of selective P2YR agonists and antagonists has made a slow progress due to 
cross-reactivity of the compounds with P2XR, interaction with other G-protein coupled receptors and 
interference with ecto-nucleotidases (Jacobson et al., 2009). In this field, more selective 
agonists/antagonists were developed to the P2Y1 and P2Y12 receptors due to their importance in platelet 
aggregation (Gachet, 2006). Thus, ADPβS is a potent and commonly used P2Y1 (EC50 of 96 nM), 
P2Y12 (EC50 of 82 nM) and P2Y13 (EC50 of 42 nM) agonist and the 2-methylthio derivative of ADP (2-
MeSADP) is an even more potent agonist at these receptors (EC50 of 6, 1 and 1 nM, respectively). As 
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for the antagonists, MRS2179 is a commonly used selective P2Y1R antagonist but MRS2279 and 
MRS2500 are more recent and equally potent antagonists with a higher affinity for the P2Y1R in 
various species (Jacobson et al., 2006; Jacobson and Boeynaems, 2010). In Table 3 are summarized the 
agonists/antagonists of P2YR and the coupled G-proteins. 
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Table 3. Pharmacological characteristics and transduction mechanisms operated by P2Y receptors. The information 
presented is reviewed in (Shaver et al., 2005; Abbracchio et al., 2006; Burnstock, 2007b; Jacobson and Boeynaems, 2010). 
 
P2Y1 P2Y2 P2Y4 P2Y6 P2Y11 P2Y12 P2Y13 P2Y14 
Agonists 
2-
MeSADP=A
DPβS>2-
MeSATP=A
DP>ATP; 
MRS2365 
UTP=ATP, 
Ins45973; 
MRS2698; 
MRS2768 
UTP=ATP; 
Ins45973 
UDP>UTP>
>ATP; 
Ins415; 
PBS-0474; 
5-iodo-UDP  
BzATP=AT
PγS>ATP; 
NF546 
ADP=2-
MeSADP>>
ATP 
ADP=2-
MeSADP>>
ATP 
UDP-
glucose=UD
P-galactose 
Antagonists 
MRS2500; 
MRS2179 
Suramin; 
RB2; PBS-
716; AR-
C1263;  
RB2; 
Suramin; 
PPADS 
MRS2578 
Suramin; 
RB2; NF340 
CT50547; 
Ins49266; 
AR-
C69931MX; 
AZD6140; 
AR-C69931; 
PBS-0739 
MRS2211 X 
Transduction 
mechanisms 
Gq/11; PLCβ 
activation 
Gq/11 and 
possibly Gi; 
PLCβ 
activation  
Gq/11 and 
possibly Gi; 
PLCβ 
activation  
Gq/11; PLCβ 
activation 
Gq/11 and GS; 
PLCβ 
activation 
Gi/0; 
inhibition of 
adenylate 
cyclase 
Gi/0; 
inhibition of 
adenylate 
cyclase 
Gi/0; 
inhibition of 
adenylate 
cyclase 
 
 
1.3.3 DISTRIBUTION OF P2 RECEPTORS IN THE CENTRAL NERVOUS SYSTEM 
 
P2 receptors are ubiquitously expressed in the central nervous system, both in neuronal and 
glial cells (Illes and Alexandre Ribeiro, 2004; Abbracchio et al., 2009). The P2X2 receptor is widely 
expressed in several brain regions such as the cerebral cortex, the hippocampus, the habenula, the 
substantia nigra pars compacta and several hypothalamic nucclei (Norenberg and Illes, 2000; Illes and 
Alexandre Ribeiro, 2004). In addition, it is also expressed in the mesencephalic trigeminal nucleus, the 
ventrolateral medulla, the dorsal vagal complex and in the nucleus of the solitary tract (Norenberg and 
Illes, 2000; Illes and Alexandre Ribeiro, 2004). The P2X3 receptor presents a high density in a 
subpopulation of small-diameter neurons of the dorsal root ganglia and in structures involved in pain 
transmission such as the nucleus tractus solitarius, the solitary tract and the spinal trigeminal nucleus 
(Norenberg and Illes, 2000; Illes and Alexandre Ribeiro, 2004). In addition, it was also found at pre-
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synaptic sites in the hippocampus (Rodrigues et al., 2005b) and in the midbrain (Diaz-Hernandez et al., 
2001). The P2X4R presents a strong expression in the rat cerebellum and spinal cord but it is also 
present in a relative high density in the cerebral cortex, the hippocampus, the thalamus and the 
brainstem (Norenberg and Illes, 2000; Illes and Alexandre Ribeiro, 2004). In particular, in the rat 
hippocampus, the P2X2R, P2X4R and the P2X6R were found in the CA1 region, at post-synaptic 
membranes opposed to terminals of Schaffer collaterals, precisely where the density of glutamate 
ionotropic receptors decrease (Rubio and Soto, 2001). Despite being mostly found in activated glial and 
immunocompetent cells (Collo et al., 1997; Butt, 2011), the P2X7 receptor was targeted at pre-synaptic 
excitatory terminals in the spinal cord and in the rat hippocampus (Deuchars et al., 2001; Sperlagh et 
al., 2002) and also in the nuclear membrane of a subgroup of inhibitory hippocampal neurons 
(Atkinson et al., 2002). In addition, it is present in synaptosomes from the midbrain and in cerebellar 
granule cells (Miras-Portugal et al., 2003). As for the P2YR, the P2Y1R and the P2Y11R subtypes are 
particularly abundant in the brain in relation to their presence in other tissues (Moore et al., 2001). The 
human P2Y1R mRNA is mostly found at neuronal structures in the basal ganglia (the striatum, nucleus 
accumbens, caudate putamen and globus pallidus) and also in the hippocampus, cerebellum and many 
regions of the cerebral cortex (Moore et al., 2000a). A similar distribution was found for the P2Y1R in 
the rat brain (Moran-Jimenez and Matute, 2000). Finally, both the P2Y12 and the P2Y13 receptors have 
a high density in neurons of the cerebellum, cerebral cortex, hippocampus, caudate nucleus, substantia 
nigra and in the ventrolateral medulla (Laitinen et al., 2001).  
 
1.3.4 SYNAPTIC MODULATION OPERATED BY P2 RECEPTORS  
 
In the central nervous system, ATP is the main adenine nucleotide released from nerve 
terminals upon stimulation (White, 1977) and, acting on P2 receptors, controls neurotransmission under 
both physiological  and pathological conditions (Illes and Alexandre Ribeiro, 2004; Burnstock et al., 
2011). Synaptic transmission can be modulated by either controlling the pre-synaptic release of 
neurotransmitters or by controlling the excitability of post-synaptic membranes (Hussl and Boehm, 
2006). The synaptic modulation operated by P2XR relies mostly on Ca
2+
 entry through their channel 
pores which leads to neurotransmitter release at the pre-synaptic sites and to membrane depolarization 
at the post-synaptic level (Surprenant and North, 2009). On the other hand, P2YR modulate ion 
channels that influence membrane excitability, as already described (Abbracchio et al., 2006; Hussl and 
Boehm, 2006). However, the modulatory effects of ATP are difficult to clarify due to its rapid 
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degradation by the ecto-enzymes and the consequent formation of another major neuromodulator, 
adenosine (Cunha and Ribeiro, 2000). The inhibitory effects of ATP can be confused with the 
activation of A1 receptors by adenosine, which maintain an inhibitory tonus on synaptic transmission 
(Ribeiro, 1995; Cunha et al., 1998). Likewise, the excitatory effects of ATP can be confused with the 
activation of adenosine A2A receptors (Cunha and Ribeiro, 2000). Nonetheless, the hippocampus is one 
of the brain areas with the highest density of P2R accompanied by functional evidence of P2R-
mediated effects (Inoue, 1998). In this brain region, it was found a facilitatory effect on glutamate 
release mediated by pre-synaptic P2XR (the P2X1, P2X2/3 and P2X3 subtypes) and an inhibitory effect 
mediated by pre-synaptic P2YR (involving the P2Y1, P2Y2 or the P2Y4 subtypes) (Mendoza-Fernandez 
et al., 2000; Rodrigues et al., 2005b). A pre-synaptic P2X2R-mediated facilitation of transmission in 
the interneurons of the stratum radiatum, in the hippocampus CA1 region, was also described (Khakh 
et al., 2003). In addition, ATP was found to cause inward currents at post-synaptic CA1 and CA3 
hippocampal subregions through P2X2-like receptors (Pankratov et al., 1998; Mori et al., 2001). Even 
though P2XR contribute to the excitatory post-synaptic current in CA1 pyramidal neurons (Pankratov 
et al., 1998; Rubio and Soto, 2001), they may also facilitate the inactivation of NMDA receptors 
through a Ca
2+
-dependent mechanism (Pankratov et al., 2002). However, P2XR desensitize during fast 
synaptic frequency allowing the NMDA-mediated current to increase and cause long-term potentiation 
(LTP) (Pankratov et al., 2002). In fact, ATP may directly induce LTP by phosphorylating the 
extracellular domain of NMDA receptors and increasing its permeability (Wieraszko et al., 1989; Chen 
et al., 1996; Fujii et al., 2002). Nonetheless, P2XR are not always excitatory; for example, in 
hippocampal slices, the activation of P2X7R was shown to induce the release of the major inhibitory 
neurotransmitter GABA (Sperlagh et al., 2002) and in the CA3 pyramidal cells, at mossy fiber 
synapses, a potent P2X7R agonist evoked a long-lasting inhibition of glutamate transmission 
(Armstrong et al., 2002). P2YR can either potentiate the currents of NMDA receptors through the 
activation of P2Y2R (Wirkner et al., 2002) or inhibit those currents through the activation of P2Y1R 
(Khakh et al., 2000; Liu et al., 2000a; Luthardt et al., 2003). Thus, the outcome of P2R-mediated 
synaptic effects are complex and depend on the P2R subtype, the type of cells in which they are 
expressed, their membrane localization and interaction with other membrane receptors and/or ion 
channels (Volonte et al., 2006; Volonte and D'Ambrosi, 2009). 
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1.3.5 P2 RECEPTORS IN GLIAL CELLS 
 
In addition to the modulation of synaptic transmission, ATP is a major glial transmitter and 
modulator (Butt, 2011; Koles et al., 2011). Glial cells make up over 70% of the total cell population of 
the central nervous system (Raghavendra and DeLeo, 2004) and are responsible for most of the 
extracellular ATP (Butt, 2011). In the brain there are three main types of glial cells: the astrocytes, the 
microglia and the oligodendrocytes, all endowed with different P2XR and P2YR (Ciccarelli et al., 
2001; Inoue, 2008; Butt, 2011).  
The astrocytes participate in multiple brain functions including neuronal development, synaptic 
activity and homeostatic control of the extracellular environment (Ciccarelli et al., 2001). Accordingly, 
astrocytes express neurotransmitter transporters and receptors and release classic neurotransmitters 
such as glutamate to activate neighbouring glial and neuronal cells (Parpura and Haydon, 2000; 
Newman, 2003; Panatier et al., 2006; Jourdain et al., 2007; Hamilton et al., 2010). In addition, these 
cells participate in inflammatory reactions by releasing and responding to inflammatory mediators such 
as chemokines and cytokines, changing their morphology and proliferating under noxious conditions 
(Abbracchio and Ceruti, 2006). Astrocytes are the major source of adenine-based (ATP and adenosine) 
and guanine-based purines (guanosine and guanosine triphosphates) in the extracellular milieu, during 
both physiological and pathological conditions (Meghji et al., 1989; Ciccarelli et al., 1999). In fact, 
these cells express most of the characterized P2R which modulate and participate in many of the 
mechanisms underlying astrocytic functions (James and Butt, 2002; Koles et al., 2011). Among the 
P2R known to be expressed in astrocytes are the subtypes P2X1,2,4,7 and the heteromer P2X1/5 (Lalo et 
al., 2011) and also the subtypes P2Y1,2,4,6,12,13R (Verkhratsky et al., 2009; Butt, 2011). Invariably, the 
CNS glial cells express P2YR linked to the IP3-mediated Ca
2+
 signalling cascade while the expression 
of P2XR is more segregated (Abbracchio et al., 2009). The subtypes P2Y1R, P2Y2R and P2Y4R were 
shown to be primarily involved in the short-term Ca
2+-
dependent signalling in astrocytes (Gallagher 
and Salter, 2003; Suadicani et al., 2004; Bennett et al., 2005), whereas multiple P2R subtypes mediate 
astrocytic long-term changes involving gene transcription (James and Butt, 2002; Neary et al., 2006). 
Activation of P2YR is linked to features of reactive gliosis such as increased production of COX-2, in 
both human and rat astrocytes (Brambilla et al., 1999; Brambilla et al., 2000; Brambilla et al., 2002). 
This is an important enzyme for prostaglandin synthesis (Hirst et al., 1999b) which play a part on 
inflammatory reactions (Rossi and Volterra, 2009). Activation of P2YR was also shown to increase 
astrocyte proliferation and the expression of the glial fibrillary acidic protein (GFAP), both in vitro 
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(Ciccarelli et al., 1994) and in vivo (Hindley et al., 1994; Franke et al., 1999). On the contrary, the 
activation of P2XR was found to stop the proliferation of astrocytes (Neary et al., 2005; Neary et al., 
2008). This opposite effect of P2YR and P2XR apparently involves the P2Y1 and P2X7 subtypes 
(Neary et al., 2005; Franke et al., 2009). The P2Y1R-mediated Ca
2+
 release from the intracellular stores 
was also shown to induce the vesicular release of glutamate from astrocytes, a process also dependent 
on the P2Y1R-induced release of TNF-α and prostaglandin from these cells (Domercq et al., 2006). A 
posterior work elegantly showed that this control of glutamate release from astrocytes by the P2Y1R 
has a prominent role in the synatic strength of proximal excitatory synapses in the hippocampus 
(Jourdain et al., 2007), which can have important consequences during both physiological and 
pathological events.  
Microglia are another main type of glial cells which account for 5 to 10% of the total CNS cell 
population (Parkhurst and Gan, 2010) and are considered the immune cells of the brain or the resident 
brain macrophages due to their functional and phylogenetic characteristics (Barron, 1995; Perry et al., 
2010). ATP has a determinant role in the activation, proliferation and attraction of microglia to the sites 
of injury, through the activation of different P2R (Inoue, 2008). In their quiescent or resting state, 
microglia cells have a small soma with thin, branched processes and undetectable levels of molecules 
belonging to the major class II histocompatibility complex (MHC) (Kreutzberg, 1996; O'Keefe et al., 
2002). However, when activated, these cells undergo hypertrophy, proliferate and acquire an amoeboid 
morphology with increased expression of MHC class II molecules, adhesion molecules and of stem cell 
antigens (Kreutzberg, 1996; O'Keefe et al., 2002; Ladeby et al., 2005). The activation of microglia by 
ATP was first shown in cultured cells from the rodent brain, where exogenously applied ATP triggered 
cationic currents and delayed outward K
+
 currents, which resulted in a P2R-dependent increase of the 
intracellular calcium and was essencial for microglial-mediated responses (Walz et al., 1993). Once 
activated, the microglial cells move and extend processes towards the sites of injury and this effect can 
be mimicked by local ATP injection and inhibited by the ATP-hydrolysing enzyme apyrase or blockers 
of P2YR (Davalos et al., 2005). Moreover, both ATP and ADP were found to induce chemotaxis in 
microglia (Honda et al., 2001) in a PTX-sensitive manner and through a mechanism independent of 
extracellular Ca
2+
 and blocked by antagonists of P2Y12R and P2Y13R (Hollopeter et al., 2001; 
Fumagalli et al., 2004). These results were corroborated by in vivo studies and provide evidence for the 
role of ATP as an „alarm signal‟ and chemoattractant molecule for microglia, inducing directional 
branch extension in these cells (Haynes et al., 2006; Ohsawa and Kohsaka, 2011).  
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An important characteristic of the late stages of microglia activation is phagocytosis (the uptake 
of particles into vacuoles) which is essential for tissue clearing of cellular debris and facilitation of 
tissue repair (Napoli and Neumann, 2009; Neumann et al., 2009). This process is initiated by the 
activation of pattern recognition receptors present on the plasma membrane of microglia (such as Fc 
receptors, the complement system, scavenger receptors and Toll-like receptors) by correspondent 
extracellular ligands (Griffiths et al., 2007), the designated “eat-me” signals present on the membrane 
of antigens (Lauber et al., 2003). Nucleotides can also act as an “eat me” signal, as microglia 
phagocytosis can be triggered through activation of P2Y6R by the extracellular UDP (Koizumi et al., 
2007). Thus, it was proposed that a gradient of purines and pyrimidines was formed in the extracellular 
space from the site of injury, modulating the activation of microglia through the sequential and 
preferential activation of specific P2R (Davalos et al., 2005; Inoue, 2008). In addition, nucleotides also 
contribute to microglia self-destruction, for example, the activation of P2X7R in these cells can trigger 
both the maturation and release of the pro-inflammatory cytokine IL-1 and the apoptotic pathway 
(Ferrari et al., 1997; Bernardino et al., 2008).  
A third main type of glial cells are the oligodendrocytes, which main function is to improve the 
conduction of electric impulses by isolating the axons of neurons, wrapping around them a sheath of 
myelin that reduce ion leakage and decrease the capacitance of the cell membrane (Fields, 2006). This 
myelin layer also increases impulse speed through saltatory propagation of action potentials  at 
the nodes of Ranvier.  The ATP and adenosine released from axons during electrical impulse activity 
regulate the migration, proliferation and differentiation of oligodendrocyte precursor cells: adenosine 
via A1 receptors (Othman et al., 2003) and ATP via P2Y1 and P2X7 receptors (Agresti et al., 2005). 
Low concentrations of ATP increase the intracellular Ca
2+ 
of oligodendrocytes mainly through the 
activation of P2Y1 receptors (IP3-mediated release of Ca
2+ 
from its intracellular stores) (Kirischuk et 
al., 1995; Moran-Jimenez and Matute, 2000; James and Butt, 2001) whereas high concentrations of 
ATP preferentially activate the P2X7 ion pore and trigger a sustained increase of the intracellular Ca
2+
 
in these cells (James and Butt, 2002). In normal conditions, the ATP-mediated Ca
2+
 signalling 
stimulates the production of myelin by the oligodendrocytes (Stevens et al., 2002) but activation of 
P2X7R during pathological and disease conditions (such as ischemia and multiple sclerosis) is known 
to cause demyelination and oligodendrocyte death (Matute et al., 2007; Domercq et al., 2010).  
Overall, purines and purine receptors can orchestrate the communication between all cell types 
in the central nervous system, for example, ATP and adenosine released from non-synaptic sites of 
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firing neurons were shown to indirectly modulate the activity of Schwann cells and oligodendrocytes 
(Fields, 2004; Fields, 2006) through the activation of astrocytes (Ishibashi et al., 2006). 
 
 
1.3.6 P2 RECEPTORS IN DISORDERS OF THE CENTRAL NERVOUS SYSTEM 
 
The key role of purines in the metabolism of cells and in the modulation of neuronal and glial 
function puts these molecules in the central stage of most neurodegenerative diseases. In the last years, 
the development of more potent and selective agonists and antagonists of P2R has allowed to unravel 
the involvement of specific receptor subtypes in the ethiopathology of several neurologic disorders 
(Franke and Illes, 2006; Burnstock, 2008). During pathological events, the extracellular levels of ATP 
raise significantly, not only because of increased neurotransmission but also due to membrane 
disruption of damaged or dying cells. Usually, brain damage results in an up-regulation of P2R in both 
neuronal and glial membranes, which contribute to the enhancement of purinergic transmission and 
sometimes to the aggravation of toxicity (Franke and Illes, 2006). In fact, direct application of ATP to 
brain primary neuronal and organotypic cultures is per se toxic (Amadio et al., 2002). Often, in these 
situations, antagonists of P2R have been neuroprotective (Franke and Illes, 2006; Di Virgilio et al., 
2009; Burnstock et al., 2011).  
In neurodegenerative conditions the focus has been on the P2X7 receptors since when activated 
for long periods by elevated concentrations of ATP, it forms large pores in the cell membranes, 
permeable to molecules up to 900 Da (Le Feuvre et al., 2002; Takenouchi et al., 2010). Moreover, the 
P2X7R elongated C-terminus is directly linked to the apoptotic pathway, activating specific protein 
kinases; caspases-1 and caspase-3 (Skaper et al., 2010). Notwithstanding, the P2Y1R and the P2Y12R 
subtypes have a prominent role in platelet aggregation (Gachet, 2008; Houston et al., 2008) which 
resulted in the clinical application of P2Y12R inhibitors to treat stroke and thrombosis (Hollopeter et 
al., 2001). In addition, the P2Y1R was found to be highly expressed in ischaemia-sensitive areas of the 
hippocampus (Moran-Jimenez and Matute, 2000) and has been recently associated with ischaemic cell 
death (Coppi et al., 2007; Olivecrona et al., 2007; Kuboyama et al., 2011). Both these and the P2X7R 
subtypes have been implicated in the ATP-mediated effects under in vivo ischaemic conditions, such as 
after permanent or transient occlusion of the middle cerebral artery in rats (Marrelli et al., 1999; 
Marrelli, 2002; Franke et al., 2004; Melani et al., 2006a; Sun et al., 2008; Yanagisawa et al., 2008; 
Kuboyama et al., 2011). In addition, the P2X2,4R subtypes were found to be up-regulated in neurons 
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and in microglia under ischaemic conditions (Cavaliere et al., 2003). Thus, unsurprisingly, antagonists 
of P2R were neuroprotective in both in vivo (Lammer et al., 2006; Kuboyama et al., 2011; Lammer et 
al., 2011) and in vitro models of ischaemia (Coppi et al., 2007; Pedata et al., 2007; Traini et al., 2011).  
As previously discussed, extracellular ATP plays a central role in the control of the reactivity, 
proliferation and survival of microglia (Davalos et al., 2005; Inoue, 2008) and astrocytes (James and 
Butt, 2002; Fields and Burnstock, 2006; Di Virgilio et al., 2009). Thus, P2R are regarded as promissing 
pharmachological targets in brain diseases with a strong inflammatory component (Di Virgilio et al., 
2009). For example, the P2X7 receptor is not only involved in the maturation and secretion of 
inflammatory mediators from glial cells (Narcisse et al., 2005; Bernardino et al., 2008) but also in the 
glia-mediated neurotoxicity by increasing reactive species in microglia (Parvathenani et al., 2003) or 
decreasing the ability of astrocytes to clear extracellular glutamate (Liu et al., 2010). 
Under excitotoxic conditions in the brain as occurs in epilepsy models, the attention has once 
again been focused on P2XR, mainly because of their facilitation of excitatory transmission in the 
hippocampus. The expression of P2X2R and P2X4R was found to be downregulated in the 
hippocampus of seizure prone gerbils (Kang et al., 2003) and during the chronic phase of pilocarpine-
induced status epilepticus in rats (Dona et al., 2009). Additionally, the expression of P2X7R was 
greatly up-regulated, in glial cells and in glutamatergic terminals, during the acute and chronic phase of 
seizures induced by both pilocarpine and kainate in the rat hippocampus (Vianna et al., 2002; Dona et 
al., 2009; Kim et al., 2009). Recently, these receptors were shown to differentially affect astroglia 
during the status epilepticus in the rat brain (Kim et al., 2010). Finally, the expression of different P2R 
was increased in seizure-induced activated microglia (Rappold et al., 2006; Avignone et al., 2008) 
where they were described to mediate microglia membrane currents during the status epilepticus 
(Avignone et al., 2008). 
The P2X7R and the P2Y1R have been implied in the pathophysiology of Alzheimer‟s disease 
(AD) (Moore et al., 2000b; Parvathenani et al., 2003; McLarnon et al., 2006; Delarasse et al., 2011). 
P2X7R were up-regulated around β-amyloid structures in a transgenic model of AD (Parvathenani et 
al., 2003) and were shown to be involved in the activation of microglia in models of this disease 
(McLarnon et al., 2006; Sanz et al., 2009; Lee et al., 2011). The P2Y1R were up-regulated in the 
hippocampus of AD patients and in characteristic AD structures such as neurofibrillary tangles, neuritic 
plaques and neuropil threads in the human entorhinal cortex and hippocampus (Moore et al., 2000b). In 
line with these findings, ATP can promote the formation of β-amyloid plaques which can be blocked 
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by suramin, a general P2R antagonist (Exley and Korchazhkina, 2001), that can also block the 
astrocytic Ca
2+
 waves induced by the β-amyloid peptide (Haughey and Mattson, 2003). 
In the rat brain, P2 receptors co-localize with dopamine receptors (Heine et al., 2007) and 
modulate the release of dopamine into the nucleus accumbens (Krugel et al., 1999; Kittner et al., 2000; 
Krugel et al., 2001b; Krugel et al., 2003) and into the ventral tegmental area (Krugel et al., 2001a). In 
addition, exogenously applied ATP stimulated the release of dopamine from the substantia nigra pars 
compacta to the striatum via P2YR (Zhang et al., 1995). Thus, P2R can also be regarded as possible 
therapeutic targets in diseases where there is a loss of dopaminergic transmission, such as in 
Parkinson‟s disease (Amadio et al., 2007). 
The P2X7R are expressed in the Müller (glial) cells of the human and rat retinas (Jabs et al., 
2000; Pannicke et al., 2000; Bringmann et al., 2001) where they are up-regulated or their pathological 
activation enhanced during some retinopathies (Bringmann et al., 2001; Sugiyama et al., 2004). P2YR 
are also expressed in Müller cells (Ward and Fletcher, 2009; Wurm et al., 2009) and were shown to 
mediate their proliferation in vitro (Moll et al., 2002). Thus, pharmacological manipulation of P2R can 
be beneficial in different types of retinopathies (Fletcher, 2010; Ward et al., 2010). Moreover, agonists 
and antagonists of P2R are also useful to either induce cytotoxicity in tumor cells or to arrest their 
cellular division (Rapaport, 1983; Agteresch et al., 1999).  
Not only in the case of diseases but also during acute and chronic alcohol and amphetamine 
consumpsion, the density and/or functioning of P2R is altered (Weight et al., 1999; Koles et al., 2008). 
Ethanol is known to modulate P2X1, P2X2, P2X3 and P2X4 subunits, desviating synaptic transmission 
from mostly excitatory to inhibitory or vice-versa, with an impact in the psico-motor and mnemonic 
effects of this drug (Asatryan et al., 2008; Asatryan et al., 2010; Popova et al., 2010). On the other 
hand, Systemic administration of amphetamine to rodents enhaced the immunoreactivity of P2Y1R in 
astrocytes and neurons of the striatum and nucleus accumbens and treatment with PPADS prevented 
astrogliosis, inflammatory markers and drug sensitization (Franke et al., 2003). 
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1.4 ADENOSINE AS A NEUROMODULATOR  
 
The role of adenosine as a neuromodulator was first described in a study by Drury and Szent-
Györgyi (1929) where the authors showed that injected adenosine caused a variety of biological 
effects: decrease of arterial blood pressure, dilatation of coronary arteries, relaxation of the small 
intestine muscles and promotion of sleep (Drury and Szent-Gyorgyi, 1929). Later on, Satin and Rall 
(1970) showed an accumulation of cAMP in cortical slices upon electrical stimulation which could be 
blocked by methylxanthines (Sattin and Rall, 1970). This finding together with the evidence that 
electrical stimulation induced adenosine release from neuronal preparations (Pull and McIlwain, 1972) 
and that exogenously applied adenosine depressed synaptic transmission in the neuromuscular junction 
(Ginsborg and Hirst, 1972) and in cortical neurons (Phillis et al., 1974) supported a role for adenosine 
as a neuromodulator. Nowadays, it is well established that extracellular adenosine, either released per 
se or resulting from the catabolism of ATP, is a major neuromodulator of cell function and 
communication in the nervous system (Cunha, 2001). 
 
1.5 ADENOSINE METABOLISM AND REGULATION OF EXTRACELLULAR LEVELS  
 
 Adenosine can be metabolized in both the intracellular and the extracellular space. Within cells, 
adenosine derives from adenosine monophosphate (AMP) by the enzymatic activity of the endo-5‟-
nucleotidase (5‟-ribonucleotide phosphohydrolase, E.C. 3.1.3.5) (Phillips and Newsholme, 1979) and 
from S-adenosyl-L-homocysteine by the activity of the S-adenosyl-L-homocysteine hydrolase (E.C. 
3.3.1.1) (Nagata et al., 1984). On the other hand, it is phosphorylated to AMP by adenosine kinase 
(AK; ATP: adenosine 5‟-phosphotransferase, E.C. 2.7.1.2.0) or deaminated to inosine by the adenosine 
deaminase (ADA; E.C. 3.5.4.4) (Fox and Kelley, 1978). At low levels of adenosine, AK has a 
prominent role converting the nucleoside to AMP and only when large amounts of adenosine have to 
be cleared it is catabolised to inosine by ADA (Fredholm et al., 2005). The normal intracellular 
concentration of adenosine is around 10-50 nM however, in situations of metabolic imbalance this 
concentration increases considerably to 1-10 μM (Cunha, 2001). This is mainly due to the activity of 
adenylate kinase (E.C. 2.7.4.3) which converts small variations in ATP (normally in the millimolar 
range inside cells) into significant variations of AMP levels and consequently of adenosine levels, both 
of which are in the nanomolar range under physiological conditions (Veech et al., 1979; Fell and 
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Sauro, 1985). This interconversion of ATP-AMP-adenosine constitutes a highly sensible intracellular 
monitor of metabolic imbalance. 
  In the extracellular space, adenosine levels are usually around 25-250 nM (Ballarin et al., 1991; 
Dunwiddie and Diao, 1994) and the maintenance of these concentrations depends on a balance between 
the release/removal of the nucleoside by membrane transporters and its formation from ATP due to the 
activity of ecto-nucleotidases (Dunwiddie et al., 1997; Dunwiddie and Masino, 2001). In mammals 
there are two types of nucleoside transporters: the family of equilibrative nucleoside transporters 
(ENT1-4) and the family of the concentrative nucleoside transporters (CNT1-3) (Parkinson et al., 
2011). Equilibrative transporters are the predominant type in the CNS and carry both purine and 
pyrimidine nucleosides, being bidirectional and driven by chemical gradients. On the contrary, the 
concentrative transporters are unidirectional and mediate the influx of nucleosides driven by the force 
of Na
+
 transmembrane electrochemical gradients (Parkinson et al., 2011). Nucleoside transporters 
support a double function of either releasing adenosine or scavenging it from the extracellular space, 
promoting de novo synthesis of nucleotides in the cytosol (Baldwin et al., 2004). They can be further 
divided into sensitive or insensitive, ENT1 and ENT2 being the predominant types in the brain, 
respectively, to the selective inhibitor nitrobenzylthioinosine (NBMPR). Both ENT1 and ENT2 are 
highly expressed in the rat brain (especially in the hippocampus, cerebellum, cortex and striatum) and 
in a variety of cell types such as neurons, astrocytes, vascular smooth cells and epithelial cells of the 
choroids plexus (Parkinson et al., 2011). The CNTs comprise 5 subclasses, two of which were detected 
in the rat brain in strutures such as the posterior hypothalamus, the superior colliculus, the brainstem, 
the striatum, the hippocampus, the cerebellum and the cortex. When the Na
+ 
electrochemical gradient is 
reversed, these transporters can also contribute to the increase of adenosine extracellular levels 
(Parkinson et al., 2011).    
As previously mentioned, adenosine can derive from ATP through the enzymatic activity of 
ecto-nucleotidases which are ubiquitously distributed in the nervous system. In this process, the ecto-
5‟-nucleotidase responsible for the conversion of AMP into adenosine and primarily found in glial cells 
(Latini and Pedata, 2001; Zimmermann, 2006) is a rate-limiting step because of the inhibition of its 
activity exerted by both ATP and ADP (Dunwiddie et al., 1997). 
The origin of the extracellular adenosine depends on the neuronal preparations used as well as 
the method used to stimulate them. In hippocampal slices, for example, the application of a high-
frequency stimulation burst leads to increased extracellular levels of adenosine mainly derived from the 
catabolism of ATP; however, after low frequency stimulation, adenosine is mainly released per se 
1. INTRODUCTION 
27 
 
(Cunha et al., 1996c). Another source of extracellular adenosine is the released cAMP via a non-
specific energy-dependent transporter (Henderson and Strauss, 1991). As illustrated in Figure 1, 
extracellular cAMP can be converted to adenosine by the ecto-5‟-nucleotidase and the alkaline 
phosphatases. Thus, neurotransmitters that link Gs-protein coupled receptors that induce adenyl cyclase 
(E.C.4.6.1.1) increasing the production of cAMP can also contribute to the raise in the extracellular 
levels of adenosine (Brundege et al., 1997).  
 
1.6 ADENOSINE RECEPTORS  
 
Adenosine receptors were suspected to exist from the early found effects of adenosine in the 
cardiac muscle (Degubareff and Sleator, 1965) and from its induction of cAMP in cortex slices (Sattin 
and Rall, 1970). Nowadays it is well established that adenosine signals through four types of cell 
surface receptors: A1 (A1R), A2A (A2AR), A2B (A2BR) and A3 (A3R) with 70 nM, 150 nM, 5.1 μM and 
6.5 μM respective affinities for the ligand (Dunwiddie and Masino, 2001). All of them are 
metabotropic; G-protein coupled receptors with seven transmembrane domains (Furlong et al., 1992). 
The classically first effector molecule of adenosine receptors is the enzyme adenyl cyclase which is 
either stimulated or inhibited (increasing or decreasing cAMP levels) according to the receptor 
triggered (van Calker et al., 1979; Londos et al., 1980). The A1R and A3R inhibit adenyl cyclase 
through the coupling to Gi1,2,3/o and to Gi2,3/Gq/11 proteins, respectively, whereas A2AR and A2BR 
stimulate adenyl cyclase through the respective coupling to GS/Golf and GS proteins (Abbracchio et al., 
1995; Kull et al., 2000; Fredholm et al., 2001). The adenosine-induced signalling is intricate, involving 
different pathways that include the cAMP-dependent protein kinase A (PKA), the PLC- IP3 and 
diacylglycerol pathways and also the MAPK pathway (Schulte and Fredholm, 2003). Both Gi- and Gq- 
coupled receptors are capable of activating different MAPKs, however, their signalling to ERK1/2 is 
better known than their signalling to the stress activated protein kinases (SAPKs) p38 and JNK. Still, 
all heterotrimeric G protein families can activate these SAPKs: Gs- coupled receptors activate p38 in a 
cAMP- and PKA- dependent manner and Gi- and Gq- coupled receptors can activate SAPK via hg 
subunits, PLC, PKC, Pyk2, focal adhesion kinases and diverse guanine nucleotide exchange factors 
 (GEFs) for the Rho-family of GTPases, among other molecules (Schulte and Fredholm, 2003). 
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1.6.1 DISTRIBUTION OF ADENOSINE RECEPTORS IN THE CENTRAL NERVOUS 
SYSTEM 
 
 In the adult brain, the A1R is one of the two predominant adenosine receptors that is present at a 
higher density in the cortex, cerebellum, hippocampus, spinal cord, eye and adrenal gland (Schindler et 
al., 2001; Rebola et al., 2003). Moreover, A1R is found in all cell types: neurons, astrocytes, microglia 
and oligodendrocytes (Gebicke-Haerter et al., 1996; Biber et al., 1997; Othman et al., 2003). In 
hippocampal neurons, A1R is mainly present in nerve terminals and enriched in the post-synaptic 
density (Tetzlaff et al., 1987; Rebola et al., 2003) where it modulates glutamate receptors and 
potassium channels (Dunwiddie and Masino, 2001). In addition, the activation of pre-synaptic A1R 
inhibit the release of neurotransmitters such as glutamate, acetylcholine and serotonin (Dunwiddie and 
Masino, 2001).     
The second most expressed adenosine receptors in the CNS are A2AR, mainly found in 
striatopallidal GABAergic neurons (in the caudate putamen and nucleus accumbens) and in the 
olfactory bulb. Much lower levels of these receptors are also found in the lateral septum, cerebellum, 
cortex and in the hippocampus (Cunha et al., 1995; Svenningsson et al., 1997; Fredholm et al., 2005). 
The A2AR is present both in neurons and in glial cells, such as astrocytes (Nishizaki, 2004) and 
microglia (Saura et al., 2005) and in the hippocampus, it is enriched at the pre-synaptic fraction of 
nerve terminals whereas in striatal synapses it predominates at the post-synaptic membranes (Rebola et 
al., 2005a).  
 In the CNS, A2BR are mainly found in the eye and in the median eminence, being also present 
in neurons and glial cells of the pituitary gland, albeit in lower levels (Daly, 1977; Fredholm et al., 
2005). The A3R is in a low density in all main types of brain cells, in regions such as the cortex, the 
striatum, the olfactory bulb, the nucleus accumbens, the hippocampus, the amygdala, the 
hypothalamus, the thalamus and the cerebellum (Fredholm et al., 2005). 
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1.6.2 PHARMACOLOGY OF ADENOSINE RECEPTORS 
  
Few compounds used to classify adenosine receptors meet the ideal criterion of differing in 
potency by at least two orders of magnitude for different receptors (Fredholm et al., 2001) and usually 
agonists and antagonists are developed from modifications of adenosine itself (Jacobson and Gao, 
2006). For example, xanthines such as caffeine and theophylline, typical non-selective antagonists of 
adenosine receptors with micromolar affinities for A1R, A2AR and A2BR (Fredholm et al., 2001), are 
often used as templates (Moro et al., 2006). The CPA and the CCPA are commonly used agonists of 
the A1R; however, in vivo, the first presents a very small half-life (of 6 minutes) in the rat blood 
(Mathot et al., 1993) and the second displays a much higher affinity for these receptors (Fredholm et 
al., 2001; Fredholm et al., 2005). As for A1R antagonists, DPCPX is a commonly used selective 
compound (Fredholm et al., 2005). In the case of A2AR, NECA, a non-selective agonist, and specially 
CGS21680, a more selective drug based in NECA, are usually used, even though the later is less potent 
and selective in humans than in rats (Hutchison et al., 1989; Kull et al., 1999). Nonetheless, CGS21680 
has the advantage of binding to sites where the A2AR density is low (Johansson et al., 1993; Cunha et 
al., 1996b). One of the most commonly used A2AR selective antagonists is SCH58261, which displays 
a high affinity for the receptor in both humans and rats (Fredholm et al., 2005; Yang et al., 2007). 
Nowadays, KW6002 is a commonly used antagonist of A2AR for in vivo studies, mainly due to its 
characteristics of bioavailability, half-life and blood-brain barrier penetration (Yang et al., 2007). In the 
case of A2BR, LUF5835 is the most potent agonist known (Beukers et al., 2004) while MRS1754 and 
MRE 2029-F20 are some of the usually used antagonists (Ji et al., 2001; Gessi et al., 2005; Jacobson 
and Gao, 2006). Finally, for the A3R, Cl-IB-MECA is a well-known agonist (Fredholm et al., 2001) 
despite the fact that this compound can also bind and activate A1R which vastly outnumber A3R in the 
brain (Klotz et al., 1998; Lopes et al., 2003). The most commonly used antagonists of A3R are 
dihydropyridines, pyridines or flavonoids (Baraldi et al., 2000). In the Table 4 bellow are listed some 
examples of agonists and antagonists of the four adenosine receptors. 
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Table 4: Pharmacology of the adenosine receptors, taken from Jacobson and Gao (2006). 
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1.6.3 ADENOSINE RECEPTORS: MODULATION OF SYNAPTIC TRANSMISSION, 
NEUROPROTECTION AND CONTROL OF NEUROINFLAMMATION 
  
 The neuromodulation exerted by adenosine in the brain seems to depend on the relative 
importance of A1R and A2AR in a given time, local and environment since these are the two receptor 
types most expressed in the CNS (Fredholm et al., 2005) and have the highest affinity for the ligand 
(Fredholm et al., 2001). However, they mediate opposite effects of adenosine in most situations 
(Cunha, 2005; Fredholm et al., 2005). The A1R-mediated effects include inhibition of neurotransmitter 
release at pre-synaptic sites (Dunwiddie and Masino, 2001) and  decrease of neuronal excitability at 
post-synaptic moieties through activation of potassium channels, decrease of NMDA receptor‟s 
currents and the inhibition of voltage-sensitive Ca
2+
 channels (de Mendonca et al., 2000; Fredholm et 
al., 2005). On the contrary, the activation of A2AR increases neuronal excitability through the 
facilitation of neurotransmitters release from nerve terminals (Cunha, 2001). However, at the post-
synaptic level, the control of NMDA currents by A2AR is still not well comprehended and different 
authors revealed some contradictory data (Wirkner et al., 2000; Gerevich et al., 2002; Wirkner et al., 
2004; Tebano et al., 2005; Rebola et al., 2008; Ferguson and Stone, 2010). Paradoxically, in the 
hippocampus, A2AR-mediated increase of excitatory transmission was found to depend on the 
activation of A1R (Lopes et al., 2002). In fact, A1R and A2AR are frequently present at the same 
synapses (Rebola et al., 2005c; Ciruela et al., 2006a). This, however, contributes to the fine-tuning of 
neurotransmission by adenosine since A2AR can also control the activity of A1R through intracellular 
transducing systems (Dixon et al., 1997; Lopes et al., 1999) or receptor dimerisation (Ciruela et al., 
2006a). In addition, adenosine modulates other neuromodulators (Sebastiao and Ribeiro, 2000) such as 
the calcitonin gene-related peptide (Correia-de-Sa and Ribeiro, 1994) and the brain derived 
neurotrophic factor (BDNF) (Diogenes et al., 2004; Assaife-Lopes et al., 2010; Sebastiao et al., 2011). 
Sometimes this control by adenosine is due to receptor heteromerization as occurs between A1R and 
dopamine D1 receptors (Gines et al., 2000), A1R and ATP P2Y1 receptors (Yoshioka et al., 2001) and 
between A1R and metabotropic glutamate type 1 receptors (mGluR1) (Ciruela et al., 2001). Moreover, 
heteromerizations between A2AR and the metabotropic glutamate type 5 receptors (mGluR5) (Ferre et 
al., 2002) and between A2AR and the endocannabinoid CB1 receptors (Ciruela et al., 2006b) have also 
been described. Finally, A2AR can also transactivate BDNF TrkB receptors (Lee and Chao, 2001). 
  In pathological situations in the brain, adenosine is known to be mainly neuroprotective 
(Andine et al., 1990; Park and Rudolphi, 1994; Tatlisumak et al., 1998; Pignataro et al., 2007). This is 
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attributed to the activation of A1R, as demonstrated in models of ischaemia (Corradetti et al., 1984), of 
methamphetamine- or 3-nitropropionic acid-induced toxicity in the striatum (Delle Donne and 
Sonsalla, 1994) and of epilepsy (O'Shaughnessy et al., 1988; Li et al., 2008b). In fact, the inhibition of 
adenosine kinase, the main enzyme responsible for the clearing of adenosine, is sufficient to prevent 
seizures in models of epilepsy (Kowaluk and Jarvis, 2000). Moreover, administration of A1R 
antagonists was shown to aggravate brain damage (de Mendonca et al., 2000). In certain situations, 
however, adenosine can exacerbate neurotoxicity and usually due to A2AR-mediated effects (Stone et 
al., 2009). The density of these receptors is frequently increased in noxious conditions (Rebola et al., 
2005b; Cunha et al., 2006; Duarte et al., 2006) and their blockade or genetic deletion is frequently 
neuroprotective (Cunha, 2005; Gomes et al., 2011).  
The neuroprotection afforded with the blockade of A2AR in so many different noxious 
conditions and especially in brain regions where the receptor is scarcely expressed is somewhat 
puzzling. However, the A2AR-mediated effects seem to “gain protagonism” when adenosine levels 
increase significantly, as occurs at high frequency of neuronal firing (Cunha et al., 1996a). Thus, A2AR 
are likely to be activated under stressful situations, when both ATP and adenosine reach high 
concentrations in the extracellular space (Cunha et al., 1996a; Cunha et al., 1996c; Pinto-Duarte et al., 
2005). Given that activation of A2AR facilitates glutamate release, one possible explanation for the 
afforded neuroprotection with the blockade of these receptors is that it prevents glutamate overflow 
(Lopes et al., 2002; Marchi et al., 2002; Rodrigues et al., 2005a). Under pathological conditions, most 
of the extracellular glutamate comes from the astrocytes (Bezzi et al., 2004; Lee and Haydon, 2007) 
due to a loss of efficiency or reversed transport of glutamate transporters (Rossi et al., 2000) that result 
in increased efflux of this neurotrasmitter (Rossi and Volterra, 2009). Adenosine receptors are also 
present in glial cells (Boison et al., 2010) where high extracellular concentrations of adenosine are 
likely formed (Pascual et al., 2005; Studer et al., 2006). Moreover, the density of the ATP degrading 
enzymes ecto-5‟-nucleotidase and ecto-NTPDase are also increased in the activated microglia, 
contributing to the formation of adenosine (Kreutzberg and Barron, 1978). Thus, the control of 
neuronal damage by adenosine receptors may involve the control of glial transmission and of 
neuroinflammation, which is a common feature of all neurological disorders and of any noxious 
condition in the CNS (Skaper, 2007). Neuroinflammation is essential for host defence, clearance of 
pathogens/cell debris and tissue recovery. However, the cytotoxicity of some inflammatory mediators 
such as pro-inflammatory cytokines and reactive species can non-specifically cause damage to local 
tissues (Ohta and Sitkovsky, 2009). Thus, the balance between the beneficial versus detrimental effects 
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of inflammation depends on a tight control of its “on” and “stop” signals. In the peripheral nervous 
system, the role of adenosine as a “stop” signal of inflammation is well established (Ohta and 
Sitkovsky, 2009). Early studies showed that cAMP inhibited the effector functions of T cells through a 
PKA-dependent pathway, which can be triggered by A2AR (Sitkovsky et al., 1988; Huang et al., 1997). 
Accordingly, elevated levels of adenosine are observed in complications of an inflammatory nature, 
such as asthma (Brown et al., 2008) and sepsis (Sitkovsky, 2003). Moreover, the ablation of A2AR 
results in prolonged and severe inflammation, with sustained production of pro-inflammatory cytokines 
(Ohta and Sitkovsky, 2001; Lukashev et al., 2004) and caffeine, a non-selective antagonist of receptors 
(Fredholm et al., 1999), exacerbates inflammation (Ohta et al., 2007). The same happens during 
induced ischemia (Day et al., 2004) and sepsis (Nemeth et al., 2006) in A2AR knock-out mice. On the 
other hand, activation of A2AR suppresses leukocyte infiltration in response to pro-inflammatory 
cytokines (Zhang et al., 2006). However, in the brain, it seems to be the blockade of A2AR that reduces 
neuroinflammation as some studies have gathered evidence for the control of the activation of 
microglia and of the effects of neuroinflammatory mediators by the blockade of A2AR (Yu et al., 2004; 
Stone and Behan, 2007; Yu et al., 2008; Rebola et al., 2011). Moreover, activation of these receptors 
inhibited glutamate uptake by astrocytes both in vitro (Li et al., 2001; Nishizaki et al., 2002) and in 
vivo (Pintor et al., 2004). Notwithstanding, the control of neuroinflammation by A2AR is still 
controversial due to opposite results in vivo (Yu et al., 2008; Dai et al., 2010) and in vitro (Saura et al., 
2005, Orr, 2009 #3451; van der Putten et al., 2009).   
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- To determine the ability of adenosine A2A receptors to control the neuroinflammation-
induced biochemical and morphologic features in the hippocampus, using a rat model of sepsis. 
 
- To test the ability of A2A receptors to control the direct effect of mediators of 
neuroinflammation such as pro-inflammatory cytokines on hippocampal neurons and to explore 
the underlying mechanism. 
 
- To test whether the ATP P2Y1 receptors also control the effects of pro-inflammatory 
cytokines in hippocampal neurons. 
 
- To explore the neuroprotection afforded with the blockade of P2Y1 receptors under 
excitotoxic conditions to hippocampal cultured neurons. 
 
- To investigate the long-term consequences of kainate-induced epileptic seizures in the 
density of P2 receptors in both synaptosomes and total membranes of the rat hippocampus.   
 
- To investigate, in vivo, the potential of the blockade of P2Y1 receptors to prevent the 
seizure-induce loss of synaptic markers, excitotoxic cell death and neuroinflammation in the 
hippocampus, using a rat model of temporal lobe epilepsy. 
 
- To further explore the neuroprotection afforded with the blockade of P2Y1 receptors 
against ischemic-induced lesion and mnemonic deficits, using a mouse model of middle 
cerebral artery occlusion. 
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3.1 THE HIPPOCAMPUS 
   
The hippocampus is one of the most studied brain structures and one that is particularly developed 
in rodents. It is part of the limbic system and is located inside the medial temporal lobe of the cerebral 
cortex, being therefore a part of the forebrain or telencephalon. The hippocampus and its associated 
medial temporal lobe structures have been described as essential for the formation, consolidation and 
retrieval of episodic memories (Morris et al., 1982; Squire and Zola, 1997; Eichenbaum, 2000; Scoville 
and Milner, 2000). Animals with lesions in the hippocampus or adjacent structures (septum, 
fimbria/fornix or parahippocampus) have been described to present impaired spatial and working 
memory (O'Keefe and Conway, 1978). 
The hippocampal formation is a bi-lateral limbic structure, which consists of two “C”-shaped 
interlocking cell layers leaning together at the top and spread apart at the base (Fig. 4). The top is 
known as the “dorsal hippocampus” and, since it is close to the septum (a structure at the midline of the 
brain) the dorsal tip of the hippocampus is called the “septal pole”. The cross-section taken 
perpendicularly to the long axis (septal-temporal) reveals the two interlocking “C”-shapes. One of the 
“C”s is the Ammon‟s Horn of Cornu Ammonis, also known as the “Hippocampus proper”. The 
principal cell layer of the Ammon‟s Horn is the stratum pyramidale, or the pyramidal cell layer. The 
other “C” is constituted by the dentate gyrus (DG), of which the stratum granulosum or granule cell 
layer is the main cell layer. This cross-section cut of the hippocampus also exhibits a strong afferent set 
of three connected pathways known as the “trisynaptic circuit” or loop (Andersen et al., 1966; Swanson 
et al., 1978; Swanson, 1982; Witter et al., 1989) which is represented by three subdivisions of the 
hippocampus: CA1, CA2 and CA3 areas (represented in Fig. 4). These areas represent a trisynaptic 
excitatory circuit that process information throughout this brain structure (Amaral and Witter, 1989). 
The connections within the hippocampus generally follow a laminar format and, as a rule, are 
unidirectional. They form well-characterized closed loops from and to the adjacent entorhinal cortex 
(Teyler and DiScenna, 1984). First, layers II and III or “surface layers” of the entorhinal cortex project 
to the granule cells of the DG via the perforant path, the major input to the hippocampus, with minor 
contributions from the deeper layers IV and V. Second, the granule cells of the dentate gyrus project to 
the large pyramidal cells of Cornu Amonnis subfield 3 (CA3), via the mossy fibers system. Third, the 
CA3 pyramidal cells project to the pyramidal cells of the CA1 subfield, via the Schaffer collateral 
system (Blackstad, 1956; Blackstad, 1958; Amaral, 1978; Bayer, 1985; Amaral and Witter, 1989; 
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Witter et al., 1989). This network primarily results from a physiologic balance between inhibitory 
GABAergic and excitatory glutamatergic neurotransmissions; however, there are other 
neurotransmitters that can have a minor contribution and, therefore, a major contribution to fine-tune 
transmition in the hippocampus (Lopes da Silva et al., 1990). 
The hippocampus is an excellent structure for experiments on the role of purine receptors in 
neurodegenerative disorders and neuroinflammation since it is one of the primarily affected brain 
regions, specially in the cases of epilepsy and ischaemia-induced damage (Back et al., 2004; Bertram, 
2009; Chen et al., 2010). Furthermore, the hippocampus has well defined circuits suited for 
biochemical studies and for the evaluation of memory processes dependent on the integrity of this area. 
  
 
Figure 4. Hippocampal pathways. The main hippocampal input comes from the lateral or medial entorhinal cortex (LEC 
or MEC, respectively) which forms connections with the dentate gyrus (DG) and CA3 pyramidal neurons via the perforant 
path (PP-split into lateral and medial). The CA3 pyramidal neurons mainly receive inputs from the DG neurons via the 
mossy fibers (MF). The CA3 pyramidal neurons send axons to CA1 pyramidal neurons via the Schaffer collateral pathway 
(SC), as well as to other CA3 pyramidal neurons or to CA1 pyramidal neurons in the contralateral hippocampus via the 
associative comissural pathway (AC). The CA1 pyramidal neurons also receive inputs directly from the perforant path and 
send axons to the subiculum (Sb). Adapted from http://www.bristol.ac.uk/synaptic/info/pathway/hippocampal.htm.   
 
3.2 BIOLOGICAL MODELS AND PREPARATIONS 
 
3.2.1 ANIMALS 
 
 The animals used in all the experiments presented in this thesis were rodents: male rats of the 
lineage Wistar, 8-10 weeks old and weighting between 250-300 g; male C57BL/6 mice, 8-10 weeks old 
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and weighting between 20-40 g and finally, 8 weeks old Swiss male mice, weighting between 30-40 g, 
for the model of focal ischemia. All animals were obtained from Charles River (Barcelona, Spain).  
 In the preparation of hippocampal primary neuronal cultures, 18 days old embryos were used from 
pregnant female Wistar rats, subjected to caesarean in deep anaesthesia (using halothane). Animals 
were handled in accordance with the EU guidelines for the use of laboratory animals and were housed 
four per cage (unless otherwise stated) and maintained under a controlled environment: 23 ± 2 ºC of 
temperature, 55 ± 5 % humidity, 12 hours light/dark cycle with standard food pellets ad libitum and tap 
acidified water. 
 
3.2.2 ANIMAL MODEL OF SEPSIS 
 
Sepsis, also commonly named septicaemia or blood poisoning, is a medical condition found in 
association with a known or suspected infection, usually caused by bacteria (Remick et al., 2000). This 
complication has been considered the main cause of death amongst hospitalized patients on intensive 
care worldwide (Remick et al., 2000). Sepsis is characterized by a rapid and exacerbated systemic 
inflammatory reaction known as the systemic inflammatory response syndrome (SIRS) which can lead 
to organ failure and be, therefore, life-threatening. The treatment involves administration of antibiotics 
to kill the infectious agent and the control of SIRS (Remick et al., 2000; Semmler et al., 2005). The 
most commonly used animal model of sepsis is the intraperitoneal (ip) administration of 
lipopolysaccharide (LPS) (Semmler et al., 2005; Dyson and Singer, 2009), an endotoxin that is a 
constituent of the cell wall of the Gram negative bacteria which is rapidly recognized by and activates 
the immune system (Dyson and Singer, 2009). Many studies focused on the peripheral most affected 
organs such as the liver, gut and kidney. However, the peripheral inflammation leads to the disruption 
of blood brain barrier which becomes permeable to peripheral pathological agents, activated immune 
cells as well as their released pro-inflammatory mediators (Banks and Erickson, 2010). In fact, septic 
encephalopathy occurs in the majority of septic patients and is the most common encephalopathy in 
intensive care units associated with a higher mortality rate (Pine et al., 1983; Sprung et al., 1990; 
Young et al., 1990). In rodent models, the acute effects triggered by LPS have been well documented 
and involve the rapid production of cytokines, chemokines, prostaglandins and nitric oxide (NO) 
(Rietschel et al., 1996). The neurotoxic effects of these pro-inflammatory mediators are also well 
known (Brown, 2007; Brown and Neher, 2010; Hu et al., 2010) and the cell death within the CNS 
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during sepsis has been described in both rodents and humans (Messaris et al., 2004; Semmler et al., 
2005; Sharshar et al., 2005).  
Overall, this model is appropriated to study not only ATP and adenosine modulation and 
control of inflammation but also to evaluate long-term consequences and/or benefits of that modulation 
in terms of cell function and integrity. Moreover, since the hippocampus is one of the brain regions 
most affected by LPS-induced inflammation, it was decided to restrict the analysis to this structure. 
 
3.2.2.1 EXPERIMENTAL PROCEDURES 
 
The following experiments were carried in order to gain further insight into the mechanism 
through which the blockade of adenosine A2A receptors control neuroinflammation:  
Groups of two months old, male Wistar rats (weighting 300-350 g) were anaesthetised with an 
ip injection of urethane (1.5 g/kg) and placed in a stereotaxic frame to allow the intracerebroventricular 
(icv) administration of drugs through a 0.5 ml Hamilton syringe into the third ventricle (coordinates: -
0.8 mm posterior to Bregma, 0.0 mm lateral, i.e. in the midline, and -6,5 mm dorsal-ventral). The rats 
were divided into 4 groups: 1) control rats injected with 5 μl saline icv and 200 μl saline ip after 30 
min; 2) LPS-treated rats injected with 5 μl saline icv and 200 μl LPS ip (1 μg/µl prepared in 0.9 % 
NaCl solution, saline) after 30 min; 3) A2A receptor antagonist-treated rats injected with 5 μl 
SCH58261 (50 nM in saline) or with 5 μl MSX-3 (1 μM in saline) icv and 200 μl saline ip after 30 min; 
4) LPS + A2A receptor antagonist-treated rats injected with 5 μl SCH58261 (50 nM) or with 5 μl MSX-
3 (1 μM) icv and 200 μl LPS (200 μg) ip after 30 min. Animals were sacrificed 4 hours after the 
intraperitoneal LPS or saline administration and the following studies were persued: quantification of 
interleukin-1β concentration; immunohistochemistry and Western blot analysis of mitogen-activated 
protein kinases (MAPKs); evaluation of caspase-3 activity; immunohistochemistry assessement of the 
profile of microglia and of the activated form of caspase-3 and analysis of both mRNA and density of 
protein markers of microglial activation through polymerase chain reaction (PCR) and Western blot 
analysis, respectively.   
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Drugs used: lipopolysaccharide (LPS) was isolated from Escherichia coli, serotype 055:B5 and 
acquired from Sigma-Aldrich, Portugal. the kit for ELISA quantification of interleukin 1β (Duoset) was 
acquired from Genzyme Diagnostics, SCH58261 (5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-
e]-1,2,4-triazolo[1,5-c]pyrimidine) was a generous gift from Scott Weiss (Vernalis, UK) and MSX-3 
(3,7-dihydro-8-[(1E)-2-(3-methoxyphenyl)ethenyl]-7-methyl-3-[3-(phosphonooxy)propyl-1-(2-
propynyl)-1H purine-2,6-dione disodium salt hydrate) was a generous gift from Sergi Ferré (NIDA, 
USA). 
The LPS dose was chosen based on previous studies that characterized the effect of peripheral 
administration on hippocampal neuronal functionality and viability (Vereker et al., 2000a; Kelly et al., 
2003; Nolan et al., 2003). The choice of SCH58261 and the administrated dose (0.00025 nmol) to 
block A2A receptor relied on antagonist affinity studies, showing that it was in the sub-nanomolar range 
(Lopes et al., 2004) and the selectivity towards the other adenosine receptors, evaluated by the 
disappearance of the selective binding of the antagonist in A2A receptor knockout mice (Lopes et al., 
2004). The concentration of the antagonist administered, 50 nM, was chose based on its equivalent 
effect, applied through reverse-microdialysis and ip injection, of neuroprotective doses of 0.01-0.1 
mg/kg (Cunha, 2005) on the evoked release of glutamate from the rat striatum (Pintor et al., 2001; 
Corsi et al., 2003). Likewise, the selected dose of MSX-3 was based on previous observation that this 
dose prevented the A2A receptor-mediated phosphorylation of proteins in the striatum upon cortical 
stimulation (Quiroz et al., 2006; Quiroz et al., 2009). 
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3.2.3 ANIMAL MODEL OF TEMPORAL LOBE EPILEPSY 
 
 
 
One of the most accepted and best characterized animal models of mesial temporal lobe epilepsy 
(MTLE) is the systemic or local administration to animals of 2-carboxy-4(1-methylethenyl)-3-
pirrolidiacetic acid (kainate), a cyclic analog of L-glutamate and about one hundred times more potent 
agonist of glutamate ionotropic receptors, which induces acute seizure episodes and subsequent 
development of spontaneous motor seizures and similar hippocampus lesions (such as specific loss of 
cell population in the Ammon‟s horn and aberrant mossy fiber sprouting) to those observed in humans 
(Nadler, 2003).  
Seizures induced by kindling have been classified into five stages based on clinical signs and this 
scale was later adopted to describe seizures in other animal models of epilepsy (Racine, 1972). 
According to the Racine‟s scale to monitor rat behaviour immediately after chemoconvulsant-induced 
seizures, there are five stages to be considered: stage I- facial automatisms; stage II- head nodding; 
stage III- forelimb clonus and lordotic posture; stage IV- forelimb clonus as the animal rears; stage V- 
forelimb clonus and rearing with falling over or loss of the righting reflex. Stages III, IV and V, 
together with “wet-dog” shake movements, are considered motor or convulsive seizures and should 
happen until two hours after kainate injection to guarantee hippocampal neuronal degeneration. 
 
3.2.3.1 EXPERIMENTAL PROCEDURE 
  
This model was performed using adult, male, Wistar rats (weighting 250-300 g). Animals were 
separated into 4 different groups: the saline group, which received artificial cerebrospinal fluid (aCSF, 
124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 10 mM glucose, 26 mM NaHCO3, 1 mM MgCl2 and 2 
mM CaCl2) icv and saline (SAL, 0.9 % NaCl) ip; the kainate group, which received aCSF icv and 10 
mg/kg kainate (KA) ip; the PPADS + KA group, that received 1 nmol/4 µl PPADS icv and 10 mg/kg 
kainate ip; the MRS + KA group, that received 1 nmol/4 µl MRS2500 icv and 10 mg/kg kainate ip  
and, finally, the PPADS and MRS groups that received 1 nmol/4 µl PPADS or MRS2500 icv and SAL 
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ip. Three days before the ip administration of kainate or saline, the animals were anaesthetized with 
sodium thiopental 50 mg/kg/ml ip and placed in a stereotaxic apparatus. The skull was opened and a 
guide cannula (CMA11 guide cannula) was introduced into the lateral ventricle and fixed to the skull 
with the help of two drills and cement, at the following coordinates relative to Bregma: -0,8 mm 
antero-posterior; -1,5 mm lateral and -3,5 mm dorso-ventral. On the icv injection day, animals were 
taken into a needle (4.2 mm length, 26-guage) connected to a PE 50 polyethylene tube. After 
unscrewing the cap, the needle was gently inserted through the guide cannula, 1 mm bellow, into the 
ventricle and drugs or saline were slowly manually infused. Administration was done at the rate of 0.5 
µl/ min and, at the end of the injection, the needle remained in place for 3 min before being slowly 
removed from the cannula, to avoid reflux. 
   
3.2.4 ANIMAL MODEL OF FOCAL CEREBRAL ISCHEMIA 
 
 
 
Stroke is the third leading cause of death in the world and 80 % are of an ischemic nature 
caused by the occlusion of the middle cerebral artery (MCA) (Howells et al., 2010). Ischemia is 
defined by a reduction of cerebral blood flow which prevents the affected tissue of normal supply of 
oxygen and nutrients, leading to cell death in the affected area (Braeuninger and Kleinschnitz, 2009). 
There are two types of in vivo experimental ischemia: global ischemia (achieved through cardiac arrest) 
and focal ischemia models. In focal ischemia models, the MCA is occluded either permanently or 
temporarily to allow reperfusion (Braeuninger and Kleinschnitz, 2009). The affected area or the area of 
stroke is designated the infarction area and is highlighted as a white region on brain slices stained with 
2,3,5-triphenyltetrazolium chloride (TTC) (Boyko et al., 2010). Microscopic visualization of this area 
shows edema and cellular swelling. The volume of stroke is calculated integrating the areas of 
infarction of a series of brain slices (Tureyen et al., 2004). Blockade of the MCA origin in rodents 
results in infarcts which incorporate the grey matter of the motor and somatosensory cortex, the 
underlying white matter tracts and the basal ganglia (caudate-putamen and thalamus) which have blood 
supplied by small perforating arteries that branch from the MCA or from adjacent segments of the 
circle of Willis (Howells et al., 2010). In accordance to its ability to affect the mencioned brain areas, 
MCA occlusion leads to motor and mnemonic impairments (Hunter et al., 2000).  
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Despite similarities, there are important differences between species and strains of animals that 
can alter the ischemic outcome. The Swiss Webster mice used in the present work have good 
sensitivity to ischemic MCA occlusion and reproducible outcome, which is dependent on the frequency 
of the sequence of posterior communicating arteries (Barone et al., 1993).  
 
3.2.4.1 EXPERIMENTAL PROCEDURE 
 
The animals were subjected to transcranial surgical, distal occlusion of MCA through cautery 
using a transorbital approach. Animals were first anesthetized with avertine (12 µL/g in mice): 10 g of 
the tribromoethyl alcohol (2, 2, 2 tribromoethanol) and 10 ml of the tertiary amyl alcohol (2 methyl-2-
butanol), prepared according to the institutional animal care and use committee- IACUC. The animal‟s 
skull was opened, the dura was breached and a hole was drilled exposing the segment of the artery to 
be blocked through electrocauterization (cut just distal to the inferior cerebral vein) which results in 
permanent MCA occlusion (MCAO) (Tamura et al., 1981; Marks et al., 2001). The wound was sutured 
and the animals were allowed to recover for 24 hours. The orbital route approach used is the least 
traumatic and, compared to procedures requiring craniotomy, results in less blood loss and artefacts 
(Sicard and Fisher, 2009). 
Ten minutes before MCA occlusion, animals were placed in a stereotaxic apparatus, and 
administered either artificial cerebrospinal fluid (vehicle, V), PPADS (0.5 nmol/µl or 1 nmol/µl) or 
MRS2500 (1 nmol/µl), intracerebroventricularly (icv) according to the following coordinates, taken 
from the Franklin and Paxinos, 1997 (The Mouse Brain in Stereotaxic Coordenates): anterior-posterior 
(AP), -1.0mm, dorso-ventral (DV), -2.0mm, and lateral (L), -0.5mm, relative to Bregma, as used in (Yu 
et al., 2008). Six groups of animals were organized as follows: the group receiving PPADS at the lower 
dose (0.5 nmol/µL); the group receiving PPADS at the higher dose (1 nmol/µl); the group receiving 
MRS2500; the group receiving vehicle; the group receiving vehicle and where the MCA was exposed 
but not occluded (sham-operated) and also a sham-operated group that received PPADS at the highest 
dose. 
Deficits in the motor function are common features of the ischemic-induced neurological status 
(Hunter et al., 2000). The neurological evaluation of animals was performed before and 24 hours after 
MCAO, according to the table 5 as described in (Hunter et al., 2000) and based on SHIRPA 
(SmithKline Beecham, Harwell, Imperial College, Royal London Hospital, phenotype assessment) 
protocol. Only animals scoring significantly different from the sham-operated mice in terms of 
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locomotion, body posture and muscle strength were further evaluated. Twenty-four hours after ichemia, 
animals were sacrificed by decapitation, brains dissected in a sucrose solution and sectioned on a 
mouse brain slicer matrix (0.5 mm coronal slice intervals, Zivic Instruments). The Infarct area was 
revealed by submersing the brain sections in a 2 % in normal saline 2,3,5-triphenyltetrazolium chloride 
(TTC, Sigma Aldrich, Portugal) solution at 37 ºC during 20 minutes, in the dark. The slices were 
washed twice in saline solution and fixed in 4 % paraformaldehyde for 30 min at room temperature. 
The slices were again passed twice by saline solution and, afterwards, both sides of sections were 
scanned on a flatbed colour scanner. TTC staining allows the evaluation of infarct area 
macroscopically. The colorless TTC is reduced to red formazan product by dehydrogenases that exist 
most abundantly in the mitochondria and therefore stain intensity correlates positively with the number 
and functionality of mitochondria. The infarcted volume is presented as a white region among the 
redness of the rest of the slice and was calculated using the image J software and as a percentage of the 
total volume of the contralateral hemisphere, to evaluate the extent of ischemic damage (Tureyen et al., 
2004).  
Three days after ischemia, another group of animals were tested for motor skills in an open field 
and for mnemonic skills in a Y-maze; a Morris water maze and a passive avoidance apparatus.  
 
Table 5. Neurological scoring in mice models of middle cerebral artery occlusion (Hatcher et al. 2002) 
 
0  NO DEFICIT  
1 
Flexion of contralateral torso and forelimb upon lifting of 
the whole animal by the tail 
2 
Circling to the contralateral side when held by tail with 
paws on the floor 
3 Spontaneous circling to the contralateral side 
4 No spontaneous motor activity 
 
3.3 BEHAVIORAL TESTS 
 
The evaluation of locomotor function was done using an open field and the assessment of 
mnemonic aspects was performed using the simple and modified Y-maze, the passive avoidance test, 
the object recognition test and the Morris water maze. The analysis of anxiety was performed on an 
elevated plus maze. 
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The behavioural tests were carried in a sound-isolated room with red light and unchanged 
environment, taking special care of spatial and odor cues. The apparatus were always carefully cleaned 
and removed of any smell before and after each animal tested and at the end of experiments. To avoid 
influences of circadian rhythms, animals were tested between 9:00 am and 4:00 pm. 
 
3.3.1 ORDER OF BEHAVIORAL TESTS 
  
To avoid stressing the animals and to minimize the interference between tests, the following 
order was used: first the animals were tested for locomotor proficiency in the open field; next, the 
animals were tested in the Y-maze, subjected to the object recognition test or tested in the Morris water 
maze for the evaluation of working memory. The evaluation of aversive memory was performed next, 
using a passive avoidance apparatus, and in the end, animals were tested for anxiety-like behaviour in 
an elevated plus maze.      
 
3.3.2 OPEN FIELD 
 
The open field test to evaluate locomotor activity was performed according to (Walsh and 
Cummins, 1976). The test takes advantage of the rodent‟s natural tendency to explore a novel 
environment. The rat open field consists in a square arena, 50 x 50 cm, which is divided into 4 squares 
of 25 cm. The mice open field has, naturally, smaller dimensions: 30 x 30 cm divided into 9 squares. 
The space is build of acrylic material painted in black to minimize the animal´s anxiety. The 
exploratory behaviour of animals was evaluated by counting the total number of line crossings 
(horizontal exploration) and the total number of rearings (vertical exploration) during 5 minutes. 
 
3.3.3 OBJECT RECOGNITION 
 
Object recognition is a useful test to study declarative memory in the rodents, taking advantage 
of their preference in exploring novel objects over familiar ones (Bevins and Besheer, 2006). 
Moreover, this type of memory test requires mechanisms dependent on hippocampal integrity. Long-
term potentiation in the hippocampus, a mechanism underlying memory consolidation and 
characterized by an activity-dependent enhancement of synaptic strength, is stimulated during this type 
of test(Clarke et al., 2010). As explained in (Dere et al., 2007) for “one trial object recognition task”, 
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the assay consists in letting the animals explore two equal objects for 5 minutes. These will be the 
familiar objects; placed equidistant from the open field walls, so that the animals have enough space to 
move around them. The objects were carefully chosen (colour, shape, dimensions, texture and odor), 
being neutral for the animals, i.e., not attractive nor repulsive. Exploration was defined as sniffing or 
touching the object with the nose and/or forepaws. Sitting on or going around the objects was not 
considered exploratory behaviour. One hour and a half later, having changed one of the objects for a 
new different one, the animals are left to explore for another 5 minutes. In both sessions, the time the 
animals spent exploring each object is recorded. It is expected that, animals without memory 
impairment will have a higher recognition index, i.e., spend more time exploring the new object. The 
recognition index is calculated as follows: 
 
Recognition index = (Time exploring the new object – Time exploring the familiar object) / Total 
time 
 
3.3.4 Y-MAZE 
 
   The Y-maze test was used to evaluate spatial working memory based on the tendency of rodents 
to alternate between equal arms of a maze in successive opportunities. The animal must remember 
which arm it entered on a previous occasion in order to alternate its choice on a following trial, 
therefore allowing evaluation of cognitive searching behaviour (Hughes, 2004). The classical Y-maze 
test was performed as described in (Canas et al., 2009), i.e., each animal, new to the maze, was placed 
in a “start” arm and left to explore between the three equal arms during 8 minutes. It was considered 
that an animal entered one arm if it got the four paws inside. To be considered a valid test, animals 
must have accomplished a minimal of 10 entries. One alternation is the consecutive entry in the three 
arms of the maze. The total percentage of alternation is calculated as follows:   Total of alternations / 
(Total arm entries – 2) X 100. The Y maze was made of black painted acrylic; in that rat Y-maze, 
each arm was 36 cm long, 16 cm high and 9 cm wide and converged at equal angles of 120º and in the 
mice Y-maze, the dimensions are 36 cm long, 16 cm high and 5 cm wide (PanLab, S.L., Power 
Reagent 5, Porto, Portugal). The modified Y-maze was performed as described in (Choy et al., 2010) in 
which one of the maze‟s arm is closed (the “novel” arm) during the first trial of the test. In the first 
trial, each animal, new to the maze, was allowed to explore the two arms (the “start” arm and the 
“other” arm) of the maze, while the novel arm was closed by a blocker made of the same material of 
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the rest of the maze, during 10 minutes. Two hours after this first trial, animals were placed in the 
“start” arm and allowed to explore all of the maze‟s arms during 5 minutes. The number of times each 
arm was visited and the duration of time spent in each arm were recorded and calculated as a 
percentage relative to the sum of the time and number of entries in all arms. It was expected increased 
number of visits and time spent (> 33%) in the novel arm compared to the other, familiar arms. This 
type of Y-maze is more robust for spatial memory evaluation since it doesn‟t depend so much on the 
randomness of chance. 
 
3.3.5 MORRIS WATER MAZE 
 
The Morris water maze, described in (Morris, 1984), is another useful test to assess spatial 
memory that depends on the correct function of the hippocampus, as this brain region, together with 
other temporal lobe structures, is one of the major structures involved in declarative memory (Squire 
and Zola, 1996; Sharma et al., 2010). The maze consists of a circular, black-painted tank filled with 
water at 22 ºC to a depth of 30 cm. The tank has a diameter of 150 cm and is 60 cm deep and has a 
circular escape platform of 12 cm, made of black plexiglass, placed in the pool 1 cm bellow the surface 
of the water, halfway between the centre and the edge of the pool and halfway between the north and 
the east. The room contained several visual cues, since animals learn the platform‟s place based on 
these. Animals were tested in four trials per day over three consecutive days, in each trial the animal 
was placed into the water facing the wall and always varying the starting location. Then, the animals 
were allowed to swim until they reached the escape platform for a maximum of 120 s, after which they 
were placed on the platform. Once on the platform, the animals remained there for 30 s and then 
removed for an interval of 30 min between trials. Spatial memory retention was evaluated 48 hours 
after the last trial by hiding the platform and allowing the mice swim for 30 s and recording the time 
spent on the area where the platform once was. 
 
3.3.6 PASSIVE AVOIDANCE 
 
Passive avoidance, as described by (Crine, 1984), is used to evaluate aversive memory in 
rodents. The test was conducted as described in (Cho et al., 2010) with few differences. First the 
animals are habituated to the passive avoidance box, which is 48 cm long, 22 cm wide and 22 cm high; 
divided into two compartments separated by a guillotine door. One of the compartments is illuminated 
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and has a thin platform, while the other is dark and made of stainless steel rods 1 cm apart, able to 
conduct electricity. Animals are placed in the illuminated compartment (which is a step-down to the 
dark, steel rods compartment) and allowed to explore the box for one minute. Thirty seconds after the 
animal is taken off the box, it is placed there again, on the illuminated side, for the test. As soon as the 
animal enters the dark side of the box, the dividing door closed and the animal receives a shock of 0.5 
mA during 1 s. Fifteen minutes later, the animal was placed again in the illuminated compartment and 
the latency time to entry the dark compartment was recorded (recent memory). Twenty four hours later, 
the animals were tested again to evaluate long-term memory or retention. This time, the animals did not 
receive a shock and the maximum latency time allowed was 300 s.  
 
3.3.7 ELEVATED PLUS MAZE 
 
  The elevated plus maze is the most popular test to evaluate anxiety-like behaviour of rodents 
(Carobrez and Bertoglio, 2005). The maze consists in an acrylic, black cross made of two opposite 
closed arms (50 cm long, 10 cm wide and 40 cm tall for rats; 31 cm long, 5 cm wide and 15 cm tall for 
mice) and two opposite open arms (50cm long and 10 cm wide for rats; 31 cm long and 5 cm wide for 
mice) set up 50 cm above the floor, for rats, and 40 cm above the floor, for mice. The central platform, 
the junction area of the four arms is 10 cm long and wide, for rats and 5 cm long and wide, for mice. 
The test was performed essentially as described in (Gazarini et al., 2011) and (Sampath et al.). Since 
the maze is elevated, the open arms are aversive per se to rodents, but given the exploratory nature of 
these animals, the less anxious they are the longer they will spend adventuring outside of the closed 
arms. Animals were placed ate the central platform of the maze facing the one of the closed arms and 
left to explore during a total of 5 minutes. During the test, the time spent in the open and closed arms, 
as well as the number of entries, was recorded. Only when the animal was with the four paws inside, 
was it considered an entry. Afterwards, the percentage of time spent in the open versus in the closed 
arms, as well as the percentage of time spent exploring was calculated as follows: time spent on open-
arms / total time X 100; time spent on closed arms / total time X 100; total time – (time spent on 
open arms + time spent on closed arms) X 100. 
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3.4 RAT HIPPOCAMPAL PRIMARY NEURONAL CULTURES 
 
 Rat hippocampal neuronal cultures were prepared as optimized by (Brewer et al., 1993) which 
allows glia-free neuronal cultures. Briefly, Wistar, female, pregnant rats were anaesthetised with 
halothane and 18 day old embryos were collected through caesarean for a container with sterile Hank‟s 
balanced salt solution without calcium and magnesium (NaCl 137 mM, KCl 5.36 mM, KH2PO4 0.44 
mM, NaHCO3 4.16 mM, Na2HPO4.2H2O 0.34 mM, Glucose 5 mM supplied with phenol red 0.001 % 
and with pH 7.2, sterilized in a 0.2 µm filter). The still anaesthetised female rats were immediately 
sacrificed by decapitation using a guillotine. All the surgical material was sterilized and kept in 75 % 
ethanol and all the procedures were executed in a flow chamber. The hippocampi were dissected in the 
already described Hank‟s solution and digested for 10 minutes in a bath at 37 ºC in 2 mg/ml of trypsin 
(from bovine pancreas, Sigma-Aldrich, Portugal) prepared in the Hank‟s solution and filtered. The 
trypsin reaction was quickly stopped with 1.5 mg/ml of trypsin inhibitor (from bovine pancreas, Sigma-
Aldrich, Portugal) prepared in the Hank‟s solution and filtered and then hippocampi were washed in 
Hank‟s solution. The Hank‟s solution was carefully removed and 1 ml of Neurobasal medium 
supplemented with B27 (1:50, GIBCO, Invitrogen, Portugal), L-glutamine (0.5 mg/ml), L-glutamate 
(25 µM) and penicillin-streptomycin antibiotic (1:100, GIBCO, Invitrogen, Portugal). The tissue was 
further dissociated mechanically with a P1000 Gilson pipetter until it was homogeneous. The cells 
were counted in a 1:3 dilution in three equal parts of cell medium and trypan blue solution (0.4% in 
PBS; Sigma-Aldrich), using a hemocytometer and a light microscope. Further dilutions until the final, 
desired concentration, were done by adding the supplemented Neurobasal medium. Finally, cells were 
plated on previously coated with poly-D-lysine (0.1 mg/ml prepared in borate buffer 166 mM, pH 8.2) 
coverslips and/or multiwells. For the viability and immunocytochemistry assays, 16 mm diameter 
coverslips were used, in 12-well dishes, and cells were plated at a 50 000/coverslip density. For the 
single cell calcium image assays, cells were plated at a density of 37 000/ coverslip in 12 mm diameter 
coverslips. For Western blot assays, cells were plated at a density of 800 000/ well in 6-well dishes. 
Neurons grew for 7 days in vitro in a 37 ºC incubator in a 95 % O2-5 % CO2 and humidity controlled 
atmosphere.     
 For Western blot analysis, the cultured neurons were lysated in RIPA buffer [Radio-
immunoprecipitation assay buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Nonidet-P40 
(IGEPAL), 0.5 % sodium-deoxycholate, 1mM EDTA and 0.1 % sodium dodecyl sulphate (SDS)] 
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supplemented with 1mM phenylmethanesulfonylfluoride (PMSF, Sigma Aldrich, Portugal), 1µg/ ml 
CLAP (protease inhibitor cocktail containing leupeptin, pepstatin A, chymostatin and aprotinin all at 
1mg/ ml; Sigma Aldrich, Portugal), 1 mM dithiothreitol (DTT), 1 mM sodium orthovanadate (Na3VO4) 
and 1 mM sodium fluoride (NaF). 
 
3.5 PREPARATION OF SYNAPTOSOMES AND TOTAL MEMBRANES  
 
Membrane preparations are a very useful tool to determine the presence and relative abundance 
of receptors. The specific localization of receptors at synaptic membranes and their subsynaptic 
distribution helps understanding their physiological role, allowing the probing of alterations in the 
density of the receptors in pathophysiological conditions. Total membrane and synaptosomal 
preparations have been extensively used in our and other groups to study the presynaptic modulatory 
roles of adenosine and ATP, as well as the localization and relative density of their respective receptors 
and of other molecules under the control of purinergic signalling. 
When homogenized, the neural tissue, which is composed of neurons and glial cells, is broken 
into fragments. The cell bodies are separated from long and/or branched processes, which also brake 
into discrete fragments. The plasma membranes of cell fragments may reseal to form osmotically active 
particles and when those particles contain the organelles of the synapse they are known as 
synaptosomes (Turner and Backelard, 1987). 
Initially, sucrose gradients were used to isolate synaptosomes; however, the concentration used 
is hypertonic making the synaptosomes shrunk. The fact that the synaptosomes had to return to a 
physiological medium and reswollen membranes are more susceptible to osmotic shock, led to 
introducing material such as Percoll or Ficoll in the isolation protocols. Moreover, sucrose gradients 
took longer times of centrifugation (Turner and Backelard, 1987).   
  
3.5.1 SIMPLE SYNAPTOSOME ISOLATION: 
 
A simple and rapid isolation of viable synaptosomes was performed as follows: animals were 
anaesthetised under halothane atmosphere before being sacrificed by decapitation. Brains were 
isolated; the hippocampi dissected and homogenized in a 0,32M sucrose solution containing 1mM 
EDTA, 10 mM HEPES and bovine serum albumin (BSA) 1 mg/ml, pH7.4 at 4ºC. Then, the 
homogenates were centrifuged at 3000x g for 10 minutes, at 4ºC, the pellet (P1) was discarded and the 
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supernatant (S1) was further centrifuged at 14000x g for 12 minutes at 4ºC. The supernatant (S2) was 
discarded and the resulting pellet (P2) was resuspended in 1ml of 45% (v/v) percoll solution prepared 
in a Krebs solution (KHR, Krebs HEPES Ringer: 140 mM NaCl, 1mM EDTA, 10mM HEPES, 5mM 
KCl, 5mM glucose, pH 7.4 at 4ºC). Then, the percoll homogenates were transferred to eppendorfs and 
centrifuged for 2 minutes at the maximum velocity of the microcentrifuge, 14000 rpm, 4ºC. The 
resulting, white, top layer (synaptosomal fraction) was removed to new eppendorfs, washed in KHR 
solution and resuspended in 1 ml of KHR for a new centrifugation of 14000 rpm, 4ºC. The pellets 
(synaptosomes) were then resuspended in different buffers according to the purpose they were intended 
for. For protein density evaluation, through Western Blot analysis, synaptosomes were homogenized in 
a solution of 5 % sodium dodecyl sulphate (SDS from Sigma-Aldrich) with 0.1 mM PMSF.  
These isolated synaptosomes are not free of contaminating particles, such as axonal fragments, 
free mitochondria, segments of axon and dendrites, myelin and glial cell fragments. The purity of the 
preparation can be assessed by probing biochemical markers expected to be enriched in the preparation 
and comparing it to other markers not expected to be there, or to be relatively low concentrated. Unlike 
synaptosomes, subcellular components derived from synaptosomes such as pre, post and extrasynaptic 
densities are sufficiently pure for biochemical analysis (Turner and Backelard, 1987).   
 
3.5.2 SYNAPTOSOME ISOLATION IN A DISCONTINUOUS GRADIENT OF PERCOLL  
 
 For a more purified preparation of synaptosomes the isolation can be achieved using a 
discontinuous Percoll gradient, as described in (Dunkley et al., 1988). The procedure used was the 
following: 
Animals were sacrificed and the hippocampi dissected as described above. The tissue was 
homogenised in a sucrose-HEPES medium (0.25 M of sucrose and 10 mM of HEPES, pH 7.4) and 
centrifuged at 2000 x g for 3 minutes at 4ºC. The resulting pellet was discarded (P1) and the 
supernatant (S1) was centrifuged at 9500 x g for 13 minutes at 4 ºC. The supernatant (S2) was 
discarded and the pellet (P2) was resuspended in 2 ml of sucrose-HEPES medium and laid on top of a 
Percoll gradient. For each sample, i.e., centrifuge tube, the gradient was built as follows: 
 
2 ml homogenate 
3 ml Percoll 3 % 
4 or 5 ml Percoll 10 % 
3 ml Percoll 23 % 
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The Percoll solutions were prepared in a 0.32 M sucrose solution with 1 mM EDTA and 0.25 
mM dithiothreitol (DTT), pH 7.4 at 4 ºC. 
The gradients were then subjected to a 25 000 x g centrifugation for 11 minutes, at 4 ºC, and 
without deceleration, to preserve the gradient. The synaptosome layer was collected from the interface 
23-10 % of Percoll and diluted in 15 ml of HEPES buffered medium without calcium (140 mM NaCl, 5 
mM KCl, 1.2  mM NaH2PO4, 5 mM NaHCO3, 1.2  mM MgCl2, 10 mM glucose and 10 mM HEPES, 
pH 7.4). Then, a new centrifugation of 22000 x g of 11 minutes at 4 ºC was performed and the resulting 
freely-moving pellet was captured with a P1000 pipetter, transferred to eppendorfs and resuspended in 
2 ml of HEPES buffered medium for washing. The synaptosomes were finally collected through a 
centrifugation of 11000 rpm during 11 minutes at 4 ºC, using a microcentrifuge.  
 
3.5.3 FRACTIONATION OF SYNAPTIC MEMBRANES 
 
To isolate the subcellular components of synaptosomes, such as the presynaptic, postsynaptic 
and extrasynaptic fractions, from rat hippocampal synaptosomes, the method used was the described by 
(Phillips et al., 2001) and adapted as in (Pinheiro et al., 2003) and (Rebola et al., 2003). This 
subsynaptic fractionation method allows an over 90 % effective separation of the active zone (enriched 
in SNAP-25 protein), postsynaptic density (enriched in PSD-95 protein) and non-active zone fraction 
(enriched in synaptophysin protein) markers and can be used to assess the subsynaptic distribution of 
receptors (Pinheiro et al., 2003; Rebola et al., 2003). 
  For synaptosomes preparation, the hippocampi were homogenised in 2.5 ml of isolation buffer 
(0.32 M sucrose, 0.1 mM CaCl2, 1 mM MgCl2, 1 µg/ml CLAP and 1 mM PMSF), keeping 100 µl of 
the homogenate at -80 ºC, for latter control analysis. The homogenate was transferred to 50 ml 
centrifuge tubes and 12 ml of 2 M sucrose solution was added as well as 5 ml of 0.1 mM CaCl2. The 
mixture was agitated at 4 ºC giving a solution of 1.25 M sucrose. This solution was divided into 2 tubes 
Ultraclear
TM
 and covered carefully with 2.5 ml/tube with 1 M sucrose solution (containing 0.1 mM 
CaCl2). The tubes were filled and equilibrated with isolation buffer and then centrifuged at 100000 x g, 
4 ºC, for 3 hours. The isolation buffer and the myelin layer present at the interface isolation buffer/ 1M 
sucrose were aspirated. The synaptosomes were captured at the interface 1.25/ 1M sucrose and then 
were diluted 1/10 in isolation buffer and centrifuged at 15000 x g during 30 minutes. The pellet was 
3. MATERIALS AND METHODS 
58 
 
resuspended in 1.1 ml isolation buffer and 100 µl of the supernatant (synaptosomal fraction) was kept 
at -80 ºC for control analysis. 
The fractionation of the synaptic membranes was then pursued: the synaptosomes were diluted 
10 x their volume in cooled 0.1 mM CaCl2 in 50 ml beakers, and a similar (10 ml) volume of 2x 
solubilization buffer pH 6.0 (40 mM Tris, 2 % Triton X-100, pH 6.0 precisely adjusted at 4 ºC) was 
added. The mixture was softly stirred during 30 minutes on ice and divided into 2 Ultraclear
TM
 tubes 
for a centrifugation at 40000 x g for 30 minutes, 4 ºC. The pellet corresponds to synaptic junctions and 
the supernatant to extrasynaptic proteins. The supernatants were kept on ice while the pellet was 
washed in once in solubilization buffer pH 6.0 (20 mM Tris, 1 % Triton X-100, pH 6.0 precisely 
adjusted at 4 ºC) and resuspended in 5 ml of solubilization buffer pH 8.0 (20 mM Tris, 1 % Triton X-
100, pH 8.0 precisely adjusted at 4 ºC). This mixture was stirred softly for 30 minutes on ice and 
centrifuged at 40000 x g for 30 minutes at 4 ºC. The pellet corresponds to the postsynaptic density and 
the supernatant to presynaptic proteins. The supernatant was transferred to centrifuge tubes and the 
pellet resuspended in 5 ml of solubilization buffer pH 8.0 and again stirred moderately on ice for 30 
minutes and centrifuged 40 000 x g for 30 minutes at 4 ºC. The supernatant was added to the 
presynaptic fraction and the pellet, correspondent to the re-extracted postsynaptic fraction, was 
resuspended in a minimal volume of 5 % SDS solution with 0.1 mM PMSF. To concentrate the 
extrasynaptic and presynaptic proteins, a maximum of cold acetone (-18 ºC) was added to the 
supernatants and kept for a minimum of 30 minutes at -20 ºC. Both fractions were pelleted by 
centrifuging at 18000 x g for 30 minutes at -15 ºC. Both pellets were resuspended in a minimal of 5 % 
SDS solution with 0.1 mM PMSF.  
 
3.5.4 ISOLATION OF TOTAL MEMBRANES 
 
Purification of total membranes was used for assessing protein density in hippocampal 
cytoplasmic membranes. Given the higher proportion of glial cells to neurons in the brain, this 
preparation is enriched in glial membranes as compared with synaptosomes.  
Animals were sacrificed and hippocampi isolated as already described. The tissue was 
homogenised in a 0.32 M sucrose solution containing 1 mM EDTA, 10 mM HEPES and 1 mg/ml BSA, 
pH7.4 at 4 ºC. Then, the homogenates were centrifuged at 3000 x g for 10 minutes, at 4 ºC. The pellet 
(P1) was discarded and the supernatant (S1) was further centrifuged at 100000 x g for 30 minutes at 4 
ºC, in an ultracentrifuge. The supernatants (S2) were discarded and the pellet (P2), correspondent 
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essentially to total cytoplasmic membranes, was resuspended in a 5 % SDS solution with 0.1 mM 
PMSF.  
 
3.6 PROTEIN QUANTIFICATION BY THE BICINCHONINIC ACID METHOD     
 
Protein quantification was carried using the bicinchoninic acid (BCA) protein assay reagent kit 
(Thermo Scientific, Pierce Biotechnology, USA), a colorimetric method compatible with high 
concentrations of most components of lysis buffers. Briefly, a standard curve was prepared in milliQ 
water, using 2, 1, 0.5, 0.25, 0.125, 0.0625 and 0 µg/µl of BSA. All the samples were diluted 1/10 in 
milliQ water, the reagent A was mixed with reagent B of the kit (BCA reagent) in a 50:1 proportion 
and protected from light. The buffer used to lyse the samples was also diluted 1/10. In a 96 well dish, 
the standard curve was prepared by pipetting 25 µl of each concentration of BSA, in triplicates, for 
different wells. To each well, 25 µl of the diluted lysis buffer was added, as well as 200 µl of the BCA 
reagent. Triplicates of the diluted samples were prepared in the same way, but 25 µl of milliQ water 
were added to each well instead of the diluted lysis buffer. The dish was protected from light and 
placed in a 37 ºC incubator for 30 minutes. Finally, the protein was read at 570 nm in a 
spectrophotometer. 
For Western blot analysis, the samples were normalized to a maximum of 2.5 µg/µl, by adding 
1/6 volume of 6x SDS-PAGE sample buffer and correcting with milliQ water. The SDS-PAGE buffer 
was used to further denaturate protein to a primary conformation, give it an overall negative charge and 
correct the pH for an optimum run in the electrophoresis gel. It is composed of 4x Tris.Cl/SDS solution 
(0.5 M Tris and 0.4 % SDS, pH 6.8 corrected with HCl and filtered with 0.45 µm pore filters), 30 % 
glycerol, 10 % SDS, 0.6 M DTT and 0.012 % of 3',3",5',5"-tetrabromophenolsulfonphthalein 
(bromophenol blue). The samples were finally boiled at 95 ºC during 5 minutes. 
 
3.7 WESTERN BLOT 
 
Western blot analysis was performed using the Bio-Rad system. The samples diluted in SDS-
PAGE buffer and the prestained molecular weight markers (dual-colour standards from BioRad, 
Portugal) were loaded and separated by SDS-PAGE electrophoresis (in 7.5 % polyacrylamide resolving 
gels with 4 % polyacrylamide stacking gels) under denaturating, reducing conditions and using a bicine 
buffered solution (20 mM Tris, 192 mM bicine and 0.1 % SDS, pH 8.3). The velocity of the running 
3. MATERIALS AND METHODS 
60 
 
was determined by applying a voltage of 80-100 mV. After separation in the electrophoresis gel, the 
proteins were electro-transferred (with 1A current, for 1.5 hours at 4 ºC and constant agitation) to 
previously activated polyvinylidene difluoride (PVDF) membranes (pore of 0.45 µm from GE 
Healthcare, UK), using a CAPS [3-(cyclohexylamino)-1-propane-sulfonic acid] buffered solution with 
methanol [10mM CAPS, 10 % (v/v) methanol, pH 11.0]. The PVDF membranes were activated during 
5-15 seconds in 100 % methanol, hydrated during 5 minutes in distilled water and equilibrated for 30 
minutes in the electrotransference buffer.  Membranes were then blocked for 1 hour at room 
temperature (RT) with 5 % low fat and Ca
2+
-free milk in Tris-buffered saline (20 mM Tris, 140 mM 
NaCl, pH7.6) with 0.1 % Tween 20 (TBS-T). Afterwards, membranes were incubated with the primary 
antibodies diluted in TBS-T with 5 % milk, overnight, at 4 ºC. After being washed three times, 15 
minutes each, in TBS-T with 0.5 % milk, the membranes were incubated with the phosphatase-linked 
secondary antibodies, also diluted in TBS-T with 5 % milk for 1 hour at RT. Again, membranes were 
washed three times, 15 minutes each, in TBS-T with 0.5 % milk and then incubated with  Enhanced 
Chemi-Fluorescence substrate (ECF, GE Healthcare, UK) for different times in a maximum of 5 
minutes. Finally, proteins were detected and analysed with Molecular Imager VersaDoc 3000 and 
Quantity One software (BioRad, Portugal). The milk used for blocking unspecific binding of antibodies 
to the membrane was substituted for 3 % BSA (and 0.5 % BSA in the washing TBS-T solution) when 
the target were phosphorylated proteins and the antibodies were phospho-specific, since milk contains 
casein, a phosphoprotein, that can react with the antibody and increase the background. 
Western blot gels were made of a polyacrylamide matrix (30 % Acrylamide/Bis solution, 
BioRad, Portugal) and were 1.5 mm thick. The stacking gel was prepared in a 0.5 M Tris-HCl at pH 6.8 
buffer (same pH of the sample buffer) and the resolving gel was prepared in a 1.5 M Tris-HCl buffer, 
pH 8.8, creating a pH gradient optimum for the separation of negatively-charged proteins. According to 
the Bio-Rad table, the gel formulations are as follows: 
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Table 6. Gel formulations in Western blot. The monomer solutions were prepared by mixing all reagents except the 
N,N,N′,N′-Tetramethylethylenediamine (TEMED from Sigma-Aldrich, a tertiary amine that catalyze the formation of free 
radicals from ammonium persulfate, which, in turn, leads to the polymerization of acrylamide and bis-acrylamide) and 10 % 
ammonium persulfate (APS from Sigma-Aldrich), added at the end. 
 
GEL (10 ml) 4 % 7.5 % 
1.5M Tris-HCl pH 8.8 (resolving gel)  3.0 ml 
0.5M Tris-HCl pH 6.8 (stacking gel) 2.5 ml  
Acrylamide 30 % 1.3 ml 2,3 ml 
Ultrapure water 6.1 ml 3,5 ml 
10 % SDS 100 µl 195µl 
TEMED 10 µl 6 µl 
10 % APS (freshly prepared in water) 50 µl 90 µl 
 
Re-probing of the same membrane with a different antibody was achieved by washing the ECF 
in 40 % methanol for 30 minutes and stripping the previous antibodies in a mild stripping solution of 
0.2 M glycine (Sigma-Aldrich, Portugal) with 0.1 % SDS and 1 % (v/v) Tween 20, pH 2.2, for 1 hour. 
The membranes were washed 3 times, 20 minutes each, in TBS-T with 0.5 % milk or BSA, between 
different solutions. Finally, before incubation with new antibodies, membranes were again blocked 
with either TBS-T with 5 % milk or TBS-T with 3 % BSA. 
Western blot analysis of the activated (phosphorylated) form of MAPKs was performed after 
incubation of cultured hippocampal neurons, 7 days in vitro, during different times of exposure and 
concentrations of  IL-1β (5, 10, 15, 20, 25, 30 or 60 minutes and 3 hours of incubation with 10 ng/ml 
IL-1β and 15 minutes of exposure to 1, 10 and 100 ng/ml IL-1β; R&D Systems, USA) and of TNF-α (1 
and 5 ng/ml of TNF-α were incubated for 10, 15, 20 and 30 minutes; TNF-α was purchased to R&D 
Systems, USA). At the mentioned endpoints, the cell medium was aspirated and the cells collected in a 
minimum volume of RIPA‟s lysis buffer and the protein quantification was performed using the BCA 
method.  
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Table 7. Primary antibodies used in the Western blot analysis. 
Antibodies Supplier Host Type Dilution 
A2A Santa Cruz Biotechnology goat polyclonal 1:500 
P2X1 Alomone labs rabbit polyclonal 1:500 
P2X2 Alomone labs rabbit polyclonal 1.500 
P2X3 Alomone labs rabbit polyclonal 1:1000 
P2X4 Alomone labs rabbit polyclonal 1:500 
P2X5 Santa Cruz Biotechnology goat polyclonal 1:200 
P2X6 Santa Cruz Biotechnology goat polyclonal 1:200 
P2X7 Alomone labs rabbit polyclonal 1:5000 
P2Y1 Alomone labs rabbit polyclonal 1:500 
P2Y2 Alomone labs rabbit polyclonal 1:500 
P2Y4 Alomone labs rabbit polyclonal 1:1000 
P2Y6 Santa Cruz Biotechnology goat polyclonal 1:500 
P2Y12 Alomone labs rabbit polyclonal 1:500 
α-tubulin Sigma-Aldrich mouse monoclonal 1:20000 
β-actin Sigma-Aldrich mouse monoclonal 1:20000 
Synaptophysin Sigma-Aldrich mouse monoclonal 1:20000 
SNAP-25 Sigma-Aldrich mouse monoclonal 1:5000 
PSD-95 Sigma-Aldrich mouse monoclonal 1:20000 
vGLUT1 Millipore guinea-pig polyclonal 1:10000 
vGLUT2 Millipore guinea-pig polyclonal 1:10000 
vGAT Calbiochem guinea-pig polyclonal 1:1000 
GFAP (Glial Fibrillary Acidic Protein) Sigma-Aldrich rabbit polyclonal 1:5000 
OX-6 Abcam mouse monoclonal 1:500 
Phospho-p38 MAPK Cell Signaling Technology mouse monoclonal 1:1000 
Total p38 MAPK Cell Signaling Technology rabbit monoclonal 1:1000 
Phospho-SAPK/JNK Cell Signaling Technology mouse monoclonal 1:1000 
Total SAPK/JNK Cell Signaling Technology rabbit monoclonal 1:1000 
Phospho-p44/p42 MAPK (Erk1/2) Cell Signaling Technology mouse monoclonal 1:1000 
Total p44/p42 MAPK (Erk1/2) Cell Signaling Technology rabbit monoclonal 1:1000 
 
Table 8. Secondary antibodies used in the Western blot analysis. 
Antibodies Supplier Host Type Dilution 
Rabbit-alkaline phosphatase conjugated 
(AP) 
Amersham Biosciences goat IgG 
(H+L) 
1:20000 
Mouse-AP Santa Cruz Biotechnology goat IgG+IgM 
(H+L) 
1:10000 
Goat-AP Santa Cruz Biotechnology rabbit IgG 1:2500 
Guinea-pig-AP Sigma-Aldrich goat IgG 1:5000 
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3.8 IMMUNOCYTOCHEMISTRY IN HIPPOCAMPAL NEURONAL CULTURES 
        
Immunocytochemistry in hippocampal neuronal cultures, 7 days in vitro, was used to evaluate 
the density and localization of the activated MAPKs induced by the pro-inflammatory cytokines IL-1β 
(100 ng/ml) and TNF-α (5 ng/ml), at 15 and 10 minutes of exposure, respectively. At the studied 
endpoints, cells were rapidly washed, once with Neurobasal medium and once with phosphate buffered 
saline (PBS, in mM: 140 NaCl, KCl, 26 NaH2PO4, 15 KH2PO4, pH 7.4), before being fixed with 4 % 
paraformaldehyde, prepared in a 0.9 % NaCl and 4 % sucrose solution, for 30 minutes. After fixation, 
cells were washed three times with PBS and permeabilized with PBS + 0.2 % Triton X-100 for 5 
minutes. After washing twice with PBS, cells were incubated with 3 % BSA in PBS during 1 hour at 
room temperature (RT), for blocking unspecific binding of antibodies. Cells were then incubated with 
primary antibodies, individually, prepared in the 3 % BSA solution, overnight, at 4 ºC. After washing 
three times with PBS, cells were incubated with secondary antibodies conjugated with a fluorophore 
(Alexa Fluor), 1 hour at RT. Vectashield mounting medium H-1500 with nucleus fluorescent marker 
4,6-diamidino-2-phenylindole (DAPI), from Vector Laboratories, UK, was used to maintain 
fluorescence. Finally, the preparations were observed with the transmission and fluorescence Zeiss 
Axiovert 200 microscope (Axiovision software 4.6, PG-Hitec, Portugal), with Zeiss/P.A.L.M. Laser 
Dissecting Microscope coupled to Axiovert 200M microscope or with a laser scanning confocal 
microscope with spectral analysis (LSM 510 Meta, Zeiss).  
 
Table 9. Primary antibodies used in immunocytochemistry. 
Antibodies Supplier Host Type Dilution 
Synaptophysin Sigma-Aldrich rabbit polyclonal 1:500 
β-III-tubulin Sigma-Aldrich rabbit polyclonal 1:600 
GFAP Sigma-Aldrich rabbit polyclonal 1:600 
Phospho-p38 MAPK Cell Signalling mouse monoclonal 1:100 
Phospho-SAPK/JNK Cell Signalling mouse monoclonal 1:100 
Anti-IL-1RI R & D systems rabbit polyclonal 1:200 
Anti-caspase 3  Cell Signalling rabbit polyclonal 1:300 
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Table 10. Secondary antibodies used in immunocytochemistry. 
Antibodies Supplier Host Type Dilution 
Anti-rabbit Alexa Fluor 594 Invitrogen Donkey IgG (H+L) 1:200 
Anti-mouse Alexa Fluor 488 Invitrogen Donkey IgG (H+L) 1:200 
 
3.9 PREPARATION OF FIXED BRAIN SLICES 
 
For immunohistochemistry analysis, brains were fixed as described in (Cunha et al., 2006) and 
(Rebola et al., 2011). The heart of the anaesthetised animal was exposed, the descending aorta clamped 
and a catheter was inserted in the ascending aorta. The right atrium was opened to allow the outflow of 
the perfusate. The animal was then perfused, first with a cold saline solution of 0.9 % NaCl and 4 % 
sucrose (200 ml) and then with cold 4 % paraformaldehyde prepared in the saline solution (200 ml) (all 
reagents were from Sigma-Aldrich, Portugal). At the end of this procedure, the brains were removed 
and kept overnight in the same paraformaldehyde solution. Subsequently, brains were transferred to 
PBS with 30 % sucrose. Once descended in this solution, brains were embedded in Tissue-Tek 
(Sakura-Americas, USA), frozen at -21 ºC and cut into 30 µm coronal sections using a cryostat 
(CM3050 S from Leica Microsystems, Portugal). Each series of brain sections comprised slices 300 
µm apart. In this way, there were sections representative of different areas of the brain structures, such 
as the hippocampus.The slices were stored in PBS with 0.01 % NaN3 (sodium azide, powder from 
Sigma-Aldrich, Portugal) and, when utilized, were mounted on slides coated with 2 % gelatine with 
0.08 % CrK(SO4)2 (chromium and potassium sulphate from Sigma-Aldrich, Portugal).   
 
3.9.1 IMMUNOHISTOCHEMISTRY FOR CD11b, GFAP AND NeuN 
 
The sections were first rinsed in PBS for 5 minutes and then three times for 5 min with Tris 
buffered saline, TBS (0.05 M Trizma base buffer containing 150 mM of NaCl, pH 7.2) at RT. Slices, 
were simultaneously permeabilized and blocked with TBS containing 0.2 % Triton X-100 and 10 % of 
normal goat serum (NGS), for 1 hour at RT. Afterwards, slices were incubated, free-floating, with the 
primary antibodies prepared in the blocking solution (anti-CD11b, 1:100 dilution, mouse or rat IgG1, 
AbD Serotec, Portugal; anti-OX-6, 1:200 dilution, mouse IgG1, abcam, USA; anti-GFAP, 1:500 
dilution, rabbit polyclonal, Sigma-Aldrich, Portugal; anti-NeuN, mouse IgG1, Chemicon/Millipore, 
Spain) overnight at RT. Sections were then rinsed 3x, 10 minutes each, in TBS and subsequently 
incubated 2 hours at RT, with goat anti-mouse, goat anti-rabbit or goat anti-rat secondary antibodies 
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(depending on the animal in which the primary antibody was produced) conjugated with a fluorophore 
(Alexa Fluor 488 or 594, diluted 1:200 in the blocking solution, Invitrogen, Portugal). After rising 3x 
for 10 minutes in TBS the brain sections were mounted on the gelatine coated slides, using Vectashield 
mounting medium H-1500 with DAPI (Vector Laboratories, UK) and allowed to dry protected from 
light before being kept at -20ºC until analysis. Sections were visualized under a transmission and 
fluorescence Zeiss Axiovert 200 microscope (Axiovision software 4.6, PG-Hitec, Portugal), with 
Zeiss/P.A.L.M. Laser Dissecting Microscope coupled to Axiovert 200M microscope or with a laser 
scanning confocal microscope with spectral analysis (LSM 510 Meta, Zeiss).  
 
3.9.2 IMMUNOHISTOCHEMISTRY FOR THE PHOSPHO-p38 MITOGEN-ACTIVATED 
KINASE AND FOR THE CLEAVED CASPASE-3  
 
Immunohistochemistry for the activated (cleaved) caspase-3 was carried out as previously 
described in (Egeland et al., 2010). Four hours after receiving an intraperitoneal injection of 
lipopolysaccharide (LPS) (200 μg from a 1 μg/ μl solution) or saline, rats (Wistar males, 10 weeks old) 
were sacrificed and the brains were fixed by trans-cardiac perfusion of a 4 % paraformaldehyde 
solution and sliced as described above. Each labelling was performed using a complete series of brain 
sections and the analysis was focused on the hippocampus. Slices were permeated and blocked in 3 % 
BSA with 3 % Triton-X-100, prepared in PBS, for 1 hour at RT, before being incubated with the 
primary antibodies (anti-phospho-p38, 1:100 dilution, rabbit, from Cell Signaling or anti-activated 
caspase-3, 1:300 dilution, rabbit, from Cell Signalling) prepared and incubated individually in the 
blocking solution. Excess of antibody was rinsed three times, 10 minutes each, with PBS before 
incubation, for 1 hour at RT, with the secondary antibody (1:200 dilution, donkey anti-rabbit Alexa 
Fluor 594, Invitrogen) prepared in PBS. After rising three times with PBS, 10 minutes each, slices were 
mounted onto 2 % gelatine-subbed microscope slides dried at RT and covered with Vectashield Hard 
Set H-1500 Mounting Medium with DAPI. For double-labelling with either anti-CD11b (1:100 
dilution, mouse anti-rat IgG1 from Serotec) or anti-NeuN (1:600 dilution, mouse from Chemicon, 
Millipore) the primary antibodies were incubated together as well as the secondary antibodies (1:200 
dilution, donkey anti-rabbit Alexa Fluor 594 and donkey anti-mouse Alexa Fluor 488, Invitrogen). 
However, the double-labelling with the phopho-p38 and the NeuN antibodies was carried out 
sequentially: first it was incubated the primary antibody for phospho-p38 followed by the respective 
secondary antibody and then it was incubated the primary antibody for NeuN followed by its secondary 
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antibody. The negative controls were performed by labelling in the absence of each or both primary 
antibodies, to check for non-specific labelling or cross-reactivity of the secondary antibodies. Images 
were acquired using a Zeiss Axiovert 200 microscope and some images were also acquired with a Zeiss 
LSM510 META confocal laser-scanning microscope. In the studies attempting to define co-localization 
of phospho-p38 or cleaved caspase-3 with either NeuN or CD11b, we only carried out a qualitative 
evaluation of the co-localization rather than a quantification of the actual relative co-localization of 
both proteins, which would require a considerably larger number of animals. 
The detection of microglia-like profiles was carried out as previously described (Cunha et al., 
2006), using an immunohistochemical detection of OX-42 and CD11b, epitopes which are up-regulated 
in activated microglia and to a lesser extent in macrophages (Jensen et al., 1997). Four hours (the same 
time period used for electrophysiological analysis) after the administration of lipopolysaccharide (200 
μg in 200 μl, ip) under urethane anaesthesia, the heart was exposed and after clamping the descending 
aorta, a catheter was inserted in the ascending aorta and the brain was fixed and sliced as described 
above. For the immunohistochemistry analysis, the sections were first rinsed for 5 min in PBS, then 
three times for 5 min with TBS (0.05 M Trizma base buffer containing 150 mM of NaCl, pH 7.2) and 
blocked with TBS containing 0.2 % Triton X-100 and 10 % goat serum during 45 min at room 
temperature. Sections were incubated in the presence of the mouse anti-CD11b antibody (1:200 
dilution in TBS containing 0.2 % Triton X-100 and 10 % normal goat serum, from Serotec) for 72 
hours at 4 ºC, rinsed three times for 10 min in TBS and subsequently incubated with goat anti-mouse 
secondary antibody conjugated with a fluorophore (Alexa Fluor 488, 1:50 dilution in 0.1 M phosphate 
buffer containing 0.2 % Triton X-100 and 10 % normal serum), for 2 hours at room temperature. The 
sections were then rinsed twice for 10 min in TBS and once for 10 min in distilled water and, finally, 
dehydrated and passed through xylol before mounting on slides, using Vectashield mounting medium 
(Vector Laboratories). Images were acquired using a Zeiss Axiovert 200 microscope and some images 
were also acquired with a Zeiss LSM510 META confocal laser-scanning microscope.  
 
3.9.3 CRESYL VIOLET STAINING 
  
Cresyl violet staining of Nissl bodies, which disappears under pathological conditions leading 
to cell degeneration, was used to evaluate neuronal morphology in hippocampal sections, as previously 
described in (Lopes et al., 2003). Sections were incubated for 10 minutes in 0.5 % cresyl violet solution 
(Sigma-Aldrich, Portugal) prepared in acetate buffer (20 % sodium acetate at 2.7 % and 80 % glacial 
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acetic acid at 1.2 %, both reagents from Merck, Portugal, pH 3.8-4.0). The staining was fixated through 
two rinses in the acetate buffer and dehydrated twice, 20 seconds each, in 100 % ethanol. Finally, 
sections are cleared in xylene (Merck, Portugal) for 5 minutes and mounted with DPX non-aqueous 
mounting medium (Merck, Portugal). 
 
3.9.4 FLUORO-JADE C STAINING  
 
 Fluoro-Jade C staining was used to evaluate general neurodegeneration in brain sections, 
regardless of specific insult or mechanism of cell death (Schmued et al., 2005). Brain sections on slides 
were defrost, dried and immersed for 5 minutes in 0.01 % sodium hydroxide (NaOH pellets from 
Sigma-Aldrich, Portugal) prepared in an 80 % ethanol solution. After rising for 2 minutes in 70 % 
ethanol and for 2 minutes in distilled water, slides were transferred to a 0.06 % potassium 
permanganate solution during 10 minutes, under agitation and protected from light. Sections were 
again rinsed in distilled water, for 2 minutes, and immersed in 0.0001 % Fluoro-Jade C (Histo-Chem 
Inc., Jefferson, AR, USA) prepared by diluting a 0.01 % stock solution (in ultrapure water) in 0.1 % of 
acetic acid vehicle. Sections remained in this solution for 10 minutes, protected from light and under 
agitation, before being rinsed three times, 1 minute each, in distilled water. Slices were dried on a slide 
warmer, dehydrated in an ethanol gradient (50 %, 70 %, 100 %) and cleared in xylene. Finally, slices 
were coversliped with DPX non-aqueous mounting medium (Merck, Portugal). Images were acquired 
with Zeiss Axiovert 200 microscope. 
 
3.10 QUANTIFICATION OF mRNA AND PROTEIN MARKERS OF MICROGLIAL 
ACTIVATION  
 
Quantitative determination of microglial activation in the dentate gyrus of the hippocampus was 
carried out by Western blot of two different markers of microglial activation, namely the CR3/43 
protein of the major histocompatibility complex class II (MHC-II) and inducible nitric oxide synthase 
(iNOS). For the 4 groups of rats (control; treated with LPS; treated with A2AR antagonists or treated 
with both LPS and A2AR antagonists), animals were sacrificed by decapitation 4 hours after the LPS 
administration and their hippocampi dissected and sliced (1 mm) to isolate the dentate gyrus. The 
dentate gyrus slices from one hippocampus were homogenised and solubilized in 5% SDS, diluted in 
sample buffer and boiled for 5 min, as described above. These samples (50 μg of protein for CR3/43 or 
3. MATERIALS AND METHODS 
68 
 
iNOS analysis) and the pre-stained molecular weight markers (from Amersham) were analysed by 
SDS-PAGE as described above, using antibodies against CR3/43 (1:200 raised in mouse from Santa 
Cruz Biotechnology) or iNOS/NOS type II (1:500, rabbit, BD Transduction Laboratories). The 
membranes were then re-probed and tested for tubulin immunoreactivity to confirm that similar 
amounts of protein were applied to the gels, as described above. The dentate gyrus slices from the other 
hippocampus were used to extract total RNA with a MagNA Lyser Instrument and MagNA Pure 
Compact RNA Isolation kit (Roche, Portugal), according to the manufacturer's instructions. The 
integrity, quantity and purity of the RNA yields were checked by electrophoresis and 
spectrophotometry. Reverse transcription for first-strand cDNA synthesis from each sample was 
performed using random hexamer primer with the Transcriptor First Strand cDNA Synthesis kit 
(Roche) according to manufacturer's instructions. Resulting cDNAs were used as template for real-time 
polymerase chain reaction (PCR), which was carried out on LightCycler instrument (Roche) using the 
FastStart DNA Master SYBR Green I kit (Roche). The A2AR and CD11b mRNA expression was 
calculated relative to β-actin mRNA expression. The following primers (obtained from Tib MolBiol, 
Germany) were used: A2AR (forward: 5‟-AGT CAG AAA GAC GGG AAC-3‟; reverse: 5‟- CAG TAA 
CAC GAA CGC AA-3‟), CD11b (forward: 5′-GAT GCT TAC TTG GGT TAT GCT T-3‟; reverse: 5′-
CGA GGT GCC CCT AAA ACC A-3‟) and β-actin (forward: 5′-AAG TCC CTC ACC CTC CCA 
AAA G-3′; reverse: 5′-AAG CAA TGC TGT CAC CTT CCC-3′). Quantification was carried out based 
on standard curves run simultaneously with the test samples, with A2AR, CD11b and β-actin standards 
being generated by conventional PCR amplification, as previously described (Duarte et al., 2007). The 
PCR products were run in a 3 % agarose gel electrophoresis to verify fragment size and the absence of 
other contaminating fragments, samples were quantified by 260 nm absorbance, and serially diluted to 
produce the standard curve (100 to 108 copies/ μl). Each real-time PCR reaction was run in triplicate 
and contained 2 μl of cDNA template, 0.3 μM of each primer, and 3.5 mM MgCl2 in a reaction volume 
of 20 μl. Cycling parameters were: 95 °C for 10 min to activate DNA polymerase, followed by 40-45 
cycles at 95 °C for 10 s, annealing temperature of 60 °C for 10 s, and a final extension step at 72 °C for 
10 s, in which fluorescence was acquired. The purity and specificity of the resulting PCR products were 
assessed by melting curve analysis and electrophoresis. Control reactions were performed to verify that 
no amplification occurred without cDNA. 
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3.11 QUANTIFICATION OF CASPASE-3 ACTIVITY  
 
Cleavage of the caspase-3 substrate (Ac-DEVD-AFC peptide, from Alexis) to its fluorescent 
product was used as a measure of caspase-3 activity, as previously described (Nolan et al., 2003). 
Briefly, slices of hippocampal tissue were washed, homogenized in ice-cold lysis buffer (25 mM 
HEPES, 5 mM MgCl2, 5 mM EDTA, 5 mM dithiothreitol, 2 mM phenylmethylsufonyl fluoride, 6.25 
μg/ml pepstatin A, 6.25 μg/ml aprotinin, pH 7.4) and lysed by cycles of freezing and thawing. Aliquots 
of these samples (50 μl) were mixed with 50 μl of reaction buffer (50 mM HEPES, 2 mM EDTA, 20% 
glycerol, 10 mM dithiothreitol, pH 7.4) and 4 μl of caspase-3 substrate (final concentration 10 μM from 
a stock solution of 250 μM in reaction buffer) and added to 96-well plates. Samples were incubated at 
37ºC for 60 min in the dark, fluorescence was assessed (excitation 400 nm; emission 505 nm) and 
enzyme activity was calculated with reference to a standard curve of 7-amino-4-
trifluoromethylcoumarin (AFC; 0-10 μM) versus absorbance. The protein concentration of each sample 
was determined using BSA as a standard (Bradford, 1976) and values expressed as nmol AFC/ mg 
protein/ min. 
 
3.12 QUANTIFICATION OF INTERLEUKIN-1β CONCENTRATION  
 
The concentration of interleukin-1β in hippocampal homogenates was assessed by enzyme-
linked immunosorbent assay, as previously described (Vereker et al., 2000a). Antibody-coated (2,0 
μg/ml final concentration, diluted in 0.1 M sodium carbonate buffer, pH 9.5; monoclonal hamster anti-
mouse interleukin-1β antibody) 96-well plates were incubated overnight at 4 ºC, then were washed four 
times with PBS containing 0.05 % Tween 20, blocked for 2 h at 37 ºC with 250 μl of blocking buffer 
(PBS, pH 7.3, 0.1 M with 4 % BSA) and incubated with interleukin-1β standards (100 μl; 0-1000 
pg/ml) or samples (supernatants of hippocampal samples homogenized in Krebs solution containing 2 
mM CaCl2) for 1 h at 37 ºC. Samples were incubated with secondary antibody (100 μl; final 
concentration 0.8 μg/ml in PBS containing 0.05 % Tween 20 and 1 % BSA; biotinylated polyclonal 
rabbit anti-mouse antibody) for 1 h at 37 ºC, washed and incubated in detection agent (100 μl; 
horseradish peroxidase-conjugated streptavidin; 1:1000 dilution in PBS containing 0.05 % Tween 20 
and 1 % BSA) and incubated for 15 min at 37 ºC. The chromogenic substract for the enzyme, 3,3‟,5,5‟-
tetramethylbenzidine (100 μl; Sigma-Aldritch), was added, samples were incubated at room 
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temperature for 30 min and absorbance was read at 450 nm. Values are expressed as pg interleukin-1β / 
mg of protein, quantified as described (Bradford, 1976).  
 
3.13 VIABILITY ASSAYS:  
 
3.13.1 ALAMAR BLUE 
 
Alamar Blue (resazurin, from Sigma-Aldrich, Portugal) is a non-toxic, cell permeable 
compound, blue in colour and non-fluorescent. Upon entering cells, resazurin is reduced to resorufin, 
which is red in colour and highly fluorescent. Viable cells continuously convert resazurin to resorufin, 
increasing the overall fluorescence and colour of the media surrounding the cells.  In cultured cells that 
do not divide, such as neurons, the Alamar Blue assay allows evaluation of cell viability along the time. 
This method is advantageous because it is simple to execute, inexpensive and non-toxic to the cells or 
the user (Nakayama et al., 1997). The Alamar Blue assay was used to evaluate the toxicity of long-term 
stimuli with agonists of glutamate ionotropic receptors, such as the kainic acid, the N-methyl-D-
aspartic acid (NMDA) and the quinolinic acid, to hippocampal neurons (all purchased from Sigma-
Aldrich, Portugal). Once found the optimal incubation time and concentration in which these toxic 
agents induced significant decrease of cellular reducing capacity, it was used the MTT assay for cell 
viability, where the risk of colour saturation does not occur. Hippocampal neuronal cultures, 7 days in 
vitro, were incubated with 10, 50, 100, 250 µM of kainate; 10, 50, 100 µM of NMDA; 50, 100, 250 and 
3000 µM of quinolinic acid, all prepared and incubated in Krebs-Ringer‟s saline (in mM: 117 NaCl, 3 
KCl, 10 glucose, 26 NaHCO3, 1,25 NaH2PO4, 10 HEPES, 2 CaCl2 and 1 MgCl2). The toxic agents and 
the Alamar Blue (10 times concentrated and added in a 10 %, v/v, of the total volume) were incubated 
for 3, 4, 6, 8 and 12 hours. At every endpoint, 100 µl of the medium from each well was pipetted in 
triplicates to a 96-well plate and the absorbance was read on a spectrophotometer, at the maximum 
absorbance wave length of 570 nm and at the reference wave length of 600 nm. The plates were 
returned to the incubator every time, until the next endpoint. Saturation curves for Alamar Blue were 
carried out under the same experimental conditions, without the toxic agents. To minimize differences 
due to uneven number of plated cells per well, each plaque had triplicates of the same condition and the 
results for each triplicate were averaged. The percentage of reduction was calculated by the quotient 
between the difference of the absorbance at 570 nm and the absorbance at 600 nm of the samples and 
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the difference of absorbance at 570 nm and at 600 nm of the negative control, in which no toxic agent 
was added. Results were analysed as percentage of control (wells incubated with vehicle).   
 
3.13.2 MTT ASSAY 
 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide from Sigma-Aldrich, 
Portugal) assay uses de same principle of Alamar Blue, i.e, evaluates the metabolic state of cells. The 
tetrazolium ring of MTT is cleaved by dehydrogenases present in the cytosol and in active 
mithocondria and precipitates as a purple formazan product. The intensity of the purple colour is 
directly proportional to the absorbance at 570 nm (600 nm is used as reference). Thus, higher 
absorbance values are related to a greater number of viable cells (Luscher and Slesinger, 2010). As the 
formazan product is toxic, this test was used for analysis of cell viability at a single, well defined 
endpoint, upon which the cell medium was aspirated and a new one with the MTT was added.  
Hippocampal neurons, 7 days in vitro, were stimulated for different times with ionotropic 
glutamate receptor agonists: 100 µM of kainate during 6 hours; 100 µM of NMDA during 12 hours and 
3 mM quinolinic acid during 24 hours prepared and incubated in Kreb-Ringer‟s saline. Upon each 
endpoint, cells were washed twice with Krebs and incubated with MTT (0.5 mg/ml), also in Krebs, for 
1 hour at 37 ºC and in a 5 % O2- 95 % CO2 atmosphere. Then, MTT was aspirated and the formazan 
formed was diluted with the same volume of dimethyl sulfoxide (DMSO, Sigma-Aldrich, Portugal), for 
1 hour at RT, under agitation and protected from light. Finally, 100 µl of each well were pipetted to a 
96-well plate in triplicates and the absorbance was read at 570 nm and 600 nm. The percentage of 
reduction was calculated as explained for the Alamar Blue assay and expressed as percentage of 
control. In order to evaluate the contribution of P2 receptors to the excitotoxicity induced by 
overactivation of glutamate ionotropic receptors, PPADS (20 μM, a non-selective P2 receptor 
antagonist, from Tocris Bioscience, Spain) was incubated 30 minutes before the stimuli and prevailed 
throughout. To evaluate the specific contribution of the subtype P2Y1 receptors, cells were pre-
incubated with MRS2500 (10 μM, a potent and selective P2Y1 receptor antagonist, Tocris Bioscience, 
Spain). The effect of a short-term exposure (25 minutes) of hippocampal neurons to the same stimuli 
and to glutamate itself (100 µM, L-glutamic acid from Sigma-Aldrich, Portugal) was also evaluated 
using the MTT assay. In this case, after 25 minutes of stimuli, neurons were washed three times with 
Krebs and fresh Neurobasal medium was added. Upon 24 hours, the medium was aspirated and the 
Krebs with MTT was added. When used, the antagonists were incubated 30 minutes before the stimuli 
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and were again added to the fresh Neurobasal medium after washing the stimuli. SCH58261 (50 nM, 
from Vernalis, UK).  
 The MTT assay was also used to evaluate pro-inflammatory cytokines interleukin-1β and 
tumor necrosis factor-α (purchased to R & D Systems) conditioning of glutamate-induced 
excitotoxicity to hippocampal neurons. Cells were incubated with either 100 ng/ml interleukin-1β or 5 
ng/ml tumor necrosis factor-α, 5 minutes prior to incubation of 100 µM glutamate, for a total of 25 
minutes. The cell viability assay was conducted as already described for the short-term stimuli, with 
analysis at 24 hours. The effect of blocking adenosine A2AR in the modulation of glutamate-induced 
neurotoxicity and on interleukin-1β exacerbation of excitotoxicity was evaluated by adding SCH58261 
(50 nM, from Vernalis, UK), a selective antagonist of A2AR, 30 minutes before the toxic agents. 
Likewise, the effect of the blockade of ATP P2Y1R was evaluated by adding a selective antagonist of 
these receptors, MRS2179 (10 μM, Tocris Bioscience, Spain). 
 
3.13.3 SYTO-13 AND PROPIDIUM IODIDE STAINING 
 
The significant results obtained with the MTT assay were further analysed through the Syto-13 
plus propidium iodide (PI) staining (both reagents from Molecular Probes, Leiden, Netherlands), as 
previously described in (Rebola et al., 2005d).  Syto-13 is a cell-permeant nucleic acid stain that shows 
a large (green) fluorescence enhancement upon biding nucleic acids. Therefore, the Syto-13 staining 
allows the visualization of viable cells (darker, homogeneous and larger green fluorescent nuclei) and 
of apoptotic cells in which the plasmatic membrane is still intact (brighter, fragmented and smaller 
green fluorescent nuclei). The propidium iodide also binds nucleic acids with resulting strong red 
fluorescent. However, this stain is not permeable to cytoplasmic membranes. Therefore, the propidium 
iodide staining labels cells in which the membrane integrity is compromised, i.e., necrotic cells (darker, 
homogeneous and larger red fluorescent nuclei) and cells undergoing secondary apoptosis (small, very 
bright red spots of fragmented nuclei). After incubation with the toxic agents, cells were washed 3x in 
Krebs and incubated with a mixture of Syto-13 (4 µM) and PI (4 µg/ml) prepared in Krebs, for 3 
minutes. After mounting the coverslips on microscope slides, cells were observed and counted using a 
fluorescence microscope. At least six fields per coverslip were analysed with a total of 300 cells, in 
average. 
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3.13.4 LACTATE DEHYDROGENASE ASSAY 
 
Lactate Dehydrogenase (LDH) is an oxidoreductase (EC 1.1.1.27) that catalyses the 
interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD
+
. When 
any form of injury damages tissues, cells release LDH into the extracellular space and, being a fairly 
stable enzyme, it has been widely used to evaluate the degree of damage induced by toxic events to 
cells (Tajeddine et al., 2008). Since LDH leakage depends on plasmatic membrane integrity, this assay 
is particularly useful when cell death occurs mainly through necrosis (Tajeddine et al., 2008). Cell 
viability assays are not consensual among the scientific community and all present some degree of 
accuracy problems depending on the experimental conditions (Galluzzi et al., 2009). Therefore, we 
also used this method to assess cell viability and, possibly, confirm the significant results previously 
obtained relative to glutamate-induced cell death, exacerbation of this effect by interleukin-1β and 
neuroprotection by blocking adenosine A2A receptors. LDH activity was measured 
spectrophotometrically according to the method developed by Bergmeyer and Brent (1974), by 
following the rate of conversion of NADH to NAD
+
, at 340 nm. Thus, 24 hours after the stimuli, the 
cell medium was aspirated (extracellular fractions) and kept in eppendorfs at 4ºC until analysis. 
Simultaneously, the plated cells were lysated on ice with 1 ml of 0.02 % Triton X-100 in 10 mM 
HEPES buffer (pH 7.4) and 3 freezing/thawing cycles. The lysates (intracellular fractions) were also 
kept at 4 ºC in eppendorfs until analysis. Before the assay, both intracellular and extracellular fractions 
were centrifuged at 14000 rpm, 10 minutes at 4 ºC. The pellets (cellular organelles and membrane 
fractions) were discarded and the supernatants were used to measure LDH activity. Fresh solutions of 
0.244 mM NADH and of 9.76 mM pyruvate were prepared in 81.3 mM Tris / 203.3 mM NaCl buffer, 
pH 7.2 at 30 ºC. Reactions were carried in cuvettes, kept at 30ºC, to which 0.5 ml of pyruvate and 100 
µl of the sample was added and, immediately before the reading, 2.5 ml of NADH was also added, 
which triggers the convertion of pyruvate to lactate by LDH. The loss of absorbance at 340 nm was 
followed with readings at 0.5 seconds intervals, during 2 minutes. The curve slope, the reaction‟s 
velocity, is directly proportional to the quantity of LDH present in the sample. Triplicates were carried 
for each sample and the results averaged. The percentage of LDH leakage was calculated using the 
ratio between extracellular LDH activity and the sum of intracellular and extracellular LDH activity. 
The blank of these experiment consisted of adding NADH to the cuvette in the absence of sample 
(LDH). Results were expressed as percentage of control values. 
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3.14 MONITORING INTRACELLULAR CALCIUM WITH SINGLE CELL CALCIUM 
IMAGING 
 
To investigate the effect of blocking adenosine A2A receptors or ATP P2Y1 receptors in the 
glutamate-induced increase of intracellular calcium ([Ca
2+
]i) and also if the interleukin-1β exacerbation 
of glutamate excitotoxic effects was associated with a deregulation of [Ca
2+
]i homeostasis, it was used 
the single cell calcium imaging as previously described in (Bernardino et al., 2008). This method takes 
advantage of Fura-2-acetoxymethyl ester (Fura-2AM) properties, a membrane-permeable, selective 
calcium radiometric dye, to measure cellular calcium concentrations by fluorescence. The probe 
crosses the plasmatic membrane and, once inside, unspecific cellular esterases remove the 
acetoxymethyl (lipophilic) groups making it membrane-impermeable. The regenerated Fura-2 
(C44H47N3O24), which is an analogous of the Ca
2+
-chelating molecule EGTA with an additional 
chemical group with fluorescent properties, is then free to bind Ca
2+
 through its four carboxyl groups 
(Grynkiewicz et al., 1985). The great advantage of Fura-2 is that, once bound to Ca
2+
 it has an 
absorption peak shift from 380 nm to 340 nm excitation wavelengths. Cytosolic Ca
2+
 transients can be 
followed by monitoring the 510 nm emission (maximum Fura-2 fluorescence) and measuring 340/380 
nm ratio of Fura-2 absorbance along the time (Hirst et al., 1999a). The use of the ratio eliminates 
variables such as uneven dye loading, cell thickness, leakage of fura-2 and bleaching. Fura-2 dye 
provides the possibility to perform measurements for about 1 hour without significant bleaching and 
given its high molar extinction coefficient (ε = 30,800 cm-1M-1), meaning a high fluorescence intensity 
per Fura-2 molecule, allows measurements of intracellular concentrations of the dye that do not cause 
significant Ca
2+
 buffering or altering of Ca
2+
 transients.  
Hippocampal neurons, 7 days in vitro, plated on coverslips, were loaded with 5 µM Fura-2AM 
(Molecular Probes, Leiden, Netherlands) and 0.02 % pluronic acid F-127 (Molecular Probes, Leiden, 
Netherlands) for 30 minutes in Krebs-Ringer saline buffer (in mM: 150 NaCl, 5 KCl, 10 glucose, 10 
HEPES, 2 CaCl2 and 1 MgCl2, pH 7.4) supplemented with 0.1 % fatty-acid free BSA, in an incubator 
with 95 % CO2- 5 % O2 atmosphere, at 37ºC. After 3 passages through Krebs buffer to wash excess of 
probe, coverslips were placed in a RC-20 perfusion chamber in a PH3 platform (Warner Instruments, 
Harvard, UK), on the stage of an inverted fluorescence microscope (Axiovert 200, Carl Zeiss, 
Germany). Hippocampal neurons were alternately excited at 340 and 380 nm using a Lambda DG4 
apparatus (Sutter Instruments Company, Novato, CA, USA) and the emitted fluorescence was collected 
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with a 40× oil objective and driven to a CoolSNAP digital camera (Roper Scientific, Trenton, NJ, 
USA). Acquired values were processed using the MetaFluor software (Universal Imaging Corporation, 
Buckinghamshire, UK). Areas of the cell bodies were drawn and the average value of pixel intensities 
was evaluated at each time point. Image acquisition was done every second during a total of 35 
minutes. Results were expressed by plotting the ratio of fluorescence intensity emitted at 510 nm (using 
a 510 nm band-pass filter from Carl Zeiss), following alternate excitation (750 milliseconds, using a 
Lambda DG4 apparatus from Sutter Instrument, Novato, CA,USA) at 340 and 380 nm, versus time 
(Resende et al., 2007). Solutions were added to the cells by perfusion using a fast-pressurized (95 % 
air, 5 % CO2 atmosphere) system (AutoMate Scientific, Inc., Berkeley, CA, USA). Drugs were 
prepared in normal Krebs solution. Basal ratio was measured during the first 2 minutes of the 
experiments. Interleukin-1β, (IL-1β, 100ng/ml), when present, was added for 5 minutes prior to 
glutamate (100 µM). Cells were left in the presence of the stimuli for the next 15 minutes after which it 
was washed through superfusion of normal Krebs. Whenever A2A receptors or P2Y1 receptors selective 
antagonists, SCH58261 (50 nM) or MRS2179 (10 µM), respectively, were present, they were incubated 
for 15 minutes prior to the beginning of the experiment and prevailed throughout. To assure that the 
selected cell bodies belonged to neurons, response to 50 mM KCl was tested before calibration, at the 
end of each experiment. The calibration was made using 10 µM ionomycin prepared in normal Krebs, 
for maximum ratio, and 10 mM MnCl2 prepared in calcium-free Krebs, to assess the background 
fluorescence. The experiments were carried as exemplified in the scheme bellow: 
 
 
 
 
Statistical analysis: values are presented as mean ± SEM of n experiments. Either a Student‟s t test for 
independent means or a one-way analysis of variance (ANOVA) followed by post hoc Bonferroni‟s 
test, was used to define statistical differences between values, which were considered significant at 
P<0.05, unless otherwise  specified.   
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4.1 ADENOSINE A2A RECEPTORS CONTROL NEUROINFLAMMATION 
 
4.1.1 INTRODUCTION 
 
The brain was considered an immunopriviledge organ for a long time, mainly due to the belief 
in a physical separation between this organ and the immune system (Medawar, 1948; Barker and 
Billingham, 1977) through what became known as the blood brain barrier (BBB) (Carson et al., 2006). 
However, in the late years, that concept changed dramatically as the BBB was found to be a dynamic 
structure in constant “cross-talk” with the peripheral nervous system (PNS) (Carson et al., 2006). 
Nowadays, it is well known that neuroinflammation is a common feature of most neurological 
disorders and pathological situations in the central nervous system (CNS) (Skaper, 2007; Glass et al., 
2010; Wee Yong, 2010). Neuroinflammation is initiated by microglia, the immuno-competent cells and 
injury/pathogen “sensors” of the CNS (Stence et al., 2001; Ransohoff and Perry, 2009; Streit and Xue, 
2009) and mainly orchestrated by these and the astrocytes (Norton et al., 1992; Skaper, 2007; Zhang et 
al., 2010a), which have a central role in the control of synaptic transmission (Perea et al., 2009), brain 
repair (Sofroniew, 2005) and in the maintenance homeostasis (Sofroniew, 2005; Zhang et al., 2010a). 
Both microglia and astrocytes rapidly respond to an adverse situation by changing their morphology, 
multiplying and migrating to the site of injury (Streit et al., 1999; Streit, 2000; Zhang et al., 2010a). 
This reaction is termed reactive gliosis (microgliosis and astrogliosis, respectively) and involves the 
expression of specific structural proteins and cell surface receptors (O'Keefe et al., 2002; Ladeby et al., 
2005; Zhang et al., 2010a), accompanied by the expression and release of several inflammatory 
mediators, including pro-inflammatory cytokines (Chakraborty et al., 2010). Uncontrolled or chronic 
neuroinflammation is involved in the etiology and/or aggravation of several noxious conditions and 
pathologies in the CNS (Marchetti and Abbracchio, 2005; Skaper, 2007; Glass et al., 2010; Wee Yong, 
2010). Accordingly, the control of neuroinflammation is associated with a general improvement in 
different neurodegenerative diseases (Allan et al., 2005; Marchetti and Abbracchio, 2005). 
Inflammation results in elevated extracellular levels of purines which in turn influence the 
inflammatory response (Abbracchio and Verderio, 2006; Abbracchio and Ceruti, 2007; Hasko and 
Pacher, 2008; Di Virgilio et al., 2009; Orr et al., 2009). In the PNS, the activation of adenosine A2ARs 
is well established as a “stop” signal of inflammation (Sitkovsky and Ohta, 2005). On the other hand, in 
the brain it is the blockade of A2ARs that is associated with the prevention or the improvement of 
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different pathological conditions (Cunha, 2005; Chen et al., 2007; Gomes et al., 2011). This was shown 
in models of Alzheimer‟s disease (Dall'Igna et al., 2003; Dall'Igna et al., 2007; Canas et al., 2009), 
ischaemia (Chen et al., 1999; Higashi et al., 2002; Yu et al., 2004), diabetes (Duarte et al., 2009), 
epilepsy (Zeraati et al., 2006; El Yacoubi et al., 2009) and in particular, in models of Parkinson‟s 
disease where A2AR antagonists have the ability to both normalize the motor function and afford a 
marked neuroprotection, being currently in phase IIb studies as anti-parkinsonian drugs (Xu et al., 
2005). Since A2ARs are expressed in brain glial cells and modulate its activity (Dare et al., 2007; Orr et 
al., 2009; Boison et al., 2010), the control of neuroinflammation may in part explain the broad 
spectrum of deleterious situations in which the blockade of A2ARs confers neuroprotection (Cunha, 
2005; Chen et al., 2007; Boison et al., 2010). However, the role of A2AR in the control of 
neuroinflammation is currently unclear given that in animal models of Parkinson‟s disease (Pierri et al., 
2005; Yu et al., 2008) and of traumatic brain injury (Dai et al., 2010) it was suggested that A2AR 
blockade control microglia activation whereas studies using primary cultures of microglia have reached 
opposite conclusions related to the control of function by A2AR (Saura et al., 2005; Orr et al., 2009; van 
der Putten et al., 2009), questioning a direct role of A2AR in the control of neuroinflammation in an in 
vivo setting.  
The present work was designed to test if the blockade of A2ARs can control specific features of 
neuroinflammation in the hippocampus, such as biochemical and morphological changes resulting from 
peripheral (intraperitoneal, ip) administration of lipopolysaccharide (LPS). This toxin from Gram 
negative bacteria is a prototypical trigger of inflammation and is also known to be a potent trigger of 
neuroinflammation (Kim et al., 2000; Chakravarty and Herkenham, 2005); furthermore considerable 
work has already been made to understand the relation between the genesis of neuroinflammation 
caused by LPS and the consequent neuronal dysfunction in the hippocampus (Vereker et al., 2000b; 
Kelly et al., 2003; Nolan et al., 2003).     
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4.1.2 RESULTS 
 
4.1.2.1 A2AR BLOCKADE PREVENTS THE LPS-INDUCED BIOCHEMICAL 
MODIFICATIONS IN THE RAT HIPPOCAMPUS 
 
Previous studies by our collaborators have suggested that the LPS-induced increase in 
hippocampal IL-1β and neuronal downstream signalling events (i.e. activation of kinases of the stress 
pathway) mediate the neuroinflamation-induced depression of synaptic plasticity in the dentate gyrus 
(DG) (Vereker et al., 2000b; Kelly et al., 2003; Nolan et al., 2003). Here it was asked whether the 
ability of SCH58261, an A2AR selective antagonist, to reverse the LPS induced impairment in LTP, as 
was shown in a recent work from our group (Rebola et al., 2011), might be paralleled by a similar 
ability to attenuate the LPS-induced increases in the phosphorylation of p38, JNK and in the activation 
of caspase-3. The LPS-induced activation of JNK and p38 was assessed by Western blot analysis of the 
phosphorylated forms of the kinases. Analysis of caspase-3 activity in hippocampal slices was assessed 
using an enzymatic kit in which the cleavage of caspase-3 substrate (Ac-DEVD-AFC peptide, from 
Alexis) gave origin to a fluorescent product, measurable in a spectrophotometer (at 400 nm excitation 
and emission at 505 nm), as previously described by (Nolan et al., 2003). As shown in Figure 1A-D, 
LPS increased the density of the phosphorylated forms of p38 and of JNK in hippocampal tissue to 
131±6% and 129±9% of control values, respectively (n=5, P<0.05). Administration of SCH58261 did 
not significantly change the density of the phosphorylated forms of p38 or JNK (103±8% and 98±9% 
of control, respectively; P>0.05 versus control, n=5), but prevented the LPS-induced increases in both 
p38 and JNK (100±5% and 98±9% of control; P<0.05 versus LPS, n=5). Activated MAPKs play 
different roles in different cell types in the central nervous system. Immunohistochemistry analysis was 
used to evaluate whether LPS-induced (4 h after LPS ip administration) p38 was on neurons or on 
microglia cells. This was achieved through double-labelling with antibodies directed against the 
phosphorylated form of p38 and against the nuclear neuronal marker (NeuN) or against the microglia 
marker CD11b. As shown in Figure 1E, LPS triggered an enhancement of the immunoreactivity of the 
phosphorylated form of p38 throughout the dentate gyrus (n=3), which was co-localised both with 
neuronal markers (NeuN, left panel of Fig. 1F) and with a microglia marker (CD11b, right panel of Fig. 
1F).  
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FIGURE 1: Effect of LPS administration (200 μg in 200 μl, ip) and/or the selective antagonist of A2AR, SCH58261 (5 
μl of a 50 nM solution, icv) on the density of the phosphorylated forms of two stress activated kinases, p38 (panels A 
and C) and JNK (panels B and D) in the rat dentate gyrus of the hippocampus. The rats were separated into 4 groups: 
1) control (icv and ip administration of saline); 2) SCH58261 (SCH58261 icv and saline ip); 3) LPS (saline icv and LPS ip); 
4) LPS + SCH58261 (SCH58261 icv and LPS ip). Four hours after LPS injection, the animals were sacrificed, the 
hippocampus dissected and homogenized for Western blot analysis. Panels A and B show a Western blot membrane 
comparing the density of immunoreactivity of the phosphorylated form of p38 (panel A) and of JNK (panel B) in the 
hippocampus of each group of rats. The re-probing of the same membranes against α-tubulin is displayed below. Panels C 
and D present the average results (mean ± SEM), obtained in 3-5 experiments, comparing the density of the  
immunoreactivity of the phosphorylated form of p38 (panel C) and of JNK (panel D) in the hippocampus of each group of 
rats. *P<0.05 between the indicated bars. Note that SCH58261 did not modify the density of phosphorylation of these two 
activated stress proteins but prevented the ability of LPS to increase their density. Immunohistochemical analysis confirmed 
an enhanced density of the phosphorylated p38 immunoreactivity in the dentate gyrus of LPS-treated rats (right photograph 
of panel E) compared to control (left photograph of panel E). This LPS-induced enhancement of phosphorylated p38 
immunoreactivity was co-localised with NeuN (neuronal nuclei), a marker of neurons (left set of photograph of panel F: i-
NeuN; ii-phosphorylated p38; iii-Hoescht 33342, which stains DNA; iv-merging of the previous 3 photographs), as well as 
with CD11b, a marker of microglia (right set of photograph of panel F: i-CD11b; ii-phosphorylated p38; iii-Hoescht 33342, 
which stains DNA; iv-merging of the previous 3 photographs). These photographs are representative of 
immunohistochemical analysis carried out in 3 LPS-treated rats. 
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The location of the LPS-induced activation of caspase-3 was also assessed in this way, in the 
dentate gyrus. In parallel with the effect of LPS on phosphorylation of JNK and p38, we report a 
significant increase in the activity of caspase-3 in hippocampal tissue prepared from LPS-treated rats 
comparing to control animals (n=5, P<0.05; Fig. 2A). Administration of SCH58261 did not 
significantly change the activity of caspase-3 (P>0.05, n=3), but prevented the LPS-induced increase of 
caspase-3 activity so that there was a significant difference (P<0.05) in the enzyme activity in 
hippocampal tissue prepared from LPS-treated rats and in tissue prepared from rats which were treated 
with LPS and SCH58261 (Fig. 2A). Immunohistochemical analysis revealed that LPS caused a 
scattered increase of activated (cleaved) caspase-3 in the dentate gyrus (Fig. 2B), which was not co-
localised with neuronal markers (NeuN, Fig. 2C) but rather with a microglia marker (CD11b, Fig. 2D). 
 
 
 
 
 
 
 
  
4. RESULTS  A2A receptor control of neuroinflammation 
84 
 
 
 
FIGURE 2: Effect of LPS administration (200 μg in 200 μl, ip) and/or the selective A2AR antagonist, SCH58261 (5 μl 
of a 50 nM solution, icv) on the activity of caspase-3 in the rat hippocampus. In panel A, the rats were separated into 4 
groups: 1) control (icv and ip administration of saline); 2) SCH58261 (SCH58261 icv and saline ip); 3) LPS (saline icv and 
LPS ip); 4) LPS + SCH58261 (SCH58261 icv and LPS ip); four hours after LPS injection, the rats were sacrificed, the 
hippocampus dissected and homogenized for the fluorimetric analysis of caspase-3 activity, quantified by the hydrolysis of 
its selective substrate, Ac-DEVD-AFC peptide, which produces a fluorescent product (emission at 505 nm after excitation 
at 400 nm). In panel A, the ordinates represent the activity of caspase-3 expressed in nmol of 7-amino-4-
trifluoromethylcoumarine (AFC), normalized by the concentration of protein in each sample. Each bar represents the mean 
± SEM of 5 experiments. *P<0.05 between the indicated bars. Note that SCH58261 did not modify the activity of caspase-3 
but prevented the LPS-induced increase in caspase-3 activity. Immunohistochemical analysis confirmed an enhanced 
density of activated (cleaved) caspase-3 immunoreactivity in the dentate gyrus of LPS-treated rats (right photograph of 
panel B) compared to control (left photograph of panel B). Panel C displays triple-labelling immunohistochemical analysis 
of cleaved caspase-3 (red), the neuronal marker (NeuN, green) and Hoescht 33342-labelled nuclei (blue) in control (left 
photograph) and LPS-treated rats (right photograph) showing that cleaved caspase-3 was not co-localised with NeuN 
immunoreactivity. Panel D displays triple labelling immunohistocehmical analysis of cleaved caspase-3 (red), the microglia 
marker (CD11b, green) and Hoescht 33342-labelled nuclei (blue) in control (left photograph) and LPS-treated rats (right 
photograph) showing that cleaved caspase-3 was instead co-localised with CD11b immunoreactivity. These photographs are 
representative of immunohistochemical analysis carried out in 3 LPS-treated rats. 
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4.1.2.2 A2A RECEPTORS BLOCKADE PREVENTS THE LPS-INDUCED ACTIVATION OF 
MICROGLIA 
 
The protective effect of the blockade of A2AR against LPS-induced inhibition of LTP might 
either result from the ability of neuronal A2AR to control the effects of inflammatory mediators on 
neurons or result from the ability of A2AR to control the reactivity of microglia and the consequent 
generation of inflammatory mediators. Thus, it was tested if the blockade of A2AR could control the 
activation of microglia and the previously-described LPS-induced increase in IL-1β (Vereker et al., 
2000a). The identification of microglial cells was carried out by immunohistochemical detection of the 
CD11b antibody, a validated marker of microglia cells (Jensen et al., 1997). As presented in Figure 3, it 
can be concluded that 4 hours after administration of LPS, there is an increase in the number of 
elements labelled with the anti-CD11b antibody (compare panels A and C from Fig. 3). Furthermore, 
the labelled profiles displayed a more intense immunoreactivity and a morphology characteristic of 
early activated microglia in situ, i.e., enlarged cell body with short and thick processes (Fig. 3C) 
(Jensen et al., 1997). Administration of SCH58261 did not modify the profile of CD11b 
immunoreactivity compared to control (n=4; Fig. 3B), but prevented the LPS-induced changes in 
CD11b immunoreactivity (n=4; Fig. 3D). 
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FIGURE 3: Effect of LPS administration (LPS, 200 μg in 200 μl, ip) and/or the selective A2AR antagonist, SCH58261 
(5 μl of a 50 nM solution, icv) on the appearance of reactive microglia in the rat dentate gyrus. The animals were 
separated into 4 groups: 1) control (icv and ip administration of saline; panel A); 2) SCH58261 (SCH58261 icv and saline 
ip; panel B); 3) LPS (saline icv and LPS ip; panel C); 4) LPS + SCH58261 (SCH58261 icv and LPS ip; panel D). Four 
hours after the drug treatments, the rats were perfused with paraformaldehyde for fixation of the brain, which was sliced 
into 20 μm sections. The coronal sections were labelled by immunohistochemistry using a mouse anti-CD11b antibody (a 
marker of microglial cells) and a goat anti-mouse secondary antibody labelled with Alexa Fluor 488 (green fluorescence). 
The inserted figures in each panels display the pattern of labelling and morphology of a single microglia cell, obtained from 
the presented picture at higher magnification. The pictures presented are representative of 3-4 experiments with 
qualitatively similar results. Note that LPS increase the general density of CD11b positive elements (panel C) displaying a 
morphology characteristic of activated microglial cells (see inserted Figure in panel C) and these LPS-induced 
modifications were prevented by SCH58261 (panel D), which by itself was devoid of effects (panel B). 
 
Accordingly, 4 hours after the administration of LPS, there was an increase in the density of 
markers of microglia activation, such as the MHC-II protein CR3/43 (n=7, Fig. 4A) and the iNOS 
(n=7, Fig. 4B). The administration of either SCH58261 or of another selective A2AR antagonist, MSX-
3, did not modify the density of each of these microglia markers, but prevented the LPS-induced 
changes in both CR3/43 (n=3-4, Fig. 4A) and iNOS (n=3-4, Fig. 4B).  
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FIGURE 4: Effect of LPS administration (200 μg in 200 μl, ip) and/or the A2AR selective antagonists, SCH58261 (5 μl 
of a 50 nM solution, icv) or MSX-3 (5 μl of a 1 μM solution, icv), on the density of markers of activated microglia 
(CR3/43 and iNOS) in the rat dentate gyrus. Rats were separated into 4 groups: 1) control (icv and ip administration of 
saline); 2) A2AR antagonist-treated (SCH58261 or MSX-3 icv and saline ip); 3) LPS-treated (saline icv and LPS ip); 4) LPS 
+ A2AR antagonist-treated (SCH58261 or MSX-3 icv and LPS ip). Four hours after LPS injection, the animals were 
sacrificed and one hippocampus was used for Western blot analysis whereas the other was used for real-time PCR analysis. 
Panels A and B present a Western blot result comparing the immunoreactivity density of the MHC-II protein CR3/43 (panel 
A) and of iNOS (panel B) in the hippocampus of each group of rats. The re-probing of the same membranes against α-
tubulin is displayed below. The graph bars below show the average results (mean ± SEM), obtained in 3-4 experiments, 
comparing the immunoreactivity density of the 2 markers of microglia activation; *P<0.05 between the indicated bars. Note 
that neither SCH58261 nor MSX-3 modified the density of each of these proteins but prevented the ability of LPS to 
increase their density. 
 
Further linking the control of LPS-induced effects by the blockade of A2AR with the control of 
the activation of microglia, it is observed a parallel increase in the expression of both CD11b (n=7; Fig. 
5C) and of A2AR mRNA (n=7, Fig. 5D) in the hippocampus, measured 4 h after the administration of 
LPS. 
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FIGURE 5: Effect of LPS administration (200 μg in 200 μl, ip) on the expression of CD11b and of A2ARs in the rat 
dentate gyrus. Rats were separated into 2 groups: 1) control (icv and ip administration of saline); 2) LPS-treated (saline icv 
and LPS ip). Four hours after the LPS injection, the animals were sacrificed; one hippocampus was used for Western blot 
analysis (results presented in Fig. 4) and the other for real-time PCR analysis. Panels A and B display the expression of 
CD11b (panel A) and of A2AR (panel B) 4 h and 45 min after LPS administration. CD11b and A2AR mRNA levels 
(copies/μl) were determined with quantitative real time PCR (QRT-PCR) and normalized to the level of β-actin mRNA. 
Bars represent mean ± SEM from 7 different rats, run in triplicate; *P<0.05 between bars. 
 
In accordance with a direct ability of A2AR to control microglia activation, it was found that 
LPS treatment caused a significant increase in hippocampal concentration of IL-1β (n=5, P<0.05; Fig. 
6). Administration of SCH58261 alone did not significantly change (P>0.05, n=3) IL-1β concentration, 
but prevented the LPS-induced increase in this pro-inflammatory cytokine (n=3, P<0.05; Fig. 6). 
 
 
 
FIGURE 6: Effect of the administration of LPS (200 μg in 200 μl, ip) and/or the selective antagonist of adenosine 
A2AR, SCH 58261 (5 μl of a 50 nM solution, icv) on the activity levels of interleukin-1β in the rat hippocampus. The 
rats were separated into 4 groups: 1) control (administration icv and ip of saline); 2) SCH 58261 (SCH 58261 icv and saline 
ip); 3) LPS (saline icv and LPS ip); 4) LPS + SCH 58261 (SCH 58261 icv and LPS ip). Four hours after LPS injection, the 
rats were sacrificed, the hippocampus dissected and homogenized for analysis by ELISA of IL-1β levels. Each bar 
represents the mean±SEM of 5 experiments. *P<0.05 between the indicated bars. Note that SCH 58261 did not modify the 
levels of IL-1β but prevented the LPS-induced increase in IL-1β levels. 
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4.1.3 DISCUSSION 
 
 
From the present study we conclude that the blockade of adenosine A2AR prevents the induction 
of a neuroinflammation triggered by LPS and the consequent biochemical modifications in the 
hippocampus. As it is well established in the literature, LPS triggers an inflammatory response that 
results in elevated levels of the pro-inflammatory cytokine IL- 1β in the brain (Buttini and Boddeke, 
1995; Quan et al., 1998; Tonelli and Postolache, 2005). This cytokine, in turn, mediates most of the 
consequences of LPS administration, such as neuronal dysfunction (Vereker et al., 2000a; Allan et al., 
2005). The mechanism by which peripherally administered LPS leads to neuroinflammation is known 
to involve the activation of CNS microglia (Kim et al., 2000), independent of systemic inflammation 
(Chakravarty and Herkenham, 2005). The mitogen-activated protein kinases (MAPKs) pathway is 
triggered both in neurons and glia in response to inflammation. In particular, activation of stress 
kinases like p38 and c-Jun N-terminal kinase (JNK) has been shown to occur in neurons, which 
negatively impact synaptic function leading to depression of LTP in dentate gyrus (Vereker et al., 
2000b; Kelly et al., 2003; Nolan et al., 2003; Srinivasan et al., 2004; Barry et al., 2005). In parallel, 
poly-ADP ribose polymerase (PARP) cleavage and activation of caspase-3 are up-regulated leading to 
a delayed LPS-induced neuronal apoptosis (Hauss-Wegrzyniak et al., 2002; Nolan et al., 2003). In the 
present study, it was observed that the blockade of A2ARs, using its selective antagonist SCH58261 see 
(Fredholm et al., 2005) for a review, prevented the principal modifications caused by LPS that are 
associated with the LPS-induced neuroinflammation and neuronal dysfunction. Administration of 
SCH58261 prevented the ability of LPS to activate p38, JNK and the apoptotic-mediator caspase-3. In 
another part of the presented work not discussed here, it was shown that SCH58261 was also able to 
prevent LPS-induced depression of LTP (Rebola et al., 2011) which is unlikely to be a direct synaptic 
effect of the A2AR antagonist (although this cannot be excluded), since this A2AR antagonist has 
previously been shown to inhibit rather than to increase LTP at other hippocampal synapses (Rebola et 
al., 2008; Costenla et al., 2011).  
It is therefore concluded that the blockade of A2AR conferred a robust protection in this model 
of neuroinflammation, as observed in other in vivo models of brain neurotoxicity, reviewed in (Cunha, 
2005; Chen et al., 2007). In the presented study, we also showed that antagonism of A2AR also 
decreased the extent of neuroinflammation caused by LPS. This was concluded by simultaneous ability 
of A2AR blockade to prevent the LPS-induced recruitment and activation of microglia and also the 
increase in IL-1β levels, a master regulator of neuroinflammation that contributes to neurodegeneration 
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(Allan et al., 2005). Furthermore, the observed ability of A2AR to prevent biochemical changes, such as 
increased phosphorylation/activation of p38 and increased cleaved caspase-3, found to be associated 
with microglia dynamics, see (Wirenfeldt et al., 2007; Ohnishi et al., 2010), further argues for a direct 
ability of A2AR on microglia cells to control LPS-induced neuroinflammation. However, it remains to 
be determined if the A2AR mainly control the chemotaxis or the activation of microglial cells. This 
might require analysis in vivo, since there is a notable difference between the impact of A2AR on 
microglia reactivity in vivo, the presented results shown in (Rebola et al., 2011) and also (Pierri et al., 
2005; Melani et al., 2006b; Minghetti et al., 2007; Yu et al., 2008), and in purified microglial cells in 
culture (Orr et al., 2009; van der Putten et al., 2009; Dai et al., 2010). It is likely that other factors or 
cell types in the brain parenchyma may play a crucial role in formatting the pattern of A2AR-mediated 
control of microglial reactivity (Saura et al., 2005; Dai et al., 2010). Furthermore, the role of A2AR in 
controlling neuroinflammation may also depend on the cell types involved in supporting brain 
inflammation. In fact, it is notable that in experimental situations associated with disruption of the 
blood brain barrier and invasion of the brain by peripheral inflammatory cells, such as brain 
hemorrhage (Mayne et al., 2001) or prolonged stenosis (Duan et al., 2009), it is the activation rather 
than the blockade of A2AR that control neuroinflammation. However, when resident microglia triggers 
and sustains neuroinflammation, such as in early periods after LPS administration (Chakravarty and 
Herkenham, 2005), the presented results indicate that it is the blockade of A2AR that controls 
neuroinflammation. These results are in agreement with a recent report describing the ability of chronic 
caffeine consumption (a non-selective antagonist of adenosine receptors) to control neuroinflammation 
(Brothers et al., 2010) and experimental autoimmune encephalomyelitis (Chen et al., 2010). A question 
that still remains to be resolved is the identity of the cell type in which A2ARs are located that mount 
the neuroinflammatory response. A previous study concluded that it were the A2ARs located in bone-
marrow cells infiltrating in the brain parenchyma that were responsible for the control of cortical 
infarct after middle cerebral artery occlusion, while blockade of A2ARs on brain resident cells only 
accounted for 20% of observed neuroprotection (Yu et al., 2004). However, ischemic brain injury 
causes an extensive disruption of the blood-brain barrier and consequent massive invasion of peripheral 
lymphoid cells, far greater than that occurring in other neurodegenerative conditions, reviewed in 
(Ballabh et al., 2004). Accordingly, in another similar study using a model of Parkinson‟s disease 
based on MPTP intoxication, we found that it was non-neuronal brain resident A2AR that contributed 
for neuroprotection, rather than infiltrating bone marrow-derived cells; this was based on the combined 
use of forebrain neuronal-selective A2AR knockout mice and bone marrow transplants after bone 
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marrow destruction by γ-irradiation (Yu et al., 2008). Given that the neuroinflammation triggered by 
intraperitoneal administration of LPS requires a response from CNS-resident cells independent of 
systemic cytokine effects (Chakravarty and Herkenham, 2005), it is most likely that it is A2AR present 
in microglia (Saura et al., 2005) or astrocytes (Nishizaki et al., 2002) that play a role in the control of 
LPS-induced neuroinflammation. The currently observed parallel increase in the expression of A2AR, 
together with markers of microglial activation in brain tissue, also observed by others in cultured cells 
(van der Putten et al., 2009) and upon different brain insults (Trincavelli et al., 2008; Yu et al., 2008), 
further strengthens the hypothesis that it may be A2AR in resident microglia cells that control 
neuroinflammation in conditions where the invasion of the brain parenchyma by peripheral 
inflammatory cells is limited. This observed ability of A2AR to control microglia recruitment and 
activation and the increase in brain levels of IL-1β prompts the hypothesis that the A2AR-mediated 
control of the genesis of neuroinflammatory processes in pathological conditions may play an 
important hitherto unrecognised role in the neuroprotective effect afforded by A2AR blockade. This 
does not rule out the possibility that A2AR located in neurons (Rebola et al., 2005a) may also contribute 
to the control of neurodegeneration, see (Dall'Igna et al., 2003; Mojsilovic-Petrovic et al., 2006; Silva 
et al., 2007; Stone and Behan, 2007; Canas et al., 2009). However, it is important to note that the 
blockade of A2AR is particularly effective when tested in vivo. In fact, blockade of A2AR affords a more 
robust neuroprotection in hippocampal regions upon in vivo ischemia (Chen et al., 1999) when 
compared with the effect found upon chemical ischemia in hippocampal slices in vitro (Latini et al., 
1999; Higashi et al., 2002). This argues that mechanisms other than a direct neuronal protection, such 
as the control of neuroinflammation, might be prominent in the neuroprotection afforded by A2AR 
blockade. Thus, the present study provides evidence to support the hypothesis that blockade of A2AR 
abrogates the LPS-induced neuroinflammation and the consequent neuronal dysfunction in the 
hippocampus. These observations support the hypothesis that the control of neuroinflammation by 
A2AR might be a common mechanism underlying the robust neuroprotection afforded by antagonists of 
these receptors against a diversity of neurodegenerative conditions which involve neuroinflammation, 
such as epilepsy, Alzheimer‟s or Parkinson‟s disease. 
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4.2 BLOCKADE OF A2A RECEPTORS PREVENTS INTERLEUKIN-1β ASSOCIATED 
NEURONAL TOXICITY 
 
4.2.1 INTRODUCTION 
  
Neuroinflammation is a common feature of most neurological disorders and pathological 
situations in the brain (Marchetti and Abbracchio, 2005; Skaper, 2007). The CNS has specific immuno-
competent cells (microglia) (Graeber, 2010) and mediators of the inflammatory response (astrocytes) 
(Zhang et al., 2010a) that when activated release a large number of inflammatory mediators, including 
cytotoxic reactive species and pro-inflammatory cytokines (Chakraborty et al., 2010). Pro-
inflammatory cytokines are usually expressed in low levels in the healthy brain where they modulate 
several physiological functions including responsiveness to different stressors (Vitkovic et al., 2000; 
Goshen and Yirmiya, 2009), sleep (Krueger et al., 2001; Opp, 2005 2003 #2943) and synaptic 
plasticity (Schneider et al., 1998; Liu et al., 2007; McAfoose and Baune, 2009; Yirmiya and Goshen, 
2011). However, during neuroinflammation the expression and release of pro-inflammatory cytokines 
greatly increases which is responsible for some of the inflammation-induced deleterious effects (Allan 
and Rothwell, 2001). In this respect, two of the best studied pro-inflammatory cytokines are the tumor 
necrosis factor alpha (TNF-α) and the interleukin-1 beta (IL-1β) (Gosselin and Rivest, 2007). During 
neuroinflammation, TNF-α can either trigger cell death or promote cell survival (McCoy and Tansey, 
2008; Kraft et al., 2009) whereas the IL-1β has been consistently associated with the increased 
susceptibility of neurons to excitotoxicity and the inhibition of synaptic plasticity (McAfoose and 
Baune, 2009; Yirmiya and Goshen, 2011). 
Despite being mainly released from microglia and astrocytes, both TNF-α and IL-1β as well as 
their receptors are expressed in neurons (Wolvers et al., 1993; Wong and Licinio, 1994; Yabuuchi et 
al., 1994) and some of their deleterious effects, such as the priming of neurons to excitotoxicity or the 
depression of long-term potentiation (LTP), arises from a direct interaction with the neuronal 
membranes, as gauged by the parallel in vivo (Vereker et al., 2000a; Ma et al., 2002; Kelly et al., 2003; 
Chaparro-Huerta et al., 2005; Bernardino et al., 2008; Chapman et al., 2010; Rebola et al., 2011) and 
in vitro results (Curran et al., 2003; Viviani et al., 2003; Leonoudakis et al., 2004; Zhang et al., 2008; 
Gardoni et al., 2011). The activation of mitogen-activated protein kinases (MAPKs) by these pro-
inflammatory cytokines on hippocampal neurons seems to underlie both the IL-1β-mediated and the 
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TNF-α-mediated inhibition of long-term potentiation (LTP) (Vereker et al., 2000b; Curran et al., 2003; 
Kelly et al., 2003; Butler et al., 2004; Pickering et al., 2005). Moreover, the mechanism through which 
these cytokines prime neurons to excitotoxic death have also been shown to involve the activation of 
MAPKs and in particular of the p38 MAPK and of the c-jun-N-terminal kinase (JNK) (Nolan et al., 
2003; Srinivasan et al., 2004; Barry et al., 2005; Chaparro-Huerta et al., 2005; Moore et al., 2007; 
Zhang et al., 2010b). Accordingly, the targeting of these pathways has been shown to control 
neurodegeneration (Borsello and Forloni, 2007; Munoz and Ammit, 2010). 
We have previously developed the concept that adenosine A2A receptors (A2ARs) control 
synaptic plasticity, reviewed in (Cunha, 2008), and neurodegeneration, reviewed in (Cunha, 2005; 
Chen et al., 2007). In addition, we have already tackled the question of whether A2ARs can control 
neuroinflammation and found that the blockade of A2ARs prevented the lipopolysaccharide (LPS)-
induced effects on the hippocampus, including the recruitment of microglia, the rise in IL-1β levels and 
the IL-1β-induced depression of LTP (Rebola et al., 2011). Accordingly, it is known that the 
adenosinergic system is tightly coupled to that of pro-inflammatory cytokines (Sperlagh et al., 2004; 
Zhu et al., 2006; Abbracchio and Ceruti, 2007) and that the activation of adenosine A2ARs is involved 
in the inflammation-induced damage (Stone and Behan, 2007; Dai et al., 2010; Rebola et al., 2011). In 
line with these findings, in the following work, it was tested whether A2ARs could also control the 
direct impact of IL-1β and TNF-α on neurons. This was tested in hippocampal neuronal cultures since 
hippocampal neurons express both of these pro-inflammatory cytokines and their receptors (Wong and 
Licinio, 1994; Yabuuchi et al., 1994; Ogoshi et al., 2005; Figiel and Dzwonek, 2007; Harry et al., 
2008; Gardoni et al., 2011) and their physio-pathological impact is well characterised in this brain 
region (Kelly et al., 2003; Pickering and O'Connor, 2007).         
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4.2.2 RESULTS 
 
4.2.2.1 EFFECT OF INTERLEUKIN-1β AND TUMOR NECROSIS FACTOR-α ON 
NEURONAL MITOGEN-ACTIVATED PROTEIN KINASES 
 
As previously stated, most of the cellular functions regulated by pro-inflammatory cytokines 
and in particular some of their deleterious effects, are triggered by the activation of MAPKs (Allan and 
Rothwell, 2001; Pickering et al., 2005). The MAPK protein family comprises three main groups: the 
extracellular signal-regulated protein kinases (ERK) and the stress-activated protein kinases (SAPK) 
p38 and c-jun N-terminal kinases (JNK) (Schulte and Fredholm, 2003). The phosphorylation of these 
proteins and the activation of its enzymatic activity are closed linked events and can be used as a 
measure of enzyme activation (Schulte and Fredholm, 2003). Thus, to begin studying the effects of pro-
inflammatory cytokines directly on neurons without the interference of glial cells, rat hippocampal 
cultured neurons, grown during 7 days in vitro (DIV), were exposed to IL-1β (1-100 ng/ml) and to 
TNF-α (1-5 ng/ml) and the impact of this exposure on the activation (i.e. phosphorylation) of different 
MAPKs was evaluated through Western blot analysis. It was first observed that IL-1β (10 ng/ml) 
rapidly activates JNK in cultured neurons in a transient way as shown in Figure 1A, reaching 
significance only at 15 min of incubation (131.2 ± 9.4 % of control; n= 8; p<0.01) and decreasing to 
basal levels thereafter until 3 hours of exposure. The activation of JNK also depended on the 
concentration of IL-1β, being significant at 10 and 100 ng/ml (p<0.001, n=8) (Fig. 1B). 
Since the highest concentration of IL-1β produced more robust results, we tested the impact of 
incubation for 5-15 minutes with 100 ng/ml of IL-1β on the activation (phosphorylation) of p38. As 
shown in Figure 2A, phosphorylated p38 levels were significantly (P<0.05) increased (192.8 ± 18.8 %, 
n= 5) in cultured neurons after 15 minutes of incubation with IL-1β. However, IL-1β (100 ng/ml) failed 
to activate ERK in hippocampal cultured neurons in the same period of incubation, 10-15 minutes (73.1 
± 16.6 % and 113.0 ± 13.6 % of control, respectively; n= 4), as shown in Figure 2C. 
Immunocytochemical analysis of hippocampal cultured neurons confirmed that the exposure to 100 
ng/ml of IL-1β for 15 minutes triggered an evident increase in the immunoreactivity of phosphorylated 
JNK throughout the neurons (Fig. 1C) and of phosphorylated p38, mainly in neuronal cell bodies (Fig. 
2B).    
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FIGURE 1: IL-1β activates JNK in hippocampal neurons in a time and concentration dependent manner. 
Hippocampal neuronal cultures, 7 DIV, were exposed to a concentration of 10 ng/ml of IL-1β (prepared in Krebs buffer, 
pH7.4) for different times (5, 10, 15, 20, 25, 30, 60 and 180 min) (A) and to different concentrations of IL-1β (1, 10 and 100 
ng/ml prepared in Krebs buffer, pH 7.4) during 15 min (B) after which cells were immediately lysed on ice in a minimum 
volume of RIPA‟s buffer. The immunoreactivity of the activated (phosphorylated) form of c-jun N-terminal kinases (p-
JNK) was quantified by Western blot analysis. Membranes were re-probed for the total form of JNK and the activity of JNK 
was calculated as the ratio between the immunoreactivity of the phosphorylated form and the immunoreactivity of the total 
form of the protein (p-JNK/JNK). The results are presented as percentage of control (neurons exposed to vehicle only). Data 
corresponds to cultures from 8 pregnant Wistar female rats (n=8) and is presented as mean ± SEM; **p<0.01 and 
***p<0.001. In the panel C are representative immunocytochemistry images of hippocampal neurons probed for the 
activated (phosphorylated) form of JNK (green fluorescence) which colocalizes with the class III β-tubulin, a constitutive 
protein exclusively of neuronal microtubules (red fluorescence). In blue are the neuronal nuclei stained with DAPI.  
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FIGURE 2: IL-1β activates p38 (but not ERK) in hippocampal neurons in a time dependent manner. Hippocampal 
neuronal cultures, 7 DIV, were exposed to 100 ng/ml of IL-1β (prepared in Krebs buffer, pH7.4) for different times 
(corresponding to the optimal conditions in which it was observed the activation of JNK by IL-1β, showed in Figure 1) after 
which cells were immediately lysed on ice in a minimum volume of RIPA‟s buffer. The immunoreactivity of the activated 
(phosphorylated) form of p38 (p-p38) was quantified by Western blot analysis. Membranes were re-probed for the total 
form of p38 (p38) and the activity of p38 was calculated as the ratio between the immunoreactivity of the p-p38 and the 
immunoreactivity of the p38 (p-p38/p38) (A). The same procedure was done for the activity of ERK (C). The results are 
presented as percentage of control (neurons exposed to vehicle only). Data corresponds to cultures from 5 pregnant Wistar 
female rats (n=5) and is presented as mean ± SEM; *p<0.05. In the panel B are representative immunocytochemistry images 
of hippocampal neurons probed for the activated (phosphorylated) form of p38 (red fluorescence) which colocalizes with 
synaptophysin (green fluorescence). In blue are the neuronal nuclei stained with DAPI. Note that p38 is mainly activated in 
the cell body of neurons. 
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On the other hand, TNF-α (5 ng/ml) strongly induced the activation (phosphorylation) of the 
p38 MAPK on hippocampal neurons in a transient way and peaking at 10 min of incubation (384.7 ± 
51.1 % of control; p< 0.01; n= 8) (Fig. 3B) but failed to activate both JNK (Fig. 3A) and ERK (Fig. 
3C) at the same times. The values of the ratio between the phosphorylated form of p38 (p-p38) and the 
total form of the protein (p38) were still higher than the control values at 15 min and 20 min of 
incubation with TNF-α (277.7 ± 56.1 % of control; p<0.05 and 190.1 ± 71.1 % of control, respectively;  
n= 6-7) decreasing rapidly to control values (129.0 ± 16.5 % of control; n= 6) at 25 min of exposure of 
the neurons to the cytokine (Fig. 3B). At the lowest concentration, TNF-α did not activate any of the 
MAPKs at any of the incubation periods tested (Fig. 3A-C). 
Immunocytochemical analysis of hippocampal cultured neurons confirmed that the exposure to 
5 ng/ml of TNF-α for 10 min triggered an evident increase in the immunoreactivity of phosphorylated 
p38 throughout the neurons (Fig. 3D).  
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Figure 3: TNF-α activates p38 (but not JNK or ERK) in hippocampal neurons in a time and concentration 
dependent manner. Hippocampal neuronal cultures, 7 DIV, were exposed to TNF-α (1 or 5 ng/ml) (prepared in Krebs 
buffer, pH 7.4) for different times after which cells were immediately lysed on ice in a minimum volume of RIPA‟s buffer. 
The immunoreactivity of the activated (phosphorylated) forms of the mitogen-activated  protein kinases (MAPKs), p-JNK, 
p-p38 and p-ERK, was quantified by Western blot analysis. Membranes were re-probed for the total form of the MAPKs 
(JNK, p38 and ERK) and their activity was calculated as the ratio between the immunoreactivity for the phosphorylated 
forms and the immunoreactivity for the respective total form of the proteins. The exposure of neurons to TNF-α (1 and 5 
ng/ml) did not activate JNK (panel A) or ERK (panel C) but activated p38 in a transient and concentration dependent 
manner (panel B). In the panel D are representative immunocytochemistry images of hippocampal neurons probed for the 
activated (phosphorylated) form of p38 (red fluorescence) which colocalizes with synaptophysin (green fluorescence).  
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4.2.2.2 BLOCKADE OF A2A RECEPTORS PREVENTS THE INTERLEUKIN-1β-INDUCED 
ACTIVATION OF NEURONAL MITOGEN-ACTIVATED PROTEIN KINASES  
 
The key question directing this study was to determine if A2A receptors control the impact of the 
pro-inflammatory cytokines IL-1β and TNF-α on neurons. For this purpose, it was tested the ability of 
a previously validated A2AR antagonist, SCH58261, to prevent both the IL-1β-induced activation of 
p38 and of JNK and the TNF-α induced activation of p38 in cultured hippocampal neurons. As shown 
in Figure 4, the addition of SCH58261 (50 nM), 20 min before exposing neurons to IL-1β (100 ng/ml) 
for 15 minutes prevented the IL-1β-induced phosphorylation of p38 (108.0 ± 20.2 % of control in the 
presence of IL-1β and SCH58261 comparing with 195.5 ± 18.8 % of control in the presence of IL-1β 
alone; n= 6; p<0.05 between IL-1β and control and between SCH58261 + IL-1β and IL-1β) (Fig. 4A) 
and of JNK (86.6 ± 14.6 % of control in the presence of IL-1β and SCH58261 comparing with 142.3 ± 
9.1% of control in the presence of IL-1β alone; n= 7; p<0.05 between IL-1β and control and p<0.01 
between IL-1β and SCH58261 + IL-1β)  (Fig. 4B) but the addition of SCH58261 (50 nM) 20 min 
before exposing neurons to TNF-α (5 ng/ml) for 10 minutes did not prevent the TNF-α-induced 
phosphorylation of p38 (435.4 ± 65.7 % of control in the presence of SCH58261 + TNF-α comparing 
with 436.4 ± 60.7 % of control in the presence of TNF-α alone; n= 7; p<0.01 between the two treated 
groups and the control group) (Fig. 4C), whereas SCH58261 failed to affect p38 (112.8 ± 14.2 % of 
control, Fig. 4A and 112.4 ± 8.7 % of control, Fig. 4C; n= 6-7) or JNK phosphorylation  (89,1 ± 8,5% 
of control, Fig. 4B; n= 7) per se (n= 6-7). 
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Figure 4: Blockade of adenosine A2AR prevents IL-1β-induced activation of p38 and JNK, but not TNF-α-induced 
activation of p38, in hippocampal neurons. Hippocampal neuronal cultures, 7 DIV, were exposed to vehicle and/or A2AR 
selective antagonist, SCH582615 (50 nM) 20 min before adding 100 ng/ml IL-1β or TNF-α (5 ng/ml) (or vehicle for the 
control groups), for 15 and 10 min, respectively. After the incubations cells were immediately lysed on ice in a minimum 
volume of RIPA‟s buffer. The immunoreactivity of the activated (phosphorylated) form of p38 (p-p38), panels A and C, and 
of the activated form of JNK (p-JNK), panel B, was quantified by Western blot analysis. Membranes were re-probed for the 
total form of p38 and JNK, respectively, and the activity of both MAPKs was calculated as the ratio between the 
immunoreactivities of the phosphorylated and total forms of the proteins. The results are presented as percentage of control 
(neurons exposed to vehicle only). Data corresponds to cultures from 6 to 7 pregnant Wistar female rats (n=6-7) and is 
presented as mean ± SEM, *p<0.05 and **p<0.01 compared to control; #p<0.05 and ##p<.0.01 compared with neurons 
exposed to IL-1β only.  
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4.2.2.3 THE EFFECT OF INTERLEUKIN-1β ON NEURONAL MITOGEN-ACTIVATED 
PROTEIN KINASES IS OPERATED BY INTERLEUKIN-1 TYPE I RECEPTORS 
   
Since the blockade of A2ARs was able to prevent the IL-1β-induced signalling on neurons, it 
was tested the involvement of IL-1 type I receptors (IL-1RI) through which IL-1β signals. Thus, 
neurons were exposed for 30 min to the endogenous antagonist of IL-1RI, IL1Ra (5 µg/ml), which 
prevents the docking of the IL1β receptor accessory protein to form the hetero-trimeric complex that is 
necessary for signal transduction. Afterwards neurons were exposed to IL-1β for 15 min. As shown in 
the Figure 5, IL-1β (100 ng/ml) induced the phosphorylation of p38 (532.3 ± 85.5 % of control; n= 4; 
p<0.01 versus control) and of JNK (151.0 ± 22.1 % of control, n= 4; p<0.05 versus control) and IL1Ra 
prevented this IL-1β-induced phosphorylation of p38 (261.3 ± 50.2 % of control, n= 4, p<0.05 versus 
the absence of IL1Ra) (Fig. 5A) and attenuated the activation (phosphorylation) of JNK (123.0 ± 20.0 
% of control, n= 3) (Fig. 5B).  
 
FIGURE 5: IL-1β type I receptor (IL-1RI) mediates the IL-1β-induced phosphorylation of JNK and p38 in 
hippocampal cultured neurons. Rat hippocampal neuronal cultures with 7 days in vitro (DIV) were exposed to 
interleukin-1β (IL-1β, 100 ng/ml) for 15 minutes in the absence or in the presence of the antagonist of interlukin 1β type I 
receptor, IL-1Ra (5 µg/ml), added 30 min before IL-1β. Cells were then lysed on ice in a minimum volume of RIPA buffer 
for Western blot analysis to quantify the immunoreactivity of the activated (phosphorylated) form of p38 (p-p38, panel A) 
or of the activated form of JNK (p-JNK, panel B). In both panels, the bar graphs display the mean ± SEM of 3-4 
experiments and the blots below illustrate a representative experiment showing that IL-1Ra prevented the IL1β-induced 
phosphorylation of p38 (panel A) and JNK (panel B). In each experiment, membranes were first used to detect the phospho-
MAPK and then re-probed for the total amount of MAPK, so that the activation of each MAPK was calculated as a ratio 
between the phosphorylated and total immunoreactivities, which were expressed as percentage of control (CTR) values (i.e. 
in the absence of any added drug). *p<0.05 and **p<0.01 compared to control; #p<0.05 compared to the effect of IL1β in 
the absence of IL1Ra. 
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4.2.2.4 SYNAPTIC AND SUB-SYNAPTIC LOCALIZATION OF THE INTERLEUKIN-1β 
TYPE I RECEPTORS  
 
Albeit several effects operated by the IL-1β type I receptor (IL-1RI) have been reported to 
occur in brain cells (Allan et al., 2005; Lynch, 2010), little is known about the localization of the IL-1β 
type I receptor in neurons (Gardoni et al., 2011). Thus, it was investigated if IL-1RI is indeed located in 
native brain neurons, taking particular attention to its putative synaptic and sub-synaptic localization. 
For this purpose, first it was compared the density of IL-1RI immunoreactivity in total membranes and 
in synaptic membranes prepared from the hippocampus of adult rats. Total membranes, which are 
mostly comprised of glial and endothelial cell membranes, are enriched with IL-1RI relative to synaptic 
membranes (Fig. 6A). For instance, when using 30 µg of protein in the Western blot analysis, total 
membranes displayed significantly higher (P<0.05) IL-1RI immunoreactivity than synaptosomal 
membranes (43.7 ± 3.2 % compared to 31.1 ± 3.8 % of total immunoreactivity, respectively, n= 4). 
This difference was also observed when loading 60 µg of protein (Fig. 6A), but disappears as the signal 
becomes saturated at 90 µg of protein (Fig. 6A). Albeit mainly located outside synaptic regions, we 
further detailed the sub-synaptic distribution of IL-1RI. As shown in Figure 6B, IL-1RI was almost 
exclusively located at post-synaptic (46.9 ± 4.8 %) and pre-synaptic sites (40.0 ± 4.3 %) with a low 
density at peri-synaptic sites (13.1 ± 1.3 %, n= 3). 
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FIGURE 6: IL-1β type 1 receptor is present in membranes from nerve terminals, both presynaptically and 
postsynaptically. Panel A compares the immunoreactivity of interleukin 1β type 1 receptor (IL-1RI) in total membranes 
(comprising neuronal, glial and endothelial, membranes) and in membranes from purified nerve terminals (synaptosomes) 
prepared from the hippocampus of adult male Wistar rats. The graph display the mean ± SEM of 4 experiments and the blot 
below illustrates a representative experiment where it was always used 3 different protein quantities (30, 60, 90 µg) of both 
total and synaptic membranes of the same hippocampus in the same electrophoresis gel. The percentage of IL-1RI 
immunoreactivity for each amount of protein was calculated relative to the maximum immunoreactivity obtained for each 
Western blot membrane. *p<0.05 and ***p<0.0001 comparing the same quantities of total and synaptosomal membranes. 
Panel B shows the subsynaptic distribution of IL-1RI upon comparison of IL-1RI immunoreactivity in synaptosomal 
membranes (SYN) and in its fractionated fractions corresponding to pre- post- and extra-synaptic membranes (PRE, POST 
and EXTRA, respectively), which purity was gauged by the segregation of the active zone marker (SNAP-25), of the 
postsynaptic density marker (PSD-95) and of the extrasynaptic (vesicular) marker (synaptophysin), as show in panel C. The 
percentage of IL-1RI immunoreactivity was calculated relative to the maximum reactivity of each membrane. The data in 
the bar graphs are mean ± SEM of n=4.  
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4.2.2.5 BLOCKADE OF A2ARs PREVENTS THE INTERLEUKIN-1β-INDUCED 
EXACERBATION OF NEUROTOXICITY  
Pro-inflammatory cytokines, in particular IL-1β and TNF-α, can worsen the outcome of 
excitotoxic conditions (Pickering et al., 2005; Fogal and Hewett, 2008). After investigating the role of 
A2ARs on the neuronal transduction pathways recruited by IL-1β and TNF-α, next it was explored 
whether A2ARs can control the impact of IL-1β and TNF-α on neurotoxicity. First, it was investigated 
the effect of IL-1β on glutamate-induced neurodegeneration. This was achieved by incubating 
hippocampal neurons with IL1β (100 ng/ml) for 5 minutes before adding glutamate (100 µM) for a 
period of 25 min. After this time, the stimuli were washed and new neurobasal medium (without the 
antibiotic, glutamate and the B27 supplements) was added to the neurons which were kept at 37ºC in a 
95% O2-5% CO2 atmosphere until analysis, 24 h later. The evaluation of cell viability was performed 
using a syto-13 and propidium iodide (PI) staining, which are nucleic acid dyes that emit fluorescence 
at different wave lengths (green in the case of syto-13 and red in the case of PI). The nucleic acid dye 
syto-13 permeates the plasma membrane while the PI dye does not. Therefore, the cells with red 
fluorescence have disrupted plasma membranes and are unviable, while the cells with green 
fluorescence may either be viable (dark green fluorescence and bigger cell bodies) or dying (small, 
bright and fragmented green fluorescent nuclei).  As shown in Figure 7A, this short time exposure to 
glutamate decreased neuronal viability by 21.0 ± 4.8 % (n= 5; p<0.05 compared to control) and IL-1β 
exacerbated this glutamate-induced neurotoxicity to 51.1 ± 13.3 % (n= 7; p<0.05 compared to the 
effect of glutamate alone), whereas IL-1β was devoid of effects per se on neuronal viability (98.5 ± 2.6 
% of viable cells, n= 6). Interestingly, SCH58261 (50 nM) prevented this exacerbation of glutamate-
induced neurotoxicity caused by IL-1β (20.0 ± 4.0 % loss of neuronal viability, n= 5; p<0.01 compared 
to the effect of glutamate in the presence of IL-1β), whereas SCH58261 failed to significantly affect 
neurotoxicity in the presence of glutamate alone (31.8 ± 17.1 % loss of neuronal viability; n= 5). 
Finally, SCH58261 had no effect per se on neuronal viability (100.0 ± 1.6 % of viable cells, 
respectively; n= 5). 
Next, it was confirmed this particular ability of A2ARs to control the exacerbation of glutamate-
induced neurotoxicity by IL-1β using another assay of neuronal damage, the release of lactate 
dehydrogenase (LDH). As shown in Figure 7B, the short term exposure to glutamate (100 µM, 25 
minutes) tended to increase LDH release by 24.8 ± 8.8 % relative to the control (n= 6, P>0.05), which 
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was significantly (P<0.05) potentiated in the presence of 100 ng/ml of IL-1β (LDH release was 62.2 ± 
14.5 % above the control, n= 6). As previously observed with propidium iodide and Syto-13, the 
blockade of A2ARs with SCH58261 (50 nM) abrogated the exacerbation of glutamate-induced 
neurotoxicity in the presence of IL-1β (LDH release was 21.1 ± 15.6 % above control; n= 6; p<0.05 
comparing to the effect of glutamate in the presence of IL-1β) (Fig. 7B).  
 
 
FIGURE 7: Blockade of adenosine A2A receptors prevents the IL-1β-induced exacerbation of glutamate-mediated 
excitotoxicity in hippocampal cultured neurons. Rat hippocampal neuronal cultures, 7 days in vitro (DIV) were exposed 
to vehicle or to interleukin-1β (IL-1β, 100 ng/ml), added 5 minutes prior to vehicle or glutamate (Glu, 100 μM), for a total 
of 25 min, in the absence or in the presence (added 20 min prior to the stimuli) of the selective A2A receptor antagonist, 
SCH58261 (50 nM), as indicated below each bar. Neurons were washed twice with Krebs buffer (pH 7.4) and fresh 
Neurobasal medium (with or without SCH58261) was added. Neurons were kept for 24 hours in the incubator (37ºC, 95% 
O2 and 5% CO2) until analysis of neuronal viability using Syto-13 plus propidium iodide (panel A) and the significant 
findings were further confirmed using the lactate dehydrogenase (LDH) assay (panel B). Results are mean ± SEM of n= 5-7 
experiments (corresponding to different cultures); *p<0.05 and ** p<0.01 comparing to control (absence of any added 
drug), #p<0.05 comparing between treated groups. Panel C displays representative images of Syto-13 (green fluorescence) 
plus propidium iodide (red fluorescence) staining of nucleic acids for the indicated experimental conditions. Note that 
neither IL-1β nor SCH58261 had any effect in cell viability per se but IL-1β exacerbated glutamate-induced neurotoxicity, 
which was abrogated by SCH58261. 
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The effect of TNF-α on the glutamate-induced neurodegeneration was tested by exposing the 
cultured hippocampal neurons to TNF-α (5 ng/ml) 5 minutes before adding glutamate (100 µM) for a 
total period of 25 min. The stimuli were washed and the evaluation of cell viability was performed 24 h 
later using the syto-13 and propidium iodide staining. As shown in Figure 8A, in these series of 
experiences glutamate decreased neuronal viability by 26.8 ± 4.0 % (n= 4; p<0.05 compared to control) 
but TNF-α had no effect on the glutamate-induced neurotoxicity (32.0 ± 3.5 % of decreased neuronal 
viability; n= 4; p<0.01 compared to control) and had no effect per se (90.8 ± 6.9 % of viable cells; n= 
4). Moreover, the blockade of A2ARs with the selective antagonist SCH58261 (50 nM) did not alter the 
lack of effect of TNF-α on glutamate-induced neurotoxicity (35.0 ± 1.6 % of decreased neuronal 
viability; n= 4; p<0.001 compared to control). 
 
 
FIGURE 8: TNF-α, in the absence or presence of an A2AR selective antagonist, does not alter the glutamate-induced 
excitotoxicity in hippocampal neurons. Rat hippocampal neuronal cultures, 7 days in vitro (DIV), were exposed to TNF-α 
(5 ng/ml) 5 minutes before adding glutamate (Glu, 100 μM) for a total of 25 min, in the absence or in the presence (added 
20 min before the stimuli) of the selective A2AR antagonist, SCH58261 (50 nM), as indicated below each bar. Neurons were 
washed twice with Krebs buffer (pH 7.4) and fresh Neurobasal medium (with or without SCH58261) was added. Neurons 
were kept in the incubator (37 ºC in a 95 % O2-5 % CO2 atmosphere) until analysis, 24 h later. The evaluation of neuronal 
viability was performed using the Syto-13 (green fluorescence) and propidium iodide (PI, red fluorescence) staining (panel 
A). In the panel B are representative images of Syto-13 + PI staining for the experimental groups. Results are presented as 
mean ± SEM of 4 different neuronal cultures (n= 4); **p<0.01 and ***p<0.001 comparing to the control (exposed to 
vehicle only). 
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4.2.2.6 BLOCKADE OF A2A RECEPTORS PREVENTS THE EXACERBATION CAUSED BY 
INTERLEUKIN-1β OF GLUTAMATE-INDUCED CALCIUM ENTRY AND CALCIUM 
DEREGULATION IN HIPPOCAMPAL NEURONS  
 
Previous studies have suggested that the impact of IL-1β on the priming of neuronal viability 
involves an abnormal activation of NMDA receptor-mediated calcium influx (Ma et al., 2002; Zhang et 
al., 2010b; Gardoni et al., 2011). Thus, it was tested if IL-1β could bolster the glutamate-induced 
calcium entry and calcium deregulation in neurons and investigated the impact of A2ARs blockade 
thereupon. This was achieved using a single cell calcium imaging approach upon loading hippocampal 
cultured neurons with the selective ratiometric calcium dye, Fura-2. As shown in Figure 9B, glutamate 
(100 µM) caused an immediate rise of intracellular free calcium concentration ([Ca
2+
]i) gauged by an 
increase of Fura-2 fluorescence ratio of 0.38 ± 0.03 above control (n= 6 cultures, 3-4 coverslips per 
culture and 30-50 neurons analysed per coverslip; P<0.05). The presence of IL-1β (100 ng/ml) 
consistently increased this effect of glutamate (ratio of 0.47 ± 0.03, n= 6 cultures, 3-4 coverslips per 
culture and an average of 30-50 neurons analysed per coverslip; P<0,05) (Fig. 9B), whereas IL-1β per 
se failed to trigger any modification in Fura-2 signal. Pre-incubation of cells with SCH58261 (50 nM) 
attenuated this effect of IL-1β on the glutamate-induced increase of [Ca2+]i (Fura-2 ratio of 0.39 ± 0.03, 
n= 6 cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed per coverslip; 
P<0.05 compared to the effect of glutamate in the presence of IL-1β) (Fig. 9B); in contrast, it was 
observed that SCH58261 actually tended to amplify the effect of glutamate alone (Fura-2 ratio of 0.50 
± 0.07, n= 4 cultures, 4 coverslips per culture and an average of 30-50 neurons analysed per coverslip) 
(Fig. 9B), whereas SCH58261 alone was devoid of effects on [Ca
2+
]i.  
Apart from this initial effect of glutamate on calcium transients, we also evaluated how IL-1β 
and A2AR blockade affected the ability of neurons to adapt to the continuous presence of glutamate. 
Thus, we evaluated the variation of the Fura-2 fluorescence ratio from its peak value shortly after the 
addition of glutamate until the end of the incubation period with glutamate (i.e. during 15 minutes). As 
shown in the Figure 9C and is represented in the Figure 9A, most neurons are able to adapt to the 
continuous presence of glutamate and decrease their [Ca
2+
]i over time (slope of -0.0022 ± 0.0008, n= 6 
cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed per coverslip); in 
contrast, in the presence of IL-1β (100 ng/ml), neurons lost their adaptive capacity to the continuous 
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presence of glutamate, as testified by their tendency to keep increasing their [Ca
2+
]i (slope of +0.0019 ± 
0.0009, n= 6 cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed per 
coverslip; P<0.01 compared with glutamate alone) (Fig. 9C). Notably, blockade of A2AR with 
SCH58261 (50 nM) inverted this effect of IL-1β (slope of -0.0015 ± 0.0008, n= 6 cultures, 3-4 
coverslips per culture and an average of 30-50 neurons analysed per coverslip; P<0.05 comparing to 
the simultaneous presence of IL-1β and glutamate) (Fig. 9C). Again, SCH58261 selectively prevented 
the exacerbation by IL-1β of glutamate-induced responses, since SCH58261 actually enhanced the 
response to glutamate alone (slope of +0.0016 ± 0.001, n= 4 cultures, 4 coverslips per culture and an 
average of 30-50 neurons analysed per coverslip; P<0.05 comparing with glutamate alone) (Fig. 9C). 
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FIGURE 9: Blockade of adenosine A2A receptors prevents IL-1β-induced exacerbation of glutamate-mediated 
calcium deregulation in hippocampal neurons. Hippocampal neurons were loaded with the calcium probe Fura-2-AM 
and the fluorescence emitted at 510 nm upon alternate excitation at 340 and 380 nm (F340 and F380, respectively) was 
followed on cell bodies every second during 35 minutes. Basal fluorescence ratio was measured during the first 2 minutes 
and drugs, prepared in normal Krebs solution, were added to the superfusion using a fast-pressurized system, as indicated by 
the arrows in the representative graphics of the panel A. Interleukin-1β (IL1β, 100 ng/ml), when present, was added for 5 
minutes prior to glutamate (Glu, 100 µM). Cells were left in the presence of the stimuli for the next 15 minutes and then 
washed through superfusion of normal Krebs. The A2A receptor selective antagonist, SCH58261 (50 nM), was incubated for 
15 minutes prior to the beginning of the experiment and prevailed throughout. The results are presented as the ratio 
(F340/F380) of recordings done in healthy neurons (accessed by the response to 50 mM KCl, after washing the stimuli). IL-1β 
increased both the glutamate-induced calcium entry (peak value of the difference between the basal ratio and the stimuli-
induced ratio) (panel B) and the glutamate-induced calcium deregulation, calculated as the slope from peak values until the 
wash out of the stimuli (panel C). SCH58261 attenuated the exacerbation by IL-1β of glutamate-induced calcium (B) and 
prevented IL-1β plus glutamate-induced calcium deregulation (C); however, SCH58261 seemed to aggravate the impact of 
glutamate alone. In the panel D are representative fluorescence images of the neuronal cell bodies in basal conditions (first 
row), in the presence of stimuli (middle row) and immediately before washing the stimuli (last row). Colour scale is 
composed of blue, green, yellow, red and white corresponding to increasing calcium concentrations. Data are mean ± SEM 
of n= 4-6 different cell cultures (480-1200 cells analysed per condition for each n), *p<0.05, **p<0.01. 
 
4.2.3 DISCUSSION 
In the present work, the interleukin-1β (IL-1β) receptor associated with signal transduction, the 
IL-1 type I receptor (IL-1RI) was shown to be present at synaptic regions in the hippocampus of adult 
rats. The comparison of total membranes, which have a high content of glial and endothelial 
membranes, with membranes from purified nerve terminals (synaptosomes), revealed that IL-1RI are 
indeed located in synapses, albeit they are more abundant in total membranes, in agreement with the 
well established predominant expression and localization of these receptors in endothelial cells in the 
brain parenchyma (Ericsson et al., 1995; Konsman et al., 2004). However, IL-1RI is also expressed in 
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neurons (Gardoni et al., 2011) and especially in conditions of brain diseases (Ravizza et al., 2006). Our 
results are in agreement with the previously reported localization of IL-1RI at the post-synaptic density 
(Gardoni et al., 2011), as expected from the ability of IL-1β to control NMDA receptor-mediated 
currents in vitro (Ma et al., 2002; Viviani et al., 2003; Zhang et al., 2010b) and in vivo (Balosso et al., 
2008). Additionally, we now report that IL-1RI are also present at the presynaptic active zone, as 
would be expected to justify the ability of IL-1β to control the release of glutamate from nerve 
terminals (Murray et al., 1997). This neuronal localization of IL-1RI in neurons, which has also been 
confirmed to occur in cultured hippocampal neurons (Zhang et al., 2010b), supports our observation 
that IL-1β can recruit different mitogen-activated protein kinases (MAPKs) in cultured neurons, in a 
manner sensitive to the antagonist of the IL-1RI (IL1Ra). Actually, both the IL-1β and the tumor 
necrosis factor-α (TNF-α) activated MAPKs on hippocampal neurons, as already described in the 
literature  (Coogan et al., 1999; Yang et al., 2002; Curran et al., 2003; Kelly et al., 2003; Srinivasan et 
al., 2004; Pickering et al., 2005; Moore et al., 2007). Despite the fact that the activation of MAPKs 
induced by these pro-inflammatory cytokines has been related to their deleterious effects on neurons 
(Curran et al., 2003; Butler et al., 2004; Barry et al., 2005; Moore et al., 2007; Chaparro-Huerta et al., 
2008; Zhang et al., 2010b), neither IL-1β nor the TNF-α had an effect on neuronal viability per se, 
which is in line with what has been reported using in vivo or ex vivo models (Bernardino et al., 2005; 
Hailer et al., 2005; Stone and Behan, 2007; Bernardino et al., 2008). However, the exposure of neurons 
to IL-1β immediately before exposing them to glutamate significantly increased the glutamate-induced 
neurotoxicity. These priming of neurons to excitotoxicity by IL-1β has also been previously observed 
in vivo and in organotypical cultures of the hippocampus (Bernardino et al., 2005; Hailer et al., 2005; 
Stone and Behan, 2007; Bernardino et al., 2008). In addition, TNF-α was also described to increase the 
susceptibility of neurons to an excitotoxic stimuli (Bernardino et al., 2005; Stellwagen et al., 2005; Zou 
and Crews, 2005), which has been related to its modulation of the glutamate AMPA receptors at the 
synaptic level (Beattie et al., 2002; Ogoshi et al., 2005; Stellwagen et al., 2005). However, in the 
present work, TNF-α did not have an effect on the glutamate-induced neurotoxicity. This may not be 
surprising when considering that TNF-α can signal through two different receptors (the TNF-α type I 
receptor, TNFRI or p55, and the TNF-α type II receptor, TNFRII or p75) (Beutler and van Huffel, 
1994), both found on neuronal membranes (Yang et al., 2002; Pickering et al., 2005; Figiel and 
Dzwonek, 2007), which mediate different cellular responses using distinct pathways (Hsu et al., 1995; 
Yang et al., 2002). In fact, the TNF-α activation of the p38 pathway on hippocampal cultured neurons 
has been related to the activation of the TNFRII (Yang et al., 2002) and thus to the TNF-α-induced  
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promotion of survival rather than neurodegeneration (Guo et al., 2001; Yang et al., 2002; Watters et 
al., 2011). Nevertheless, a higher concentration of this cytokine may be needed in order to result in the 
exacerbation of the glutamate-induced neurotoxicity (Yang et al., 2002; Bernardino et al., 2005; Stone 
and Behan, 2007). 
In addition to the direct priming of neurons to excitotoxicity by IL-1β, the present study adds a 
new mechanistic insight by showing that IL-1β causes a larger glutamate-induced calcium entry into 
neurons and a late calcium deregulation upon exposure of cultured hippocampal neurons to glutamate. 
The later is of particular interest in view of the tight association between late calcium deregulation and 
the irreversible loss of cellular, especially of neuronal viability. This opens new avenues of research to 
explore the underlying mechanisms of this IL-1β-induced late calcium deregulation, which may be of 
key importance in the control of the inflammatory-mediated amplificatory loop mediating the 
propagation of brain damage (Giacomello et al., 2007). 
As important as defining the mechanisms of inflammation-associated amplification of 
excitotoxic neuronal damage, is the identification of novel strategies to control this mechanism 
associated with the evolution of brain damage. We now show that the blockade of adenosine A2A 
receptors (A2AR) blunts the negative impact of IL-1β on neurons. This is of particular relevance in view 
of the ability of A2AR antagonists to prevent neuronal damage caused by different noxious brain insults 
(Cunha, 2005; Chen et al., 2007; Gomes et al., 2011). Notably, A2AR blockade is effective both 
prophylactically as well as therapeutically (Gomes et al., 2011). Given that A2AR are enriched in 
glutamatergic synapses (Rebola et al., 2005a), the prophylactic effect of A2AR antagonists is most 
probably related to the ability of A2AR to prevent synaptic dysfunction and damage, one of the early 
features of different brain disorders {Coleman, 2004 #4061;Waites, 2011 #3986}. In contrast, the 
therapeutic beneficial effect of A2AR antagonists should depend on their ability to control a general 
feature associated with the amplification of brain damage and neuroinflammation emerges as a 
potentially relevant candidate mechanism (Cunha, 2005; Chen et al., 2007; Yu et al., 2008; Gomes et 
al., 2011). Accordingly, we previously reported that A2AR antagonists prevent the induction of 
neuroinflammation (Dai et al., 2010; Rebola et al., 2011). This is now complemented by the 
demonstration that A2AR also controls the impact of a main pro-inflammatory cytokine on neuronal 
viability. Thus, A2AR blockade displayed a particular ability to control the exacerbation of glutamate-
induced neurodegeneration caused by IL-1β, extending the previous observation that A2AR blockade 
prevented the combined neurotoxicity of IL-1β and quinolinic acid (Stone and Behan, 2007). 
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Furthermore, the present study further argues for a prime importance of p38 MAPK as the transduction 
pathway associated with A2AR neuroprotection, as previously reported to occur upon different noxious 
brain conditions (Melani et al., 2006b; Canas et al., 2009; Rebola et al., 2011). Finally, the present 
results also pave the way to explore the potential role of A2AR in the control of glutamate-induced 
calcium deregulation; this is of particular interest since we have previously found that A2AR control 
mitochondria function (Silva et al., 2007; Canas et al., 2009), which plays a key role in the occurrence 
of calcium deregulation leading to neuronal damage (Giacomello et al., 2007) and is known to be 
involved in the etiology of diverse neurodegenerative disorders (Lin and Beal, 2006).  
In conclusion, the present study demonstrates that A2ARs can control the signalling of IL-1β in 
neurons and the priming by IL-1β of glutamate-induced calcium entry and late calcium deregulation 
that results in the exacerbation of neuronal damage. Therefore, the present results prompt the 
hypothesis that the A2AR-mediated control of the priming effects of IL-1β might be a possible 
mechanism underlying the striking ability of A2AR antagonists to curtail neuronal damage caused by a 
variety of brain insults involving glutamate-induced neurotoxicity and neuroinflammation.   
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4.3 THE BLOCKADE OF P2Y1 RECEPTORS PREVENTS BOTH GLUTAMATE AND 
INTERLEUKIN-1β-INDUCED EFFECTS ON HIPPOCAMPAL NEURONS 
 
 
4.3.1 INTRODUCTION 
 
In addition to adenosine, ATP is also a major modulator of cell-to-cell communication and a 
glial transmitter par excellence (Butt, 2011). The activation of P2 receptors by purines is involved in 
the different stages of microglia activation (Inoue, 2008) and also in the patho-physiology of astrocytes 
and of oligodendrocytes (Ciccarelli et al., 2001; Fields and Burnstock, 2006). Thus, ATP can control 
neuroinflammation not only by generating adenosine and activating P1 receptors, but also by acting on 
its ubiquitously expressed P2 receptors (Di Virgilio et al., 2009). 
The coupling of the purinergic system to the release of pro-inflammatory cytokines from 
different immunocompetent cells is well established (Ferrari et al., 2000; Liu et al., 2000b; Inoue, 
2002; Narcisse et al., 2005; Bernardino et al., 2008) and both P2R and pro-inflammatory cytokines can 
modulate cell fate through the activation of MAPKs (Allan and Rothwell, 2001; Pickering et al., 2005; 
Abbracchio et al., 2006). The activation of the extracellular signal-regulated protein kinase 1/2 
(ERK1/2) has been implied in the P2R-induced activation of glial cells (Neary and Kang, 2005) and in 
the production of inflammatory mediators (Brambilla et al., 2002; Gendron et al., 2003). Also, the 
activation of the p38 pathway was shown to correlate with the ATP-induced secretion of interleukin-1β 
(IL-1β) by microglia (Clark et al., 2010). 
The long-term effects of ATP on glial cells are thought to involve mainly the activation of P2Y 
receptors (Abbracchio et al., 2009; Verkhratsky et al., 2009; Butt, 2011). In particular, the P2Y1 
receptors (P2Y1R) were shown to be central for the initiation and propagation of the astrocytic Ca
2+
 
waves (Gallagher and Salter, 2003; Suadicani et al., 2004; Bennett et al., 2005), which are altered 
under pathological situations (Tsurusawa et al., 2010), and were found to influence K
+
 currents in 
microglia (Walz et al., 1993), of importance in the physiology and pathophysiology of these cells 
(Skaper, 2011). In addition to their fundamental role in the glia, P2Y1R modulate synaptic events in 
hippocampal neurons, such as the release of glutamate from pre-synaptic sites (Rodrigues et al., 2005b) 
and the inhibition of K
+
 currents at post-synaptic sites (Filippov et al., 2006). Moreover, an alteration 
of the expression and/or function of P2Y1R has been associated with pathological situations in the brain 
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such as in Alzheimer‟s disease (Moore et al., 2000b) or in ischaemic/hypoxic conditions in the 
hippocampus (Coppi et al., 2007; Kuboyama et al., 2011; Traini et al., 2011). Thus, as previously done 
in relation to adenosine A2A receptors, here it was investigated whether the blockade of P2Y1R could 
control the direct impact of the pro-inflammatory cytokines IL-1β and tumor necrosis factor-α (TNF-α) 
on cultured hippocampal neurons, including the priming of neurons to excitotoxic death by IL-1β.    
      
4.3.2 RESULTS 
 
4.3.2.1 BLOCKADE OF P2Y1 RECEPTORS PARTIALLY PREVENTS THE INTERLEUKIN-
1β-INDUCED ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASES  
 
To beging answering the question of whether the blockade of P2Y1Rs can control the impact of 
pro-inflammatory cytokines on neurons, it was tested the ability of a potent and selective antagonist of 
P2Y1Rs (MRS2179) to prevent the already established (see Chapter 4.2) IL-1β- and TNF-α- induced 
activation of p38 and the IL-1β- induced activation of c-jun-N-terminal kinases (JNK) in cultured 
hippocampal neurons.  
As shown in Figure 1A, the presence of MRS2179 (10 µM), 20 min before exposing neurons to 
IL-1β (100 ng/ml) for another 15 minutes, prevented the IL-1β-induced phosphorylation of JNK (86.0 
± 11.0 % of control comparing with 134.8 ± 7.0 %; n= 8; p<0.01) (Fig. 1A) and attenuated the IL-1β-
induced phosphorylation of p38 (136.0 ± 20.1 % of control comparing with 180.4 ± 17.3%; n= 8) (Fig. 
1B) while not altering the phosphorylation of JNK (101.7 ± 4.7 % of control; n= 8) (Fig. 1A) or the 
phosphorylation of the p38 (117.0 ± 4.7 % of control; n= 8) (Fig. 1B) per se. On the other hand, 
MRS2179 did not alter the TNF-α-induced (exposure to 5 ng/ml for 10 minutes) phosphorylation of 
p38 (350.3 ± 92.8 % of control comparing with 436.4 ± 60.7 %; n= 8) (Fig. 1C) and once again failed 
to affect the phosphorylation of p38 per se (112.4 ± 8.7 % of control; n= 8) (Fig. 1C). 
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Figure 1: Blockade of the ATP P2Y1 receptors partially prevents the IL-1β-induced signaling, but not the TNF-α-
induced signaling, in hippocampal neurons. Hippocampal neuronal cultures, 7 DIV, were exposed to vehicle and/or 
P2Y1R selective antagonist, MRS2179 (10 µM) 20 min before adding IL-1β (100 ng/ml) or TNF-α (5 ng/ml) (or vehicle for 
the control groups), for 15 and 10 min, respectively. After the stimuli cells were immediately lysed on ice in a minimum 
volume of RIPA‟s buffer. The immunoreactivity of the activated (phosphorylated) form of JNK (p-JNK) (panel A) and of 
the activated (phosphorylated) form of p38 (p-p38), panels B and C, was quantified by Western blot analysis. Membranes 
were re-probed for the total form of JNK and p38, respectively, and the activity of both mitogen-activated protein kinases 
(MAPKs) was calculated as the ratio between the immunoreactivities of the phosphorylated and total forms of the proteins. 
The results are presented as percentage of control (neurons exposed to vehicle only). Data corresponds to cultures from 8 
pregnant Wistar female rats (n= 8) and is presented as mean ± SEM, *p<0.05 and **p<0.01 compared to control; ##p<0.01 
compared with neurons exposed to IL-1β only. 
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4.3.2.2 BLOCKADE OF P2Y1 RECEPTORS PREVENTS BOTH GLUTAMATE-INDUCED 
NEUROTOXICITY AND THE EXACERBATION OF THE EXCITOTOXICITY BY 
INTERLEUKIN-1β 
 
Since the blockade of P2Y1 receptors partially prevented the signalling induced by IL-1β on 
neurons, in the next experiment it was tested whether it could also control the impact of IL-1β on the 
glutamate-induced neurotoxicity. As previously described (see Chapter 4.2), the exposure of cultured 
hippocampal neurons to IL-1β (100 ng/ml) for 5 minutes before adding glutamate (100 µM) for a total 
of 25 minutes, resulted in an exacerbation of the glutamate-induced excitotoxicity (21.0 ± 4.8 % 
decrease in neuronal viability with glutamate alone comparing with 51.1 ± 13.3 % decrease in neuronal 
viability with glutamate in the presence of IL-1β; n= 5-7; p<0.05), as evaluated using the Syto-13 and 
propidium iodide staining, 24 hours after the end of the stimuli (Fig. 2A). The presence of IL-1β or of 
the antagonist of P2Y1R (MRS2179, 10 µM) were devoid of effects per se on the neuronal viability 
(98.5 ± 2.6 % and 97.0 ± 2.9 % of viable cells, respectively; n= 6) (Fig. 2A). The blockade of P2Y1Rs 
with MRS2179 (10 µM), added 20 minutes before the stimuli, prevented both the glutamate-induced 
toxicity (98.3 ± 4.0 % of viable cells; n= 5; p<0.05 comparing with glutamate alone) (Fig.2A) and the 
exacerbation of the glutamate-induced toxicity by IL-1β (81 ± 4.1% of viable cells; n= 4; p<0.05 
comparing with glutamate in the presence of IL-1β) (Fig. 2A).        
Next, it was confirmed this ability of P2Y1Rs to control both the glutamate-induced 
neurotoxicity and the exacerbation of it by IL-1β using the lactate dehydrogenase (LDH) assay. As 
shown in Figure 2B, the short term exposure to glutamate (100 µM, 25 minutes) tended to increase 
LDH release by 24.8 ± 8.8 % relative to the control (n= 6, P>0.05), which was significantly (P<0.05) 
potentiated in the presence of 100 ng/ml of IL-1β (LDH release of 62.2 ± 14.5 % above the control, n= 
6). Again, the blockade of P2Y1Rs with MRS2179 (10 µM) abrogated the exacerbation of glutamate-
induced neurotoxicity by IL-1β (LDH release of 25.0 ± 8.5 % above the control; n= 6; p<0.05 
comparing to the effect of glutamate in the presence of IL-1β) (Fig. 2B). 
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FIGURE 2: Blockade of the ATP P2Y1 receptors prevents both the glutamate-induced neurotoxicity and the 
exacerbation of it by IL-1β in hippocampal cultured neurons. Rat hippocampal neuronal cultures, 7 DIV, were exposed 
to vehicle or to interleukin-1β (IL-1β, 100 ng/ml), added 5 minutes prior to vehicle or glutamate (Glu, 100 μM), for a total 
of 25 min, in the absence or in the presence (added 20 min prior to the stimuli) of the selective P2Y1 receptor antagonist, 
MRS2179 (10 µM), as indicated below each bar. Neurons were washed twice with Krebs buffer (pH 7.4) and then fresh 
Neurobasal medium (with or without MRS2179) was added. Neurons were kept for 24 hours in the incubator (37ºC, 95% 
O2 and 5% CO2) until analysis of neuronal viability using the Syto-13 plus propidium iodide staining (panel A) and the 
significant findings were further confirmed using the lactate dehydrogenase (LDH) assay (panel B). Results are mean ± 
SEM of n= 5-7 experiments (corresponding to different cultures); *p<0.05 and ** p<0.01 comparing to control (absence of 
any added drug), #p<0.05 comparing between treated groups. Panel C displays representative images of Syto-13 (green 
fluorescence) plus propidium iodide (red fluorescence) staining of nucleic acids for the indicated experimental conditions. 
Note that neither IL-1β nor MRS2179 had any effect in cell viability per se but IL-1β exacerbated glutamate-induced 
neurotoxicity. The presence of MRS2179 abrogated both the glutamate-induced neurotoxicity and the exacerbation of it by 
IL-1β. 
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4.3.2.3 BLOCKADE OF P2Y1 RECEPTORS PREVENTS THE GLUTAMATE-INDUCED 
CALCIUM ENTRY AND CALCIUM DEREGULATION AND ATTENUATES THE 
INTERLEUKIN-1β EFFECTS  
 
 In the following experiments it was investigated the effect of the blockade of P2Y1 receptors on 
the glutamate-induced increase of the intracellular calcium and in the bolstering of the glutamate 
effects by IL-1β. This was achieved using the single cell calcium imaging approach upon loading 
hippocampal cultured neurons with the selective ratiometric calcium dye, Fura-2. As shown in Figure 
3B, glutamate (100 µM) caused an immediate rise of intracellular free calcium concentration ([Ca
2+
]i) 
gauged by an increase of Fura-2 fluorescence ratio of 0.38 ± 0.02 above control (n= 6 cultures, 3-4 
coverslips per culture and 30-50 neurons analysed per coverslip; P<0.05). The presence of IL-1β (100 
ng/ml) consistently increased this effect of glutamate (ratio of 0.45 ± 0.03, n= 6 cultures, 3-4 coverslips 
per culture and an average of 30-50 neurons analysed per coverslip; P<0.05) (Fig. 3B), whereas IL-1β 
per se failed to trigger any modification in Fura-2 signal. Pre-incubation of cells with MRS2179 (10 
µM) attenuated this effect of IL-1β on the glutamate-induced increase of [Ca2+]i (Fura-2 ratio of 0.38 ± 
0.03, n= 4 cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed per coverslip; 
P<0.05 compared to the effect of glutamate in the presence of IL-1β) (Fig. 3B). However, MRS2179 
also significantly prevented the glutamate-induced increase in the [Ca
2+
]i (Fura-2 ratio of 0.32 ± 0.01, 
n= 4 cultures, 4 coverslips per culture and an average of 30-50 neurons analysed per coverslip) whereas 
MRS2179 alone was devoid of effects (Fig. 3B).  
As can be observed in the graph of the Figure 3C and in the representative curves of the Figure 
3A, the analysis of the variation of the Fura-2 fluorescence ratio from its peak value, shortly after the 
addition of the stimuli, until the end of the incubation period (i.e. during 15 minutes) showed that 
neurons continuously adapt to the presence of glutamate and decrease their [Ca
2+
]i over time (slope of -
0.0020 ± 0.0010, n= 6 cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed 
per coverslip); in contrast, in the presence of IL-1β (100 ng/ml), neurons lost their adaptive capacity to 
the continuous presence of glutamate, as testified by their tendency to keep increasing their [Ca
2+
]i 
(slope of + 0.0011 ± 0.0009, n= 6 cultures, 3-4 coverslips per culture and an average of 30-50 neurons 
analysed per coverslip; P<0.01 compared with glutamate alone). The blockade of P2Y1 receptors with 
MRS2179 (10 µM) attenuated this effect of IL-1β albeit not significantly (slope of -0.0013 ± 0.0017, 
n= 4 cultures, 3-4 coverslips per culture and an average of 30-50 neurons analysed per coverslip) (Fig. 
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3C). On the other hand, the presence of MRS2179 resulted in a greater ability of neurons to adapt to the 
continuous presence of glutamate, resulting in a faster recovery of the [Ca
2+
]i towards basal values 
(slope of -0.0071 ± 0.0003; n= 4 cultures, 3-4 coverslips per culture and an average of 30-50 neurons 
analysed per coverslip; P<0.05 compared with glutamate alone) (Fig. 3C). 
 
FIGURE 3: Blockade of P2Y1 receptors prevents the glutamate-induced calcium deregulation and attenuates the IL-
1β-induced exacerbation of the glutamate effects in hippocampal neurons. Hippocampal neurons were loaded with the 
calcium probe Fura-2-AM and the fluorescence emitted at 510 nm upon alternate excitation at 340 and 380 nm (F340 and 
F380, respectively) was followed on cell bodies every second during 35 minutes. Basal fluorescence ratio was measured 
during the first 2 minutes and drugs, prepared in normal Krebs solution, were added to the superfusion using a fast-
pressurized system. Interleukin-1β (IL1β, 100 ng/ml), when present, was added for 5 minutes prior to glutamate (Glu, 100 
µM). Cells were left in the presence of the stimuli for the next 15 minutes and then washed through superfusion of normal 
Krebs. The P2Y1 receptor selective antagonist, MRS2179 (10 µM), was incubated for 15 minutes prior to the beginning of 
the experiment and prevailed throughout. The results are presented as the ratio (F340/F380) of recordings done in healthy 
neurons (accessed by the response to 50 mM KCl, after washing the stimuli). In the panel A are representative curves of all 
experimental conditions. IL-1β increased both the glutamate-induced calcium entry (peak value of the difference between 
the basal ratio and the stimuli-induced ratio) (panel B) and the glutamate-induced calcium deregulation, calculated as the 
slope from peak values until the wash out of the stimuli (panel C). MRS2179 attenuated the exacerbation by IL-1β of 
glutamate-induced calcium (B) the IL-1β plus glutamate-induced calcium deregulation (C); however, MRS2179 
significantly prevented the impact of glutamate alone (panels B and C). Data are mean ± SEM of n= 4-6 different cell 
cultures (480-1200 cells analysed per condition for each n); *p<0.05 comparing between the indicated groups; #p<0.05 
comparing between the glutamate in the presence of MRS2179 and glutamate alone. 
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4.3.3 DISCUSSION  
 
The main conclusion of this work is that the blockade of P2Y1 receptors (P2Y1Rs) partially 
prevents the direct effects of the interleukin-1β (IL-1β) on hippocampal neurons, by preventing the IL-
1β-induced activation of the JNK pathway and attenuating the IL-1β-induced activation of the p38 
pathway and the IL-1β-induced exacerbation of the glutamate-evoked calcium entry and calcium 
deregulation. On the other hand and in line with previous findings in the group (Cunha et al., 2007), the 
blockade of P2Y1Rs abrogated the glutamate-induced effects on hippocampal cultured neurons. This is 
at odd with the inhibitory role of these receptors at glutamatergic synapses where they were shown to 
either inhibit glutamate release (Rodrigues et al., 2005b) or to inhibit the glutamate NMDA receptor 
currents (Wirkner et al., 2002; Luthardt et al., 2003; Guzman et al., 2005). Notwithstanding, P2Y1Rs 
can also increase the [Ca
2+
]i by promoting the leakage from intracellular Ca
2+
 stores (Leon et al., 2006; 
Rubini et al., 2006) and control neuronal excitability by triggering Ca
2+
-dependent K
+
 currents 
(Schicker et al., 2010) or inhibiting the M-type K
+
 currents, as was shown for native P2Y1Rs in 
hippocampal neuronal cultures (Filippov et al., 2006). Thus, it remains to be investigated whether the 
effects of the blockade of P2Y1Rs on glutamate-induced calcium are a direct effect on glutamate 
receptors or an effect on other ion channels and/or intracellular Ca
2+
 reservoirs.  
In the present work, the effect of the blockade of P2Y1Rs in the IL-1β-induced exacerbation of 
the glutamate-mediated excitotoxicity is partially masked by the neuroprotection afforded against 
glutamate-induced effects. However, it is clear that the antagonism of P2Y1 receptors prevents some of 
the IL-1β direct actions on neurons. Thus, given their widespread distribution in the hippocampus 
(Moore et al., 2000a; Moore et al., 2001) and their importance in noxious conditions involving both 
excitotoxic and inflammatory-mediated cell death, such as in ischaemia/hypoxia (Coppi et al., 2007; 
Kuboyama et al., 2011; Traini et al., 2011), the P2Y1 receptors can be important targets to afford 
neuroprotection in different neurodegenerative conditions in the brain.                
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4.4 BLOCKADE OF P2 RECEPTORS DIFERENTIALLY AFFECTS KAINATE- AND NMDA-
INDUCED NEUROTOXICITY IN CULTURED HIPPOCAMPAL NEURONS  
 
4.4.1 INTRODUCTION 
 
Glutamate is the major excitatory neurotransmitter in the mammalian brain and plays a 
fundamental role in higher functions such as body movements, learning and memory, emotions and 
sensory perception (Hudspith, 1997). However, overactivation of glutamate receptors result in 
excitotoxic neuronal degeneration which contributes to the pathogenesis of many different disorders 
(Sattler and Tymianski, 2000), including ischemic stroke (Paschen, 1996), Alzheimer‟s disease (Hynd 
et al., 2004) and epilepsy (Meldrum, 1994). Excitotoxicity is mediated by glutamate-induced Ca
2+
 
influx which, if not rapidly removed or buffered, initiates a cascade of events involving oxygen radical 
production, mitochondrial dysfunction and protease activation, ultimately leading to cell death (Sattler 
and Tymianski, 2000). There are two types of glutamate receptors: ligand-gated ion channels 
(ionotropic receptors) and GTP-binding protein-coupled receptors (metabotropic receptors) (Nakanishi, 
1992). Glutamate-mediated excitotoxicity occurs primarily through overactivation of ionotropic 
receptors (Sattler and Tymianski, 2000), which can be divided into those selectively activated by N-
methyl-D-aspartic acid (NMDA) and non-NMDA receptors, i.e., those responsive to the agonists 2-
amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid (AMPA), kainate and quisqualate. The 
NMDA receptors are heteromeric complexes formed by an obligatory NR1 subunit and one or more 
NR2 subunits termed NR2A-D and their channel opening is dependent upon glutamate binding and 
prior membrane depolarization, resulting in Ca
2+
 influx (Michaelis, 1998). The AMPA receptors are 
heterodimers composed of subunits GluR1-GluR4 and are permeable to both Na
+
 and Ca
2+
 ions 
(Michaelis, 1998).  
Upon any type of brain injury or toxic stimuli, the extracellular concentration of ATP raises 
significantly through the leakage from damaged cells and as a consequence of increased neuronal and 
glial transmission (Abbracchio and Verderio, 2006). High extracellular concentrations of ATP are toxic 
to cell cultures (Amadio et al., 2002) and in vivo (Ryu et al., 2002), mediating degeneration of fully 
differentiated neurons and comprising both apoptotic and necrotic features such as cellular swelling, 
lactic acid dehydrogenase (LDH) release, increase of intracellular reactive oxygen species and nuclear 
fragmentation (Volonte et al., 2003). In cerebellar granule neurons, agonists of P2 receptors had toxic 
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effects which could be prevented both by P2 receptor antagonists and by competitive and non-
competitive NMDA receptor antagonists (Amadio et al., 2002), demonstrating an interplay between P2 
receptors and glutamate ionotropic receptors in the mediation of toxic events. In agreement, P2 
receptors can modulate glutamate release from hippocampal terminals, facilitating or inhibiting it 
through presynaptic P2X (P2X1, P2X2/3, P2X3) and P2Y (P2Y1, P2Y2, P2Y4) receptors, respectively 
(Rodrigues et al., 2005b) and a post-synaptic co-operativity between extracellular ATP and NMDA 
receptors in the induction of long-term potentiation in the hippocampus has also been described (Fujii 
et al., 1999; Fujii et al., 2002). In face of the tight control of the glutamatargic system operated by P2 
receptors in the hippocampus and of the previously observed neuroprotection afforded with the 
blockade of P2Y1 receptors under pathological conditions (Coppi et al., 2007; Kuboyama et al., 2011; 
Traini et al., 2011), the following experiments were designed to test the neuroprotective potential of P2 
receptors and, in particular, of P2Y1 receptors against different excitotoxic stimuli to hippocampal 
neurons.  
 
4.4.2 RESULTS 
 
 
4.4.2.1 P2 RECEPTORS AND IN PARTICULAR P2Y1 RECEPTORS CONTROL NMDA-
MEDIATED EXCITOTOXICITY IN HIPPOCAMPAL CULTURED NEURONS   
 
To tackle the question of whether P2 receptors can control different excitotoxic stimuli in 
hippocampal neurons, hippocampal neuronal cultures (grown for 7 days in vitro) were exposed to 
different agonists of glutamate ionotropic receptors: N-methyl-D-aspartic acid (NMDA, 100 μM), 
kainate (KA, 100 µM) and quinolinic acid (QA, 3 mM), for different times and in the presence or 
absence of phosphate-6-azophenyl-2′,4′-disulfonic acid tetrasodium salt (PPADS, 20μM), a non-
selective P2 receptor antagonist, or of MRS2500 (10 μM), a selective and potent P2Y1 receptor 
antagonist, both added 20 min before the excitotoxic stimuli and prevailing throughout. Neuronal 
damage was estimated by modifications of the ability of neurons to reduce MTT and by Syto-13 and 
propidium iodide nucleic acid staining. Within 25 min, only NMDA was able to decrease the ability of 
cells to reduce the MTT (68.9 ± 3.9 % of control; n= 6; p<0.01) and the blockade of P2 receptors 
before and during the stimulus diminished the NMDA effect (86.5 ± 9.4 % of control; n= 6). Likewise, 
though to a lesser extent, the blockade of P2Y1 receptors also decreased the NMDA-induced toxicity 
(77.24 ± 3.6% of control; n= 6); however these results were only significant when the antagonists were 
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also present after withdrawing the stimulus (PPADS: 94.6 ± 3.1 %; p<0.01; MRS2500: 85.8 ± 6.3 %; 
p<0.05 comparing to NMDA; n= 6) (Fig. 1).  
 
 
 
 
FIGURE 1: Blockade of P2 receptors and of the P2Y1 receptors subtype protects hippocampal neurons against 
excitotoxicity induced by short-term exposure to NMDA. Hipocampal neuronal cultures, 7 DIV, were exposed for 25 
min in Krebs buffer (pH 7.4) to vehicle or agonists of glutamate ionotropic receptors: kainate, KA (100 µM), quinolinic 
acid, QA (3 mM) and N-Methyl-D-aspartic acid, NMDA (100 µM). When present, the general antagonist of P2 receptors, 
PPPADS (20 µM) and the selective antagonist of P2Y1 receptors, MRS 2500 (10 µM), were added to the medium 20 min 
before the stimuli and prevailed throughout the experiment until analysis, unless otherwise stated. After incubation, cells 
were washed twice with Krebs buffer and fresh Neurobasal medium was added. Neurons were kept in the incubator (37ºC, 
95% O2-5% CO2) until analysis of cell ability to reduce the MTT, 24 h after the stimuli. Results are presented as percentage 
of control (neurons incubated with vehicle only); mean ± SEM; n= 6 (each n corresponds to different cultures); *p<0.05 and 
**p<0.01 comparing to control, #p<0.05 and ##p<0.01 comparing to NMDA. Note that only NMDA decreased cell ability 
to reduce MTT and that the blockade of P2 receptors or of the P2Y1 receptors alone prevented this effect when the 
antagonists were present before and after the stimuli. 
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The results obtained with the MTT assay were further confirmed through Syto-13 (green 
fluorescence) and propidium iodide (red fluorescence) staining of the neuronal nuclei. The exposure of 
hippocampal neuronal cultures to NMDA for 25 minutes reduced cell viability, 24 hours after, in 22.0 
± 1.5 % bellow the control (n= 4; p<0.01) and the effect was prevented by both P2 receptors blockade 
(99.0 ± 4.2 %; n= 4; p<0.01, comparing to NMDA) and by the blockade of P2Y1 receptors (89.5 ± 3.9 
% of control; n= 4; p<0.05, comparing to NMDA) (Fig. 2).  
 
 
 
FIGURE 2: Blockade of P2 receptors and of P2Y1 receptors prevents NMDA-induced degeneration of hippocampal 
neurons. Hipocampal neuronal cultures, 7 DIV, were exposed for 25 min in Krebs buffer (pH 7.4) to vehicle or to NMDA 
(100 µM). When present, the P2 receptors antagonist, PPADS (20 µM), and the P2Y1 receptors selective antagonist, 
MRS2500 (10 µM), were added to the medium 20 min before NMDA and prevailed throughout the experiment until 
analysis. After incubation, cells were washed twice with Krebs buffer and fresh Neurobasal medium was added. Neurons 
were kept in the incubator (37ºC, in a 95% O2-5% CO2 atmosphere) until evaluation of cell viability, 24 h after the stimulus, 
using the Syto-13 (green fluorescence) plus propidium iodide (red fluorescence) staining of the nuclei. Results are presented 
as mean ± SEM; n=4 (each n corresponds to different cultures); **p<0.01 comparing to control; #p<0.05 and ##p<0.01 
comparing to NMDA. Note that NMDA reduced neuron viability and that this was prevented by the blockade of both P2 
receptors and of P2Y1 receptors. 
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 Since a short-term exposure to different agonists of glutamate ionotropic receptors, in our 
experimental conditions, resulted in neurodegeneration of hippocampal neurons, evaluated 24 hours 
later, mediated only by NMDA receptors, next it was confirmed that the neuronal dysfunction caused 
by the exposure of neurons to glutamate for 25 minutes could be prevented by the pre-incubation (20 
minutes before glutamate) with a non-competitive and selective antagonist of the NMDA receptors, 
MK-801 (10 µM). As shown in Figure 3, glutamate (Glu, 100 µM) diminished the ability of cells to 
reduce the MTT (60.3 ± 10.0 % of control; n= 5; p<0.01) that was completely prevented by the pre-
incubation of neurons with MK-801 (98.0 ± 2.6 % of control; n= 5). 
 
FIGURE 3: The neuronal dysfunction resulting from a short-time exposure of hippocampal cultured neurons to 
glutamate is mediated by the activation of NMDA receptors. Hippocampal neuronal cultures, 7 DIV, were exposed to 
glutamate (100 µM) in Krebs buffer (pH 7.4) for 25 minutes in the presence or absence of the selective antagonist of 
NMDA receptors, MK-801 (10 µM), after which the stimulus was washed twice and fresh Neurobasal medium was added 
to the cells with or without MK-801. Neurons were kept in the incubator (37ºC, in 95% O2-5% CO2 atmosphere) until 
evaluation of their ability to reduce the MTT, 24 hours after, by reading the absorbance at 570 nm (using 600 nm as a 
reference). Results are presented as percentage of control (wells incubated with vehicle only); mean ± SEM; n=5-7 (each n 
corresponds to different cultures); **p<0.01 comparing to control, #p<0.01 comparison between the indicated groups.  
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Longer exposures of the hippocampal neurons to the same agonists of glutamate receptors 
reduced cell viability through activation of both NMDA and AMPA receptors (Fig. 4). The exposure of 
neurons to kainate (100 µM) for 6 hours decreased neuronal viability in circa 43 % (57.6 ± 3.7 % of 
control; n= 6; p<0.001); incubation with quinolinic acid (3 mM) for 24 hours diminished cell viability 
in circa 33 % (67.0 ± 1,9 % of control; n= 6; p<0.001) and exposure of neurons to NMDA (100 µM) 
for 12 hours lead to a decrease in MTT reduction of approximately 53 % (47.8 ± 1.1% of control; n= 6; 
p<0.001) (Fig. 4). Blockade of P2 receptors with the general antagonist PPADS (20 µM), added 20 
minutes before the stimuli and prevailing throughout, did not prevent the kainate-induced dysfunction 
of the metabolic state of neurons (56.7 ± 6.7 % of control; n= 6). The same happened with the selective 
blockade of P2Y1 receptors (62.3 ± 5.7 % of control; n= 6) (Fig. 4). Accordingly, elimination of the 
putative kainate-induced extracellular ATP by incubating neurons with apyrase (20 U/ml), an enzyme 
(EC 3.6.1.5) that catalyses the hydrolysis of ATP to AMP and inorganic phosphate, added 5 minutes 
before the stimulus, did not prevent the effect of kainate (62.8 ± 1.6% of control; n= 6) (Fig. 4). On the 
other hand, decreased MTT reduction due to stimulation of neurons with quinolinic acid, an 
endogenous agonist of NMDA receptors, was prevented by the blockade of P2 receptors (82.6 ± 3.5 % 
of control; n= 6; p<0.01 comparing with quinolinic acid) but not by the selective blockade of P2Y1 
receptors (74.6 ± 4.7% of control, n= 6) (Fig. 4). As expected, the elimination of the putative 
extracellular ATP induced by the quinolinic acid, through the incubation of neurons with apyrase just 
before the stimuli, prevented the effect of quinolinic acid (92.3 ± 4.5 %; n= 6; p<0.01) (Fig. 4). 
Likewise, the excitotoxicity induced by NMDA was prevented by the blockade of P2 receptors (63.9 ± 
2.5 % of control; n= 6; p<0.01 comparing to NMDA) but not by the selective blockade of P2Y1 
receptors (50.1 ± 2.4 % of control; n= 6) (Fig. 3). Again, the catabolism of the extracellular ATP upon 
the NMDA stimulus prevented the effect of NMDA (74.7 ± 9.7 % of control; n= 6; p<0.001 comparing 
to NMDA) (Fig. 4). In order to know if the blockade of P2 receptors or the selective blockade of P2Y1 
receptors could specifically prevent apoptotic cell death, neurons were exposed to staurosporine (STS; 
30 nM), a prototypical apoptotic inducer, for 24 hours in the presence or absence of PPADS, MRS2500 
or apyrase. The results, in the last graphic of Figure 4, show that staurosporine caused a decrease in the 
ability of neurons to reduce the MTT of approximately 30 % (69.4 ± 4.0 % of control; n= 6; p<0.001) 
which was prevented by the blockade of P2 receptors with PPADS (88.9 ± 4.9 % of control; n= 6; 
p<0.01 comparing to staurosporine) and also by the blockade of P2Y1 receptors with MRS2500 (83.1 ± 
4.1 % of control; n= 6; p<0.05 comparing to staurosporine) and by apyrase (87.8 ± 3.5 % of control; n= 
6; p<0.01 comparing to staurosporine). 
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FIGURE 4: The general blockade of P2 receptors, but not the selective blockade of P2Y1 receptors, protects 
hippocampal neurons against the excitotoxicity induced by long-term exposures to agonists of the NMDA receptors. 
Hipocampal neuronal cultures, 7 DIV, were exposed for different periods, in Krebs buffer (pH 7.4), to vehicle or agonists of 
Glu ionotropic receptors: kainate, KA (100 µM; 6h), quinolinic acid, QA (3 mM; 24 h) and N-methyl-D-aspartic acid, 
NMDA (100 µM; 12 h). In addition, neurons were exposed to staurosporine (STS, 30 nM; 24h), a prototypic apoptotic 
inducer. When present, the general anatagonist of P2 receptors, PPADS (20 µM) and the selective antagonist of P2Y1 
receptors, MRS2500 (10 µM) were added to the medium 20 minutes before the stimuli and prevailed throughout the 
experiment until analysis. The enzyme that catalyses the hydrolysis of ATP, apyrase (20 U/mL), when present, was added 5 
minutes before the stimuli. Evaluation of cell viability was performed through the MTT assay after the indicated incubation 
times. Results are presented as percentage of control (wells incubated with vehicle only); mean ± SEM; n= 6 (each n 
corresponds to different cultures); *p<0.05, **p<0.01, ***p<0.001 in comparison to control; #p<0.05 and ##p<0.01 in 
comparison to the respective excitotoxic stimuli. Note that all Glu receptor agonists decreased cell ability to reduce the 
MTT and that the blockade of P2 receptors but not the selective blockade of P2Y1 receptors prevented the effect mediated 
by the quinolinic acid and by the NMDA. Also, the blockade P2 receptors or the selective blockade of P2Y1 receptors alone 
prevented the staurosporine-induced dysfunction.   
 
The prevention of the effect of a long-term exposure of hippocampal neurons to NMDA by the 
blockade of P2 receptors was confirmed by the Syto-13 and propidium iodide staining of the neuronal 
nuclei. As shown in Figure 5, the exposure of cells to quinolinic acid for 24 hours induced 
approximately 25 % of cell death (74.5 ± 2.3 % of control; n= 4; p<0.001) which was prevented by the 
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blockade of P2 receptors with PPADS (87.3± 4.4% of control; n= 4; p<0.05 comparing to quinolinic 
acid) but not by the selective blockade of P2Y1 receptors with MRS2500 (77.5 ± 3.2 % of control; n= 
4). The exposure of neurons to NMDA for 12 hours resulted in approximately 36 % of loss of viable 
cells (63.5 ± 3.8% of control; n= 4; p<0.01) which was again prevented by the blockade of P2 receptors 
with PPADS (90.8 ± 7.8 % of control; n= 4; p<0.05 comparing to NMDA) but not by the selective 
blockade of P2Y1 receptors with MRS2500 (73.8 ± 8.5 % of control; n= 5).  
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FIGURE 5: Blockade of P2 receptors, but not of the P2Y1 receptors, prevents the effects of long-term exposure of 
hippocampal neurons to quinolinic acid and to NMDA. Hippocampal neuronal cultures, 7 DIV, were exposed to 
quinolinic acid (QA; 100 µM; 24 h) or to N-methyl-D-aspartic acid (NMDA; 100 µM; 12 h) in Krebs buffer (pH 7.4). When 
present, the antagonist of P2 receptors (PPADS; 20 µM) and the selective antagonist of P2Y1 receptors (MRS2500; 10 µM) 
were added to the medium 20 min before the stimuli and prevailed throughout the experiment until analysis. Evaluation of 
cell viability was performed through Syto-13 (green fluorescence) plus propidium iodide (red fluorescence) staining of the 
neuronal nuclei nucleic after the indicated periods of incubation with the stimuli. Results are presented as percentage of 
control (wells incubated with vehicle only); mean ± SEM; n= 4-5 (each n corresponds to different cultures); *p<0.05, 
**p<0.01, ***p<0.001 in comparison to control; #p<0.05 in comparison to the respective excitotoxic stimuli. Note that the 
general blockade of P2 receptors blockade, but not the selective antagonism of P2Y1 receptors, prevented the effect 
mediated by the quinolinic acid and by the NMDA. 
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4.4.3 DISCUSSION 
The present results show that hippocampal neurons are differently affected by short and long-
term exposure to the same agonists of glutamate receptors. Long-term exposures (hours) to these 
agonists, result in neurodegeneration mainly mediated by the activation of AMPA/kainate receptors 
while short-term exposure (25 minutes) results in cell death mediated exclusively by NMDA receptors. 
Accordingly, incubation of hippocampal neurons with glutamate for 25 minutes resulted in 
approximately 20 % of cell death 24 hours later, which was completely prevented by previously adding 
an NMDA receptor selective and non-competitive antagonist (MK-801). These results are in agreement 
with the rapid desensitization of AMPA/kainate receptors in hippocampal neurons (Ambrosio et al., 
2000; Silva et al., 2001) and the absence of neurodegeneration mediated by these receptors during 
short-term activation which can be reverted by the presence of cyclothiazide, a positive allosteric 
modulator of the AMPA receptors that eliminates their rapid desensitization and potentiates their 
currents (Ambrosio et al., 2000). In the extracellular space, ATP induces cell death in fully 
differentiated neurons of the CNS, which express both P2X and P2Y receptors, causing cell 
degeneration with necrotic and apoptotic features (Amadio et al., 2002). Thus, unsurprisingly, agonists 
of P2 receptors were shown to aggravate toxicity whereas antagonists were neuroprotective (Amadio et 
al., 2002; Ryu et al., 2002; Volonte et al., 2003). However, the modulation by distinct P2 receptors of 
the neuronal response to glutamate is still controverse, for example, P2Y receptors were found to 
increase the conductance NMDA receptors in the pyramidal neurons of the V layer of the rat prefrontal 
cortex (Wirkner et al., 2002) whereas others found the opposite (Luthardt et al., 2003). Curiously, both 
competitive and non-competitive antagonists of NMDA receptors are able to prevent the noxious 
effects of ATP (Amadio et al., 2002) and in turn, some P2 receptor antagonists prevent glutamate-
evoked Ca
2+
 influx, neurotransmitter release and excitotoxicity (Volonte et al., 1999; Volonte et al., 
2003). In the present work, long-term exposures to the glutamate receptor agonists resulted in cell 
death mediated by both AMPA/kainate receptors and NMDA receptors, but the blockade of P2 
receptors only prevented the neurodegeneration mediated by the last, confirming a close interaction 
between P2 and NMDA receptors. In agreement with these results, in cortical and hippocampal 
neuronal cultures, PPADS was ineffective in preventing AMPA/kainate receptor currents, though more 
selective P2Y receptor antagonists reversibly decreased their amplitude (Zona et al., 2000).  
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Presynaptic activation of P2X receptors in the hippocampus elicits glutamate release (Rodrigues 
et al., 2005b) thus potentiating glutamate-mediated excitotoxicity. At the post-synaptic level, 
immediate Ca
2+
 entry through P2X receptors, which co-localize with glutamate ionotropic receptors at 
post-synaptic membranes (Rubio and Soto, 2001), can also increase excitotoxicity (Volonte et al., 
2003). Thus, excitotoxicity can be prevented by the blockade of P2X receptors (Volonte et al., 1999). 
Nevertheless, the Gq/11-linked P2Y receptors can also mediate excitotoxic events through  
phospholipase C (PKC)-dependent mobilization of Ca
2+
 from its intracellular stores (von Kugelgen and 
Harden, 2011). In addition, P2Y receptors can activate mitogen-activated protein kinases resulting in 
caspase-3 activation and apoptosis (Sellers et al., 2001). In the present work, the neuroprotection 
afforded with the blockade of P2 receptors and in particular, with the selective blockade of P2Y1 
receptors was associated with the prevention of the NMDA receptor-mediated neurodegeneration only; 
thus there seems to be a particular interaction between these two types of receptors. On the other hand, 
P2Y1 can also control a large variety of neuronal ion channels, such as voltage-activated Ca
2+
 channels 
and K
+ 
channels involved in the excitability of post-synaptic membranes, as was recently shown in 
primary cultures of hippocampal neurons (Filippov et al., 2006; Schicker et al., 2010), therefore this 
interaction may result from an indirect mechanism. The present results also show that when the general 
antagonist of P2 receptors (PPADS) or the selective antagonist of P2Y1 receptors (MRS2500) are 
present after the excitotoxic stimuli rather than just before and during, the prevention of excitotoxicity 
is more robust, indicating that ATP released after the initial damage continues to play an important part 
in neurodegenerative processes. In conclusion, the blockade of P2 receptors might be particularly 
effective for long-term insults that mainly involve the activation of NMDA receptors for expression of 
neurotoxicity whereas the P2Y1 receptor subtype might be important in the expression of early NMDA-
induced neurodegenerative events. 
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4.5 P2 RECEPTORS CONTROL NEUROINFLAMMATION AND NEURODEGENERATION 
IN A RAT MODEL OF TEMPORAL LOBE EPILEPSY 
 
4.5.1 INTRODUCTION 
 
Epilepsy is a multietiological disease with a high incidence worldwide and its treatment consists 
basically in alleviating symptoms (DeLorenzo et al., 1992). One of the most common adult forms of 
treatment-resistant epilepsy is the temporal lobe epilepsy (TLE), characterized by a state of chronic 
neuronal hyperexcitability and hypersynchrony manifested as recurrent partial seizures (Bernasconi and 
Bernhardt, 2010). Seizures occur as the result of an imbalance between the inhibitory and excitatory 
transmission, involving an impairment of GABAergic and glutamatergic systems, respectively, that is 
perperctuated by the abnormal expression of glutamate and GABA receptors and their acquired 
pathophysiology (Sharma et al., 2007). In fact, epilepsy leaves a long-term impact in the brain 
characterized by synaptic rearrangements and aberrant mossy fiber sprouting underlying the 
phenomenon known as “epileptic long-term potentiation” (Ben-Ari, 2001).  
The hippocampus is the brain region most affected by epileptic seizures since glutamatergic 
transmission is prominent is this area (de Lanerolle and Lee, 2005). Accordingly, the most frequent 
types of TLE are the mesial temporal lobe epilepsies (MTLE), characterized by seizure generation from 
the mesial temporal lobe with prominent neuronal loss and gliosis in the hippocampus (Yang et al., 
2010). About 70% of patients with MTLE-induced sclerosis of the hippocampus present neuronal 
degeneration, astrogliosis and aberrant mossy fiber sprouting in the inner molecular layer of the dentate 
gyrus (Sharma et al., 2007).  
One of the best characterized animal models of MTLE is the systemic or local administration to 
animals of 2-carboxy-4(1-methylethenyl)-3-pirrolidiacetic acid (kainate), a potent agonist of AMPA 
and kainate receptors which induces acute convulsive episodes followed by the development of 
spontaneous motor seizures (Ben-Ari and Cossart, 2000). The hippocampus CA3 subregion is 
especially sensitive since it is enriched in kainate receptors (Fisahn, 2005); however, in this animal 
model, apoptotic cell death and reactive gliosis (both astrogliosis and microgliosis) can be detected in 
all hippocampal subregions from 24 hours to 4 weeks after the administration of kainate (Ben-Ari and 
Cossart, 2000). The aberrant neuronal firing and excitotoxicity characteristic of the epileptic 
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hippocampus result in elevated concentrations of ATP in the extracellular melieu (Kumaria et al., 
2008). Accordingly, ATP-mediated pathophysiology and altered P2 receptor expression has been 
described in the hippocampus of animal models of TLE (Vianna et al., 2002; Rappold et al., 2006; 
Avignone et al., 2008; Dona et al., 2009). The prominent role for P2 receptors in the physiology of 
glial cells in the brain (Inoue, 2008; Butt, 2011) and therefore in neuroinflammation (Di Virgilio et al., 
2009) has been driving attention to these receptors as possible targets in neurological disorders with an 
important inflammatory component as is the case of epilepsy (Kumaria et al., 2008; Vezzani et al., 
2011). Considering the modulation of the glutamatergic system operated by P2 receptors and in 
particular by P2Y1 receptors, in both neurons (Fujii et al., 2002; Rodrigues et al., 2005b; Franke et al., 
2006) and glial cells (Domercq et al., 2006) and the previously found neuroprotection afforded with the 
blockade of P2 receptors under excitotoxic conditions, next it was tested if the same neuroprotection 
could be observed in vivo, in a rodent model of TLE. 
 
4.5.2 RESULTS 
 
4.5.2.1 KAINATE-INDUCED CONVULSIONS RESULT IN LONG-TERM CHANGES IN THE 
DENSITY OF P2 RECEPTORS IN THE RAT HIPPOCAMPUS  
 
To investigate the seizure-induced impact on the purinergic system, adult rats were injected 
intraperitoneally (ip) with saline or with 10 mg/kg of kainate and sacrificed 1, 7 and 30 days after the 
kainate-induced convulsions. Only the animals reaching at least the level IV of the Racine‟s scale for 
motor seizures (Racine, 1972) were further analysed in order to assure kainate-induced hippocampal 
damage. Upon sacrifice, the hippocampi were isolated and the density of the different P2 receptors was 
evaluated through western blot analysis in both total and synaptic membranes.  
As shown in Figure 1, most of the P2X receptor subtypes are altered after the kainate-induced 
seizures in either total membranes or synaptosomes, comparing to the saline-injected animals (control 
group). Moreover, the density of some P2X receptors is significantly altered up until 1 month after the 
kainate administration. In particular, in both synaptic and total membranes, the density of P2X1 
receptors is significantly increased (125.2 ± 5.2 % of control; n= 4; p<0.05 and 163.0 ± 2.6 % of 
control; n= 4; p<0.01, respectively) 24 hours after the kainate stimulus. The P2X2 receptors are down-
regulated in synaptosomes 30 days after the kainate injection (67.2 ± 5.7 % of control; n= 4; p<0.05) 
and up-regulated in total membranes both 24 hours (138.2 ± 6.0 % of average of control; n= 4; p<0.05) 
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and 30 days after the kainate administration (166.9 ± 12.7 % of control; n= 4; p<0.01). The P2X3 
receptors density is only different from control in synaptosomes, 30 days after the kainate injection 
(130.1 ± 5.7 % of control; n= 4; p<0.01). Likewise, the density of P2X4 receptors is only up-regulated 
30 days after the kainate-induced seizures but in total membranes (247.3 ± 30.6 % of; n= 4; p<0.05). 
The P2X5 receptors are increased in both synaptosomes and total membranes 1 day after the toxic insult 
(144.2 ± 12.9 % and 235.1 ± 30.3 % of control, respectively; n=4; p<0.05) and the P2X6 receptors are 
increased in synaptosomes both 1 and 30 days after the kainate administration (244.7 ± 18.3 % of 
control; n=4; p<0.01 and 191.8 ± 14.9 % of control; n=4; p<0.01, respectively). Finally, the P2X7 
receptors are significantly up-regulated in total membranes, 7 days upon the kainate-induced seizures 
(134.3 ± 7.1 %; n= 4; p<0.05) (Fig. 1). 
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FIGURE 1: The density of P2X receptors is altered in the rat hippocampal membranes at different periods after the 
convulsions induced by the systemic administration of kainate. Male Wistar rats (2 months old and weighting between 
250-300g) were injected intraperitoneally with 10 mg/kg of kainate or with saline (control). The animals that convulsed, i.e., 
reached at least the stage IV of Racine‟s scale for motor seizures, were sacrificed 1, 7 and 30 days later. Hippocampal total 
membranes and synaptosomes were prepared and the samples were run in electrophoresis gels for Western blot analysis. 
The results are presented as percentage of the averaged control ± SEM (n= 4-5); *p<0.05 and **p<0.01 comparing with the 
control; #p<0.05 and ##p<0.01 comparing between total and synaptic membranes.     
 
The Figure 2 shows the density profiles for the P2Y receptors in synaptosomal and total 
membranes of the hippocampus, at different times after the systemic administration of kainate to rats. 
As can be observed, the density of P2Y1 receptors significantly increases 1 day after the kainate-
induced convulsions in both synaptosomes and total membranes (157.5 ± 5.3 % and 143.2 ± 3.6 % of 
control; n= 4; p<0.01) and remains increased 7 days later, in total membranes (158.3 ± 11.8 % of 
control; n= 4; p<0.05). The P2Y2 receptor‟s density is also up-regulated in total membranes 1 and 7 
days after the kainate injection (126.9 ± 4.6 % and 139.7 ± 11.4 % of control, respectively; n= 4; 
p<0.05) as are the P2Y4 receptors, 1 day after kainate, in total membranes (157.0 ± 13.5 % of control; 
n= 4; p<0.05), 7 days after, in synaptosomes (193.1 ± 15.6 % of control; n= 4; p<0.01) and 30 days 
after, in total membranes again (216.3 ± 32.9 % of control; n= 5; p<0.05). Finally, the P2Y6 receptor 
levels are significantly increased in both synaptic and total hippocampal membranes, 1 day upon 
kainate-induced seizures (175.5 ± 14.7 % and 317.2 ± 12.3 % of control; n= 4; p<0.05 and p<0.001, 
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respectively); however, it is significantly decreased in total membranes, 7 days upon kainate-induced 
seizures (81.6 ± 2.1 % of control; n= 4; p<0.01) but increased again, this time in synaptosomes, 30 days 
after (157.6 ± 11.3 % of control; n= 4; p<0.05). 
 
 
 
 
FIGURE 2: The density of P2Y receptors is altered in the rat hippocampal membranes at different periods after the 
convulsions induced by the systemic administration of kainate. Male Wistar rats (2 months old and weighting between 
250-300g) were injected intraperitoneally with 10 mg/kg of kainate or with saline (control). The animals that convulsed, i.e., 
reached at least the stage IV of Racine‟s scale for motor seizures, were sacrificed 1, 7 and 30 days later. Hippocampal total 
membranes and synaptosomes were prepared and the samples run in electrophoresis gels for Western blot analysis. The 
results are presented as percentage of averaged control ± SEM (n= 4-5); *p<0.05, **p<0.01 and ***p<0.001 comparing 
with the control; #p<0.05, ##p<0.01 and ###p<0.001 comparing between total and synaptic membranes.     
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4.5.2.2 PHARMACOLOGICAL BLOCKADE OF P2Y1 RECEPTORS PREVENTS SEIZURE-
INDUCED LOSS OF SYNAPTIC MARKERS 
 
The previous results show that the synaptic and non-synaptic density of P2 receptors is altered 
in the hippocampus as a result of kainate-induced seizures, in agreement with the central role of ATP in 
the pathophysiology of epilepsy. Many neurodegenerative diseases are now recognized to start with an 
early synaptic toxicity before the onset of neurodegeneration, as is the case of Alzheimer‟s disease 
(Coleman et al., 2004; Canas et al., 2009). Nowadays, the targeting of the synapse as a strategy to 
prevent neurodegeneration is being considered for other brain disorders (Coleman et al., 2004). A 
synaptotoxicity also occurs as a consequence of epileptic seizures (Cognato et al., 2010) thus, next it 
was investigated whether the general blockade of P2 receptors with the antagonist PPADS or the 
selective blockade of P2Y1 receptors with the selective antagonist MRS2500, were able to prevent the 
seizure-induced loss of synaptic markers. First the animals were cannulated at the lateral ventricle in 
order to allow the intracerebroventricular (icv) administration of drugs. After recovering from the 
surgery during 3 to 4 days, the rats received a 10 mg/kg intraperitoneal (ip) injection of kainate (KA) or 
saline, 15 minutes after receiving PPADS/MRS2500 or ACSF (artificial cerebrospinal fluid) icv. The 
experimental groups were as follows: the control group or ACSF/SAL (ip and icv administration of 
ACSF); the KA group, ACSF/KA (icv administration of ACSF and ip injection of KA); the 
PPADS/SAL group (icv administration of 1 nmol/4 μL PPADS and ip injection of ACSF); the 
MRS/SAL group (icv administration of 1 nmol/4 μL MRS2500 and ip injection of ACSF); the 
PPADS/KA group (icv administration of 1 nmol/4μL PPADS and ip injection of 10 mg/kg KA) and 
finally the MRS/KA group (1 nmol/ 4μL MRS2500 icv and ip injection of 10 mg/kg KA). The animals 
were sacrificed 24 hours after the kainate-induced seizures and total membranes were prepared from 
the ipsilateral hippocampi for Western blot analysis.   
  In Figure 3 it can be observed that the kainate injection induced a dramatic decrease of the 
membrane content in the synaptosomal-associated protein 25 (SNAP-25), a pre-synaptic terminal 
marker, in 94.4 ± 2.8 % bellow the average of the group that received only saline (ACSF/SAL or 
control), which was only rescued by the blockade of P2Y1 receptors, through administration of 
MRS2500 (1 nmol/4 µl, icv) before the kainate injection (65.9 ± 5.6 % of the average control; n= 4; 
p<0.001) (Fig. 3A). The membrane content in the post-synaptic density protein (PSD-95) is also 
decreased by seizures (44.9 ± 15.2 % of the average control; n= 4; p<0.05), albeit not significantly 
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prevented by PPADS or MRS2500 (Fig. 3B). No significant differences were found in the density of 
the major synaptic vesicle protein, synaptophysin (Fig. 3C) but, on the other hand, there was significant 
loss of the membrane content in syntaxin (41.0 ± 5.4 % of the average control; n= 4; p<0.01), a family 
of proteins that are part of the Q-SNARE complex (a complex of proteins involved in the vesicular 
exocytosis), which was completely prevented by the selective blockade of P2Y1 receptors (101.5 ± 12.4 
% of control; n= 4; p<0.01 comparing to the ACSF/KA group) (Fig. 3D). Again, the kainate injection 
resulted in a decrease of the glutamate vesicular transporter 1 (vGLUT1) indicative of a loss of 
glutamatergic terminals (24.3 ± 10.9 % of average control; n= 4; p<0.01) which was rescued only by 
the previous administration of MRS2500 (77.6 ± 8.7 % of average control; n= 4; p<0.05 comparing to 
the ACSF/KA group) (Fig. 3E). Moreover, the blockade of P2Y1 receptors also prevented the loss of 
the GABAergic terminal marker vGAT (77.0 ± 10.0 % of average control of the MRS/KA group 
comparing with 31.7 ± 5.5 % of average control of the ACSF/KA group; n= 4; p<0.01) (Fig. 3F). 
Finally, the blockade of P2Y1 receptors prevented the loss of a marker of the GABAergic post-synaptic 
density, gephyrin (90.4 ± 8.7 % of control of the MRS/KA group comparing with 41.8 ± 10.7 % of 
control of the ACSF/KA group; n= 4; p<0.05) (Fig. 3G).  
 
 
4. RESULTS                                                                                      P2 receptors blockade in TLE model                                                                                                                                                            
          
142 
 
 
 
FIGURE 3: Blockade of P2Y1 receptors prevents the loss of synaptic markers induced by seizures in the rat 
hippocampus. Wistar male rats were cannulated at the lateral ventricle to allow the intracerebroventricular (icv) 
administration of drugs. After recovering from the surgery, the animals received a 10 mg/kg intraperitoneal (ip) injection of 
kainate (KA) or of saline, 15 minutes upon receiving PPADS, MRS2500 or ACSF (artificial cerebrospinal fluid) icv. Thus, 
the animals were grouped as follows: the control group or ACSF/SAL (ip and icv administration of ACSF); the kainate 
(KA) group, ACSF/KA (icv administration of ACSF and ip injection of KA); the PPADS/SAL group (icv administration of 
1 nmol/4 μL PPADS and ip injection of ACSF); the MRS/SAL group (icv administration of 1 nmol/4 μL MRS2500 and ip 
injection of ACSF); the PPADS/KA group (icv administration of 1 nmol/4μL PPADS and ip injection of 10 mg/kg KA) and 
finally the MRS/KA group (1 nmol/ 4μL MRS2500 icv and ip injection of 10 mg/kg KA). Animals were sacrificed 24 hours 
after kainate-induced seizures and total membranes were prepared from the ipsilateral hippocampus for Western blot 
analysis. The results are presented as percentage of averaged control ± SEM (n= 4); *p<0.05, **p<0.01 and ***p<0.001 
comparing with the control; #p<0.05, ##p<0.01 and ###p<0.001 comparing between the ACSF/KA group and the indicated 
group.     
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4.5.2.3 BLOCKADE OF P2 RECEPTORS OR OF P2Y1 RECEPTORS DECREASES THE 
SEIZURE-INDUCED MICROGLIOSIS AND NEURODEGENERATION IN THE RAT 
HIPPOCAMPUS  
 
 The same experimental procedure was performed in a second group of rats but this time the 
ipsilateral hippocampus was fixed through transcardiacal perfusion, 24 hours after the kainate 
administration, for immunohistochemistry analysis. The activation of microglia was evaluated through 
immunohistochemistry for CD11b, a constitutive protein of microglia that is up-regulated upon the 
activation of these cells, being a marker of microgliosis (Rotshenker, 2009). The immunoreactivity of 
CD11b was quantified in a series of 8 coronal sections (30 µm thick and 300 µm apart) representative 
of the ipsilateral hippocampus, in 4 animals of each of the 6 experimental groups. The mean 
fluorescence intensity (MFI) was used as a measure of the CD11b immunoreactivity and was quantified 
using the program Image J. The values of MFI obtained for the control group (ACSF/SAL) were 
averaged and all of the MFI values were calculated as a percentage of that value. 
 As shown in the panels A-C of the Figure 4 and in the graphs of the panel D, 24 hours after the 
systemic administration of kainate there is an obvious microgliosis in all hippocampal subregions 
(CA1; CA3 and dentate gyrus, DG), which is significantly prevented in the CA1 subregion by the 
previous icv administration of MRS2500 (137.9 ± 32.3 % of control for the MRS/KA group comparing 
with 281.9 ± 32.6 % of control for the ACSF/KA group; n=4; p<0.01), in the CA3 subregion by the 
administration of both MRS2500 and PPADS (108.1 ± 34.6 % of control for the MRS/KA group and 
138.0 ± 38.1 % of control for the PPADS/KA group comparing with 291.8 ± 65.5 % of control for the 
ACSF/KA group; n= 4; p<0.01 and p<0.05, respectively) and in the DG subregion by the MRS2500 
alone (109.2 ± 23.2 % of control for the MRS/KA group comparing with 217.8 ± 23.7 % of control for 
the ACSF/KA group; n=4; p<0.05).                                                                              
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FIGURE 4: Blockade of P2Y1 receptors prevents the microgliosis induced by seizures in all subregions of the rat 
hippocampus. Wistar male rats were cannulated at the lateral ventricle to allow the intracerebroventricular (icv) administration of 
drugs. After recovering from the surgery, the animals received a 10 mg/kg intraperitoneal (ip) injection of kainate (KA) or of 
saline (SAL), 15 minutes upon receiving PPADS, MRS2500 or artificial cerebrospinal fluid (ACSF) icv. Thus, the animals were 
grouped as follows: the control group or ACSF/SAL (ip and icv administration of ACSF); the kainate group, ACSF/KA (icv 
administration of ACSF and ip injection of KA); the PPADS/SAL group (icv administration of 1 nmol/4 μL PPADS and ip 
injection of ACSF); the MRS/SAL group (icv administration of 1 nmol/4 μL MRS2500 and ip injection of ACSF); the 
PPADS/KA group (icv administration of 1 nmol/4μL PPADS and ip injection of 10 mg/kg KA) and finally the MRS/KA group (1 
nmol/ 4μL MRS2500 icv and ip injection of 10 mg/kg KA). Animals were sacrificed 24 hours after the KA administration  
through transcardiacal perfusion of 4% paraformaldehyde (prepared in saline) to fixe the brain. Coronal hippocampal sections of 
the hippocampus were then obtained and used for immunohistochemistry analysis of the ipsilateral hippocampus probed for the 
microglia marker, CD11b (green fluorescence). The immunoreactivity of CD11b was quantified in a series of 8 coronal sections 
(30 µm thick and 300 µm apart) representative of the ipsilateral hippocampus in 4 animals of each of the 6 experimental groups. 
The panel D shows the quantification of the mean fluorescence intensity (MFI), used as a measure of the CD11b 
immunoreactivity, that was calculated using the program Image J. The values of MFI obtained for the control group (ACSF/SAL) 
were averaged and all of the MFI values were calculated as a percentage of that mean. The results are presented as percentage of 
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averaged control ± SEM (n= 4); *p<0.05, **p<0.01 and ***p<0.001 comparing with the control; #p<0.05 and ##p<0.01 
comparing with the ACSF/KA group.     
 
Next, it was investigated whether the blockade of P2 or of P2Y1 receptors could prevent the 
seizure-induced neurodegeneration through the staining of dead cells with FluoroJade C. As shown in 
the representative pictures of Figure 5 (A-C), while neither PPADS nor MRS2500 completely 
prevented the the kainate-induced neurodegeneration in the hippocampus, 24 hours after the ip 
injection of kainate, both attenuated it and especially in the CA1 subregion (Fig. 5A). 
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FIGURE 5: Blockade of P2 and of P2Y1 receptors attenuates the neurodegeneration induced by seizures in the rat 
hippocampus. Wistar male rats were cannulated at the lateral ventricle to allow the intracerebroventricular (icv) administration of 
drugs. After recovering from the surgery, the animals received a 10 mg/kg intraperitoneal (ip) injection of kainate (KA) or of 
saline (SAL), 15 minutes upon receiving PPADS, MRS2500 or artificial cerebrospinal fluid (ACSF) icv. Thus, the animals were 
grouped as follows: the control group or ACSF/SAL (ip and icv administration of ACSF); the kainate group, ACSF/KA (icv 
administration of ACSF and ip injection of KA); the PPADS/SAL group (icv administration of 1 nmol/4 μL PPADS and ip 
injection of ACSF); the MRS/SAL group (icv administration of 1 nmol/4 μL MRS2500 and ip injection of ACSF); the 
PPADS/KA group (icv administration of 1 nmol/4μL PPADS and ip injection of 10 mg/kg KA) and finally the MRS/KA group (1 
nmol/ 4μL MRS2500 icv and ip injection of 10 mg/kg KA). The animals were sacrificed 24 hours after the KA injection through 
transcardiacal perfusion of 4% paraformaldehyde (prepared in saline) to fix the brain. Coronal hippocampal sections were then 
obtained and used for FluoroJade C staining of dead cells in the ipsilateral hippocampi (bright, green fluorescence). The 
FluoroJade C staining was performed in a series of 8 coronal sections (30 µm thick and 300 µm apart), representative of the 
hippocampus, for each of a total of 4 animals from all of the experimental groups. The panels show representative images obtained 
for the indicated experimental groups, of the CA1 (A), CA3 (B) and DG (C) subregions.   
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4.5.3 DISCUSSION 
 
In the present work, it was shown that the density of P2 receptors at hippocampal membranes 
(glial and synaptic) was greatly affected by the seizures resultant from the systemic administration of 
kainate. Previous works have already hinted at the involvement of ATP and P2 receptors in epilepsy: 
an early study showed that seizure prone mice had increased extracellular ATP levels, owing in part to 
increased neuronal firing and to decreased activity of the brain ectonucleotidases (Wieraszko et al., 
1989) and more recent works supported the involvement of P2 receptors in the pathophysiology of 
seizures (Vianna et al., 2002; Rappold et al., 2006; Avignone et al., 2008; Dona et al., 2009; Kim et 
al., 2009). The present results showed that the altered density of P2 receptors lasted, in some cases, 
until one month after the kainate injection but was mainly evident at 24 hours, where most of them 
were up-regulated both in synaptosomes and in total membranes. Moreover, at this endpoint there is an 
evident microgliosis and neurodegeneration in all of the hippocampal subregions which were prevented 
and attenuated, respectively, by the blockade of P2 receptors and, especially, by the blockade of P2Y1 
receptors alone. The role of P2Y1 receptors in microglia is still largely unknown even though recent 
studies have suggested an involvement of these receptors in the migration of microglia (De Simone et 
al., 2010; Lambert et al., 2010). Despite the fact that glial cells are endowed with both P2X and P2Y 
receptors (James and Butt, 2002; Inoue, 2008; Di Virgilio et al., 2009) the last ones seem to have a 
prominent role in these cells, as was shown in the optic nerve glia where high levels of extracellular 
ATP induced large and prolonged P2Y-mediated increases in the [Ca
2+
]i (James and Butt, 2001). 
Additionally, a crutial role for P2 receptors in the pathophysiology of microglia has been recently 
unravelled (Davalos et al., 2005) and the P2Y6 and the P2Y12 receptors were shown to modulate 
microglia phagocytosis and directional motility (chemotaxis), respectively (Haynes et al., 2006; 
Koizumi et al., 2007). Notwithstanding, the P2X7 receptors have a well defined role in the maturation 
and production of the pro-inflammatory cytokine interleukin-1β from microglia (Narcisse et al., 2005) 
and were shown to induce the production of the superoxide radical, associated with the cytotoxic 
phenotype of these cells (Parvathenani et al., 2003). The P2X4 receptors were also shown to be up-
regulated in the activated microglia and to play a part in the inflammation-mediated neuropathic pain 
(Inoue, 2006), contributing to the rapid ATP-mediated Ca
2+
 response in these cells (Light et al., 2006). 
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Thus, the prevention of kainate-induced microgliosis with the general blockade of P2 receptors is not 
surprising. Nevertheless, in the present work, a previously unknown role for P2Y1 receptors in the 
control of neuroinflammation is suggested since the blockade of these receptors was even more 
effective at preventing the kainate-induced effects in microglia. However, this control operated by 
P2Y1 receptors may also be indirect since these receptors hold important functions both at 
glutamatergic (Luthardt et al., 2003; Guzman et al., 2005; Rodrigues et al., 2005b) and GABAergic 
synapses (Kawamura et al., 2004; Safiulina et al., 2006), which are highly compromised during 
epileptic activity. In fact, the present results also show a prevention of the kainate-induced loss of 
synaptic markers in hippocampal membranes, including markers of GABAergic and glutamatergic 
terminals, with the pharmacological ablation of P2Y1-mediated signalling. This is particularly 
importante when considering the growing evidence that many neurological disorders begin with a 
synaptotoxicity before progressing to neurodegeneration (Coleman et al., 2004; Canas et al., 2009). 
Additionally, P2Y1 receptors have a prominent role in the physiology of astrocytes, namely controlling 
the astrocytic calcium waves (Fam et al., 2003; Gallagher and Salter, 2003) and the glutamate release 
from these cells (Domercq et al., 2006). This is especially relevant under pathological conditions since 
the astrocytic Ca
2+
 waves increase with neuronal firing (Araque et al., 2002) and the glutamate released 
from astrocytes modulates synaptic transmission (Parpura and Haydon, 2000). In fact, an impairment in 
the astrocytic Ca
2+
 wave is regarded as a putative initial event in epileptic seizures, leading to the 
characteristic hypersynchronous neuronal firing (Tian et al., 2005; Kumaria et al., 2008). 
In conclusion, the results obtained support a role for P2Y1 receptors in the deleterious effects 
induced by epileptic seizures in the hippocampus and the view of these receptors as possible targets for 
the development of new neuroprotective drugs.    
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4.6 NEUROPROTECTION AFFORDED BY P2Y1 RECEPTORS BLOCKADE DURING IN 
VIVO ISCHAEMIA 
 
4.6.1 INTRODUCTION 
 
Ischaemia is defined by a reduction of cerebral blood flow which prevents the affected tissue of 
the normal supply of oxygen and nutrients, leading to cell death in the affected area (Braeuninger and 
Kleinschnitz, 2009). The area of stroke is designated the infarction area and can be highlighted as a 
white region on brain slices stained with 2,3,5-Triphenyltetrazolium chloride (TTC) (Sicard and Fisher, 
2009). The central area immediately affected is called the core of the infarct and the ischemic region 
around the core is called the ischemic penumbra (Braeuninger and Kleinschnitz, 2009). The process of 
cell degeneration within the affected area is a snow ball of deleterious events: deprivation of oxygen 
and glucose results in accumulation of acidic byproducts of the metabolism. The loss of substrate and 
decrease in pH levels leads to cessation of the electron transport chain activity within the mitochondria, 
resulting in a rapid decline in ATP concentration (Smith, 2004). This, in turn, leads to failure of the 
K
+
/Na
+
-ATPase, increase in Na
+
 concentration and cell depolarization, resulting in increased Ca
2+
 entry 
and overexcitation (Smith, 2004; Sicard and Fisher, 2009). Neurons inside the core infarct area fire 
repeatedly, releasing their transmitters locally and at distant targets. At the core of the infarct area there 
is a greater depletion of ATP and cells die essentially by necrosis, whilst in the penumbra region 
apoptotic cell death is more common (Smith, 2004). Thus, the ATP accumulated in the extracellular 
milieu plays a part in the pathophysiologic events resultant from an ischemic insult (Burnstock and 
Kennedy, 2011). The outflow of ATP during ischemic conditions has been observed both in 
hippocampal slices (Juranyi et al., 1999; Frenguelli et al., 2007) and in vivo (Melani et al., 2005). In 
addition, the involvement of P2 receptors in the deleterious consequences of ischemia was 
demonstrated in brain slices, organotypical cultures (Cavaliere et al., 2003; Runden-Pran et al., 2005) 
and in animal models of ischemia (Kharlamov et al., 2002). A time-dependent up-regulation of P2X7 
receptors was found in both glia and neurons (Franke et al., 2004) and P2 receptor antagonists like 
reactive blue 2 (Melani et al., 2006a) and PPADS (Lammer et al., 2006) were shown to improve the 
neurological deficit and to reduce the damage induced by focal ischemia. However, in most works the 
attention has relayed on P2X receptors (Cavaliere et al., 2007; Sperlagh et al., 2007; Milius et al., 
2008) while the involvement of P2Y receptors in ischemic damage is still poorly understood. 
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Therefore, in the following work, it was tested the neuroprotective potential of P2Y1 receptors blockade 
in a mouse model of permanent focal ischemia as compared to the general antagonism of P2 receptors.  
 
4.6.2 RESULTS 
 
4.6.2.1 BLOCKADE OF P2 RECEPTORS OR OF P2Y1 RECEPTORS PROTECTS AGAINST 
ISCHAEMIA-INDUCED INJURY 
 
In the present work, distal occlusion of the medial cerebral artery (MCAO) was performed in 
Swiss male, adult mice via a transorbital approach. The dura was removed and a segment of the artery 
was exposed and electrocoagulated, cut just distal to the inferior cerebral vein as described in (Marks et 
al., 2001). Previous to MCAO (10 minutes before) the animals were placed in the stereotaxic under 
anesthesia for the intracerebroventricular administration of drugs or saline. The mice were organized in 
the following experimental groups: the Sham-operated group (SO + V, in which the animals received 
saline icv and then received the same procedure as the operated animals except for the cauterizing of 
the MCA); the MCAO group (MCAO + V, in which mice received saline icv and underwent MCAO 
10 minutes after); the PPADS group (PPADS + MCAO, mice that received different doses of PPADS, 
0.5 nmol/ µl and 1 nmol/µl, icv, 10 minutes before MCAO) and the MRS2500 group (MRS2500 + 
MCAO, mice that received 1nmol/ µl MRS2500, icv, 10 minutes before MCAO). The highest dose of 
PPADS (1 nmol/ µl, icv) was also tested in the Sham-operated animals (SO + PPADS). The ischaemia 
outcome was investigated 24 hours after MCAO, through the evaluation of motor and mnemonic skills 
and quantification of the ischaemia-induced infarct volume.   
As shown in the image of Figure 1, the ischemia induced by MCAO resulted in tissue damage 
involving the cortical peri-infarct area of coronal brain sections affecting the frontoparietal cortex and 
the hippocampus as was previously described (Franke et al., 2004; Gunther et al., 2005). Also in Figure 
1, it can be observed that the sham-operated (SO) animals that received saline (V) icv or the non-
selective antagonist of P2 receptors, PPADS (1 nmol in 1 µl, icv) before the surgical procedures did not 
present any ischemic-like lesion. The treatment with either PPADS (0.5 or 1 nmol/ 1µl) or with the 
selective P2Y1 receptor antagonist MRS2500 (1 nmol/1µl, icv), 15 min before MCAO, greatly reduced 
the ischemic-induced lesion, revealed as a white region in the TTC coloured brain slices shown in the 
picture of Figure 1. The infarct volume induced by MCAO was of 6.8 ± 1.0 mm
3
 (MCAO + V group) 
which was significantly different (p<0.001) from the values obtained with the SO + V group (0.9 ± 0.1 
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mm
3
) and with the SO + PPADS 1.0 group (1.2 ± 0.1 mm
3
) (Fig. 1). Previous icv administration of 0.5 
nmol of PPADS (MCAO + PPADS 0.5 group) significantly reduced the lesion induced by MCAO to 
2.2 ± 0.3 mm
3
 (p<0.001) as well as the higher dose of 1 nmol PPADS (MCAO + PPADS 1.0 group) 
which reduced the infarct volume to 1.9 ± 0.2 mm
3
 (p<0.001) (Fig.1). The antagonism of P2Y1 
receptors alone, with MRS2500 (1 nmol), was equally effective in reducing the ischemic lesion (2.3 ± 
0.3 mm
3
; p<0.001 comparing with the MCAO + V group) (Fig. 1).       
 
 
 
 
FIGURE 1: Blockade of P2 receptors or of P2Y1 receptors significantly reduces the ischemia-induced infarct area. 
Swiss male mice (2 months old, weighting between 30-40g) received saline, the non-selective antagonist of P2 receptors 
PPADS (0.5 nmol or 1 nmol in 1µL) or the selective antagonist of P2Y1 receptors MRS2500 (1 nmol in 1µL), icv, 10 min 
before middle cerebral artery occlusion (MCAO). The SO (sham-operated) + V (vehicle) is the control group that received 
saline icv and were operated without the occlusion of the middle cerebral artery (MCA). After 24 hours, animals were 
sacrificed and their brains were isolated and sliced using a mouse brain slicer matrix (0.5 mm coronal slice intervals). The 
infarct area was revealed by submersing the brain sections in a 2% in normal saline 2,3,5-Triphenyltetrazolium chloride 
(TTC) solution at 37ºC during 20 minutes, in the dark. The slices were washed twice in saline solution and fixed in 4% 
paraformaldehyde for 30 min at room temperature. Slices were again passed twice by saline solution and, afterwards, both 
sides of sections were scanned on a flatbed colour scanner. The colorless TTC is reduced to the red formazan product by 
dehydrogenases. The stain intensity correlates positively with the number and functionality of mitochondrias. The infarct 
volume is presented as a white region in the slice and was calculated integrating the infarct areas of the scanned images 
corresponding to the whole series of brain slices. Results are presented as a percentage of the total volume of the 
contralateral hemisphere and are described as mean ± SEM; n= 6 animals per group. ***p<0.001 comparing to the SO + V 
group and ###p<0.001 comparing with the MCAO + V group. Note that both doses of PPADS and the MRS2500 were 
effective at preventing MCAO-induced ischemic brain lesion. 
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4.6.2.2 BLOCKADE OF P2 RECEPTORS PREVENTS ISCHAEMIA-INDUCED MOTOR AND 
SPATIAL MEMORY DEFICITS 
 
A second group of animals was sacrificed three days after MCAO, when the ischemia-induced 
neurodegeneration is prominent. At this endpoint mice presented significant deficits in motor skills, as 
evaluated by counting the number of crossings (MCAO + V, 69 ± 7 comparing to 96 ± 8 of the SO + V 
group; n= 8; p<0.05) and rearings (MCAO + V, 10 ± 2 comparing to 20 ± 2 of the SO + V group; n= 8; 
p<0.01) in an open field (Fig. 2). Blockade of P2 receptors with PPADS significantly prevented the 
motor deficits, in a dose-dependent manner: the number of crossings of animals that received 0.5 nmol 
of PPADS, icv, before MCAO were 90 ± 4 (n= 8; p<0.05 comparing to the MCAO + V group) and the 
number of crossing of the animals that received 1 nmol of PPADS were of 106 ± 9 (n= 8; p<0.01 
comparing to the MCAO + V group) (Fig. 2). In terms of rearings, the PPADS 0.5 nmol + MCAO 
group had a better scoring (27 ± 3) comparing to the MCAO + V group (10 ± 2; n= 8; p<0.001) and the 
same was observed with the PPADS 1 nmol + MCAO group (21 ± 4; n= 8; p<0.05). Moreover, the 
highest dose of PPADS had no effect per se in the performance of the animals (SO + PPADS 1.0 ; 90 ± 
12 crossings and 21 ± 3 rearings) (Fig 2).    
 
FIGURE 2: Blockade of P2 receptors prevents ischemia-induced locomotor deficits. Swiss male mice (2 months old, weighting 
between 30-40g) received saline or the non-selective antagonist of P2 receptors, PPADS (0.5 nmol or 1 nmol in 1µL), icv, 10 min before 
middle cerebral artery occlusion (MCAO). The SO (sham-operated) + V (vehicle) is the control group that received saline icv and were 
operated, 10 min later, without the occlusion of the middle cerebral artery. After 3 days, locomotor performance was evaluated in an open 
field and the number of crossings and rearings were counted. The results are presented as mean ± SEM values; n= 8. *p<0.05 and 
**p<0.01 comparing to the SO + V group and #p<0.05, ##p<0.01 or ###p<0.001 comparing with the MCAO + V group. Note that both 
doses of PPADS prevented MCAO-induced locomotor deficits. 
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4.6.2.3 BLOCKADE OF P2 RECEPTORS PREVENTS ISCHAEMIA-INDUCED SPATIAL 
MEMORY DEFICITS  
 
Since the MCAO-induced lesion affects the cortical areas of the striatum and of the 
hippocampus, it likely affects spatial working memory (Hodges et al., 1997; Block, 1999). the effects 
of ischemia and of the PPADS treatment before MCAO in the spatial working memory of mice were 
evaluated 3 days after MCAO, as the percentage of alternation in a Y-maze. As shown in Figure 3, 
mice with MCAO (MCAO + V) performed significantly worse (57 ± 3% of alternation; p<0.01; n= 8) 
than the sham-operated mice (SO + V; 74 ± 2% of alternation; p<0.01; n= 8). Both doses of PPADS 
prevented this effect (0.5 nmol PPADS: 77 ± 2% of alternation; p<0.01 comparing with MCAO + V; 
n= 8; 1 nmol PPADS: 73 ± 4% of alternation; p<0.01 comparing with MCAO + V; n= 8) and had no 
effect per se in the animal‟s performance (SO + PPADS 1nmol: 71 ± 5% of alternation; n= 8) (Fig. 3).     
 
 
FIGURE 3: Blockade of P2 receptors prevents ischemia-induced spatial working memory deficits. Swiss male mice (2 
months old, weighting between 30-40g) received saline or the non-selective antagonist of P2 receptors PPADS (0.5 nmol or 
1 nmol in 1µL), icv, 10 min before middle cerebral artery occlusion (MCAO). The SO (sham-operated) + V (vehicle) is the 
control group that received saline icv and were operated, 10 min later, without middle cerebral artery occlusion. After 3 
days, the ability of animals to alternate in a Y-maze was evaluated. Both doses of PPADS prevented MCAO-induced 
decrease of alternation in the Y-maze. The percentage of alternation was calculated according to the formula: total of 
alternations / (Total arm entries – 2) X 100 and the results are presented as mean ± SEM; n= 8. **p<0.01 comparing to the 
SO + V group and ##p<0.01 comparing with the MCAO + V group. 
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4.6.2.3.1 BLOCKADE OF P2 RECEPTORS PREVENTS ISCHEMIA-INDUCED AVERSIVE 
MEMORY DEFICITS 
 
The MCAO effect on the aversive memory of mice was also tested 3 days after the surgery. As 
shown in the Figure 4, the group MCAO + V performed poorly in a passive avoidance apparatus, a test 
commonly used to evaluate aversive memory in rodents. Animals were first habituated to the passive 
avoidance box, being allowed to explore for 1 minute. Thirty seconds after this exploring period, mice 
were returned to the box where they received a 0.5 mA shock for 1 s, as soon as they entered the dark 
compartment. The recent aversive memory of the animals was evaluated by recording the latency time 
to enter this compartment, fifteen minutes after the shock. The same was done at twenty four hours 
after the shock to evaluate long-term memory or retention (late aversive memory), allowing a 
maximum latency time of 300 s. The MCAO + V group had significant worst results in early aversive 
memory, i.e., 15 min after the electric shock most animals did not remember it and took less time to 
step-down to the dark compartment of the box than the SO + V group (97.8 ± 26.9 s and 237.5 ± 29.6 s, 
respectively; p<0.01; n= 8) (Fig. 4). The PPADS effect was dose-dependent and significantly improved 
the performances (MCAO + PPADS 0.5 nmol, 240.8 ± 29.6 s and MCAO + PPADS 1nmol, 299.7 ± 
0.29 s; n= 8; p<0.01 and p<0.001, respectively, comparing to the MCAO + V group) (Fig. 4). The 
sham-operated animals that received PPADS did not display a different behavior from the sham-
operated animals that were administered saline (SO + PPADS 1nmol: 203.2 ± 35.2 s and SO + V: 
237.0 ± 29.6 s, respectively) (Fig. 4). In terms of long-term or late aversive memory, tested 24 hours 
after the electric shock, the MCAO + V group also performed significantly worst than the SO + V 
group (92.5 ± 24.9 s comparing to 235.0 ± 33.3 s, respectively, p<0.01; n= 8) (Fig. 4). In this case, only 
the highest dose of PPADS prevented the MCAO effect (MCAO + PPADS 1 nmol: 219.6 ± 41.4 s; 
p<0.05; n= 8) even though the 0.5 nmol dose also tended to improve the animal‟s performance (MCAO 
+ PPADS 0.5 nmol: 175.0 ± 34.6 s; n= 8) (Fig. 4).    
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FIGURE 4: Blockade of P2 receptors prevents ischemia-induced early and late aversive memory deficits. Swiss male 
mice (2 months old, weighting between 30-40g) received saline or the non-selective P2 receptors antagonist PPADS (0.5 
nmol or 1 nmol in 1µL, non-selective P2R antagonist), icv, 10 min before the middle cerebral artery occlusion (MCAO). 
The SO (sham-operated) + V (vehicle) is the control group that received saline icv and were operated, 10 min later, without 
middle cerebral artery occlusion. After 3 days, the ability of the mice to remember an aversive event (electric shock of 0.5 
mA during 1 s) was tested on a passive avoidance box. Fifteen minutes after the shock, the animals were placed on the 
platform compartment and the time taken for them to step down to the dark compartment where the shock took place 
(latency) was measured (early memory). The same was done 24 hours after the shock for the evaluation of late memory. 
The results are expressed as mean ± SEM; n= 8. **p<0.01 comparing to the SO + V group and #p<0.05, ##p<0.01 or 
###p<0.001 comparing with the MCAO + V group. Note that MCAO resulted in decreased early and late memory 
performances which were both prevented by PPADS in a dose-dependent manner. 
 
4.6.2.4 BLOCKADE OF P2Y1 RECEPTORS PREVENTS ISCHAEMIA-INDUCED 
NEUROLOGIC AND MOTOR DEFICITS 
 
The specific blockade of P2Y1 receptors with the selective antagonist MRS2500 (1 nmol in 1µl, 
icv), 10 min before the MCAO, significantly prevented the ischemia-induced neurological deficits, 24 
hours after, evaluated as described in (Hunter et al., 2000). The neurological scoring for the control 
group, SO + V, was of 18 ± 0.2 scores and for the MCAO + V group was of 15 ± 1.0 scores (p<0.05; 
n= 8). Blockade of P2Y1 receptors effectively prevented this effect of the MCAO (17 ± 0.5 scores, 
p<0.01 comparing to MCAO + V; n= 8). Three days after the MCAO-induced ischemia, the MCAO + 
V group also presented locomotor deficits comparing with the SO + V group, as evaluated by the 
number of crossings in an open field (86 ± 12 vs 120 ±7, respectively, p<0.05; n= 8) and MRS2500 
prevented this effect (130 ± 8; p<0.05 comparing to the MCAO + V group; n= 8) (Fig. 5).    
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FIGURE 5: Blockade of P2Y1 receptors improves ischemia-induced neurologic scoring and motor deficits. Swiss 
male mice (2 months old, weighting between 30-40g) received saline or the selective antagonist of P2Y1 receptors 
MRS2500 (1 nmol in 1µL), icv, 10 min before the middle cerebral artery occlusion (MCAO). The SO (sham-operated) + V 
(vehicle) is the control group that received saline icv and were operated, 10 min after, without middle cerebral artery 
occlusion. After 24 hours, neurological scoring was evaluated according to Hunter et al., 2000 and the SHIRPA protocol. 
Three days after ischemia, locomotor performance was evaluated in an open field and the number of crossings was counted. 
The results are presented as mean ± SEM values; n=8. *p<0.05 comparing with the SO + V group and #p<0.05 comparing 
with the MCAO + V group. Note that the MRS2500 prevented both the MCAO-induced neurologic and motor deficits. 
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4.6.2.5 BLOCKADE OF P2Y1 RECEPTORS PREVENTS ISCHEMIA-INDUCED SPATIAL 
MEMORY DEFICITS 
 
The Morris water maze was used to evaluate the effect of the blockade of P2Y1 receptors on the 
spatial working memory deficits induced by ischemia. This test was developed by Morris in 1984 
(Morris, 1984) and is a useful assay to test spatial memory that depends on the integrity of the 
hippocampus. The test consists in evaluating the animal‟s ability to find a platform (placed 1 cm bellow 
the surface) from visual cues in a room while swimming in a round water pool.  The animals were 
tested in four trials per day over three consecutive days and allowed to swim until they reached the 
escape platform for a maximum of 120 s, after which they were placed on the platform. Spatial 
memory retention was evaluated 48 hours after the last trial by hiding the platform and allowing the 
mice to swim for 30 s, recording the time spent on the area where the platform once was. On 
consecutive days, the MCAO + V group performed significantly worse than the mice of the SO + V 
group, having spent successively more time to find the platform (Fig. 6). The blockade of P2Y1 
receptors (MCAO + MRS2500 group) prevented this effect since the animals performed as well as the 
non-ischemic mice (Fig. 6, graphic on the left). Moreover, MRS2500 tended to improve memory 
retention (22.0 ± 2.4 s spent on the platform area) which was affected by the MCAO-induced ischemia 
(18.9 ± 0.9 s versus 25.4 ± 26 s of the SO + V group; n= 8) (Fig. 6, graphic on the right).     
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FIGURE 6: Blockade of P2Y1 receptors prevents the ischemia-induced deficits in spatial memory. Swiss male mice (2 
months old, weighting between 30-40g) received saline or the selective antagonist MRS2500 (1 nmol in 1µL), icv, 10 min 
before middle cerebral artery occlusion (MCAO). The SO (sham-operated) + V (vehicle) is the control group that received 
saline icv and were operated, 10 min after, without middle cerebral artery occlusion. Three days after ischemia, spatial 
memory performance was evaluated in the Morris water maze by measuring the time to find a platform based on visual cues 
in a room, during 4 trials on 3 consecutive days (left graph). Memory retention was evaluated 48 hours after the last trial by 
measuring the time the mice spent on the area of the hidden platform (right graphic). The results are presented as mean ± 
SEM values; n=8. *p<0.05 comparing to the SO + V group and #p<0.05 comparing with the MCAO + V group. Note that 
MRS2500 prevented the MCAO-induced spatial memory learning. 
 
 
4.6.3 DISCUSSION 
 
A role for P2 receptors in the ischemia-induced neurodegeneration and neuroinflammation has 
been unraveled through in vitro studies using superfused brain slices and organotypical cultures, 
subjected to oxygen and glucose deprivation (Juranyi et al., 1999; Cavaliere et al., 2003; Runden-Pran 
et al., 2005). However, until recently, the ATP-mediated effects in ischemia models have been mostly 
attributed to the activation of P2X receptors (Cavaliere et al., 2003; Runden-Pran et al., 2005; 
Cavaliere et al., 2007; Sperlagh et al., 2007; Milius et al., 2008). Thus, the neuroprotective effects of 
antagonists of P2 receptors, namely of the non-selective antagonist PPADS, have been argued to occur 
essentially due to the blockade of these receptors. Even though the involvement of ionotropic P2X 
receptors, and especially of P2X7 receptors, in mediating excitotoxicity is well described (Apolloni et 
al., 2009; Skaper et al., 2010), it is also true that P2Y receptors have a prominent role in the patho-
physiology of glial cells and in the control of synaptic transmission, as discussed in previous chapters. 
In particular, the P2Y1 receptors play an important part in many of these mechanisms (Domercq et al., 
P2 receptors blockade in MCAO model                                                                                 4. RESULTS 
161 
  
2006; Hussl and Boehm, 2006; Di Virgilio et al., 2009). Thus, it was hypothesised that the blockade of 
these receptors could, therefore, afford a robust neuroprotection against ischemic damage as was found 
in other disease models. The blockade of P2 receptors, using PPADS, during the in vivo MCAO model 
of ischemia was recently addressed by (Lammer et al., 2006). Here, the authors found that PPADS 
effectively prevented both morphological and behavioral deficits induced by permanent MCAO. These 
results also correlate with previous findings using other non-selective antagonist of P2 receptors, 
suramin (Kharlamov et al., 2002). Moreover, in vivo administration of PPADS counteracts the release 
of glutamate induced by the extracellular ATP (Krugel et al., 2004). To tackle the question of whether 
the selective blockade of P2Y1 receptors could prevent the ischemic-induced deleterious events in 
comparison to the general antagonism of P2 receptors, animals were administered either PPADS or 
MRS2500 (icv) 10 minutes before the MCAO. The choice of PPADS relied on studies showing that 
among the available P2 receptor antagonists, this one affects a greater number of P2 receptors subtypes 
(P2Y1,2,4,6 receptors; recombinant homomeric P2X1,2,3,5 receptors and heteromeric P2X2,3 and P2X1/5 
receptors) (Ralevic and Burnstock, 1998) and, unlike the other antagonists, does not affect glutamate 
receptors (Tschopl et al., 1992). This late characteristic is particularly important under ischemic 
conditions since glutamate plays an important part in ischemic-induced excitotoxicity. On the other 
hand, PPADS also inhibits ecto-nucleotidases resulting in higher extracellular ATP concentrations and 
less ATP-derived adenosine (Windscheif et al., 1994; Chen et al., 1996), which remains an unsolved 
problem when dealing with ATP antagonists. 
In the present study, both the blockade of P2 receptors in general and the antagonism of P2Y1 
receptors alone equally improved the MCAO-induced ischemia outcome in mice, effectively 
preventing MCAO-induced infarct volume, neurological scores and mnemonic deficits. The results 
obtained with the blockade of P2Y1 receptors under noxious and generally excitotoxic conditions both 
in vitro and in vivo, though promising, seem at odd with the inhibitory role of these receptors under 
physiological conditions at the synaptic level (Kawamura et al., 2004; Guzman et al., 2005; Rodrigues 
et al., 2005b) and also with their mediation of cell survival mechanisms in glia (Fujita et al., 2009). 
However, there is increasing evidence of neuroprotection afforded through the blockade of P2Y1 
receptors under ischemic conditions. In this regard, Coppi et al. (2007) have recently shown that under 
normoxia, in hippocampal slices, ATP decreased field excitatory post-synaptic potentials (fEPSP) and 
population spikes at the CA1 region. This effect was in part mediated by ATP-derived adenosine acting 
on A1 receptors and in part by ATP acting on P2Y1 receptors. On the other hand, under ischemic 
conditions, such as oxygen and glucose deprivation (OGD), the selective blockade of P2Y1R prevented 
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OGD-induced appearance of anoxic depression and the consequent irreversible loss of fEPSP. The 
protective effect of the antagonist of P2Y1 receptors may also pertain to a direct inhibition of 
intracellular Ca
2+ 
in glial cells and consequent reactive gliosis (Troadec et al., 1999; Schipke et al., 
2002) and also to the prevention of P2Y1 receptors-mediated release of glutamate from astrocytes 
(Domercq et al., 2006; Jourdain et al., 2007). 
In conclusion, the present work further encourages the view of P2 receptors and specifically of 
P2Y1 receptors as possible new targets for neuroprotection under excitotoxic and pro-inflammatory 
conditions. 
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The goal of the work presented in this thesis was to explore the control of neuroinflammation 
by adenosine A2A receptors and the neuroprotection afforded with the blockade of ATP P2Y1 receptors 
under deleterious conditions in the hippocampus.   
The purinergic system controls most cellular activity and communication in the brain 
(Burnstock, 2006; Burnstock, 2009b). During noxious conditions, the extracellular concentration of 
ATP dramatically increases due to a combination of events such as metabolic failure, increased 
neuronal firing and cell degeneration (Melani et al., 2005; Franke and Illes, 2006). Once in the 
extracellular space, ATP rapidly originates adenosine (which can also be released per se from cells) 
due to the catabolic activity of ectonucleotidases (Cunha et al., 1998; Zimmermann, 2000; 
Zimmermann, 2006). Being a more stable molecule, adenosine is a recognizable major neuromodulator 
(Sebastiao and Ribeiro, 2000; Cunha, 2001), mostly through the activation of A1 or of A2A receptors, 
which are the most abundant adenosine receptors in the brain (Cunha, 2005). The excitatory activity 
mediated by the activation of A2A receptors is particularly relevant upon noxious conditions, since both 
adenosine and the density of these receptors are increased (Cunha et al., 2006; Duarte et al., 2006; 
Costenla et al., 2011). Accordingly, the blockade of A2A receptors is neuroprotective in such situations 
(Cunha, 2005; Gomes et al., 2011) and particularly in vivo, in animal models of brain disorders such as 
Alzheimer‟s disease (Canas et al., 2009), ischaemia (Latini et al., 1999), epilepsy (Boison, 2010) and 
Parkinson‟s disease (Kalda et al., 2006; Yu et al., 2008). The control of neuroinflammation may 
explain the broad spectrum of pathologies in which this blockade is beneficial. The presented work 
strongly suggests that A2A receptors can control the recruitment and activation of microglia and thus 
the genesis of neuroinflammation. In addition, it is also shown that A2A receptors are able to modulate 
the direct, deleterious impact of neuroinflammation on neurons, such as the priming of neurons to 
excitotoxicity induced by the pro-inflammatory cytokine interleukin-1β. Overall, these results 
contribute to further elucidate the beneficial impact of the blockade of A2A receptors in so many 
different pathologies. 
ATP receptors are also involved in the pathophysiology of many brain diseases and their 
expression and density is frequently and sometimes chronically altered in such situations (Illes and 
Alexandre Ribeiro, 2004; Franke and Illes, 2006). The instability of extracellular ATP and its rapid 
conversion to adenosine has complicated the unraveling of its direct effects on cells (Cunha and 
Ribeiro, 2000). However, the development of new, more potent and selective drugs for the different 
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ATP receptors has helped to better understand both their physiology and pathophysiology. Typically, 
the deleterious effects of ATP have been attributed to the activation of the excitatory P2X receptors and 
especially to the activation of P2X7 receptors (Aswad and Dennert, 2006; Coutinho-Silva et al., 2007; 
Bernardino et al., 2008) that form large pores on the cellular membranes linked to the apoptotic 
pathway (Atkinson et al., 2002). However, the modulatory effects of P2Y receptors are receiving 
increasing attention. 
In the present work, it was found that the antagonism of P2Y1 receptors partially inhibited the 
signaling induced by the interleukin-1β in hippocampal neurons and attenuated the exacerbation of 
excitotoxicity by this cytokine. In addition and importantly, the blockade of these receptors completely 
prevented the noxious effects of glutamate in hippocampal cultured neurons. It was also found that 
P2Y1 receptors influenced the early effects of glutamate through NMDA receptors and its blockade 
effectively protected neurons against glutamate-induced neurotoxicity at short-time exposures to the 
aminoacid. These results seem at odd with the synaptic inhibitory role of P2Y1 receptors since they 
were found to inhibit glutamate release pre-synaptically (Rodrigues et al., 2005b) and to decrease 
NMDA currents post-synaptically (Luthardt et al., 2003). However, they also inhibit the M-type k
+
 
currents in hippocampal pyramidal cells (Filippov et al., 2006) which contributes to increase neuronal 
excitability. In addition, P2Y1 receptors were implied in the pathophysiology of Alzheimer‟s disease 
(Moore et al., 2000b) and in the ischemia-induced damage to hippocampal slices (Traini et al., 2011), 
which is suggestive of a role in both excitotoxic- and inflammation-induced damage. In fact, these 
receptors have a widespread distribution in the mammalian brain, in both glial and neuronal structures 
(Moore et al., 2000a; Moran-Jimenez and Matute, 2000) and are crucial for the formation of the 
astrocytic calcium waves (Fam et al., 2003; Gallagher and Salter, 2003) and in the  control of glutamate 
transport in these cells (Domercq et al., 2006; Zeng et al., 2009). These findings, added to the ability of 
P2Y1 receptors to control the glutamate-induced damage in the hippocampus, lead to further exploring 
their targeting in animal models of diseases where there is an overexcitability of neurons and 
neuroinflammation-induced damage in the hippocampus, such as in epilepsy. The blockade of P2Y1 
receptors was tested in a rat model of temporal lobe epilepsy induced by the systemic administration of 
kainate. The characterization of the density of P2 receptors in the hippocampal membranes, at different 
times after the kainate-induced seizures, showed a significant (long-term) altered density of most 
subtypes of P2 receptors, both in synaptosomes and in total membranes. This altered density evidences 
the contribution of ATP signaling in the pathophysiology of seizures. Most P2 receptor subtypes were 
up-regulated in the hippocampus 24 hours after the systemic insult with kainate. Thus, this endpoint 
5. CONCLUDING REMARKS 
167 
 
was chosen for the subsequent analysis. In fact, at this time, there was also a clear loss of terminal 
markers in the hippocampal membranes, an evident microgliosis and neurodegeneration in all 
hippocampal subregions. In particular, at 24 hours after the kainate administration, the P2Y1 receptors 
were significantly up-regulated in both synaptic and total membranes, which is indicative of their 
importance in both synaptic and non-synaptic sites. Moreover, the intracerebroventricular 
administration of a selective antagonist of P2Y1 receptors (MRS2500) prevented the loss of most 
terminal markers in hippocampal membranes. This is especially important considering that many 
neurological disorders may start with a synaptotoxicity before evoluting to neurodegeneration 
(Coleman et al., 2004; Canas et al., 2009; Cognato et al., 2010) thus, giving a window of opportunity 
to profilatic treatment in these diseases. In addition, MRS2500 also prevented the strong microgliosis 
and attenuated the neurodegeneration induced by kainate in the hippocampus. 
Finally, the blockade of P2Y1 receptors significantly prevented the ischemia-induced damage in 
the brain of mice subjected to the permanent occlusion of the medial cerebral artery (MCAO) and 
abrogated both the neurological and mnemonic deficits induced by MCAO.               
Overall, the presented data supports a role for the blockade of A2A receptors in the control of 
neuroinflammation and the potential targeting of P2Y1 receptors under pro-inflammatory and 
excitotoxic conditions in the brain.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. REFERENCES 
171 
 
 
6. REFERENCES 
 
Abbracchio, MP, Brambilla, R, Ceruti, S, Kim, HO, von Lubitz, DK, Jacobson, KA and Cattabeni, F 
(1995). "G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat 
brain." Mol Pharmacol 48(6): 1038-1045. 
Abbracchio, MP and Burnstock, G (1994). "Purinoceptors: are there families of P2X and P2Y 
purinoceptors?" Pharmacol Ther 64(3): 445-475. 
Abbracchio, MP, Burnstock, G, Boeynaems, JM, Barnard, EA, Boyer, JL, Kennedy, C, Knight, GE, 
Fumagalli, M, Gachet, C, Jacobson, KA and Weisman, GA (2006). "International Union of 
Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from 
molecular mechanisms and pathophysiology to therapy." Pharmacol Rev 58(3): 281-341. 
Abbracchio, MP, Burnstock, G, Verkhratsky, A and Zimmermann, H (2009). "Purinergic signalling in 
the nervous system: an overview." Trends Neurosci 32(1): 19-29. 
Abbracchio, MP and Ceruti, S (2006). "Roles of P2 receptors in glial cells: focus on astrocytes." 
Purinergic Signal 2(4): 595-604. 
Abbracchio, MP and Ceruti, S (2007). "P1 receptors and cytokine secretion." Purinergic Signal 3(1-2): 
13-25. 
Abbracchio, MP and Verderio, C (2006). "Pathophysiological roles of P2 receptors in glial cells." 
Novartis Found Symp 276: 91-103. 
Agresti, C, Meomartini, ME, Amadio, S, Ambrosini, E, Serafini, B, Franchini, L, Volonte, C, Aloisi, F 
and Visentin, S (2005). "Metabotropic P2 receptor activation regulates oligodendrocyte 
progenitor migration and development." Glia 50(2): 132-144. 
Agteresch, HJ, Dagnelie, PC, van den Berg, JW and Wilson, JH (1999). "Adenosine triphosphate: 
established and potential clinical applications." Drugs 58(2): 211-232. 
Allan, SM and Rothwell, NJ (2001). "Cytokines and acute neurodegeneration." Nat Rev Neurosci 
2(10): 734-744. 
Allan, SM, Tyrrell, PJ and Rothwell, NJ (2005). "Interleukin-1 and neuronal injury." Nat Rev Immunol 
5(8): 629-640. 
Amadio, S, D'Ambrosi, N, Cavaliere, F, Murra, B, Sancesario, G, Bernardi, G, Burnstock, G and 
Volonte, C (2002). "P2 receptor modulation and cytotoxic function in cultured CNS neurons." 
Neuropharmacology 42(4): 489-501. 
Amadio, S, Montilli, C, Picconi, B, Calabresi, P and Volonte, C (2007). "Mapping P2X and P2Y 
receptor proteins in striatum and substantia nigra: An immunohistological study." Purinergic 
Signal 3(4): 389-398. 
Amaral, DG (1978). "A Golgi study of cell types in the hilar region of the hippocampus in the rat." J 
Comp Neurol 182(4 Pt 2): 851-914. 
Amaral, DG and Witter, MP (1989). "The three-dimensional organization of the hippocampal 
formation: a review of anatomical data." Neuroscience 31(3): 571-591. 
Ambrosio, AF, Silva, AP, Malva, JO, Mesquita, JF, Carvalho, AP and Carvalho, CM (2000). "Role of 
desensitization of AMPA receptors on the neuronal viability and on the [Ca2+]i changes in 
cultured rat hippocampal neurons." Eur J Neurosci 12(6): 2021-2031. 
Andersen, P, Holmqvist, B and Voorhoeve, PE (1966). "Excitatory synapses on hippocampal apical 
dendrites activated by entorhinal stimulation." Acta Physiol Scand 66(4): 461-472. 
Andine, P, Rudolphi, KA, Fredholm, BB and Hagberg, H (1990). "Effect of propentofylline (HWA 
285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during 
transient ischaemia." Br J Pharmacol 100(4): 814-818. 
6. REFERENCES 
 
172 
 
Apolloni, S, Montilli, C, Finocchi, P and Amadio, S (2009). "Membrane compartments and purinergic 
signalling: P2X receptors in neurodegenerative and neuroinflammatory events." FEBS J 276(2): 
354-364. 
Araque, A, Martin, ED, Perea, G, Arellano, JI and Buno, W (2002). "Synaptically released 
acetylcholine evokes Ca2+ elevations in astrocytes in hippocampal slices." J Neurosci 22(7): 
2443-2450. 
Armstrong, JN, Brust, TB, Lewis, RG and MacVicar, BA (2002). "Activation of presynaptic P2X7-like 
receptors depresses mossy fiber-CA3 synaptic transmission through p38 mitogen-activated 
protein kinase." J Neurosci 22(14): 5938-5945. 
Asatryan, L, Popova, M, Perkins, D, Trudell, JR, Alkana, RL and Davies, DL (2010). "Ivermectin 
antagonizes ethanol inhibition in purinergic P2X4 receptors." J Pharmacol Exp Ther 334(3): 
720-728. 
Asatryan, L, Popova, M, Woodward, JJ, King, BF, Alkana, RL and Davies, DL (2008). "Roles of 
ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and 
P2X3 receptors." Neuropharmacology 55(5): 835-843. 
Assaife-Lopes, N, Sousa, VC, Pereira, DB, Ribeiro, JA, Chao, MV and Sebastiao, AM (2010). 
"Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-
mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation." J 
Neurosci 30(25): 8468-8480. 
Aswad, F and Dennert, G (2006). "P2X7 receptor expression levels determine lethal effects of a purine 
based danger signal in T lymphocytes." Cell Immunol 243(1): 58-65. 
Atkinson, L, Milligan, CJ, Buckley, NJ and Deuchars, J (2002). "An ATP-gated ion channel at the cell 
nucleus." Nature 420(6911): 42. 
Avignone, E, Ulmann, L, Levavasseur, F, Rassendren, F and Audinat, E (2008). "Status epilepticus 
induces a particular microglial activation state characterized by enhanced purinergic signaling." 
J Neurosci 28(37): 9133-9144. 
Back, T, Hemmen, T and Schuler, OG (2004). "Lesion evolution in cerebral ischemia." J Neurol 
251(4): 388-397. 
Baldwin, SA, Beal, PR, Yao, SY, King, AE, Cass, CE and Young, JD (2004). "The equilibrative 
nucleoside transporter family, SLC29." Pflugers Arch 447(5): 735-743. 
Ballabh, P, Braun, A and Nedergaard, M (2004). "The blood-brain barrier: an overview: structure, 
regulation, and clinical implications." Neurobiol Dis 16(1): 1-13. 
Ballarin, M, Fredholm, BB, Ambrosio, S and Mahy, N (1991). "Extracellular levels of adenosine and 
its metabolites in the striatum of awake rats: inhibition of uptake and metabolism." Acta Physiol 
Scand 142(1): 97-103. 
Ballerini, P, Di Iorio, P, Ciccarelli, R, Nargi, E, D'Alimonte, I, Traversa, U, Rathbone, MP and 
Caciagli, F (2002). "Glial cells express multiple ATP binding cassette proteins which are 
involved in ATP release." Neuroreport 13(14): 1789-1792. 
Balosso, S, Maroso, M, Sanchez-Alavez, M, Ravizza, T, Frasca, A, Bartfai, T and Vezzani, A (2008). 
"A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta." 
Brain 131(Pt 12): 3256-3265. 
Banks, WA and Erickson, MA (2010). "The blood-brain barrier and immune function and 
dysfunction." Neurobiol Dis 37(1): 26-32. 
Baraldi, PG, Cacciari, B, Romagnoli, R, Merighi, S, Varani, K, Borea, PA and Spalluto, G (2000). 
"A(3) adenosine receptor ligands: history and perspectives." Med Res Rev 20(2): 103-128. 
Barker, CF and Billingham, RE (1977). "Immunologically privileged sites." Adv Immunol 25: 1-54. 
6. REFERENCES 
173 
 
Barone, FC, Knudsen, DJ, Nelson, AH, Feuerstein, GZ and Willette, RN (1993). "Mouse strain 
differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy." J 
Cereb Blood Flow Metab 13(4): 683-692. 
Barrera, NP, Ormond, SJ, Henderson, RM, Murrell-Lagnado, RD and Edwardson, JM (2005). "Atomic 
force microscopy imaging demonstrates that P2X2 receptors are trimers but that P2X6 receptor 
subunits do not oligomerize." J Biol Chem 280(11): 10759-10765. 
Barron, KD (1995). "The microglial cell. A historical review." J Neurol Sci 134 Suppl: 57-68. 
Barry, CE, Nolan, Y, Clarke, RM, Lynch, A and Lynch, MA (2005). "Activation of c-Jun-N-terminal 
kinase is critical in mediating lipopolysaccharide-induced changes in the rat hippocampus." J 
Neurochem 93(1): 221-231. 
Bayer, SA (1985). "Neuron production in the hippocampus and olfactory bulb of the adult rat brain: 
addition or replacement?" Ann N Y Acad Sci 457: 163-172. 
Beattie, EC, Stellwagen, D, Morishita, W, Bresnahan, JC, Ha, BK, Von Zastrow, M, Beattie, MS and 
Malenka, RC (2002). "Control of synaptic strength by glial TNFalpha." Science 295(5563): 
2282-2285. 
Ben-Ari, Y (2001). "Cell death and synaptic reorganizations produced by seizures." Epilepsia 42 Suppl 
3: 5-7. 
Ben-Ari, Y and Cossart, R (2000). "Kainate, a double agent that generates seizures: two decades of 
progress." Trends Neurosci 23(11): 580-587. 
Benitez-Rajal, J, Lorite, MJ, Burt, AD, Day, CP and Thompson, MG (2006). "Phospholipase D and 
extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth 
factor and extracellular nucleotides." Am J Physiol Gastrointest Liver Physiol 291(5): G977-
986. 
Bennett, MR, Farnell, L and Gibson, WG (2005). "A quantitative model of purinergic junctional 
transmission of calcium waves in astrocyte networks." Biophys J 89(4): 2235-2250. 
Bernardino, L, Balosso, S, Ravizza, T, Marchi, N, Ku, G, Randle, JC, Malva, JO and Vezzani, A 
(2008). "Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to 
excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1beta release." J Neurochem 
106(1): 271-280. 
Bernardino, L, Xapelli, S, Silva, AP, Jakobsen, B, Poulsen, FR, Oliveira, CR, Vezzani, A, Malva, JO 
and Zimmer, J (2005). "Modulator effects of interleukin-1beta and tumor necrosis factor-alpha 
on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures." J Neurosci 
25(29): 6734-6744. 
Bernasconi, N and Bernhardt, BC (2010). "Temporal lobe epilepsy is a progressive disorder." Nat Rev 
Neurol 6(3): 1. 
Bertram, EH (2009). "Temporal lobe epilepsy: where do the seizures really begin?" Epilepsy Behav 14 
Suppl 1: 32-37. 
Beukers, MW, Chang, LC, von Frijtag Drabbe Kunzel, JK, Mulder-Krieger, T, Spanjersberg, RF, 
Brussee, J and AP, IJ (2004). "New, non-adenosine, high-potency agonists for the human 
adenosine A2B receptor with an improved selectivity profile compared to the reference agonist 
N-ethylcarboxamidoadenosine." J Med Chem 47(15): 3707-3709. 
Beutler, B and van Huffel, C (1994). "Unraveling function in the TNF ligand and receptor families." 
Science 264(5159): 667-668. 
Bevins, RA and Besheer, J (2006). "Object recognition in rats and mice: a one-trial non-matching-to-
sample learning task to study 'recognition memory'." Nat Protoc 1(3): 1306-1311. 
Bezzi, P, Gundersen, V, Galbete, JL, Seifert, G, Steinhauser, C, Pilati, E and Volterra, A (2004). 
"Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of 
glutamate." Nat Neurosci 7(6): 613-620. 
6. REFERENCES 
 
174 
 
Biber, K, Klotz, KN, Berger, M, Gebicke-Harter, PJ and van Calker, D (1997). "Adenosine A1 
receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of 
receptor expression." J Neurosci 17(13): 4956-4964. 
Blackstad, TW (1956). "Commissural connections of the hippocampal region in the rat, with special 
reference to their mode of termination." J Comp Neurol 105(3): 417-537. 
Blackstad, TW (1958). "On the termination of some afferents to the hippocampus and fascia dentata; an 
experimental study in the rat." Acta Anat (Basel) 35(3): 202-214. 
Block, F (1999). "Global ischemia and behavioural deficits." Prog Neurobiol 58(3): 279-295. 
Boison, D (2010). "Adenosine dysfunction and adenosine kinase in epileptogenesis." Open Neurosci J 
4: 93-101. 
Boison, D, Chen, JF and Fredholm, BB (2010). "Adenosine signaling and function in glial cells." Cell 
Death Differ 17(7): 1071-1082. 
Borsello, T and Forloni, G (2007). "JNK signalling: a possible target to prevent neurodegeneration." 
Curr Pharm Des 13(18): 1875-1886. 
Boyko, M, Zlotnik, A, Gruenbaum, BF, Gruenbaum, SE, Ohayon, S, Goldsmith, T, Kotz, R, Leibowitz, 
A, Sheiner, E, Shapira, Y and Teichberg, VI (2010). "An experimental model of focal ischemia 
using an internal carotid artery approach." J Neurosci Methods 193(2): 246-253. 
Bradford, MM (1976). "A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding." Anal Biochem 72: 248-254. 
Braeuninger, S and Kleinschnitz, C (2009). "Rodent models of focal cerebral ischemia: procedural 
pitfalls and translational problems." Exp Transl Stroke Med 1: 8. 
Brake, AJ, Wagenbach, MJ and Julius, D (1994). "New structural motif for ligand-gated ion channels 
defined by an ionotropic ATP receptor." Nature 371(6497): 519-523. 
Brambilla, R and Abbracchio, MP (2001). "Modulation of cyclooxygenase-2 and brain reactive 
astrogliosis by purinergic P2 receptors." Ann N Y Acad Sci 939: 54-62. 
Brambilla, R, Burnstock, G, Bonazzi, A, Ceruti, S, Cattabeni, F and Abbracchio, MP (1999). "Cyclo-
oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis." Br J Pharmacol 126(3): 563-
567. 
Brambilla, R, Ceruti, S, Malorni, W, Cattabeni, F and Abbracchio, MP (2000). "A novel gliotic P2 
receptor mediating cyclooxygenase-2 induction in rat and human astrocytes." J Auton Nerv Syst 
81(1-3): 3-9. 
Brambilla, R, Neary, JT, Cattabeni, F, Cottini, L, D'Ippolito, G, Schiller, PC and Abbracchio, MP 
(2002). "Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is 
dependent on ERK1/2 but independent of calcium signalling." J Neurochem 83(6): 1285-1296. 
Brederson, JD and Jarvis, MF (2008). "Homomeric and heteromeric P2X3 receptors in peripheral 
sensory neurons." Curr Opin Investig Drugs 9(7): 716-725. 
Brewer, GJ, Torricelli, JR, Evege, EK and Price, PJ (1993). "Optimized survival of hippocampal 
neurons in B27-supplemented Neurobasal, a new serum-free medium combination." J Neurosci 
Res 35(5): 567-576. 
Bringmann, A, Pannicke, T, Moll, V, Milenkovic, I, Faude, F, Enzmann, V, Wolf, S and Reichenbach, 
A (2001). "Upregulation of P2X(7) receptor currents in Muller glial cells during proliferative 
vitreoretinopathy." Invest Ophthalmol Vis Sci 42(3): 860-867. 
Brothers, HM, Marchalant, Y and Wenk, GL (2010). "Caffeine attenuates lipopolysaccharide-induced 
neuroinflammation." Neurosci Lett 480(2): 97-100. 
Brown, DA, Filippov, AK and Barnard, EA (2000). "Inhibition of potassium and calcium currents in 
neurones by molecularly-defined P2Y receptors." J Auton Nerv Syst 81(1-3): 31-36. 
Brown, DA and Passmore, GM (2009). "Neural KCNQ (Kv7) channels." Br J Pharmacol 156(8): 1185-
1195. 
6. REFERENCES 
175 
 
Brown, GC (2007). "Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase." 
Biochem Soc Trans 35(Pt 5): 1119-1121. 
Brown, GC and Neher, JJ (2010). "Inflammatory neurodegeneration and mechanisms of microglial 
killing of neurons." Mol Neurobiol 41(2-3): 242-247. 
Brown, RA, Spina, D and Page, CP (2008). "Adenosine receptors and asthma." Br J Pharmacol 153(1): 
S446-456. 
Brundege, JM, Diao, L, Proctor, WR and Dunwiddie, TV (1997). "The role of cyclic AMP as a 
precursor of extracellular adenosine in the rat hippocampus." Neuropharmacology 36(9): 1201-
1210. 
Burnstock, G (2004). "Cotransmission." Curr Opin Pharmacol 4(1): 47-52. 
Burnstock, G (2006). "Purinergic signalling--an overview." Novartis Found Symp 276: 26-48; 
discussion 48-57, 275-281. 
Burnstock, G (2007a). "Physiology and pathophysiology of purinergic neurotransmission." Physiol Rev 
87(2): 659-797. 
Burnstock, G (2007b). "Purine and pyrimidine receptors." Cell Mol Life Sci 64(12): 1471-1483. 
Burnstock, G (2008). "Purinergic signalling and disorders of the central nervous system." Nat Rev 
Drug Discov 7(7): 575-590. 
Burnstock, G (2009a). "Purinergic cotransmission." F1000 Biol Rep 1: 46. 
Burnstock, G (2009b). "Purinergic signalling: past, present and future." Braz J Med Biol Res 42(1): 3-
8. 
Burnstock, G, Campbell, G, Satchell, D and Smythe, A (1970). "Evidence that adenosine triphosphate 
or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves 
in the gut." Br J Pharmacol 40(4): 668-688. 
Burnstock, G and Kennedy, C (1985). "Is there a basis for distinguishing two types of P2-
purinoceptor?" Gen Pharmacol 16(5): 433-440. 
Burnstock, G and Kennedy, C (2011). "P2X receptors in health and disease." Adv Pharmacol 61: 333-
372. 
Burnstock, G, Krugel, U, Abbracchio, MP and Illes, P (2011). "Purinergic signalling: From normal 
behaviour to pathological brain function." Prog Neurobiol 95(2): 229-274. 
Butler, MP, O'Connor, JJ and Moynagh, PN (2004). "Dissection of tumor-necrosis factor-alpha 
inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-
dependent mechanism which maps to early-but not late-phase LTP." Neuroscience 124(2): 319-
326. 
Butt, AM (2011). "ATP: a ubiquitous gliotransmitter integrating neuron-glial networks." Semin Cell 
Dev Biol 22(2): 205-213. 
Buttini, M and Boddeke, H (1995). "Peripheral lipopolysaccharide stimulation induces interleukin-1 
beta messenger RNA in rat brain microglial cells." Neuroscience 65(2): 523-530. 
Canas, PM, Porciuncula, LO, Cunha, GM, Silva, CG, Machado, NJ, Oliveira, JM, Oliveira, CR and 
Cunha, RA (2009). "Adenosine A2A receptor blockade prevents synaptotoxicity and memory 
dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase 
pathway." J Neurosci 29(47): 14741-14751. 
Carobrez, AP and Bertoglio, LJ (2005). "Ethological and temporal analyses of anxiety-like behavior: 
the elevated plus-maze model 20 years on." Neurosci Biobehav Rev 29(8): 1193-1205. 
Carson, MJ, Doose, JM, Melchior, B, Schmid, CD and Ploix, CC (2006). "CNS immune privilege: 
hiding in plain sight." Immunol Rev 213: 48-65. 
Cavaliere, F, Amadio, S, Dinkel, K, Reymann, KG and Volonte, C (2007). "P2 receptor antagonist 
trinitrophenyl-adenosine-triphosphate protects hippocampus from oxygen and glucose 
deprivation cell death." J Pharmacol Exp Ther 323(1): 70-77. 
6. REFERENCES 
 
176 
 
Cavaliere, F, Florenzano, F, Amadio, S, Fusco, FR, Viscomi, MT, D'Ambrosi, N, Vacca, F, Sancesario, 
G, Bernardi, G, Molinari, M and Volonte, C (2003). "Up-regulation of P2X2, P2X4 receptor 
and ischemic cell death: prevention by P2 antagonists." Neuroscience 120(1): 85-98. 
Chakraborty, S, Kaushik, DK, Gupta, M and Basu, A (2010). "Inflammasome signaling at the heart of 
central nervous system pathology." J Neurosci Res 88(8): 1615-1631. 
Chakravarty, S and Herkenham, M (2005). "Toll-like receptor 4 on nonhematopoietic cells sustains 
CNS inflammation during endotoxemia, independent of systemic cytokines." J Neurosci 25(7): 
1788-1796. 
Chaparro-Huerta, V, Flores-Soto, ME, Gudino-Cabrera, G, Rivera-Cervantes, MC, Bitzer-Quintero, 
OK and Beas-Zarate, C (2008). "Role of p38 MAPK and pro-inflammatory cytokines 
expression in glutamate-induced neuronal death of neonatal rats." Int J Dev Neurosci 26(5): 
487-495. 
Chaparro-Huerta, V, Rivera-Cervantes, MC, Flores-Soto, ME, Gomez-Pinedo, U and Beas-Zarate, C 
(2005). "Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity 
mediated by p38 MAPK in the hippocampus of neonatal rats." J Neuroimmunol 165(1-2): 53-
62. 
Chapman, TR, Barrientos, RM, Ahrendsen, JT, Maier, SF and Patterson, SL (2010). "Synaptic 
correlates of increased cognitive vulnerability with aging: peripheral immune challenge and 
aging interact to disrupt theta-burst late-phase long-term potentiation in hippocampal area 
CA1." J Neurosci 30(22): 7598-7603. 
Chen, GQ, Chen, YY, Wang, XS, Wu, SZ, Yang, HM, Xu, HQ, He, JC, Wang, XT, Chen, JF and 
Zheng, RY (2010). "Chronic caffeine treatment attenuates experimental autoimmune 
encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats." Brain Res 
1309: 116-125. 
Chen, JF, Huang, Z, Ma, J, Zhu, J, Moratalla, R, Standaert, D, Moskowitz, MA, Fink, JS and 
Schwarzschild, MA (1999). "A(2A) adenosine receptor deficiency attenuates brain injury 
induced by transient focal ischemia in mice." J Neurosci 19(21): 9192-9200. 
Chen, JF, Sonsalla, PK, Pedata, F, Melani, A, Domenici, MR, Popoli, P, Geiger, J, Lopes, LV and de 
Mendonca, A (2007). "Adenosine A2A receptors and brain injury: broad spectrum of 
neuroprotection, multifaceted actions and "fine tuning" modulation." Prog Neurobiol 83(5): 
310-331. 
Chen, W, Wieraszko, A, Hogan, MV, Yang, HA, Kornecki, E and Ehrlich, YH (1996). "Surface 
protein phosphorylation by ecto-protein kinase is required for the maintenance of hippocampal 
long-term potentiation." Proc Natl Acad Sci U S A 93(16): 8688-8693. 
Cho, KJ, Seo, JM, Shin, Y, Yoo, MH, Park, CS, Lee, SH, Chang, YS, Cho, SH and Kim, JH (2010). 
"Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-
affinity leukotriene B4 receptor." Am J Respir Cell Mol Biol 42(3): 294-303. 
Choi, RC, Man, ML, Ling, KK, Ip, NY, Simon, J, Barnard, EA and Tsim, KW (2001). "Expression of 
the P2Y1 nucleotide receptor in chick muscle: its functional role in the regulation of 
acetylcholinesterase and acetylcholine receptor." J Neurosci 21(23): 9224-9234. 
Chorna, NE, Santiago-Perez, LI, Erb, L, Seye, CI, Neary, JT, Sun, GY, Weisman, GA and Gonzalez, 
FA (2004). "P2Y receptors activate neuroprotective mechanisms in astrocytic cells." J 
Neurochem 91(1): 119-132. 
Choy, KH, Dean, O, Berk, M, Bush, AI and van den Buuse, M (2010). "Effects of N-acetyl-cysteine 
treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-
one-treated rats." Eur J Pharmacol 649(1-3): 224-228. 
6. REFERENCES 
177 
 
Ciccarelli, R, Ballerini, P, Sabatino, G, Rathbone, MP, D'Onofrio, M, Caciagli, F and Di Iorio, P 
(2001). "Involvement of astrocytes in purine-mediated reparative processes in the brain." Int J 
Dev Neurosci 19(4): 395-414. 
Ciccarelli, R, Di Iorio, P, Ballerini, P, Ambrosini, G, Giuliani, P, Tiboni, GM and Caciagli, F (1994). 
"Effects of exogenous ATP and related analogues on the proliferation rate of dissociated 
primary cultures of rat astrocytes." J Neurosci Res 39(5): 556-566. 
Ciccarelli, R, Di Iorio, P, Bruno, V, Battaglia, G, D'Alimonte, I, D'Onofrio, M, Nicoletti, F and 
Caciagli, F (1999). "Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors 
enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes." 
Glia 27(3): 275-281. 
Ciruela, F, Casado, V, Rodrigues, RJ, Lujan, R, Burgueno, J, Canals, M, Borycz, J, Rebola, N, 
Goldberg, SR, Mallol, J, Cortes, A, Canela, EI, Lopez-Gimenez, JF, Milligan, G, Lluis, C, 
Cunha, RA, Ferre, S and Franco, R (2006a). "Presynaptic control of striatal glutamatergic 
neurotransmission by adenosine A1-A2A receptor heteromers." J Neurosci 26(7): 2080-2087. 
Ciruela, F, Escriche, M, Burgueno, J, Angulo, E, Casado, V, Soloviev, MM, Canela, EI, Mallol, J, 
Chan, WY, Lluis, C, McIlhinney, RA and Franco, R (2001). "Metabotropic glutamate 1alpha 
and adenosine A1 receptors assemble into functionally interacting complexes." J Biol Chem 
276(21): 18345-18351. 
Ciruela, F, Ferre, S, Casado, V, Cortes, A, Cunha, RA, Lluis, C and Franco, R (2006b). "Heterodimeric 
adenosine receptors: a device to regulate neurotransmitter release." Cell Mol Life Sci 63(21): 
2427-2431. 
Clark, AK, Staniland, AA, Marchand, F, Kaan, TK, McMahon, SB and Malcangio, M (2010). "P2X7-
dependent release of interleukin-1beta and nociception in the spinal cord following 
lipopolysaccharide." J Neurosci 30(2): 573-582. 
Clarke, JR, Cammarota, M, Gruart, A, Izquierdo, I and Delgado-Garcia, JM (2010). "Plastic 
modifications induced by object recognition memory processing." Proc Natl Acad Sci U S A 
107(6): 2652-2657. 
Cognato, GP, Agostinho, PM, Hockemeyer, J, Muller, CE, Souza, DO and Cunha, RA (2010). 
"Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and 
synaptotoxicity in adult rats triggered by a convulsive episode in early life." J Neurochem 
112(2): 453-462. 
Coleman, P, Federoff, H and Kurlan, R (2004). "A focus on the synapse for neuroprotection in 
Alzheimer disease and other dementias." Neurology 63(7): 1155-1162. 
Collo, G, Neidhart, S, Kawashima, E, Kosco-Vilbois, M, North, RA and Buell, G (1997). "Tissue 
distribution of the P2X7 receptor." Neuropharmacology 36(9): 1277-1283. 
Coogan, AN, O'Neill, LA and O'Connor, JJ (1999). "The P38 mitogen-activated protein kinase 
inhibitor SB203580 antagonizes the inhibitory effects of interleukin-1beta on long-term 
potentiation in the rat dentate gyrus in vitro." Neuroscience 93(1): 57-69. 
Coppi, E, Pugliese, AM, Stephan, H, Muller, CE and Pedata, F (2007). "Role of P2 purinergic receptors 
in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat 
hippocampal slices." Purinergic Signal 3(3): 203-219. 
Corradetti, R, Lo Conte, G, Moroni, F, Passani, MB and Pepeu, G (1984). "Adenosine decreases 
aspartate and glutamate release from rat hippocampal slices." Eur J Pharmacol 104(1-2): 19-26. 
Correia-de-Sa, P and Ribeiro, JA (1994). "Potentiation by tonic A2a-adenosine receptor activation of 
CGRP-facilitated [3H]-ACh release from rat motor nerve endings." Br J Pharmacol 111(2): 
582-588. 
6. REFERENCES 
 
178 
 
Corsi, C, Pinna, A, Gianfriddo, M, Melani, A, Morelli, M and Pedata, F (2003). "Adenosine A2A 
receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats." Eur J 
Pharmacol 464(1): 33-38. 
Costenla, AR, Diogenes, MJ, Canas, PM, Rodrigues, RJ, Nogueira, C, Maroco, J, Agostinho, PM, 
Ribeiro, JA, Cunha, RA and de Mendonca, A (2011). "Enhanced role of adenosine A(2A) 
receptors in the modulation of LTP in the rat hippocampus upon ageing." Eur J Neurosci 34(1): 
12-21. 
Coutinho-Silva, R, Robson, T, Beales, PE and Burnstock, G (2007). "Changes in expression of P2X7 
receptors in NOD mouse pancreas during the development of diabetes." Autoimmunity 40(2): 
108-116. 
Crine, AF (1984). "[Modulators of passive avoidance behavior]." Annee Psychol 84(1): 85-94. 
Cunha, GM, Canas, PM, Oliveira, CR and Cunha, RA (2006). "Increased density and synapto-
protective effect of adenosine A2A receptors upon sub-chronic restraint stress." Neuroscience 
141(4): 1775-1781. 
Cunha, RA (2001). "Adenosine as a neuromodulator and as a homeostatic regulator in the nervous 
system: different roles, different sources and different receptors." Neurochem Int 38(2): 107-
125. 
Cunha, RA (2005). "Neuroprotection by adenosine in the brain: From A(1) receptor activation to A 
(2A) receptor blockade." Purinergic Signal 1(2): 111-134. 
Cunha, RA, Silva, CG, Rodrigues, RJ, Oses, JP, Porciúncula, LO (2007). "Increased extracellular ATP 
and P2Y1 receptor activation mediate glutamate-induced neurotoxicity in cultured hippocampal 
neurons". In the annual meeting of the Society for Neuroscience, 2007, San Diego, USA.  
Cunha, RA (2008). "Different cellular sources and different roles of adenosine: A1 receptor-mediated 
inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-
mediated facilitation of plasticity." Neurochem Int 52(1-2): 65-72. 
Cunha, RA, Correia-de-Sa, P, Sebastiao, AM and Ribeiro, JA (1996a). "Preferential activation of 
excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine 
formed from released adenine nucleotides." Br J Pharmacol 119(2): 253-260. 
Cunha, RA, Johansson, B, Constantino, MD, Sebastiao, AM and Fredholm, BB (1996b). "Evidence for 
high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat 
hippocampus and cerebral cortex that are different from striatal A2A receptors." Naunyn 
Schmiedebergs Arch Pharmacol 353(3): 261-271. 
Cunha, RA, Johansson, B, Fredholm, BB, Ribeiro, JA and Sebastiao, AM (1995). "Adenosine A2A 
receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus." 
Neurosci Lett 196(1-2): 41-44. 
Cunha, RA and Ribeiro, JA (2000). "ATP as a presynaptic modulator." Life Sci 68(2): 119-137. 
Cunha, RA, Sebastiao, AM and Ribeiro, JA (1998). "Inhibition by ATP of hippocampal synaptic 
transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine 
and channeling to adenosine A1 receptors." J Neurosci 18(6): 1987-1995. 
Cunha, RA, Vizi, ES, Ribeiro, JA and Sebastiao, AM (1996c). "Preferential release of ATP and its 
extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation 
of rat hippocampal slices." J Neurochem 67(5): 2180-2187. 
Curran, BP, Murray, HJ and O'Connor, JJ (2003). "A role for c-Jun N-terminal kinase in the inhibition 
of long-term potentiation by interleukin-1beta and long-term depression in the rat dentate gyrus 
in vitro." Neuroscience 118(2): 347-357. 
Dahl, G and Locovei, S (2006). "Pannexin: to gap or not to gap, is that a question?" IUBMB Life 
58(7): 409-419. 
6. REFERENCES 
179 
 
Dai, SS, Zhou, YG, Li, W, An, JH, Li, P, Yang, N, Chen, XY, Xiong, RP, Liu, P, Zhao, Y, Shen, HY, 
Zhu, PF and Chen, JF (2010). "Local glutamate level dictates adenosine A2A receptor 
regulation of neuroinflammation and traumatic brain injury." J Neurosci 30(16): 5802-5810. 
Dall'Igna, OP, Fett, P, Gomes, MW, Souza, DO, Cunha, RA and Lara, DR (2007). "Caffeine and 
adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits 
in mice." Exp Neurol 203(1): 241-245. 
Dall'Igna, OP, Porciuncula, LO, Souza, DO, Cunha, RA and Lara, DR (2003). "Neuroprotection by 
caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity." Br J Pharmacol 
138(7): 1207-1209. 
Daly, JW (1977). "The formation, degradation, and function of cyclic nucleotides in the nervous 
system." Int Rev Neurobiol 20: 105-168. 
Dare, E, Schulte, G, Karovic, O, Hammarberg, C and Fredholm, BB (2007). "Modulation of glial cell 
functions by adenosine receptors." Physiol Behav 92(1-2): 15-20. 
Davalos, D, Grutzendler, J, Yang, G, Kim, JV, Zuo, Y, Jung, S, Littman, DR, Dustin, ML and Gan, 
WB (2005). "ATP mediates rapid microglial response to local brain injury in vivo." Nat 
Neurosci 8(6): 752-758. 
Day, YJ, Marshall, MA, Huang, L, McDuffie, MJ, Okusa, MD and Linden, J (2004). "Protection from 
ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of 
chemokine induction." Am J Physiol Gastrointest Liver Physiol 286(2): G285-293. 
de Lanerolle, NC and Lee, TS (2005). "New facets of the neuropathology and molecular profile of 
human temporal lobe epilepsy." Epilepsy Behav 7(2): 190-203. 
de Mendonca, A, Sebastiao, AM and Ribeiro, JA (2000). "Adenosine: does it have a neuroprotective 
role after all?" Brain Res Brain Res Rev 33(2-3): 258-274. 
De Simone, R, Niturad, CE, De Nuccio, C, Ajmone-Cat, MA, Visentin, S and Minghetti, L (2010). 
"TGF-beta and LPS modulate ADP-induced migration of microglial cells through P2Y1 and 
P2Y12 receptor expression." J Neurochem 115(2): 450-459. 
De Vuyst, E, Decrock, E, De Bock, M, Yamasaki, H, Naus, CC, Evans, WH and Leybaert, L (2007). 
"Connexin hemichannels and gap junction channels are differentially influenced by 
lipopolysaccharide and basic fibroblast growth factor." Mol Biol Cell 18(1): 34-46. 
Degubareff, T and Sleator, W, Jr. (1965). "Effects of Caffeine on Mammalian Atrial Muscle, and Its 
Interaction with Adenosine and Calcium." J Pharmacol Exp Ther 148: 202-214. 
Delarasse, C, Auger, R, Gonnord, P, Fontaine, B and Kanellopoulos, JM (2011). "The purinergic 
receptor P2X7 triggers alpha-secretase-dependent processing of the amyloid precursor protein." 
J Biol Chem 286(4): 2596-2606. 
Delle Donne, KT and Sonsalla, PK (1994). "Protection against methamphetamine-induced 
neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation." J 
Pharmacol Exp Ther 271(3): 1320-1326. 
DeLorenzo, RJ, Towne, AR, Pellock, JM and Ko, D (1992). "Status epilepticus in children, adults, and 
the elderly." Epilepsia 33 Suppl 4: S15-25. 
Dere, E, Huston, JP and De Souza Silva, MA (2007). "The pharmacology, neuroanatomy and 
neurogenetics of one-trial object recognition in rodents." Neurosci Biobehav Rev 31(5): 673-
704. 
Deuchars, SA, Atkinson, L, Brooke, RE, Musa, H, Milligan, CJ, Batten, TF, Buckley, NJ, Parson, SH 
and Deuchars, J (2001). "Neuronal P2X7 receptors are targeted to presynaptic terminals in the 
central and peripheral nervous systems." J Neurosci 21(18): 7143-7152. 
Di Virgilio, F, Ceruti, S, Bramanti, P and Abbracchio, MP (2009). "Purinergic signalling in 
inflammation of the central nervous system." Trends Neurosci 32(2): 79-87. 
6. REFERENCES 
 
180 
 
Diaz-Hernandez, M, Gomez-Villafuertes, R, Hernando, F, Pintor, J and Miras-Portugal, MT (2001). 
"Presence of different ATP receptors on rat midbrain single synaptic terminals. Involvement of 
the P2X(3) subunits." Neurosci Lett 301(3): 159-162. 
Diogenes, MJ, Fernandes, CC, Sebastiao, AM and Ribeiro, JA (2004). "Activation of adenosine A2A 
receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in 
hippocampal slices." J Neurosci 24(12): 2905-2913. 
Dixon, AK, Widdowson, L and Richardson, PJ (1997). "Desensitisation of the adenosine A1 receptor 
by the A2A receptor in the rat striatum." J Neurochem 69(1): 315-321. 
Domercq, M, Brambilla, L, Pilati, E, Marchaland, J, Volterra, A and Bezzi, P (2006). "P2Y1 receptor-
evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and 
prostaglandins." J Biol Chem 281(41): 30684-30696. 
Domercq, M, Perez-Samartin, A, Aparicio, D, Alberdi, E, Pampliega, O and Matute, C (2010). "P2X7 
receptors mediate ischemic damage to oligodendrocytes." Glia 58(6): 730-740. 
Dona, F, Ulrich, H, Persike, DS, Conceicao, IM, Blini, JP, Cavalheiro, EA and Fernandes, MJ (2009). 
"Alteration of purinergic P2X4 and P2X7 receptor expression in rats with temporal-lobe 
epilepsy induced by pilocarpine." Epilepsy Res 83(2-3): 157-167. 
Drury, AN and Szent-Gyorgyi, A (1929). "The physiological activity of adenine compounds with 
especial reference to their action upon the mammalian heart." J Physiol 68(3): 213-237. 
Duan, W, Gui, L, Zhou, Z, Liu, Y, Tian, H, Chen, JF and Zheng, J (2009). "Adenosine A2A receptor 
deficiency exacerbates white matter lesions and cognitive deficits induced by chronic cerebral 
hypoperfusion in mice." J Neurol Sci 285(1-2): 39-45. 
Duarte, JM, Carvalho, RA, Cunha, RA and Gruetter, R (2009). "Caffeine consumption attenuates 
neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats." J 
Neurochem 111(2): 368-379. 
Duarte, JM, Nogueira, C, Mackie, K, Oliveira, CR, Cunha, RA and Kofalvi, A (2007). "Increase of 
cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats." 
Exp Neurol 204(1): 479-484. 
Duarte, JM, Oliveira, CR, Ambrosio, AF and Cunha, RA (2006). "Modification of adenosine A1 and 
A2A receptor density in the hippocampus of streptozotocin-induced diabetic rats." Neurochem 
Int 48(2): 144-150. 
Dunkley, PR, Heath, JW, Harrison, SM, Jarvie, PE, Glenfield, PJ and Rostas, JA (1988). "A rapid 
Percoll gradient procedure for isolation of synaptosomes directly from an S1 fraction: 
homogeneity and morphology of subcellular fractions." Brain Res 441(1-2): 59-71. 
Dunwiddie, TV and Diao, L (1994). "Extracellular adenosine concentrations in hippocampal brain 
slices and the tonic inhibitory modulation of evoked excitatory responses." J Pharmacol Exp 
Ther 268(2): 537-545. 
Dunwiddie, TV, Diao, L and Proctor, WR (1997). "Adenine nucleotides undergo rapid, quantitative 
conversion to adenosine in the extracellular space in rat hippocampus." J Neurosci 17(20): 
7673-7682. 
Dunwiddie, TV and Masino, SA (2001). "The role and regulation of adenosine in the central nervous 
system." Annu Rev Neurosci 24: 31-55. 
Dyson, A and Singer, M (2009). "Animal models of sepsis: why does preclinical efficacy fail to 
translate to the clinical setting?" Crit Care Med 37(1 Suppl): S30-37. 
Edwards, FA and Gibb, AJ (1993). "ATP--a fast neurotransmitter." FEBS Lett 325(1-2): 86-89. 
Egan, TM and Khakh, BS (2004). "Contribution of calcium ions to P2X channel responses." J Neurosci 
24(13): 3413-3420. 
6. REFERENCES 
181 
 
Egeland, M, Warner-Schmidt, J, Greengard, P and Svenningsson, P (2010). "Neurogenic effects of 
fluoxetine are attenuated in p11 (S100A10) knockout mice." Biol Psychiatry 67(11): 1048-
1056. 
Eichenbaum, H (2000). "A cortical-hippocampal system for declarative memory." Nat Rev Neurosci 
1(1): 41-50. 
El Yacoubi, M, Ledent, C, Parmentier, M, Costentin, J and Vaugeois, JM (2009). "Adenosine A2A 
receptor deficient mice are partially resistant to limbic seizures." Naunyn Schmiedebergs Arch 
Pharmacol 380(3): 223-232. 
Ericsson, A, Liu, C, Hart, RP and Sawchenko, PE (1995). "Type 1 interleukin-1 receptor in the rat 
brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation." J 
Comp Neurol 361(4): 681-698. 
Evans, RJ, Lewis, C, Buell, G, Valera, S, North, RA and Surprenant, A (1995). "Pharmacological 
characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors)." 
Mol Pharmacol 48(2): 178-183. 
Exley, C and Korchazhkina, OV (2001). "Promotion of formation of amyloid fibrils by aluminium 
adenosine triphosphate (AlATP)." J Inorg Biochem 84(3-4): 215-224. 
Fam, SR, Gallagher, CJ, Kalia, LV and Salter, MW (2003). "Differential frequency dependence of 
P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes." J Neurosci 23(11): 4437-4444. 
Feldberg, W and Hebb, C (1948). "The stimulating action of phosphate compounds on the perfused 
superior cervical ganglion of the cat." J Physiol 107(2): 210-221. 
Fell, DA and Sauro, HM (1985). "Metabolic control and its analysis. Additional relationships between 
elasticities and control coefficients." Eur J Biochem 148(3): 555-561. 
Ferguson, AL and Stone, TW (2010). "Glutamate-induced depression of EPSP-spike coupling in rat 
hippocampal CA1 neurons and modulation by adenosine receptors." Eur J Neurosci 31(7): 
1208-1218. 
Ferrari, D, Chiozzi, P, Falzoni, S, Dal Susino, M, Collo, G, Buell, G and Di Virgilio, F (1997). "ATP-
mediated cytotoxicity in microglial cells." Neuropharmacology 36(9): 1295-1301. 
Ferrari, D, La Sala, A, Chiozzi, P, Morelli, A, Falzoni, S, Girolomoni, G, Idzko, M, Dichmann, S, 
Norgauer, J and Di Virgilio, F (2000). "The P2 purinergic receptors of human dendritic cells: 
identification and coupling to cytokine release." Faseb J 14(15): 2466-2476. 
Ferre, S, Karcz-Kubicha, M, Hope, BT, Popoli, P, Burgueno, J, Gutierrez, MA, Casado, V, Fuxe, K, 
Goldberg, SR, Lluis, C, Franco, R and Ciruela, F (2002). "Synergistic interaction between 
adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function." 
Proc Natl Acad Sci U S A 99(18): 11940-11945. 
Fields, RD (2004). "Volume transmission in activity-dependent regulation of myelinating glia." 
Neurochem Int 45(4): 503-509. 
Fields, RD (2006). "Nerve impulses regulate myelination through purinergic signalling." Novartis 
Found Symp 276: 148-158; discussion 158-161, 233-147, 275-181. 
Fields, RD and Burnstock, G (2006). "Purinergic signalling in neuron-glia interactions." Nat Rev 
Neurosci 7(6): 423-436. 
Figiel, I and Dzwonek, K (2007). "TNFalpha and TNF receptor 1 expression in the mixed neuronal-
glial cultures of hippocampal dentate gyrus exposed to glutamate or trimethyltin." Brain Res 
1131(1): 17-28. 
Filippov, AK, Choi, RC, Simon, J, Barnard, EA and Brown, DA (2006). "Activation of P2Y1 
nucleotide receptors induces inhibition of the M-type K+ current in rat hippocampal pyramidal 
neurons." J Neurosci 26(36): 9340-9348. 
Filippov, AK, Simon, J, Barnard, EA and Brown, DA (2003). "Coupling of the nucleotide P2Y4 
receptor to neuronal ion channels." Br J Pharmacol 138(2): 400-406. 
6. REFERENCES 
 
182 
 
Filippov, AK, Webb, TE, Barnard, EA and Brown, DA (1998). "P2Y2 nucleotide receptors expressed 
heterologously in sympathetic neurons inhibit both N-type Ca2+ and M-type K+ currents." J 
Neurosci 18(14): 5170-5179. 
Filippov, AK, Webb, TE, Barnard, EA and Brown, DA (1999). "Dual coupling of heterologously-
expressed rat P2Y6 nucleotide receptors to N-type Ca2+ and M-type K+ currents in rat 
sympathetic neurones." Br J Pharmacol 126(4): 1009-1017. 
Fisahn, A (2005). "Kainate receptors and rhythmic activity in neuronal networks: hippocampal gamma 
oscillations as a tool." J Physiol 562(Pt 1): 65-72. 
Fletcher, EL (2010). "Mechanisms of photoreceptor death during retinal degeneration." Optom Vis Sci 
87(4): 269-275. 
Fogal, B and Hewett, SJ (2008). "Interleukin-1beta: a bridge between inflammation and 
excitotoxicity?" J Neurochem 106(1): 1-23. 
Fountain, SJ and Burnstock, G (2009). "An evolutionary history of P2X receptors." Purinergic Signal 
5(3): 269-272. 
Fox, IH and Kelley, WN (1978). "The role of adenosine and 2'-deoxyadenosine in mammalian cells." 
Annu Rev Biochem 47: 655-686. 
Franke, H, Grummich, B, Hartig, W, Grosche, J, Regenthal, R, Edwards, RH, Illes, P and Krugel, U 
(2006). "Changes in purinergic signaling after cerebral injury -- involvement of glutamatergic 
mechanisms?" Int J Dev Neurosci 24(2-3): 123-132. 
Franke, H, Gunther, A, Grosche, J, Schmidt, R, Rossner, S, Reinhardt, R, Faber-Zuschratter, H, 
Schneider, D and Illes, P (2004). "P2X7 receptor expression after ischemia in the cerebral 
cortex of rats." J Neuropathol Exp Neurol 63(7): 686-699. 
Franke, H and Illes, P (2006). "Involvement of P2 receptors in the growth and survival of neurons in 
the CNS." Pharmacol Ther 109(3): 297-324. 
Franke, H, Kittner, H, Grosche, J and Illes, P (2003). "Enhanced P2Y1 receptor expression in the brain 
after sensitisation with d-amphetamine." Psychopharmacology (Berl) 167(2): 187-194. 
Franke, H, Krugel, U and Illes, P (1999). "P2 receptor-mediated proliferative effects on astrocytes in 
vivo." Glia 28(3): 190-200. 
Franke, H, Sauer, C, Rudolph, C, Krugel, U, Hengstler, JG and Illes, P (2009). "P2 receptor-mediated 
stimulation of the PI3-K/Akt-pathway in vivo." Glia 57(10): 1031-1045. 
Fredholm, BB, AP, IJ, Jacobson, KA, Klotz, KN and Linden, J (2001). "International Union of 
Pharmacology. XXV. Nomenclature and classification of adenosine receptors." Pharmacol Rev 
53(4): 527-552. 
Fredholm, BB, Battig, K, Holmen, J, Nehlig, A and Zvartau, EE (1999). "Actions of caffeine in the 
brain with special reference to factors that contribute to its widespread use." Pharmacol Rev 
51(1): 83-133. 
Fredholm, BB, Chen, JF, Cunha, RA, Svenningsson, P and Vaugeois, JM (2005). "Adenosine and brain 
function." Int Rev Neurobiol 63: 191-270. 
Frenguelli, BG, Wigmore, G, Llaudet, E and Dale, N (2007). "Temporal and mechanistic dissociation 
of ATP and adenosine release during ischaemia in the mammalian hippocampus." J Neurochem 
101(5): 1400-1413. 
Fujii, S, Kato, H and Kuroda, Y (1999). "Extracellular adenosine 5'-triphosphate plus activation of 
glutamatergic receptors induces long-term potentiation in CA1 neurons of guinea pig 
hippocampal slices." Neurosci Lett 276(1): 21-24. 
Fujii, S, Kato, H and Kuroda, Y (2002). "Cooperativity between extracellular adenosine 5'-triphosphate 
and activation of N-methyl-D-aspartate receptors in long-term potentiation induction in 
hippocampal CA1 neurons." Neuroscience 113(3): 617-628. 
6. REFERENCES 
183 
 
Fujita, T, Tozaki-Saitoh, H and Inoue, K (2009). "P2Y1 receptor signaling enhances neuroprotection 
by astrocytes against oxidative stress via IL-6 release in hippocampal cultures." Glia 57(3): 
244-257. 
Fumagalli, M, Trincavelli, L, Lecca, D, Martini, C, Ciana, P and Abbracchio, MP (2004). "Cloning, 
pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) 
receptor." Biochem Pharmacol 68(1): 113-124. 
Furlong, TJ, Pierce, KD, Selbie, LA and Shine, J (1992). "Molecular characterization of a human brain 
adenosine A2 receptor." Brain Res Mol Brain Res 15(1-2): 62-66. 
Gachet, C (2006). "Regulation of platelet functions by P2 receptors." Annu Rev Pharmacol Toxicol 46: 
277-300. 
Gachet, C (2008). "P2 receptors, platelet function and pharmacological implications." Thromb 
Haemost 99(3): 466-472. 
Gallagher, CJ and Salter, MW (2003). "Differential properties of astrocyte calcium waves mediated by 
P2Y1 and P2Y2 receptors." J Neurosci 23(17): 6728-6739. 
Galluzzi, L, Aaronson, SA, Abrams, J, Alnemri, ES, Andrews, DW, Baehrecke, EH, Bazan, NG, 
Blagosklonny, MV, Blomgren, K, Borner, C, Bredesen, DE, Brenner, C, Castedo, M, 
Cidlowski, JA, Ciechanover, A, Cohen, GM, De Laurenzi, V, De Maria, R, Deshmukh, M, 
Dynlacht, BD, El-Deiry, WS, Flavell, RA, Fulda, S, Garrido, C, Golstein, P, Gougeon, ML, 
Green, DR, Gronemeyer, H, Hajnoczky, G, Hardwick, JM, Hengartner, MO, Ichijo, H, Jaattela, 
M, Kepp, O, Kimchi, A, Klionsky, DJ, Knight, RA, Kornbluth, S, Kumar, S, Levine, B, Lipton, 
SA, Lugli, E, Madeo, F, Malomi, W, Marine, JC, Martin, SJ, Medema, JP, Mehlen, P, Melino, 
G, Moll, UM, Morselli, E, Nagata, S, Nicholson, DW, Nicotera, P, Nunez, G, Oren, M, 
Penninger, J, Pervaiz, S, Peter, ME, Piacentini, M, Prehn, JH, Puthalakath, H, Rabinovich, GA, 
Rizzuto, R, Rodrigues, CM, Rubinsztein, DC, Rudel, T, Scorrano, L, Simon, HU, Steller, H, 
Tschopp, J, Tsujimoto, Y, Vandenabeele, P, Vitale, I, Vousden, KH, Youle, RJ, Yuan, J, 
Zhivotovsky, B and Kroemer, G (2009). "Guidelines for the use and interpretation of assays for 
monitoring cell death in higher eukaryotes." Cell Death Differ 16(8): 1093-1107. 
Gardoni, F, Boraso, M, Zianni, E, Corsini, E, Galli, CL, Cattabeni, F, Marinovich, M, Di Luca, M and 
Viviani, B (2011). "Distribution of interleukin-1 receptor complex at the synaptic membrane 
driven by interleukin-1beta and NMDA stimulation." J Neuroinflammation 8(1): 14. 
Gazarini, L, Stern, CA and Bertoglio, LJ (2011). "Protein synthesis in dorsal hippocampus supports the 
drug tolerance induced by prior elevated plus-maze experience." Neuroscience 179: 179-187. 
Gebicke-Haerter, PJ, Christoffel, F, Timmer, J, Northoff, H, Berger, M and Van Calker, D (1996). 
"Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation." 
Neurochem Int 29(1): 37-42. 
Gendron, FP, Neary, JT, Theiss, PM, Sun, GY, Gonzalez, FA and Weisman, GA (2003). "Mechanisms 
of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells." Am J 
Physiol Cell Physiol 284(2): C571-581. 
Gerevich, Z, Muller, C and Illes, P (2005). "Metabotropic P2Y1 receptors inhibit P2X3 receptor-
channels in rat dorsal root ganglion neurons." Eur J Pharmacol 521(1-3): 34-38. 
Gerevich, Z, Wirkner, K and Illes, P (2002). "Adenosine A2A receptors inhibit the N-methyl-D-
aspartate component of excitatory synaptic currents in rat striatal neurons." Eur J Pharmacol 
451(2): 161-164. 
Gessi, S, Varani, K, Merighi, S, Cattabriga, E, Pancaldi, C, Szabadkai, Y, Rizzuto, R, Klotz, KN, 
Leung, E, Mac Lennan, S, Baraldi, PG and Borea, PA (2005). "Expression, pharmacological 
profile, and functional coupling of A2B receptors in a recombinant system and in peripheral 
blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20." Mol 
Pharmacol 67(6): 2137-2147. 
6. REFERENCES 
 
184 
 
Giacomello, M, Drago, I, Pizzo, P and Pozzan, T (2007). "Mitochondrial Ca2+ as a key regulator of 
cell life and death." Cell Death Differ 14(7): 1267-1274. 
Gines, S, Hillion, J, Torvinen, M, Le Crom, S, Casado, V, Canela, EI, Rondin, S, Lew, JY, Watson, S, 
Zoli, M, Agnati, LF, Verniera, P, Lluis, C, Ferre, S, Fuxe, K and Franco, R (2000). "Dopamine 
D1 and adenosine A1 receptors form functionally interacting heteromeric complexes." Proc 
Natl Acad Sci U S A 97(15): 8606-8611. 
Ginsborg, BL and Hirst, GD (1972). "The effect of adenosine on the release of the transmitter from the 
phrenic nerve of the rat." J Physiol 224(3): 629-645. 
Glass, CK, Saijo, K, Winner, B, Marchetto, MC and Gage, FH (2010). "Mechanisms underlying 
inflammation in neurodegeneration." Cell 140(6): 918-934. 
Goding, JW, Grobben, B and Slegers, H (2003). "Physiological and pathophysiological functions of the 
ecto-nucleotide pyrophosphatase/phosphodiesterase family." Biochim Biophys Acta 20(1): 1-
19. 
Gomes, CV, Kaster, MP, Tome, AR, Agostinho, PM and Cunha, RA (2011). "Adenosine receptors and 
brain diseases: neuroprotection and neurodegeneration." Biochim Biophys Acta 5(99): 9. 
Goshen, I and Yirmiya, R (2009). "Interleukin-1 (IL-1): a central regulator of stress responses." Front 
Neuroendocrinol 30(1): 30-45. 
Gosselin, D and Rivest, S (2007). "Role of IL-1 and TNF in the brain: twenty years of progress on a 
Dr. Jekyll/Mr. Hyde duality of the innate immune system." Brain Behav Immun 21(3): 281-289. 
Graeber, MB (2010). "Changing face of microglia." Science 330(6005): 783-788. 
Green, T, Heinemann, SF and Gusella, JF (1998). "Molecular neurobiology and genetics: investigation 
of neural function and dysfunction." Neuron 20(3): 427-444. 
Griffiths, M, Neal, JW and Gasque, P (2007). "Innate immunity and protective neuroinflammation: 
new emphasis on the role of neuroimmune regulatory proteins." Int Rev Neurobiol 82: 29-55. 
Grynkiewicz, G, Poenie, M and Tsien, RY (1985). "A new generation of Ca2+ indicators with greatly 
improved fluorescence properties." J Biol Chem 260(6): 3440-3450. 
Gunther, A, Kuppers-Tiedt, L, Schneider, PM, Kunert, I, Berrouschot, J, Schneider, D and Rossner, S 
(2005). "Reduced infarct volume and differential effects on glial cell activation after hyperbaric 
oxygen treatment in rat permanent focal cerebral ischaemia." Eur J Neurosci 21(11): 3189-
3194. 
Guo, YL, Kang, B, Han, J and Williamson, JR (2001). "p38beta MAP kinase protects rat mesangial 
cells from TNF-alpha-induced apoptosis." J Cell Biochem 82(4): 556-565. 
Guzman, SJ, Gerevich, Z, Hengstler, JG, Illes, P and Kleemann, W (2005). "P2Y1 receptors inhibit 
both strength and plasticity of glutamatergic synaptic neurotransmission in the rat prefrontal 
cortex." Synapse 57(4): 235-238. 
Hailer, NP, Vogt, C, Korf, HW and Dehghani, F (2005). "Interleukin-1beta exacerbates and 
interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after 
excitotoxic damage in organotypic hippocampal slice cultures." Eur J Neurosci 21(9): 2347-
2360. 
Hamilton, N, Vayro, S, Wigley, R and Butt, AM (2010). "Axons and astrocytes release ATP and 
glutamate to evoke calcium signals in NG2-glia." Glia 58(1): 66-79. 
Harry, GJ, Lefebvre d'Hellencourt, C, McPherson, CA, Funk, JA, Aoyama, M and Wine, RN (2008). 
"Tumor necrosis factor p55 and p75 receptors are involved in chemical-induced apoptosis of 
dentate granule neurons." J Neurochem 106(1): 281-298. 
Hasko, G and Pacher, P (2008). "A2A receptors in inflammation and injury: lessons learned from 
transgenic animals." J Leukoc Biol 83(3): 447-455. 
Haughey, NJ and Mattson, MP (2003). "Alzheimer's amyloid beta-peptide enhances ATP/gap junction-
mediated calcium-wave propagation in astrocytes." Neuromolecular Med 3(3): 173-180. 
6. REFERENCES 
185 
 
Hauss-Wegrzyniak, B, Lynch, MA, Vraniak, PD and Wenk, GL (2002). "Chronic brain inflammation 
results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell 
synapses." Exp Neurol 176(2): 336-341. 
Haynes, SE, Hollopeter, G, Yang, G, Kurpius, D, Dailey, ME, Gan, WB and Julius, D (2006). "The 
P2Y12 receptor regulates microglial activation by extracellular nucleotides." Nat Neurosci 
9(12): 1512-1519. 
Heine, C, Wegner, A, Grosche, J, Allgaier, C, Illes, P and Franke, H (2007). "P2 receptor expression in 
the dopaminergic system of the rat brain during development." Neuroscience 149(1): 165-181. 
Henderson, GB and Strauss, BP (1991). "Evidence for cAMP and cholate extrusion in C6 rat glioma 
cells by a common anion efflux pump." J Biol Chem 266(3): 1641-1645. 
Higashi, H, Meno, JR, Marwaha, AS and Winn, HR (2002). "Hippocampal injury and neurobehavioral 
deficits following hyperglycemic cerebral ischemia: effect of theophylline and ZM 241385." J 
Neurosurg 96(1): 117-126. 
Hindley, S, Herman, MA and Rathbone, MP (1994). "Stimulation of reactive astrogliosis in vivo by 
extracellular adenosine diphosphate or an adenosine A2 receptor agonist." J Neurosci Res 
38(4): 399-406. 
Hirst, RA, Harrison, C, Hirota, K and Lambert, DG (1999a). "Measurement of [Ca2+]i in whole cell 
suspensions using fura-2." Methods Mol Biol 114: 31-39. 
Hirst, WD, Young, KA, Newton, R, Allport, VC, Marriott, DR and Wilkin, GP (1999b). "Expression of 
COX-2 by normal and reactive astrocytes in the adult rat central nervous system." Mol Cell 
Neurosci 13(1): 57-68. 
Hodges, H, Nelson, A, Virley, D, Kershaw, TR and Sinden, JD (1997). "Cognitive deficits induced by 
global cerebral ischaemia: prospects for transplant therapy." Pharmacol Biochem Behav 56(4): 
763-780. 
Hollopeter, G, Jantzen, HM, Vincent, D, Li, G, England, L, Ramakrishnan, V, Yang, RB, Nurden, P, 
Nurden, A, Julius, D and Conley, PB (2001). "Identification of the platelet ADP receptor 
targeted by antithrombotic drugs." Nature 409(6817): 202-207. 
Holton, P (1959). "The liberation of adenosine triphosphate on antidromic stimulation of sensory 
nerves." J Physiol 145(3): 494-504. 
Honda, S, Sasaki, Y, Ohsawa, K, Imai, Y, Nakamura, Y, Inoue, K and Kohsaka, S (2001). 
"Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y 
receptors." J Neurosci 21(6): 1975-1982. 
Houston, D, Costanzi, S, Jacobson, KA and Harden, TK (2008). "Development of selective high 
affinity antagonists, agonists, and radioligands for the P2Y1 receptor." Comb Chem High 
Throughput Screen 11(6): 410-419. 
Howells, DW, Porritt, MJ, Rewell, SS, O'Collins, V, Sena, ES, van der Worp, HB, Traystman, RJ and 
Macleod, MR (2010). "Different strokes for different folks: the rich diversity of animal models 
of focal cerebral ischemia." J Cereb Blood Flow Metab 30(8): 1412-1431. 
Hsu, H, Xiong, J and Goeddel, DV (1995). "The TNF receptor 1-associated protein TRADD signals 
cell death and NF-kappa B activation." Cell 81(4): 495-504. 
Hu, H, Lu, W, Zhang, M, Zhang, X, Argall, AJ, Patel, S, Lee, GE, Kim, YC, Jacobson, KA, Laties, 
AM and Mitchell, CH (2010). "Stimulation of the P2X7 receptor kills rat retinal ganglion cells 
in vivo." Exp Eye Res 91(3): 425-432. 
Huang, S, Apasov, S, Koshiba, M and Sitkovsky, M (1997). "Role of A2a extracellular adenosine 
receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and 
expansion." Blood 90(4): 1600-1610. 
Hudspith, MJ (1997). "Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS 
injury." Br J Anaesth 78(6): 731-747. 
6. REFERENCES 
 
186 
 
Hughes, RN (2004). "The value of spontaneous alternation behavior (SAB) as a test of retention in 
pharmacological investigations of memory." Neurosci Biobehav Rev 28(5): 497-505. 
Hunter, AJ, Hatcher, J, Virley, D, Nelson, P, Irving, E, Hadingham, SJ and Parsons, AA (2000). 
"Functional assessments in mice and rats after focal stroke." Neuropharmacology 39(5): 806-
816. 
Hussl, S and Boehm, S (2006). "Functions of neuronal P2Y receptors." Pflugers Arch 452(5): 538-551. 
Hutchison, AJ, Webb, RL, Oei, HH, Ghai, GR, Zimmerman, MB and Williams, M (1989). "CGS 
21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity." J 
Pharmacol Exp Ther 251(1): 47-55. 
Hynd, MR, Scott, HL and Dodd, PR (2004). "Glutamate-mediated excitotoxicity and 
neurodegeneration in Alzheimer's disease." Neurochem Int 45(5): 583-595. 
Iglesias, R, Dahl, G, Qiu, F, Spray, DC and Scemes, E (2009). "Pannexin 1: the molecular substrate of 
astrocyte "hemichannels"." J Neurosci 29(21): 7092-7097. 
Ikeuchi, Y and Nishizaki, T (1995). "ATP-evoked potassium currents in rat striatal neurons are 
mediated by a P2 purinergic receptor." Neurosci Lett 190(2): 89-92. 
Ikeuchi, Y and Nishizaki, T (1996). "P2 purinoceptor-operated potassium channel in rat cerebellar 
neurons." Biochem Biophys Res Commun 218(1): 67-71. 
Ikeuchi, Y, Nishizaki, T and Okada, Y (1996). "Repetitive applications of ATP potentiate potassium 
current by Ca2+/calmodulin kinase in cultured rat hippocampal neurons." Neurosci Lett 203(2): 
115-118. 
Illes, P and Alexandre Ribeiro, J (2004). "Molecular physiology of P2 receptors in the central nervous 
system." Eur J Pharmacol 483(1): 5-17. 
Inoue, K (1998). "The functions of ATP receptors in the hippocampus." Pharmacol Res 38(5): 323-331. 
Inoue, K (2002). "Microglial activation by purines and pyrimidines." Glia 40(2): 156-163. 
Inoue, K (2006). "The function of microglia through purinergic receptors: neuropathic pain and 
cytokine release." Pharmacol Ther 109(1-2): 210-226. 
Inoue, K (2008). "Purinergic systems in microglia." Cell Mol Life Sci 65(19): 3074-3080. 
Ishibashi, T, Dakin, KA, Stevens, B, Lee, PR, Kozlov, SV, Stewart, CL and Fields, RD (2006). 
"Astrocytes promote myelination in response to electrical impulses." Neuron 49(6): 823-832. 
Jabs, R, Guenther, E, Marquordt, K and Wheeler-Schilling, TH (2000). "Evidence for P2X(3), P2X(4), 
P2X(5) but not for P2X(7) containing purinergic receptors in Muller cells of the rat retina." 
Brain Res Mol Brain Res 76(2): 205-210. 
Jacobson, KA and Boeynaems, JM (2010). "P2Y nucleotide receptors: promise of therapeutic 
applications." Drug Discov Today 15(13-14): 570-578. 
Jacobson, KA, Costanzi, S, Joshi, BV, Besada, P, Shin, DH, Ko, H, Ivanov, AA and Mamedova, L 
(2006). "Agonists and antagonists for P2 receptors." Novartis Found Symp 276: 58-68. 
Jacobson, KA and Gao, ZG (2006). "Adenosine receptors as therapeutic targets." Nat Rev Drug Discov 
5(3): 247-264. 
Jacobson, KA, Ivanov, AA, de Castro, S, Harden, TK and Ko, H (2009). "Development of selective 
agonists and antagonists of P2Y receptors." Purinergic Signal 5(1): 75-89. 
Jahr, CE and Jessell, TM (1983). "ATP excites a subpopulation of rat dorsal horn neurones." Nature 
304(5928): 730-733. 
James, G and Butt, AM (2001). "P2X and P2Y purinoreceptors mediate ATP-evoked calcium 
signalling in optic nerve glia in situ." Cell Calcium 30(4): 251-259. 
James, G and Butt, AM (2002). "P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell 
pathology in the central nervous system." Eur J Pharmacol 447(2-3): 247-260. 
6. REFERENCES 
187 
 
Jensen, MB, Finsen, B and Zimmer, J (1997). "Morphological and immunophenotypic microglial 
changes in the denervated fascia dentata of adult rats: correlation with blood-brain barrier 
damage and astroglial reactions." Exp Neurol 143(1): 103-116. 
Ji, X, Kim, YC, Ahern, DG, Linden, J and Jacobson, KA (2001). "[3H]MRS 1754, a selective 
antagonist radioligand for A(2B) adenosine receptors." Biochem Pharmacol 61(6): 657-663. 
Johansson, B, Georgiev, V, Parkinson, FE and Fredholm, BB (1993). "The binding of the adenosine A2 
receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to rat striatum." 
Eur J Pharmacol 247(2): 103-110. 
Joseph, SM, Pifer, MA, Przybylski, RJ and Dubyak, GR (2004). "Methylene ATP analogs as 
modulators of extracellular ATP metabolism and accumulation." Br J Pharmacol 142(6): 1002-
1014. 
Jourdain, P, Bergersen, LH, Bhaukaurally, K, Bezzi, P, Santello, M, Domercq, M, Matute, C, Tonello, 
F, Gundersen, V and Volterra, A (2007). "Glutamate exocytosis from astrocytes controls 
synaptic strength." Nat Neurosci 10(3): 331-339. 
Juranyi, Z, Sperlagh, B and Vizi, ES (1999). "Involvement of P2 purinoceptors and the nitric oxide 
pathway in [3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat 
hippocampal slices." Brain Res 823(1-2): 183-190. 
Kalda, A, Yu, L, Oztas, E and Chen, JF (2006). "Novel neuroprotection by caffeine and adenosine 
A(2A) receptor antagonists in animal models of Parkinson's disease." J Neurol Sci 248(1-2): 9-
15. 
Kang, TC, An, SJ, Park, SK, Hwang, IK and Won, MH (2003). "P2X2 and P2X4 receptor expression is 
regulated by a GABA(A) receptor-mediated mechanism in the gerbil hippocampus." Brain Res 
Mol Brain Res 116(1-2): 168-175. 
Kawamura, M, Gachet, C, Inoue, K and Kato, F (2004). "Direct excitation of inhibitory interneurons by 
extracellular ATP mediated by P2Y1 receptors in the hippocampal slice." J Neurosci 24(48): 
10835-10845. 
Kelly, A, Vereker, E, Nolan, Y, Brady, M, Barry, C, Loscher, CE, Mills, KH and Lynch, MA (2003). 
"Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and 
interleukin-1 beta on long term potentiation in rat dentate gyrus." J Biol Chem 278(21): 19453-
19462. 
Kennedy, C, Assis, TS, Currie, AJ and Rowan, EG (2003). "Crossing the pain barrier: P2 receptors as 
targets for novel analgesics." J Physiol 553(Pt 3): 683-694. 
Khakh, BS (2001). "Molecular physiology of P2X receptors and ATP signalling at synapses." Nat Rev 
Neurosci 2(3): 165-174. 
Khakh, BS and Burnstock, G (2009). "The double life of ATP." Sci Am 301(6): 84-90, 92. 
Khakh, BS, Burnstock, G, Kennedy, C, King, BF, North, RA, Seguela, P, Voigt, M and Humphrey, PP 
(2001). "International union of pharmacology. XXIV. Current status of the nomenclature and 
properties of P2X receptors and their subunits." Pharmacol Rev 53(1): 107-118. 
Khakh, BS, Gittermann, D, Cockayne, DA and Jones, A (2003). "ATP modulation of excitatory 
synapses onto interneurons." J Neurosci 23(19): 7426-7437. 
Khakh, BS, Zhou, X, Sydes, J, Galligan, JJ and Lester, HA (2000). "State-dependent cross-inhibition 
between transmitter-gated cation channels." Nature 406(6794): 405-410. 
Kharlamov, A, Jones, SC and Kim, DK (2002). "Suramin reduces infarct volume in a model of focal 
brain ischemia in rats." Exp Brain Res 147(3): 353-359. 
Kim, JE, Kwak, SE, Jo, SM and Kang, TC (2009). "Blockade of P2X receptor prevents astroglial death 
in the dentate gyrus following pilocarpine-induced status epilepticus." Neurol Res 31(9): 982-
988. 
6. REFERENCES 
 
188 
 
Kim, JE, Ryu, HJ, Yeo, SI and Kang, TC (2010). "P2X7 receptor differentially modulates astroglial 
apoptosis and clasmatodendrosis in the rat brain following status epilepticus." Hippocampus. 
Kim, WG, Mohney, RP, Wilson, B, Jeohn, GH, Liu, B and Hong, JS (2000). "Regional difference in 
susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia." J 
Neurosci 20(16): 6309-6316. 
Kirischuk, S, Scherer, J, Kettenmann, H and Verkhratsky, A (1995). "Activation of P2-purinoreceptors 
triggered Ca2+ release from InsP3-sensitive internal stores in mammalian oligodendrocytes." J 
Physiol 483 ( Pt 1): 41-57. 
Kittner, H, Krugel, U, Hoffmann, E and Illes, P (2000). "Effects of intra-accumbens injection of 2-
methylthio ATP: a combined open field and electroencephalographic study in rats." 
Psychopharmacology (Berl) 150(2): 123-131. 
Klotz, KN, Hessling, J, Hegler, J, Owman, C, Kull, B, Fredholm, BB and Lohse, MJ (1998). 
"Comparative pharmacology of human adenosine receptor subtypes - characterization of stably 
transfected receptors in CHO cells." Naunyn Schmiedebergs Arch Pharmacol 357(1): 1-9. 
Koizumi, S, Shigemoto-Mogami, Y, Nasu-Tada, K, Shinozaki, Y, Ohsawa, K, Tsuda, M, Joshi, BV, 
Jacobson, KA, Kohsaka, S and Inoue, K (2007). "UDP acting at P2Y6 receptors is a mediator of 
microglial phagocytosis." Nature 446(7139): 1091-1095. 
Koles, L, Gerevich, Z, Kittner, H, Krugel, U, Franke, H and Illes, P (2008). "[Purinergic modulation of 
the brain dopaminergic transmission: behavioral-pharmacologic conclusions]." 
Neuropsychopharmacol Hung 10(2): 97-102. 
Koles, L, Leichsenring, A, Rubini, P and Illes, P (2011). "P2 receptor signaling in neurons and glial 
cells of the central nervous system." Adv Pharmacol 61: 441-493. 
Konsman, JP, Vigues, S, Mackerlova, L, Bristow, A and Blomqvist, A (2004). "Rat brain vascular 
distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of 
inducible cyclooxygenase expression by peripheral inflammatory stimuli." J Comp Neurol 
472(1): 113-129. 
Kowaluk, EA and Jarvis, MF (2000). "Therapeutic potential of adenosine kinase inhibitors." Expert 
Opin Investig Drugs 9(3): 551-564. 
Kraft, AD, McPherson, CA and Harry, GJ (2009). "Heterogeneity of microglia and TNF signaling as 
determinants for neuronal death or survival." Neurotoxicology 30(5): 785-793. 
Kreutzberg, GW (1996). "Microglia: a sensor for pathological events in the CNS." Trends Neurosci 
19(8): 312-318. 
Kreutzberg, GW and Barron, KD (1978). "5'-Nucleotidase of microglial cells in the facial nucleus 
during axonal reaction." J Neurocytol 7(5): 601-610. 
Krueger, JM, Obal, FJ, Fang, J, Kubota, T and Taishi, P (2001). "The role of cytokines in physiological 
sleep regulation." Ann N Y Acad Sci 933: 211-221. 
Krugel, U, Kittner, H, Franke, H and Illes, P (2001a). "Stimulation of P2 receptors in the ventral 
tegmental area enhances dopaminergic mechanisms in vivo." Neuropharmacology 40(8): 1084-
1093. 
Krugel, U, Kittner, H, Franke, H and Illes, P (2003). "Purinergic modulation of neuronal activity in the 
mesolimbic dopaminergic system in vivo." Synapse 47(2): 134-142. 
Krugel, U, Kittner, H and Illes, P (1999). "Adenosine 5'-triphosphate-induced dopamine release in the 
rat nucleus accumbens in vivo." Neurosci Lett 265(1): 49-52. 
Krugel, U, Kittner, H and Illes, P (2001b). "Mechanisms of adenosine 5'-triphosphate-induced 
dopamine release in the rat nucleus accumbens in vivo." Synapse 39(3): 222-232. 
Krugel, U, Schraft, T, Regenthal, R, Illes, P and Kittner, H (2004). "Purinergic modulation of 
extracellular glutamate levels in the nucleus accumbens in vivo." Int J Dev Neurosci 22(7): 565-
570. 
6. REFERENCES 
189 
 
Kuboyama, K, Harada, H, Tozaki-Saitoh, H, Tsuda, M, Ushijima, K and Inoue, K (2011). "Astrocytic 
P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral 
damage in a rat model of cerebral ischemia." J Cereb Blood Flow Metab 31(9): 1930-1941. 
Kull, B, Ferre, S, Arslan, G, Svenningsson, P, Fuxe, K, Owman, C and Fredholm, BB (1999). 
"Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese 
hamster ovary cells co-transfected with the two receptors." Biochem Pharmacol 58(6): 1035-
1045. 
Kull, B, Svenningsson, P and Fredholm, BB (2000). "Adenosine A(2A) receptors are colocalized with 
and activate g(olf) in rat striatum." Mol Pharmacol 58(4): 771-777. 
Kumaria, A, Tolias, CM and Burnstock, G (2008). "ATP signalling in epilepsy." Purinergic Signal 
4(4): 339-346. 
Ladeby, R, Wirenfeldt, M, Dalmau, I, Gregersen, R, Garcia-Ovejero, D, Babcock, A, Owens, T and 
Finsen, B (2005). "Proliferating resident microglia express the stem cell antigen CD34 in 
response to acute neural injury." Glia 50(2): 121-131. 
Laitinen, JT, Uri, A, Raidaru, G and Miettinen, R (2001). "[(35)S]GTPgammaS autoradiography 
reveals a wide distribution of G(i/o)-linked ADP receptors in the nervous system: close 
similarities with the platelet P2Y(ADP) receptor." J Neurochem 77(2): 505-518. 
Lalo, U, Verkhratsky, A and Pankratov, Y (2011). "Ionotropic ATP receptors in neuronal-glial 
communication." Semin Cell Dev Biol 22(2): 220-228. 
Lambert, C, Ase, AR, Seguela, P and Antel, JP (2010). "Distinct migratory and cytokine responses of 
human microglia and macrophages to ATP." Brain Behav Immun 24(8): 1241-1248. 
Lammer, A, Gunther, A, Beck, A, Krugel, U, Kittner, H, Schneider, D, Illes, P and Franke, H (2006). 
"Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-
induced injury in rats." Eur J Neurosci 23(10): 2824-2828. 
Lammer, AB, Beck, A, Grummich, B, Forschler, A, Krugel, T, Kahn, T, Schneider, D, Illes, P, Franke, 
H and Krugel, U (2011). "The P2 receptor antagonist PPADS supports recovery from 
experimental stroke in vivo." PLoS One 6(5): 17. 
Lange, K and Brandt, U (1993). "Rapid uptake of calcium, ATP, and inositol 1,4,5-trisphosphate via 
cation and anion channels into surface-derived vesicles from HIT cells containing the inositol 
1,4,5-trisphosphate-sensitive calcium store." FEBS Lett 325(3): 205-209. 
Latini, S, Bordoni, F, Corradetti, R, Pepeu, G and Pedata, F (1999). "Effect of A2A adenosine receptor 
stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat 
hippocampal slices." Br J Pharmacol 128(5): 1035-1044. 
Latini, S and Pedata, F (2001). "Adenosine in the central nervous system: release mechanisms and 
extracellular concentrations." J Neurochem 79(3): 463-484. 
Lauber, K, Bohn, E, Krober, SM, Xiao, YJ, Blumenthal, SG, Lindemann, RK, Marini, P, Wiedig, C, 
Zobywalski, A, Baksh, S, Xu, Y, Autenrieth, IB, Schulze-Osthoff, K, Belka, C, Stuhler, G and 
Wesselborg, S (2003). "Apoptotic cells induce migration of phagocytes via caspase-3-mediated 
release of a lipid attraction signal." Cell 113(6): 717-730. 
Lazarowski, ER, Boucher, RC and Harden, TK (2003). "Mechanisms of release of nucleotides and 
integration of their action as P2X- and P2Y-receptor activating molecules." Mol Pharmacol 
64(4): 785-795. 
Le Feuvre, R, Brough, D and Rothwell, N (2002). "Extracellular ATP and P2X7 receptors in 
neurodegeneration." Eur J Pharmacol 447(2-3): 261-269. 
Lee, FS and Chao, MV (2001). "Activation of Trk neurotrophin receptors in the absence of 
neurotrophins." Proc Natl Acad Sci U S A 98(6): 3555-3560. 
6. REFERENCES 
 
190 
 
Lee, HG, Won, SM, Gwag, BJ and Lee, YB (2011). "Microglial P2X receptor expression is 
accompanied by neuronal damage in the cerebral cortex of the APPswe/PS1dE9 mouse model 
of Alzheimer's disease." Exp Mol Med 43(1): 7-14. 
Lee, SY and Haydon, PG (2007). "Astrocytic glutamate targets NMDA receptors." J Physiol 581(Pt 3): 
887-888. 
Lee, SY and O'Grady, SM (2003). "Modulation of ion channel function by P2Y receptors." Cell 
Biochem Biophys 39(1): 75-88. 
Leon, D, Hervas, C and Miras-Portugal, MT (2006). "P2Y1 and P2X7 receptors induce 
calcium/calmodulin-dependent protein kinase II phosphorylation in cerebellar granule neurons." 
Eur J Neurosci 23(11): 2999-3013. 
Leonoudakis, D, Braithwaite, SP, Beattie, MS and Beattie, EC (2004). "TNFalpha-induced AMPA-
receptor trafficking in CNS neurons; relevance to excitotoxicity?" Neuron Glia Biol 1(3): 263-
273. 
Li, M, Chang, TH, Silberberg, SD and Swartz, KJ (2008a). "Gating the pore of P2X receptor channels." 
Nat Neurosci 11(8): 883-887. 
Li, M, Kawate, T, Silberberg, SD and Swartz, KJ (2010). "Pore-opening mechanism in trimeric P2X 
receptor channels." Nat Commun 1(44). 
Li, T, Ren, G, Lusardi, T, Wilz, A, Lan, JQ, Iwasato, T, Itohara, S, Simon, RP and Boison, D (2008b). 
"Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice." J 
Clin Invest 118(2): 571-582. 
Li, XX, Nomura, T, Aihara, H and Nishizaki, T (2001). "Adenosine enhances glial glutamate efflux via 
A2a adenosine receptors." Life Sci 68(12): 1343-1350. 
Light, AR, Wu, Y, Hughen, RW and Guthrie, PB (2006). "Purinergic receptors activating rapid 
intracellular Ca increases in microglia." Neuron Glia Biol 2(2): 125-138. 
Lin, MT and Beal, MF (2006). "Mitochondrial dysfunction and oxidative stress in neurodegenerative 
diseases." Nature 443(7113): 787-795. 
Lipmann, F (1941). "Metabolic generation and utilization of phosphate bond energy." Adv Enzymol 1: 
99-162. 
Liu, F, Wan, Q, Pristupa, ZB, Yu, XM, Wang, YT and Niznik, HB (2000a). "Direct protein-protein 
coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors." 
Nature 403(6767): 274-280. 
Liu, JS, John, GR, Sikora, A, Lee, SC and Brosnan, CF (2000b). "Modulation of interleukin-1beta and 
tumor necrosis factor alpha signaling by P2 purinergic receptors in human fetal astrocytes." J 
Neurosci 20(14): 5292-5299. 
Liu, YL, Zhou, LJ, Hu, NW, Xu, JT, Wu, CY, Zhang, T, Li, YY and Liu, XG (2007). "Tumor necrosis 
factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal 
horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK." 
Neuropharmacology 52(3): 708-715. 
Liu, YP, Yang, CS, Chen, MC, Sun, SH and Tzeng, SF (2010). "Ca(2+)-dependent reduction of 
glutamate aspartate transporter GLAST expression in astrocytes by P2X(7) receptor-mediated 
phosphoinositide 3-kinase signaling." J Neurochem 113(1): 213-227. 
Londos, C, Cooper, DM and Wolff, J (1980). "Subclasses of external adenosine receptors." Proc Natl 
Acad Sci U S A 77(5): 2551-2554. 
Lopes da Silva, FH, Witter, MP, Boeijinga, PH and Lohman, AH (1990). "Anatomic organization and 
physiology of the limbic cortex." Physiol Rev 70(2): 453-511. 
Lopes, LV, Cunha, RA, Kull, B, Fredholm, BB and Ribeiro, JA (2002). "Adenosine A(2A) receptor 
facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor 
inhibition." Neuroscience 112(2): 319-329. 
6. REFERENCES 
191 
 
Lopes, LV, Cunha, RA and Ribeiro, JA (1999). "Cross talk between A(1) and A(2A) adenosine 
receptors in the hippocampus and cortex of young adult and old rats." J Neurophysiol 82(6): 
3196-3203. 
Lopes, LV, Halldner, L, Rebola, N, Johansson, B, Ledent, C, Chen, JF, Fredholm, BB and Cunha, RA 
(2004). "Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the 
cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice." Br J Pharmacol 141(6): 
1006-1014. 
Lopes, LV, Rebola, N, Pinheiro, PC, Richardson, PJ, Oliveira, CR and Cunha, RA (2003). "Adenosine 
A3 receptors are located in neurons of the rat hippocampus." Neuroreport 14(12): 1645-1648. 
Lukashev, D, Ohta, A, Apasov, S, Chen, JF and Sitkovsky, M (2004). "Cutting edge: Physiologic 
attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor 
in vivo." J Immunol 173(1): 21-24. 
Luscher, C and Slesinger, PA (2010). "Emerging roles for G protein-gated inwardly rectifying 
potassium (GIRK) channels in health and disease." Nat Rev Neurosci 11(5): 301-315. 
Lustig, KD, Shiau, AK, Brake, AJ and Julius, D (1993). "Expression cloning of an ATP receptor from 
mouse neuroblastoma cells." Proc Natl Acad Sci U S A 90(11): 5113-5117. 
Luthardt, J, Borvendeg, SJ, Sperlagh, B, Poelchen, W, Wirkner, K and Illes, P (2003). "P2Y(1) 
receptor activation inhibits NMDA receptor-channels in layer V pyramidal neurons of the rat 
prefrontal and parietal cortex." Neurochem Int 42(2): 161-172. 
Lynch, MA (2010). "Age-related neuroinflammatory changes negatively impact on neuronal function." 
Front Aging Neurosci 1: 6. 
Ma, XC, Gottschall, PE, Chen, LT, Wiranowska, M and Phelps, CP (2002). "Role and mechanisms of 
interleukin-1 in the modulation of neurotoxicity." Neuroimmunomodulation 10(4): 199-207. 
Marchetti, B and Abbracchio, MP (2005). "To be or not to be (inflamed)--is that the question in anti-
inflammatory drug therapy of neurodegenerative disorders?" Trends Pharmacol Sci 26(10): 
517-525. 
Marchi, M, Raiteri, L, Risso, F, Vallarino, A, Bonfanti, A, Monopoli, A, Ongini, E and Raiteri, M 
(2002). "Effects of adenosine A1 and A2A receptor activation on the evoked release of 
glutamate from rat cerebrocortical synaptosomes." Br J Pharmacol 136(3): 434-440. 
Marks, L, Carswell, HV, Peters, EE, Graham, DI, Patterson, J, Dominiczak, AF and Macrae, IM 
(2001). "Characterization of the microglial response to cerebral ischemia in the stroke-prone 
spontaneously hypertensive rat." Hypertension 38(1): 116-122. 
Marrelli, SP (2002). "Altered endothelial Ca2+ regulation after ischemia/reperfusion produces 
potentiated endothelium-derived hyperpolarizing factor-mediated dilations." Stroke 33(9): 
2285-2291. 
Marrelli, SP, Khorovets, A, Johnson, TD, Childres, WF and Bryan, RM, Jr. (1999). "P2 purinoceptor-
mediated dilations in the rat middle cerebral artery after ischemia-reperfusion." Am J Physiol 
276(1 Pt 2): H33-41. 
Marteau, F, Communi, D, Boeynaems, JM and Suarez Gonzalez, N (2004). "Involvement of multiple 
P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on 
human monocyte-derived dendritic cells." J Leukoc Biol 76(4): 796-803. 
Marteau, F, Gonzalez, NS, Communi, D, Goldman, M and Boeynaems, JM (2005). "Thrombospondin-
1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic 
cells." Blood 106(12): 3860-3866. 
Marteau, F, Le Poul, E, Communi, D, Labouret, C, Savi, P, Boeynaems, JM and Gonzalez, NS (2003). 
"Pharmacological characterization of the human P2Y13 receptor." Mol Pharmacol 64(1): 104-
112. 
6. REFERENCES 
 
192 
 
Martin, TW and Michaelis, K (1989). "P2-purinergic agonists stimulate phosphodiesteratic cleavage of 
phosphatidylcholine in endothelial cells. Evidence for activation of phospholipase D." J Biol 
Chem 264(15): 8847-8856. 
Mathot, RA, Appel, S, van Schaick, EA, Soudijn, W, AP, IJ and Danhof, M (1993). "High-
performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and 
the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in 
rats." J Chromatogr 620(1): 113-120. 
Matute, C, Torre, I, Perez-Cerda, F, Perez-Samartin, A, Alberdi, E, Etxebarria, E, Arranz, AM, Ravid, 
R, Rodriguez-Antiguedad, A, Sanchez-Gomez, M and Domercq, M (2007). "P2X(7) receptor 
blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental 
autoimmune encephalomyelitis." J Neurosci 27(35): 9525-9533. 
Mayne, M, Fotheringham, J, Yan, HJ, Power, C, Del Bigio, MR, Peeling, J and Geiger, JD (2001). 
"Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death 
following intracerebral hemorrhage." Ann Neurol 49(6): 727-735. 
McAfoose, J and Baune, BT (2009). "Evidence for a cytokine model of cognitive function." Neurosci 
Biobehav Rev 33(3): 355-366. 
McCoy, MK and Tansey, MG (2008). "TNF signaling inhibition in the CNS: implications for normal 
brain function and neurodegenerative disease." J Neuroinflammation 5: 45. 
McLarnon, JG, Ryu, JK, Walker, DG and Choi, HB (2006). "Upregulated expression of purinergic 
P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in 
peptide-injected rat hippocampus." J Neuropathol Exp Neurol 65(11): 1090-1097. 
Medawar, PB (1948). "Immunity to homologous grafted skin; the fate of skin homografts transplanted 
to the brain, to subcutaneous tissue, and to the anterior chamber of the eye." Br J Exp Pathol 
29(1): 58-69. 
Meghji, P, Tuttle, JB and Rubio, R (1989). "Adenosine formation and release by embryonic chick 
neurons and glia in cell culture." J Neurochem 53(6): 1852-1860. 
Melani, A, Amadio, S, Gianfriddo, M, Vannucchi, MG, Volonte, C, Bernardi, G, Pedata, F and 
Sancesario, G (2006a). "P2X7 receptor modulation on microglial cells and reduction of brain 
infarct caused by middle cerebral artery occlusion in rat." J Cereb Blood Flow Metab 26(7): 
974-982. 
Melani, A, Gianfriddo, M, Vannucchi, MG, Cipriani, S, Baraldi, PG, Giovannini, MG and Pedata, F 
(2006b). "The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, 
brain damage and activation of p38 MAPK in rat focal cerebral ischemia." Brain Res 1073-
1074: 470-480. 
Melani, A, Turchi, D, Vannucchi, MG, Cipriani, S, Gianfriddo, M and Pedata, F (2005). "ATP 
extracellular concentrations are increased in the rat striatum during in vivo ischemia." 
Neurochem Int 47(6): 442-448. 
Meldrum, BS (1994). "The role of glutamate in epilepsy and other CNS disorders." Neurology 44(11 
Suppl 8): S14-23. 
Mendoza-Fernandez, V, Andrew, RD and Barajas-Lopez, C (2000). "ATP inhibits glutamate synaptic 
release by acting at P2Y receptors in pyramidal neurons of hippocampal slices." J Pharmacol 
Exp Ther 293(1): 172-179. 
Messaris, E, Memos, N, Chatzigianni, E, Konstadoulakis, MM, Menenakos, E, Katsaragakis, S, 
Voumvourakis, C and Androulakis, G (2004). "Time-dependent mitochondrial-mediated 
programmed neuronal cell death prolongs survival in sepsis." Crit Care Med 32(8): 1764-1770. 
Michaelis, EK (1998). "Molecular biology of glutamate receptors in the central nervous system and 
their role in excitotoxicity, oxidative stress and aging." Prog Neurobiol 54(4): 369-415. 
6. REFERENCES 
193 
 
Milius, D, Sperlagh, B and Illes, P (2008). "Up-regulation of P2X7 receptor-immunoreactivity by in 
vitro ischemia on the plasma membrane of cultured rat cortical neurons." Neurosci Lett 446(1): 
45-50. 
Minghetti, L, Greco, A, Potenza, RL, Pezzola, A, Blum, D, Bantubungi, K and Popoli, P (2007). 
"Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 
expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of 
striatal neurodegeneration." J Neuropathol Exp Neurol 66(5): 363-371. 
Miras-Portugal, MT, Diaz-Hernandez, M, Giraldez, L, Hervas, C, Gomez-Villafuertes, R, Sen, RP, 
Gualix, J and Pintor, J (2003). "P2X7 receptors in rat brain: presence in synaptic terminals and 
granule cells." Neurochem Res 28(10): 1597-1605. 
Mojsilovic-Petrovic, J, Jeong, GB, Crocker, A, Arneja, A, David, S, Russell, DS and Kalb, RG (2006). 
"Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk 
receptors." J Neurosci 26(36): 9250-9263. 
Moll, V, Weick, M, Milenkovic, I, Kodal, H, Reichenbach, A and Bringmann, A (2002). "P2Y 
receptor-mediated stimulation of Muller glial DNA synthesis." Invest Ophthalmol Vis Sci 
43(3): 766-773. 
Moore, D, Chambers, J, Waldvogel, H, Faull, R and Emson, P (2000a). "Regional and cellular 
distribution of the P2Y(1) purinergic receptor in the human brain: striking neuronal 
localisation." J Comp Neurol 421(3): 374-384. 
Moore, D, Iritani, S, Chambers, J and Emson, P (2000b). "Immunohistochemical localization of the 
P2Y1 purinergic receptor in Alzheimer's disease." Neuroreport 11(17): 3799-3803. 
Moore, DJ, Chambers, JK, Wahlin, JP, Tan, KB, Moore, GB, Jenkins, O, Emson, PC and Murdock, PR 
(2001). "Expression pattern of human P2Y receptor subtypes: a quantitative reverse 
transcription-polymerase chain reaction study." Biochim Biophys Acta 31: 1-3. 
Moore, M, Piazza, A, Nolan, Y and Lynch, MA (2007). "Treatment with dexamethasone and vitamin 
D3 attenuates neuroinflammatory age-related changes in rat hippocampus." Synapse 61(10): 
851-861. 
Moran-Jimenez, MJ and Matute, C (2000). "Immunohistochemical localization of the P2Y(1) 
purinergic receptor in neurons and glial cells of the central nervous system." Brain Res Mol 
Brain Res 78(1-2): 50-58. 
Mori, M, Heuss, C, Gahwiler, BH and Gerber, U (2001). "Fast synaptic transmission mediated by P2X 
receptors in CA3 pyramidal cells of rat hippocampal slice cultures." J Physiol 535(Pt 1): 115-
123. 
Moro, S, Gao, ZG, Jacobson, KA and Spalluto, G (2006). "Progress in the pursuit of therapeutic 
adenosine receptor antagonists." Med Res Rev 26(2): 131-159. 
Morris, R (1984). "Developments of a water-maze procedure for studying spatial learning in the rat." J 
Neurosci Methods 11(1): 47-60. 
Morris, RG, Garrud, P, Rawlins, JN and O'Keefe, J (1982). "Place navigation impaired in rats with 
hippocampal lesions." Nature 297(5868): 681-683. 
Munoz, L and Ammit, AJ (2010). "Targeting p38 MAPK pathway for the treatment of Alzheimer's 
disease." Neuropharmacology 58(3): 561-568. 
Murray, CA, McGahon, B, McBennett, S and Lynch, MA (1997). "Interleukin-1 beta inhibits 
glutamate release in hippocampus of young, but not aged, rats." Neurobiol Aging 18(3): 343-
348. 
Nadler, JV (2003). "The recurrent mossy fiber pathway of the epileptic brain." Neurochem Res 28(11): 
1649-1658. 
Nagata, H, Mimori, Y, Nakamura, S and Kameyama, M (1984). "Regional and subcellular distribution 
in mammalian brain of the enzymes producing adenosine." J Neurochem 42(4): 1001-1007. 
6. REFERENCES 
 
194 
 
Nakanishi, S (1992). "Molecular diversity of glutamate receptors and implications for brain function." 
Science 258(5082): 597-603. 
Nakayama, GR, Caton, MC, Nova, MP and Parandoosh, Z (1997). "Assessment of the Alamar Blue 
assay for cellular growth and viability in vitro." J Immunol Methods 204(2): 205-208. 
Nakazawa, K, Inoue, K, Ito, K and Koizumi, S (1995). "Inhibition by suramin and reactive blue 2 of 
GABA and glutamate receptor channels in rat hippocampal neurons." Naunyn Schmiedebergs 
Arch Pharmacol 351(2): 202-208. 
Napoli, I and Neumann, H (2009). "Microglial clearance function in health and disease." Neuroscience 
158(3): 1030-1038. 
Narcisse, L, Scemes, E, Zhao, Y, Lee, SC and Brosnan, CF (2005). "The cytokine IL-1beta transiently 
enhances P2X7 receptor expression and function in human astrocytes." Glia 49(2): 245-258. 
Neary, JT and Kang, Y (2005). "Signaling from P2 nucleotide receptors to protein kinase cascades 
induced by CNS injury: implications for reactive gliosis and neurodegeneration." Mol 
Neurobiol 31(1-3): 95-103. 
Neary, JT, Kang, Y and Shi, YF (2005). "Cell cycle regulation of astrocytes by extracellular 
nucleotides and fibroblast growth factor-2." Purinergic Signal 1(4): 329-336. 
Neary, JT, Kang, Y, Shi, YF, Tran, MD and Wanner, IB (2006). "P2 receptor signalling, proliferation 
of astrocytes, and expression of molecules involved in cell-cell interactions." Novartis Found 
Symp 276: 131-143; discussion 143-137, 233-137, 275-181. 
Neary, JT, Shi, YF, Kang, Y and Tran, MD (2008). "Opposing effects of P2X(7) and P2Y 
purine/pyrimidine-preferring receptors on proliferation of astrocytes induced by fibroblast 
growth factor-2: implications for CNS development, injury, and repair." J Neurosci Res 86(14): 
3096-3105. 
Nemeth, ZH, Csoka, B, Wilmanski, J, Xu, D, Lu, Q, Ledent, C, Deitch, EA, Pacher, P, Spolarics, Z and 
Hasko, G (2006). "Adenosine A2A receptor inactivation increases survival in polymicrobial 
sepsis." J Immunol 176(9): 5616-5626. 
Neumann, H, Kotter, MR and Franklin, RJ (2009). "Debris clearance by microglia: an essential link 
between degeneration and regeneration." Brain 132(Pt 2): 288-295. 
Newman, EA (2003). "Glial cell inhibition of neurons by release of ATP." J Neurosci 23(5): 1659-
1666. 
Nicke, A, Baumert, HG, Rettinger, J, Eichele, A, Lambrecht, G, Mutschler, E and Schmalzing, G 
(1998). "P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated 
ion channels." Embo J 17(11): 3016-3028. 
Nishizaki, T (2004). "ATP- and adenosine-mediated signaling in the central nervous system: adenosine 
stimulates glutamate release from astrocytes via A2a adenosine receptors." J Pharmacol Sci 
94(2): 100-102. 
Nishizaki, T, Nagai, K, Nomura, T, Tada, H, Kanno, T, Tozaki, H, Li, XX, Kondoh, T, Kodama, N, 
Takahashi, E, Sakai, N, Tanaka, K and Saito, N (2002). "A new neuromodulatory pathway with 
a glial contribution mediated via A(2a) adenosine receptors." Glia 39(2): 133-147. 
Nolan, Y, Vereker, E, Lynch, AM and Lynch, MA (2003). "Evidence that lipopolysaccharide-induced 
cell death is mediated by accumulation of reactive oxygen species and activation of p38 in rat 
cortex and hippocampus." Exp Neurol 184(2): 794-804. 
Norenberg, W and Illes, P (2000). "Neuronal P2X receptors: localisation and functional properties." 
Naunyn Schmiedebergs Arch Pharmacol 362(4-5): 324-339. 
North, RA (2002). "Molecular physiology of P2X receptors." Physiol Rev 82(4): 1013-1067. 
Norton, WT, Aquino, DA, Hozumi, I, Chiu, FC and Brosnan, CF (1992). "Quantitative aspects of 
reactive gliosis: a review." Neurochem Res 17(9): 877-885. 
6. REFERENCES 
195 
 
O'Keefe, GM, Nguyen, VT and Benveniste, EN (2002). "Regulation and function of class II major 
histocompatibility complex, CD40, and B7 expression in macrophages and microglia: 
Implications in neurological diseases." J Neurovirol 8(6): 496-512. 
O'Keefe, J and Conway, DH (1978). "Hippocampal place units in the freely moving rat: why they fire 
where they fire." Exp Brain Res 31(4): 573-590. 
O'Shaughnessy, CT, Aram, JA and Lodge, D (1988). "A1 adenosine receptor-mediated block of 
epileptiform activity induced in zero magnesium in rat neocortex in vitro." Epilepsy Res 2(5): 
294-301. 
Ogoshi, F, Yin, HZ, Kuppumbatti, Y, Song, B, Amindari, S and Weiss, JH (2005). "Tumor necrosis-
factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels in a subset of 
hippocampal pyramidal neurons." Exp Neurol 193(2): 384-393. 
Ohnishi, M, Katsuki, H, Izumi, Y, Kume, T, Takada-Takatori, Y and Akaike, A (2010). "Mitogen-
activated protein kinases support survival of activated microglia that mediate thrombin-induced 
striatal injury in organotypic slice culture." J Neurosci Res 88(10): 2155-2164. 
Ohsawa, K and Kohsaka, S (2011). "Dynamic motility of microglia: Purinergic modulation of 
microglial movement in the normal and pathological brain." Glia. 
Ohta, A, Lukashev, D, Jackson, EK, Fredholm, BB and Sitkovsky, M (2007). "1,3,7-trimethylxanthine 
(caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological 
immunosuppressive mechanism." J Immunol 179(11): 7431-7438. 
Ohta, A and Sitkovsky, M (2001). "Role of G-protein-coupled adenosine receptors in downregulation 
of inflammation and protection from tissue damage." Nature 414(6866): 916-920. 
Ohta, A and Sitkovsky, M (2009). "The adenosinergic immunomodulatory drugs." Curr Opin 
Pharmacol 9(4): 501-506. 
Olivecrona, GK, Gotberg, M, Harnek, J, Jacobson, KA, Jern, S and Erlinge, D (2007). "The ADP 
receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia." J Thromb 
Thrombolysis 24(2): 115-122. 
Opp, MR (2005). "Cytokines and sleep." Sleep Med Rev 9(5): 355-364. 
Orr, AG, Orr, AL, Li, XJ, Gross, RE and Traynelis, SF (2009). "Adenosine A(2A) receptor mediates 
microglial process retraction." Nat Neurosci 12(7): 872-878. 
Ortinau, S, Laube, B and Zimmermann, H (2003). "ATP inhibits NMDA receptors after heterologous 
expression and in cultured hippocampal neurons and attenuates NMDA-mediated 
neurotoxicity." J Neurosci 23(12): 4996-5003. 
Othman, T, Yan, H and Rivkees, SA (2003). "Oligodendrocytes express functional A1 adenosine 
receptors that stimulate cellular migration." Glia 44(2): 166-172. 
Panatier, A, Theodosis, DT, Mothet, JP, Touquet, B, Pollegioni, L, Poulain, DA and Oliet, SH (2006). 
"Glia-derived D-serine controls NMDA receptor activity and synaptic memory." Cell 125(4): 
775-784. 
Pankratov, Y, Castro, E, Miras-Portugal, MT and Krishtal, O (1998). "A purinergic component of the 
excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons of the rat 
hippocampus." Eur J Neurosci 10(12): 3898-3902. 
Pankratov, Y, Lalo, U, Verkhratsky, A and North, RA (2006). "Vesicular release of ATP at central 
synapses." Pflugers Arch 452(5): 589-597. 
Pankratov, YV, Lalo, UV and Krishtal, OA (2002). "Role for P2X receptors in long-term potentiation." 
J Neurosci 22(19): 8363-8369. 
Pannicke, T, Fischer, W, Biedermann, B, Schadlich, H, Grosche, J, Faude, F, Wiedemann, P, Allgaier, 
C, Illes, P, Burnstock, G and Reichenbach, A (2000). "P2X7 receptors in Muller glial cells from 
the human retina." J Neurosci 20(16): 5965-5972. 
6. REFERENCES 
 
196 
 
Park, CK and Rudolphi, KA (1994). "Antiischemic effects of propentofylline (HWA 285) against focal 
cerebral infarction in rats." Neurosci Lett 178(2): 235-238. 
Parkhurst, CN and Gan, WB (2010). "Microglia dynamics and function in the CNS." Curr Opin 
Neurobiol 20(5): 595-600. 
Parkinson, FE, Damaraju, VL, Graham, K, Yao, SY, Baldwin, SA, Cass, CE and Young, JD (2011). 
"Molecular biology of nucleoside transporters and their distributions and functions in the 
brain." Curr Top Med Chem 11(8): 948-972. 
Parpura, V and Haydon, PG (2000). "Physiological astrocytic calcium levels stimulate glutamate 
release to modulate adjacent neurons." Proc Natl Acad Sci U S A 97(15): 8629-8634. 
Parvathenani, LK, Tertyshnikova, S, Greco, CR, Roberts, SB, Robertson, B and Posmantur, R (2003). 
"P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic 
mouse model of Alzheimer's disease." J Biol Chem 278(15): 13309-13317. 
Paschen, W (1996). "Glutamate excitotoxicity in transient global cerebral ischemia." Acta Neurobiol 
Exp (Wars) 56(1): 313-322. 
Pascual, O, Casper, KB, Kubera, C, Zhang, J, Revilla-Sanchez, R, Sul, JY, Takano, H, Moss, SJ, 
McCarthy, K and Haydon, PG (2005). "Astrocytic purinergic signaling coordinates synaptic 
networks." Science 310(5745): 113-116. 
Pedata, F, Melani, A, Pugliese, AM, Coppi, E, Cipriani, S and Traini, C (2007). "The role of ATP and 
adenosine in the brain under normoxic and ischemic conditions." Purinergic Signal 3(4): 299-
310. 
Peoples, RW and Li, C (1998). "Inhibition of NMDA-gated ion channels by the P2 purinoceptor 
antagonists suramin and reactive blue 2 in mouse hippocampal neurones." Br J Pharmacol 
124(2): 400-408. 
Perea, G, Navarrete, M and Araque, A (2009). "Tripartite synapses: astrocytes process and control 
synaptic information." Trends Neurosci 32(8): 421-431. 
Perry, VH, Nicoll, JA and Holmes, C (2010). "Microglia in neurodegenerative disease." Nat Rev 
Neurol 6(4): 193-201. 
Phillips, E and Newsholme, EA (1979). "Maximum activities, properties and distribution of 5' 
nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain." J Neurochem 
33(2): 553-558. 
Phillips, GR, Huang, JK, Wang, Y, Tanaka, H, Shapiro, L, Zhang, W, Shan, WS, Arndt, K, Frank, M, 
Gordon, RE, Gawinowicz, MA, Zhao, Y and Colman, DR (2001). "The presynaptic particle 
web: ultrastructure, composition, dissolution, and reconstitution." Neuron 32(1): 63-77. 
Phillis, JW, Kostopoulos, GK and Limacher, JJ (1974). "Depression of corticospinal cells by various 
purines and pyrimidines." Can J Physiol Pharmacol 52(6): 1226-1229. 
Phillis, JW, Kostopoulos, GK and Limacher, JJ (1975). "A potent depressant action of adenine 
derivatives on cerebral cortical neurones." Eur J Pharmacol 30(1): 125-129. 
Pickering, M, Cumiskey, D and O'Connor, JJ (2005). "Actions of TNF-alpha on glutamatergic synaptic 
transmission in the central nervous system." Exp Physiol 90(5): 663-670. 
Pickering, M and O'Connor, JJ (2007). "Pro-inflammatory cytokines and their effects in the dentate 
gyrus." Prog Brain Res 163: 339-354. 
Pierri, M, Vaudano, E, Sager, T and Englund, U (2005). "KW-6002 protects from MPTP induced 
dopaminergic toxicity in the mouse." Neuropharmacology 48(4): 517-524. 
Pignataro, G, Simon, RP and Boison, D (2007). "Transgenic overexpression of adenosine kinase 
aggravates cell death in ischemia." J Cereb Blood Flow Metab 27(1): 1-5. 
Pine, RW, Wertz, MJ, Lennard, ES, Dellinger, EP, Carrico, CJ and Minshew, BH (1983). 
"Determinants of organ malfunction or death in patients with intra-abdominal sepsis. A 
discriminant analysis." Arch Surg 118(2): 242-249. 
6. REFERENCES 
197 
 
Pinheiro, PS, Rodrigues, RJ, Silva, AP, Cunha, RA, Oliveira, CR and Malva, JO (2003). 
"Solubilization and immunological identification of presynaptic alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors in the rat hippocampus." Neurosci Lett 336(2): 97-
100. 
Pinto-Duarte, A, Coelho, JE, Cunha, RA, Ribeiro, JA and Sebastiao, AM (2005). "Adenosine A2A 
receptors control the extracellular levels of adenosine through modulation of nucleoside 
transporters activity in the rat hippocampus." J Neurochem 93(3): 595-604. 
Pintor, A, Galluzzo, M, Grieco, R, Pezzola, A, Reggio, R and Popoli, P (2004). "Adenosine A 2A 
receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate 
uptake inhibitors." J Neurochem 89(1): 152-156. 
Pintor, A, Quarta, D, Pezzola, A, Reggio, R and Popoli, P (2001). "SCH 58261 (an adenosine A(2A) 
receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum." 
Eur J Pharmacol 421(3): 177-180. 
Popova, M, Asatryan, L, Ostrovskaya, O, Wyatt, LR, Li, K, Alkana, RL and Davies, DL (2010). "A 
point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of 
ethanol in P2X4 receptors." J Neurochem 112(1): 307-317. 
Potter, PE and White, TD (1982). "Lack of effect of 6-hydroxydopamine pretreatment on 
depolarization-induced release of ATP fron rat brain synaptosomes." Eur J Pharmacol 80(1): 
143-147. 
Pull, I and McIlwain, H (1972). "Adenine derivatives as neurohumoral agents in the brain. The 
quantities liberated on excitation of superfused cerebral tissues." Biochem J 130(4): 975-981. 
Quan, N, Whiteside, M and Herkenham, M (1998). "Time course and localization patterns of 
interleukin-1beta messenger RNA expression in brain and pituitary after peripheral 
administration of lipopolysaccharide." Neuroscience 83(1): 281-293. 
Quiroz, C, Gomes, C, Pak, AC, Ribeiro, JA, Goldberg, SR, Hope, BT and Ferre, S (2006). "Blockade 
of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by 
cortical stimulation." J Neurosci 26(42): 10808-10812. 
Quiroz, C, Lujan, R, Uchigashima, M, Simoes, AP, Lerner, TN, Borycz, J, Kachroo, A, Canas, PM, 
Orru, M, Schwarzschild, MA, Rosin, DL, Kreitzer, AC, Cunha, RA, Watanabe, M and Ferre, S 
(2009). "Key modulatory role of presynaptic adenosine A2A receptors in cortical 
neurotransmission to the striatal direct pathway." ScientificWorldJournal 9: 1321-1344. 
Racine, RJ (1972). "Modification of seizure activity by electrical stimulation. II. Motor seizure." 
Electroencephalogr Clin Neurophysiol 32(3): 281-294. 
Raghavendra, V and DeLeo, JA (2004). Advances in molecular and cell biology Elsevier B.V. 
Ralevic, V and Burnstock, G (1998). "Receptors for purines and pyrimidines." Pharmacol Rev 50(3): 
413-492. 
Ransohoff, RM and Perry, VH (2009). "Microglial physiology: unique stimuli, specialized responses." 
Annu Rev Immunol 27: 119-145. 
Rapaport, E (1983). "Treatment of human tumor cells with ADP or ATP yields arrest of growth in the 
S phase of the cell cycle." J Cell Physiol 114(3): 279-283. 
Rappold, PM, Lynd-Balta, E and Joseph, SA (2006). "P2X7 receptor immunoreactive profile confined 
to resting and activated microglia in the epileptic brain." Brain Res 1089(1): 171-178. 
Ravizza, T, Boer, K, Redeker, S, Spliet, WG, van Rijen, PC, Troost, D, Vezzani, A and Aronica, E 
(2006). "The IL-1beta system in epilepsy-associated malformations of cortical development." 
Neurobiol Dis 24(1): 128-143. 
Rebola, N, Canas, PM, Oliveira, CR and Cunha, RA (2005a). "Different synaptic and subsynaptic 
localization of adenosine A2A receptors in the hippocampus and striatum of the rat." 
Neuroscience 132(4): 893-903. 
6. REFERENCES 
 
198 
 
Rebola, N, Lujan, R, Cunha, RA and Mulle, C (2008). "Adenosine A2A receptors are essential for 
long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses." Neuron 57(1): 
121-134. 
Rebola, N, Pinheiro, PC, Oliveira, CR, Malva, JO and Cunha, RA (2003). "Subcellular localization of 
adenosine A(1) receptors in nerve terminals and synapses of the rat hippocampus." Brain Res 
987(1): 49-58. 
Rebola, N, Porciuncula, LO, Lopes, LV, Oliveira, CR, Soares-da-Silva, P and Cunha, RA (2005b). 
"Long-term effect of convulsive behavior on the density of adenosine A1 and A 2A receptors in 
the rat cerebral cortex." Epilepsia 5: 159-165. 
Rebola, N, Rodrigues, RJ, Lopes, LV, Richardson, PJ, Oliveira, CR and Cunha, RA (2005c). 
"Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in 
glutamatergic nerve terminals of the rat hippocampus." Neuroscience 133(1): 79-83. 
Rebola, N, Rodrigues, RJ, Oliveira, CR and Cunha, RA (2005d). "Different roles of adenosine A1, 
A2A and A3 receptors in controlling kainate-induced toxicity in cortical cultured neurons." 
Neurochem Int 47(5): 317-325. 
Rebola, N, Simoes, AP, Canas, PM, Tome, AR, Andrade, GM, Barry, CE, Agostinho, PM, Lynch, MA 
and Cunha, RA (2011). "Adenosine A2A receptors control neuroinflammation and consequent 
hippocampal neuronal dysfunction." J Neurochem 117(1): 100-111. 
Remick, DG, Newcomb, DE, Bolgos, GL and Call, DR (2000). "Comparison of the mortality and 
inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and 
puncture." Shock 13(2): 110-116. 
Resende, R, Pereira, C, Agostinho, P, Vieira, AP, Malva, JO and Oliveira, CR (2007). "Susceptibility 
of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2+ 
homeostasis." Brain Res 1143: 11-21. 
Ribeiro, JA (1995). "Purinergic inhibition of neurotransmitter release in the central nervous system." 
Pharmacol Toxicol 77(5): 299-305. 
Rietschel, ET, Brade, H, Holst, O, Brade, L, Muller-Loennies, S, Mamat, U, Zahringer, U, Beckmann, 
F, Seydel, U, Brandenburg, K, Ulmer, AJ, Mattern, T, Heine, H, Schletter, J, Loppnow, H, 
Schonbeck, U, Flad, HD, Hauschildt, S, Schade, UF, Di Padova, F, Kusumoto, S and 
Schumann, RR (1996). "Bacterial endotoxin: Chemical constitution, biological recognition, host 
response, and immunological detoxification." Curr Top Microbiol Immunol 216: 39-81. 
Robbins, J (2001). "KCNQ potassium channels: physiology, pathophysiology, and pharmacology." 
Pharmacol Ther 90(1): 1-19. 
Robson, SC, Sevigny, J and Zimmermann, H (2006). "The E-NTPDase family of ectonucleotidases: 
Structure function relationships and pathophysiological significance." Purinergic Signal 2(2): 
409-430. 
Rodrigues, RJ, Alfaro, TM, Rebola, N, Oliveira, CR and Cunha, RA (2005a). "Co-localization and 
functional interaction between adenosine A(2A) and metabotropic group 5 receptors in 
glutamatergic nerve terminals of the rat striatum." J Neurochem 92(3): 433-441. 
Rodrigues, RJ, Almeida, T, Richardson, PJ, Oliveira, CR and Cunha, RA (2005b). "Dual presynaptic 
control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and inhibitory 
P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus." J Neurosci 25(27): 6286-6295. 
Rodrigues, RJ, Porciúncula, LO, Canas, PM, Gachet, C, Oliveira, CR, Cunha, RA (2006). "Blockade of 
P2Y1 receptors prevents synaptotoxicity and memory impairment caused by Aβ1-42 
administration". In the international Symposium on Adenosine and Adenine nucleotides, 2006, 
Ferrara, Italy. Abstracts in Purinergic Signalling, 2006, v.2. p. 136. 
 
6. REFERENCES 
199 
 
Rossi, D and Volterra, A (2009). "Astrocytic dysfunction: insights on the role in neurodegeneration." 
Brain Res Bull 80(4-5): 224-232. 
Rossi, DJ, Oshima, T and Attwell, D (2000). "Glutamate release in severe brain ischaemia is mainly by 
reversed uptake." Nature 403(6767): 316-321. 
Rotshenker, S (2009). "The role of Galectin-3/MAC-2 in the activation of the innate-immune function 
of phagocytosis in microglia in injury and disease." J Mol Neurosci 39(1-2): 99-103. 
Rubini, P, Pinkwart, C, Franke, H, Gerevich, Z, Norenberg, W and Illes, P (2006). "Regulation of 
intracellular Ca2+ by P2Y1 receptors may depend on the developmental stage of cultured rat 
striatal neurons." J Cell Physiol 209(1): 81-93. 
Rubio, ME and Soto, F (2001). "Distinct Localization of P2X receptors at excitatory postsynaptic 
specializations." J Neurosci 21(2): 641-653. 
Runden-Pran, E, Tanso, R, Haug, FM, Ottersen, OP and Ring, A (2005). "Neuroprotective effects of 
inhibiting N-methyl-D-aspartate receptors, P2X receptors and the mitogen-activated protein 
kinase cascade: a quantitative analysis in organotypical hippocampal slice cultures subjected to 
oxygen and glucose deprivation." Neuroscience 136(3): 795-810. 
Ryu, JK, Kim, J, Choi, SH, Oh, YJ, Lee, YB, Kim, SU and Jin, BK (2002). "ATP-induced in vivo 
neurotoxicity in the rat striatum via P2 receptors." Neuroreport 13(13): 1611-1615. 
Sabirov, RZ and Okada, Y (2005). "ATP release via anion channels." Purinergic Signal 1(4): 311-328. 
Safiulina, VF, Afzalov, R, Khiroug, L, Cherubini, E and Giniatullin, R (2006). "Reactive oxygen 
species mediate the potentiating effects of ATP on GABAergic synaptic transmission in the 
immature hippocampus." J Biol Chem 281(33): 23464-23470. 
Salgado, AH, Prado, MA, Moraes-Santos, T, Romano-Silva, MA and Gomez, MV (1997). 
"Tityustoxin-induced release of ATP from rat brain cortical synaptosomes." Neurosci Lett 
229(2): 113-116. 
Salt, TE and Hill, RG (1983). "Excitation of single sensory neurones in the rat caudal trigeminal 
nucleus by iontophoretically applied adenosine 5'-triphosphate." Neurosci Lett 35(1): 53-57. 
Sampath, C, Holbik, M, Krenn, L and Butterweck, V "Anxiolytic effects of fractions obtained from 
Passiflora incarnata L. in the elevated plus maze in mice." Phytother Res 25(6): 789-795. 
Sanz, JM, Chiozzi, P, Ferrari, D, Colaianna, M, Idzko, M, Falzoni, S, Fellin, R, Trabace, L and Di 
Virgilio, F (2009). "Activation of microglia by amyloid {beta} requires P2X7 receptor 
expression." J Immunol 182(7): 4378-4385. 
Sattin, A and Rall, TW (1970). "The effect of adenosine and adenine nucleotides on the cyclic 
adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices." Mol Pharmacol 6(1): 
13-23. 
Sattler, R and Tymianski, M (2000). "Molecular mechanisms of calcium-dependent excitotoxicity." J 
Mol Med (Berl) 78(1): 3-13. 
Saura, J, Angulo, E, Ejarque, A, Casado, V, Tusell, JM, Moratalla, R, Chen, JF, Schwarzschild, MA, 
Lluis, C, Franco, R and Serratosa, J (2005). "Adenosine A2A receptor stimulation potentiates 
nitric oxide release by activated microglia." J Neurochem 95(4): 919-929. 
Sawada, K, Echigo, N, Juge, N, Miyaji, T, Otsuka, M, Omote, H, Yamamoto, A and Moriyama, Y 
(2008). "Identification of a vesicular nucleotide transporter." Proc Natl Acad Sci U S A 
105(15): 5683-5686. 
Sawynok, J, Downie, JW, Reid, AR, Cahill, CM and White, TD (1993). "ATP release from dorsal 
spinal cord synaptosomes: characterization and neuronal origin." Brain Res 610(1): 32-38. 
Schicker, KW, Chandaka, GK, Geier, P, Kubista, H and Boehm, S (2010). "P2Y1 receptors mediate an 
activation of neuronal calcium-dependent K+ channels." J Physiol 588(Pt 19): 3713-3725. 
Schindler, M, Harris, CA, Hayes, B, Papotti, M and Humphrey, PP (2001). "Immunohistochemical 
localization of adenosine A1 receptors in human brain regions." Neurosci Lett 297(3): 211-215. 
6. REFERENCES 
 
200 
 
Schipke, CG, Boucsein, C, Ohlemeyer, C, Kirchhoff, F and Kettenmann, H (2002). "Astrocyte Ca2+ 
waves trigger responses in microglial cells in brain slices." Faseb J 16(2): 255-257. 
Schmued, LC, Stowers, CC, Scallet, AC and Xu, L (2005). "Fluoro-Jade C results in ultra high 
resolution and contrast labeling of degenerating neurons." Brain Res 1035(1): 24-31. 
Schneider, H, Pitossi, F, Balschun, D, Wagner, A, del Rey, A and Besedovsky, HO (1998). "A 
neuromodulatory role of interleukin-1beta in the hippocampus." Proc Natl Acad Sci U S A 
95(13): 7778-7783. 
Schulte, G and Fredholm, BB (2003). "Signalling from adenosine receptors to mitogen-activated 
protein kinases." Cell Signal 15(9): 813-827. 
Schwiebert, EM (1999). "ABC transporter-facilitated ATP conductive transport." Am J Physiol 276(1 
Pt 1): C1-8. 
Scoville, WB and Milner, B (2000). "Loss of recent memory after bilateral hippocampal lesions. 1957." 
J Neuropsychiatry Clin Neurosci 12(1): 103-113. 
Sebastiao, AM, Assaife-Lopes, N, Diogenes, MJ, Vaz, SH and Ribeiro, JA (2011). "Modulation of 
brain-derived neurotrophic factor (BDNF) actions in the nervous system by adenosine A(2A) 
receptors and the role of lipid rafts." Biochim Biophys Acta 1808(5): 1340-1349. 
Sebastiao, AM and Ribeiro, JA (2000). "Fine-tuning neuromodulation by adenosine." Trends 
Pharmacol Sci 21(9): 341-346. 
Sellers, LA, Simon, J, Lundahl, TS, Cousens, DJ, Humphrey, PP and Barnard, EA (2001). "Adenosine 
nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and 
induce apoptosis." J Biol Chem 276(19): 16379-16390. 
Semmler, A, Okulla, T, Sastre, M, Dumitrescu-Ozimek, L and Heneka, MT (2005). "Systemic 
inflammation induces apoptosis with variable vulnerability of different brain regions." J Chem 
Neuroanat 30(2-3): 144-157. 
Sharma, AK, Reams, RY, Jordan, WH, Miller, MA, Thacker, HL and Snyder, PW (2007). "Mesial 
temporal lobe epilepsy: pathogenesis, induced rodent models and lesions." Toxicol Pathol 
35(7): 984-999. 
Sharma, S, Kumar, V, Khosla, R, Kajal, N, Sarin, B and Sehajpal, P (2010). "Association of P2X7 
receptor +1513 (A-->C) polymorphism with tuberculosis in a Punjabi population." Int J Tuberc 
Lung Dis 14(9): 1159-1163. 
Sharshar, T, Hopkinson, NS, Orlikowski, D and Annane, D (2005). "Science review: The brain in 
sepsis--culprit and victim." Crit Care 9(1): 37-44. 
Shaver, SR, Rideout, JL, Pendergast, W, Douglass, JG, Brown, EG, Boyer, JL, Patel, RI, Redick, CC, 
Jones, AC, Picher, M and Yerxa, BR (2005). "Structure-activity relationships of dinucleotides: 
Potent and selective agonists of P2Y receptors." Purinergic Signal 1(2): 183-191. 
Sicard, KM and Fisher, M (2009). "Animal models of focal brain ischemia." Exp Transl Stroke Med 1: 
7. 
Silva, AP, Malva, JO, Ambrosio, AF, Salgado, AJ, Carvalho, AP and Carvalho, CM (2001). "Role of 
kainate receptor activation and desensitization on the [Ca(2+)](i) changes in cultured rat 
hippocampal neurons." J Neurosci Res 65(5): 378-386. 
Silva, CG, Porciuncula, LO, Canas, PM, Oliveira, CR and Cunha, RA (2007). "Blockade of adenosine 
A(2A) receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons." 
Neurobiol Dis 27(2): 182-189. 
Sitkovsky, MV (2003). "Use of the A(2A) adenosine receptor as a physiological immunosuppressor 
and to engineer inflammation in vivo." Biochem Pharmacol 65(4): 493-501. 
Sitkovsky, MV and Ohta, A (2005). "The 'danger' sensors that STOP the immune response: the A2 
adenosine receptors?" Trends Immunol 26(6): 299-304. 
6. REFERENCES 
201 
 
Sitkovsky, MV, Trenn, G and Takayama, H (1988). "Cyclic AMP-dependent protein kinase as a part of 
the possible down-regulating pathway in the antigen receptor-regulated cytotoxic T lymphocyte 
conjugate formation and granule exocytosis." Ann N Y Acad Sci 532: 350-358. 
Skaper, SD (2007). "The brain as a target for inflammatory processes and neuroprotective strategies." 
Ann N Y Acad Sci: 23-34. 
Skaper, SD (2011). "Ion channels on microglia: therapeutic targets for neuroprotection." CNS Neurol 
Disord Drug Targets 10(1): 44-56. 
Skaper, SD, Debetto, P and Giusti, P (2010). "The P2X7 purinergic receptor: from physiology to 
neurological disorders." FASEB J 24(2): 337-345. 
Smith, WS (2004). "Pathophysiology of focal cerebral ischemia: a therapeutic perspective." J Vasc 
Interv Radiol 15(1 Pt 2): S3-12. 
Sofroniew, MV (2005). "Reactive astrocytes in neural repair and protection." Neuroscientist 11(5): 
400-407. 
Soto, F, Lambrecht, G, Nickel, P, Stuhmer, W and Busch, AE (1999). "Antagonistic properties of the 
suramin analogue NF023 at heterologously expressed P2X receptors." Neuropharmacology 
38(1): 141-149. 
Sperlagh, B, Baranyi, M, Hasko, G and Vizi, ES (2004). "Potent effect of interleukin-1 beta to evoke 
ATP and adenosine release from rat hippocampal slices." J Neuroimmunol 151(1-2): 33-39. 
Sperlagh, B, Kofalvi, A, Deuchars, J, Atkinson, L, Milligan, CJ, Buckley, NJ and Vizi, ES (2002). 
"Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat 
hippocampus." J Neurochem 81(6): 1196-1211. 
Sperlagh, B, Magloczky, Z, Vizi, ES and Freund, TF (1998a). "The triangular septal nucleus as the 
major source of ATP release in the rat habenula: a combined neurochemical and morphological 
study." Neuroscience 86(4): 1195-1207. 
Sperlagh, B, Sershen, H, Lajtha, A and Vizi, ES (1998b). "Co-release of endogenous ATP and 
[3H]noradrenaline from rat hypothalamic slices: origin and modulation by alpha2-
adrenoceptors." Neuroscience 82(2): 511-520. 
Sperlagh, B, Zsilla, G, Baranyi, M, Illes, P and Vizi, ES (2007). "Purinergic modulation of glutamate 
release under ischemic-like conditions in the hippocampus." Neuroscience 149(1): 99-111. 
Sprung, CL, Peduzzi, PN, Shatney, CH, Schein, RM, Wilson, MF, Sheagren, JN and Hinshaw, LB 
(1990). "Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans 
Administration Systemic Sepsis Cooperative Study Group." Crit Care Med 18(8): 801-806. 
Squire, LR and Zola, SM (1996). "Structure and function of declarative and nondeclarative memory 
systems." Proc Natl Acad Sci U S A 93(24): 13515-13522. 
Squire, LR and Zola, SM (1997). "Amnesia, memory and brain systems." Philos Trans R Soc Lond B 
Biol Sci 352(1362): 1663-1673. 
Srinivasan, D, Yen, JH, Joseph, DJ and Friedman, W (2004). "Cell type-specific interleukin-1beta 
signaling in the CNS." J Neurosci 24(29): 6482-6488. 
Stellwagen, D, Beattie, EC, Seo, JY and Malenka, RC (2005). "Differential regulation of AMPA 
receptor and GABA receptor trafficking by tumor necrosis factor-alpha." J Neurosci 25(12): 
3219-3228. 
Stence, N, Waite, M and Dailey, ME (2001). "Dynamics of microglial activation: a confocal time-lapse 
analysis in hippocampal slices." Glia 33(3): 256-266. 
Stevens, B, Porta, S, Haak, LL, Gallo, V and Fields, RD (2002). "Adenosine: a neuron-glial transmitter 
promoting myelination in the CNS in response to action potentials." Neuron 36(5): 855-868. 
Stone, TW and Behan, WM (2007). "Interleukin-1beta but not tumor necrosis factor-alpha potentiates 
neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist." J 
Neurosci Res 85(5): 1077-1085. 
6. REFERENCES 
 
202 
 
Stone, TW, Ceruti, S and Abbracchio, MP (2009). "Adenosine receptors and neurological disease: 
neuroprotection and neurodegeneration." Handb Exp Pharmacol 193: 535-587. 
Strata, P and Harvey, R (1999). "Dale's principle." Brain Res Bull 50(5-6): 349-350. 
Streit, WJ (2000). "Microglial response to brain injury: a brief synopsis." Toxicol Pathol 28(1): 28-30. 
Streit, WJ, Walter, SA and Pennell, NA (1999). "Reactive microgliosis." Prog Neurobiol 57(6): 563-
581. 
Streit, WJ and Xue, QS (2009). "Life and death of microglia." J Neuroimmune Pharmacol 4(4): 371-
379. 
Studer, FE, Fedele, DE, Marowsky, A, Schwerdel, C, Wernli, K, Vogt, K, Fritschy, JM and Boison, D 
(2006). "Shift of adenosine kinase expression from neurons to astrocytes during postnatal 
development suggests dual functionality of the enzyme." Neuroscience 142(1): 125-137. 
Suadicani, SO, Brosnan, CF and Scemes, E (2006). "P2X7 receptors mediate ATP release and 
amplification of astrocytic intercellular Ca2+ signaling." J Neurosci 26(5): 1378-1385. 
Suadicani, SO, Flores, CE, Urban-Maldonado, M, Beelitz, M and Scemes, E (2004). "Gap junction 
channels coordinate the propagation of intercellular Ca2+ signals generated by P2Y receptor 
activation." Glia 48(3): 217-229. 
Sugiyama, T, Kobayashi, M, Kawamura, H, Li, Q and Puro, DG (2004). "Enhancement of P2X(7)-
induced pore formation and apoptosis: an early effect of diabetes on the retinal 
microvasculature." Invest Ophthalmol Vis Sci 45(3): 1026-1032. 
Sun, JJ, Liu, Y and Ye, ZR (2008). "Effects of P2Y1 receptor on glial fibrillary acidic protein and glial 
cell line-derived neurotrophic factor production of astrocytes under ischemic condition and the 
related signaling pathways." Neurosci Bull 24(4): 231-243. 
Surprenant, A (1996). "Functional properties of native and cloned P2X receptors." Ciba Found Symp 
198: 208-219. 
Surprenant, A and North, RA (2009). "Signaling at purinergic P2X receptors." Annu Rev Physiol 71: 
333-359. 
Surprenant, A, Schneider, DA, Wilson, HL, Galligan, JJ and North, RA (2000). "Functional properties 
of heteromeric P2X(1/5) receptors expressed in HEK cells and excitatory junction potentials in 
guinea-pig submucosal arterioles." J Auton Nerv Syst 81(1-3): 249-263. 
Svenningsson, P, Hall, H, Sedvall, G and Fredholm, BB (1997). "Distribution of adenosine receptors in 
the postmortem human brain: an extended autoradiographic study." Synapse 27(4): 322-335. 
Swanson, LW (1982). "The projections of the ventral tegmental area and adjacent regions: a combined 
fluorescent retrograde tracer and immunofluorescence study in the rat." Brain Res Bull 9(1-6): 
321-353. 
Swanson, LW, Wyss, JM and Cowan, WM (1978). "An autoradiographic study of the organization of 
intrahippocampal association pathways in the rat." J Comp Neurol 181(4): 681-715. 
Tajeddine, N, Galluzzi, L, Kepp, O, Hangen, E, Morselli, E, Senovilla, L, Araujo, N, Pinna, G, 
Larochette, N, Zamzami, N, Modjtahedi, N, Harel-Bellan, A and Kroemer, G (2008). 
"Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death." Oncogene 
27(30): 4221-4232. 
Takenouchi, T, Sekiyama, K, Sekigawa, A, Fujita, M, Waragai, M, Sugama, S, Iwamaru, Y, Kitani, H 
and Hashimoto, M (2010). "P2X7 receptor signaling pathway as a therapeutic target for 
neurodegenerative diseases." Arch Immunol Ther Exp (Warsz) 58(2): 91-96. 
Tamura, A, Graham, DI, McCulloch, J and Teasdale, GM (1981). "Focal cerebral ischaemia in the rat: 
2. Regional cerebral blood flow determined by [14C]iodoantipyrine autoradiography following 
middle cerebral artery occlusion." J Cereb Blood Flow Metab 1(1): 61-69. 
6. REFERENCES 
203 
 
Tatlisumak, T, Takano, K, Carano, RA, Miller, LP, Foster, AC and Fisher, M (1998). "Delayed 
treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with 
temporary middle cerebral artery occlusion." Stroke 29(9): 1952-1958. 
Tebano, MT, Martire, A, Rebola, N, Pepponi, R, Domenici, MR, Gro, MC, Schwarzschild, MA, Chen, 
JF, Cunha, RA and Popoli, P (2005). "Adenosine A2A receptors and metabotropic glutamate 5 
receptors are co-localized and functionally interact in the hippocampus: a possible key 
mechanism in the modulation of N-methyl-D-aspartate effects." J Neurochem 95(4): 1188-
1200. 
Terrian, DM, Hernandez, PG, Rea, MA and Peters, RI (1989). "ATP release, adenosine formation, and 
modulation of dynorphin and glutamic acid release by adenosine analogues in rat hippocampal 
mossy fiber synaptosomes." J Neurochem 53(5): 1390-1399. 
Tetzlaff, W, Schubert, P and Kreutzberg, GW (1987). "Synaptic and extrasynaptic localization of 
adenosine binding sites in the rat hippocampus." Neuroscience 21(3): 869-875. 
Teyler, TJ and DiScenna, P (1984). "The topological anatomy of the hippocampus: a clue to its 
function." Brain Res Bull 12(6): 711-719. 
Tian, GF, Azmi, H, Takano, T, Xu, Q, Peng, W, Lin, J, Oberheim, N, Lou, N, Wang, X, Zielke, HR, 
Kang, J and Nedergaard, M (2005). "An astrocytic basis of epilepsy." Nat Med 11(9): 973-981. 
Tominaga, M, Wada, M and Masu, M (2001). "Potentiation of capsaicin receptor activity by 
metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia." 
Proc Natl Acad Sci U S A 98(12): 6951-6956. 
Tonazzini, I, Trincavelli, ML, Montali, M and Martini, C (2008). "Regulation of A1 adenosine receptor 
functioning induced by P2Y1 purinergic receptor activation in human astroglial cells." J 
Neurosci Res 86(13): 2857-2866. 
Tonazzini, I, Trincavelli, ML, Storm-Mathisen, J, Martini, C and Bergersen, LH (2007). "Co-
localization and functional cross-talk between A1 and P2Y1 purine receptors in rat 
hippocampus." Eur J Neurosci 26(4): 890-902. 
Tonelli, LH and Postolache, TT (2005). "Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 
and major histocompatibility complex molecules in the normal brain and after peripheral 
immune challenge." Neurol Res 27(7): 679-684. 
Torres, GE, Egan, TM and Voigt, MM (1999). "Hetero-oligomeric assembly of P2X receptor subunits. 
Specificities exist with regard to possible partners." J Biol Chem 274(10): 6653-6659. 
Traini, C, Pedata, F, Cipriani, S, Mello, T, Galli, A, Giovannini, MG, Cerbai, F, Volpini, R, Cristalli, G 
and Pugliese, AM (2011). "P2 receptor antagonists prevent synaptic failure and extracellular 
signal-regulated kinase 1/2 activation induced by oxygen and glucose deprivation in rat CA1 
hippocampus in vitro." Eur J Neurosci 33(12): 2203-2215. 
Trincavelli, ML, Melani, A, Guidi, S, Cuboni, S, Cipriani, S, Pedata, F and Martini, C (2008). 
"Regulation of A(2A) adenosine receptor expression and functioning following permanent focal 
ischemia in rat brain." J Neurochem 104(2): 479-490. 
Troadec, JD, Thirion, S, Petturiti, D, Bohn, MT and Poujeol, P (1999). "ATP acting on P2Y receptors 
triggers calcium mobilization in primary cultures of rat neurohypophysial astrocytes 
(pituicytes)." Pflugers Arch 437(5): 745-753. 
Tschopl, M, Harms, L, Norenberg, W and Illes, P (1992). "Excitatory effects of adenosine 5'-
triphosphate on rat locus coeruleus neurones." Eur J Pharmacol 213(1): 71-77. 
Tsurusawa, M, Shimomura, Y, Asami, K, Kikuta, A, Watanabe, A, Horikoshi, Y, Matsushita, T, 
Kanegane, H, Ohta, S, Iwai, A, Mugishima, H and Koizumi, S (2010). "Long-term results of the 
Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on 
childhood acute lymphoblastic leukemia." Leukemia 24(2): 335-344. 
6. REFERENCES 
 
204 
 
Tung, EK, Choi, RC, Siow, NL, Jiang, JX, Ling, KK, Simon, J, Barnard, EA and Tsim, KW (2004). 
"P2Y2 receptor activation regulates the expression of acetylcholinesterase and acetylcholine 
receptor genes at vertebrate neuromuscular junctions." Mol Pharmacol 66(4): 794-806. 
Tureyen, K, Vemuganti, R, Sailor, KA and Dempsey, RJ (2004). "Infarct volume quantification in 
mouse focal cerebral ischemia: a comparison of triphenyltetrazolium chloride and cresyl violet 
staining techniques." J Neurosci Methods 139(2): 203-207. 
Valera, S, Hussy, N, Evans, RJ, Adami, N, North, RA, Surprenant, A and Buell, G (1994). "A new 
class of ligand-gated ion channel defined by P2x receptor for extracellular ATP." Nature 
371(6497): 516-519. 
van Calker, D, Muller, M and Hamprecht, B (1979). "Adenosine regulates via two different types of 
receptors, the accumulation of cyclic AMP in cultured brain cells." J Neurochem 33(5): 999-
1005. 
van der Putten, C, Zuiderwijk-Sick, EA, van Straalen, L, de Geus, ED, Boven, LA, Kondova, I, AP, IJ 
and Bajramovic, JJ (2009). "Differential expression of adenosine A3 receptors controls 
adenosine A2A receptor-mediated inhibition of TLR responses in microglia." J Immunol 
182(12): 7603-7612. 
Veech, RL, Lawson, JW, Cornell, NW and Krebs, HA (1979). "Cytosolic phosphorylation potential." J 
Biol Chem 254(14): 6538-6547. 
Vereker, E, Campbell, V, Roche, E, McEntee, E and Lynch, MA (2000a). "Lipopolysaccharide inhibits 
long term potentiation in the rat dentate gyrus by activating caspase-1." J Biol Chem 275(34): 
26252-26258. 
Vereker, E, O'Donnell, E and Lynch, MA (2000b). "The inhibitory effect of interleukin-1beta on long-
term potentiation is coupled with increased activity of stress-activated protein kinases." J 
Neurosci 20(18): 6811-6819. 
Verkhratsky, A, Krishtal, OA and Burnstock, G (2009). "Purinoceptors on neuroglia." Mol Neurobiol 
39(3): 190-208. 
Vezzani, A, French, J, Bartfai, T and Baram, TZ (2011). "The role of inflammation in epilepsy." Nat 
Rev Neurol 7(1): 31-40. 
Vial, C, Tobin, AB and Evans, RJ (2004). "G-protein-coupled receptor regulation of P2X1 receptors 
does not involve direct channel phosphorylation." Biochem J 382(Pt 1): 101-110. 
Vianna, EP, Ferreira, AT, Naffah-Mazzacoratti, MG, Sanabria, ER, Funke, M, Cavalheiro, EA and 
Fernandes, MJ (2002). "Evidence that ATP participates in the pathophysiology of pilocarpine-
induced temporal lobe epilepsy: fluorimetric, immunohistochemical, and Western blot studies." 
Epilepsia 43 Suppl 5: 227-229. 
Vitkovic, L, Bockaert, J and Jacque, C (2000). ""Inflammatory" cytokines: neuromodulators in normal 
brain?" J Neurochem 74(2): 457-471. 
Viviani, B, Bartesaghi, S, Gardoni, F, Vezzani, A, Behrens, MM, Bartfai, T, Binaglia, M, Corsini, E, 
Di Luca, M, Galli, CL and Marinovich, M (2003). "Interleukin-1beta enhances NMDA 
receptor-mediated intracellular calcium increase through activation of the Src family of 
kinases." J Neurosci 23(25): 8692-8700. 
Volonte, C, Amadio, S, Cavaliere, F, D'Ambrosi, N, Vacca, F and Bernardi, G (2003). "Extracellular 
ATP and neurodegeneration." Curr Drug Targets CNS Neurol Disord 2(6): 403-412. 
Volonte, C, Amadio, S, D'Ambrosi, N, Colpi, M and Burnstock, G (2006). "P2 receptor web: 
complexity and fine-tuning." Pharmacol Ther 112(1): 264-280. 
Volonte, C, Ciotti, MT, D'Ambrosi, N, Lockhart, B and Spedding, M (1999). "Neuroprotective effects 
of modulators of P2 receptors in primary culture of CNS neurones." Neuropharmacology 38(9): 
1335-1342. 
6. REFERENCES 
205 
 
Volonte, C and D'Ambrosi, N (2009). "Membrane compartments and purinergic signalling: the 
purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters." 
FEBS J 276(2): 318-329. 
von Kugelgen, I and Harden, TK (2011). "Molecular pharmacology, physiology, and structure of the 
P2Y receptors." Adv Pharmacol 61: 373-415. 
von Kugelgen, I and Wetter, A (2000). "Molecular pharmacology of P2Y-receptors." Naunyn 
Schmiedebergs Arch Pharmacol 362(4-5): 310-323. 
Walsh, RN and Cummins, RA (1976). "The Open-Field Test: a critical review." Psychol Bull 83(3): 
482-504. 
Walz, W, Ilschner, S, Ohlemeyer, C, Banati, R and Kettenmann, H (1993). "Extracellular ATP 
activates a cation conductance and a K+ conductance in cultured microglial cells from mouse 
brain." J Neurosci 13(10): 4403-4411. 
Ward, MM and Fletcher, EL (2009). "Subsets of retinal neurons and glia express P2Y1 receptors." 
Neuroscience 160(2): 555-566. 
Ward, MM, Puthussery, T, Vessey, KA and Fletcher, EL (2010). "The role of purinergic receptors in 
retinal function and disease." Adv Exp Med Biol 664: 385-391. 
Watters, O, Pickering, M and O'Connor, JJ (2011). "Preconditioning effects of tumor necrosis factor-
alpha and glutamate on calcium dynamics in rat organotypic hippocampal cultures." J 
Neuroimmunol 234(1-2): 27-39. 
Webb, TE, Simon, J, Krishek, BJ, Bateson, AN, Smart, TG, King, BF, Burnstock, G and Barnard, EA 
(1993). "Cloning and functional expression of a brain G-protein-coupled ATP receptor." FEBS 
Lett 324(2): 219-225. 
Wee Yong, V (2010). "Inflammation in neurological disorders: a help or a hindrance?" Neuroscientist 
16(4): 408-420. 
Weight, FF, Li, C and Peoples, RW (1999). "Alcohol action on membrane ion channels gated by 
extracellular ATP (P2X receptors)." Neurochem Int 35(2): 143-152. 
Werry, TD, Christie, MI, Dainty, IA, Wilkinson, GF and Willars, GB (2002). "Ca(2+) signalling by 
recombinant human CXCR2 chemokine receptors is potentiated by P2Y nucleotide receptors in 
HEK cells." Br J Pharmacol 135(5): 1199-1208. 
White, PJ, Webb, TE and Boarder, MR (2003). "Characterization of a Ca2+ response to both UTP and 
ATP at human P2Y11 receptors: evidence for agonist-specific signaling." Mol Pharmacol 
63(6): 1356-1363. 
White, TD (1977). "Direct detection of depolarisation-induced release of ATP from a synaptosomal 
preparation." Nature 267(5606): 67-68. 
Wieraszko, A, Goldsmith, G and Seyfried, TN (1989). "Stimulation-dependent release of adenosine 
triphosphate from hippocampal slices." Brain Res 485(2): 244-250. 
Wilkin, F, Duhant, X, Bruyns, C, Suarez-Huerta, N, Boeynaems, JM and Robaye, B (2001). "The 
P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic 
cells." J Immunol 166(12): 7172-7177. 
Windscheif, U, Ralevic, V, Baumert, HG, Mutschler, E, Lambrecht, G and Burnstock, G (1994). 
"Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric 
arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors." Br 
J Pharmacol 113(3): 1015-1021. 
Wirenfeldt, M, Dissing-Olesen, L, Anne Babcock, A, Nielsen, M, Meldgaard, M, Zimmer, J, Azcoitia, 
I, Leslie, RG, Dagnaes-Hansen, F and Finsen, B (2007). "Population control of resident and 
immigrant microglia by mitosis and apoptosis." Am J Pathol 171(2): 617-631. 
6. REFERENCES 
 
206 
 
Wirkner, K, Assmann, H, Koles, L, Gerevich, Z, Franke, H, Norenberg, W, Boehm, R and Illes, P 
(2000). "Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat 
neostriatal neurons." Br J Pharmacol 130(2): 259-269. 
Wirkner, K, Gerevich, Z, Krause, T, Gunther, A, Koles, L, Schneider, D, Norenberg, W and Illes, P 
(2004). "Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-
mediated synaptic currents in a subpopulation of rat striatal neurons." Neuropharmacology 
46(7): 994-1007. 
Wirkner, K, Koles, L, Thummler, S, Luthardt, J, Poelchen, W, Franke, H, Furst, S and Illes, P (2002). 
"Interaction between P2Y and NMDA receptors in layer V pyramidal neurons of the rat 
prefrontal cortex." Neuropharmacology 42(4): 476-488. 
Witter, MP, Groenewegen, HJ, Lopes da Silva, FH and Lohman, AH (1989). "Functional organization 
of the extrinsic and intrinsic circuitry of the parahippocampal region." Prog Neurobiol 33(3): 
161-253. 
Wolvers, DA, Marquette, C, Berkenbosch, F and Haour, F (1993). "Tumor necrosis factor-alpha: 
specific binding sites in rodent brain and pituitary gland." Eur Cytokine Netw 4(5): 377-381. 
Wong, AY, Burnstock, G and Gibb, AJ (2000). "Single channel properties of P2X ATP receptors in 
outside-out patches from rat hippocampal granule cells." J Physiol 3: 529-547. 
Wong, ML and Licinio, J (1994). "Localization of interleukin 1 type I receptor mRNA in rat brain." 
Neuroimmunomodulation 1(2): 110-115. 
Wurm, A, Erdmann, I, Bringmann, A, Reichenbach, A and Pannicke, T (2009). "Expression and 
function of P2Y receptors on Muller cells of the postnatal rat retina." Glia 57(15): 1680-1690. 
Xin, C, Ren, S, Pfeilschifter, J and Huwiler, A (2004). "Heterologous desensitization of the 
sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells." Br J 
Pharmacol 143(5): 581-589. 
Xu, K, Bastia, E and Schwarzschild, M (2005). "Therapeutic potential of adenosine A(2A) receptor 
antagonists in Parkinson's disease." Pharmacol Ther 105(3): 267-310. 
Yabuuchi, K, Minami, M, Katsumata, S and Satoh, M (1994). "Localization of type I interleukin-1 
receptor mRNA in the rat brain." Brain Res Mol Brain Res 27(1): 27-36. 
Yanagisawa, D, Kitamura, Y, Takata, K, Hide, I, Nakata, Y and Taniguchi, T (2008). "Possible 
involvement of P2X7 receptor activation in microglial neuroprotection against focal cerebral 
ischemia in rats." Biol Pharm Bull 31(6): 1121-1130. 
Yang, L, Lindholm, K, Konishi, Y, Li, R and Shen, Y (2002). "Target depletion of distinct tumor 
necrosis factor receptor subtypes reveals hippocampal neuron death and survival through 
different signal transduction pathways." J Neurosci 22(8): 3025-3032. 
Yang, M, Soohoo, D, Soelaiman, S, Kalla, R, Zablocki, J, Chu, N, Leung, K, Yao, L, Diamond, I, 
Belardinelli, L and Shryock, JC (2007). "Characterization of the potency, selectivity, and 
pharmacokinetic profile for six adenosine A2A receptor antagonists." Naunyn Schmiedebergs 
Arch Pharmacol 375(2): 133-144. 
Yang, T, Zhou, D and Stefan, H (2010). "Why mesial temporal lobe epilepsy with hippocampal 
sclerosis is progressive: uncontrolled inflammation drives disease progression?" J Neurol Sci 
296(1-2): 1-6. 
Yegutkin, GG (2008). "Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of 
purinergic signalling cascade." Biochim Biophys Acta 1783(5): 673-694. 
Yirmiya, R and Goshen, I (2011). "Immune modulation of learning, memory, neural plasticity and 
neurogenesis." Brain Behav Immun 25(2): 181-213. 
Yoshioka, K, Hosoda, R, Kuroda, Y and Nakata, H (2002). "Hetero-oligomerization of adenosine A1 
receptors with P2Y1 receptors in rat brains." FEBS Lett 531(2): 299-303. 
6. REFERENCES 
207 
 
Yoshioka, K and Nakata, H (2004). "ATP- and adenosine-mediated signaling in the central nervous 
system: purinergic receptor complex: generating adenine nucleotide-sensitive adenosine 
receptors." J Pharmacol Sci 94(2): 88-94. 
Yoshioka, K, Saitoh, O and Nakata, H (2001). "Heteromeric association creates a P2Y-like adenosine 
receptor." Proc Natl Acad Sci U S A 98(13): 7617-7622. 
Young, GB, Bolton, CF, Austin, TW, Archibald, YM, Gonder, J and Wells, GA (1990). "The 
encephalopathy associated with septic illness." Clin Invest Med 13(6): 297-304. 
Yu, L, Huang, Z, Mariani, J, Wang, Y, Moskowitz, M and Chen, JF (2004). "Selective inactivation or 
reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant 
contribution to the development of ischemic brain injury." Nat Med 10(10): 1081-1087. 
Yu, L, Shen, HY, Coelho, JE, Araujo, IM, Huang, QY, Day, YJ, Rebola, N, Canas, PM, Rapp, EK, 
Ferrara, J, Taylor, D, Muller, CE, Linden, J, Cunha, RA and Chen, JF (2008). "Adenosine A2A 
receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms." 
Ann Neurol 63(3): 338-346. 
Zeng, JW, Liu, XH, Zhao, YD, Xiao, Z, He, WJ, Hu, ZA and Ruan, HZ (2009). "Role of P2Y1 
receptor in astroglia-to-neuron signaling at dorsal spinal cord." J Neurosci Res 87(12): 2667-
2676. 
Zeraati, M, Mirnajafi-Zadeh, J, Fathollahi, Y, Namvar, S and Rezvani, ME (2006). "Adenosine A1 and 
A2A receptors of hippocampal CA1 region have opposite effects on piriform cortex kindled 
seizures in rats." Seizure 15(1): 41-48. 
Zhang, D, Hu, X, Qian, L, O'Callaghan, JP and Hong, JS (2010a). "Astrogliosis in CNS pathologies: is 
there a role for microglia?" Mol Neurobiol 41(2-3): 232-241. 
Zhang, N, Yang, D, Dong, H, Chen, Q, Dimitrova, DI, Rogers, TJ, Sitkovsky, M and Oppenheim, JJ 
(2006). "Adenosine A2a receptors induce heterologous desensitization of chemokine receptors." 
Blood 108(1): 38-44. 
Zhang, R, Sun, L, Hayashi, Y, Liu, X, Koyama, S, Wu, Z and Nakanishi, H (2010b). "Acute p38-
mediated inhibition of NMDA-induced outward currents in hippocampal CA1 neurons by 
interleukin-1beta." Neurobiol Dis 38(1): 68-77. 
Zhang, R, Yamada, J, Hayashi, Y, Wu, Z, Koyama, S and Nakanishi, H (2008). "Inhibition of NMDA-
induced outward currents by interleukin-1beta in hippocampal neurons." Biochem Biophys Res 
Commun 372(4): 816-820. 
Zhang, YX, Yamashita, H, Ohshita, T, Sawamoto, N and Nakamura, S (1995). "ATP increases 
extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum." 
Brain Res 691(1-2): 205-212. 
Zhu, G, Okada, M, Yoshida, S, Mori, F, Hirose, S, Wakabayashi, K and Kaneko, S (2006). 
"Involvement of Ca(2+)-induced Ca2+ releasing system in interleukin-1beta-associated 
adenosine release." Eur J Pharmacol 532(3): 246-252. 
Zimmermann, H (2000). "Extracellular metabolism of ATP and other nucleotides." Naunyn 
Schmiedebergs Arch Pharmacol 362(4-5): 299-309. 
Zimmermann, H (2006). "Ectonucleotidases in the nervous system." Novartis Found Symp 276: 113-
128. 
Zimmermann, H, Braun, N, Kegel, B and Heine, P (1998). "New insights into molecular structure and 
function of ectonucleotidases in the nervous system." Neurochem Int 32(5-6): 421-425. 
Zona, C, Marchetti, C, Volonte, C, Mercuri, NB and Bernardi, G (2000). "Effect of P2 purinoceptor 
antagonists on kainate-induced currents in rat cultured neurons." Brain Res 882(1-2): 26-35. 
Zou, JY and Crews, FT (2005). "TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate 
uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition." Brain 
Res 1034(1-2): 11-24. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
